Nothing Special   »   [go: up one dir, main page]

WO2008013622A2 - Fungicidal azocyclic amides - Google Patents

Fungicidal azocyclic amides Download PDF

Info

Publication number
WO2008013622A2
WO2008013622A2 PCT/US2007/014647 US2007014647W WO2008013622A2 WO 2008013622 A2 WO2008013622 A2 WO 2008013622A2 US 2007014647 W US2007014647 W US 2007014647W WO 2008013622 A2 WO2008013622 A2 WO 2008013622A2
Authority
WO
WIPO (PCT)
Prior art keywords
bond
trifluoromethyl
independently
ring
alkyl
Prior art date
Application number
PCT/US2007/014647
Other languages
French (fr)
Other versions
WO2008013622A3 (en
Inventor
Robert James Pasteris
Mary Ann Hanagan
Rafael Shapiro
Original Assignee
E. I. Du Pont De Nemours And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by E. I. Du Pont De Nemours And Company filed Critical E. I. Du Pont De Nemours And Company
Priority to CN201710112212.2A priority Critical patent/CN107021962A/en
Priority to DK07836278.7T priority patent/DK2049111T3/en
Priority to CN201510114576.5A priority patent/CN104774201A/en
Priority to JP2009521846A priority patent/JP6118011B2/en
Priority to EP17172140.0A priority patent/EP3239137B1/en
Priority to PL07836278T priority patent/PL2049111T3/en
Priority to PT78362787T priority patent/PT2049111T/en
Priority to MEP-23/09A priority patent/ME00586A/en
Priority to KR1020147033282A priority patent/KR101564187B1/en
Priority to ES07836278.7T priority patent/ES2637336T3/en
Priority to PCT/US2007/016875 priority patent/WO2008013925A2/en
Priority to CN200780028120.0A priority patent/CN101888843B/en
Priority to CN201410806789.XA priority patent/CN104478805B/en
Priority to EP17172323.2A priority patent/EP3239145B1/en
Priority to CN201710113323.5A priority patent/CN106986866B/en
Priority to EP13196711.9A priority patent/EP2712616B1/en
Priority to US12/303,256 priority patent/US8642634B2/en
Priority to KR1020097004083A priority patent/KR20090033496A/en
Priority to EP07836278.7A priority patent/EP2049111B1/en
Priority to CN201210260720.2A priority patent/CN102816148B/en
Priority to MYPI20090076A priority patent/MY148424A/en
Priority to BRPI0713833-4A priority patent/BRPI0713833B1/en
Priority to LTEP07836278.7T priority patent/LT2049111T/en
Priority to ES13196711.9T priority patent/ES2632597T3/en
Priority to SI200731951T priority patent/SI2049111T1/en
Priority to AU2007277157A priority patent/AU2007277157B2/en
Priority to MX2009000920A priority patent/MX2009000920A/en
Priority to MX2014005660A priority patent/MX337779B/en
Priority to CA2653640A priority patent/CA2653640C/en
Priority to PL17172323T priority patent/PL3239145T3/en
Priority to NZ572915A priority patent/NZ572915A/en
Priority to GEAP200711072A priority patent/GEP20125505B/en
Priority to PL17172140T priority patent/PL3239137T3/en
Publication of WO2008013622A2 publication Critical patent/WO2008013622A2/en
Publication of WO2008013622A3 publication Critical patent/WO2008013622A3/en
Priority to IL195509A priority patent/IL195509A/en
Priority to CO09005501A priority patent/CO6150154A2/en
Priority to IL224109A priority patent/IL224109A/en
Priority to US14/087,481 priority patent/US9090604B2/en
Priority to IL231012A priority patent/IL231012A/en
Priority to JP2015006554A priority patent/JP2015110611A/en
Priority to US14/748,390 priority patent/US9920030B2/en
Priority to US14/748,372 priority patent/US9604962B2/en
Priority to JP2016200559A priority patent/JP6333913B2/en
Priority to HRP20171019TT priority patent/HRP20171019T1/en
Priority to CY20171100880T priority patent/CY1120559T1/en
Priority to JP2017245666A priority patent/JP6572294B2/en
Priority to NL350089C priority patent/NL350089I2/en
Priority to LTPA2019008C priority patent/LTC2049111I2/en
Priority to LTPA2021503C priority patent/LTPA2021503I1/en
Priority to FR22C1026C priority patent/FR22C1026I1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/56—1,2-Diazoles; Hydrogenated 1,2-diazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
    • A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2477—Hemicellulases not provided in a preceding group
    • C12N9/2488—Mannanases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01024—Alpha-mannosidase (3.2.1.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to certain carboxamides, their iV-oxides, salts and compositions, and methods of their use as fungicides.
  • World Patent Publication WO 05/003128 discloses thiazolylpiperidine derivatives of Formula i as MTP (Microsomal Triglyceride transfer Protein) inhibitors.
  • MTP Mericrosomal Triglyceride transfer Protein
  • A is a radical selected from the radicals al and a2 below al a2 and R 1 , R 2 , R 2 ', R 3 , R 4 and R 5 are as defined in the disclosure.
  • World Patent Publication WO 04/058751 discloses piperidinyl-thiazole carboxamide derivatives for altering vascular tone.
  • This invention relates to compounds of Formula 1 including all geometric and stereoisomers, N-oxides, and salts thereof, agricultural compositions containing them and their use as fungicides: wherein
  • R 1 is an optionally substituted phenyl, naphthalenyl or 5- or 6-membered heteroaromatic ring; A iS CHR 15 Or NR 1 *;
  • R 15 is H, halogen, cyano, hydroxy, -CHO, Cj- C 4 alkyl, C2-C 4 alkenyl, C 2 - C4 alkynyl, Cj-C 4 haloalkyl, C 2 -C4 haloalkenyl, C 2 -C4 haloalkynyl, C 2 -C 4 alkoxyalkyl, C 2 -C 4 alkylthioalkyl, C 2 -C 4 alkylsulfinylalkyl, C 2 -C 4 alkylsulfbnylalkyl, C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl, C 2 -Cs alkoxycarbonyl, C3-C 5 alkoxycarbonylalkyl, C 2 -Cs alkylaminocarbonyl, C3-C5 dialkylaminocarbonyl, C 1 -C 4 alkoxy,
  • R 16 is H 5 C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 haloalkyl, C 2 -C 4 haloalkenyl, C 2 -C 4 haloalkynyl, C 2 -C 4 alkoxyalkyl, C 2 -C 4 alkylthioalkyl, C 2 -
  • W is O or S;
  • X is a radical selected from
  • G is an optionally substituted 5-membered heteroaromatic ring or 5-membered saturated or partially saturated heterocyclic ring;
  • R 25 is H 5 C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, C 2 -C 6 alkylcarbonyl, C 2 -
  • R 26 is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, C 2 -C 6 alkylcarbonyl, C 2 -C 6 haloalkylcarbonyl, C 2 -Cg alkoxycarbonyl, C 2 -Cg haloalkoxycarbonyl or -Z 4 Q; each R 17 and R 18 is independently C 1 -C 5 alkyl, C 2 -C 5 alkenyl, C 2 -C 5 alkynyl, C 3 -
  • each Q is independently phenyl, benzyl, naphthalenyl, a 5- or 6-membered heteroaromatic ring or an 8- to 11-membered heteroaromatic bicyclic ring system, each optionally substituted with 1 to 5 substituents independently selected from R 7 on carbon atom ring members and R 12 on nitrogen atom ring members; or each Q is independently a 3- to 7-membered nonaromatic carbocyclic ring, a 5-, 6- or 7-membered nonaromatic heterocyclic ring or an 8- to 11-membere
  • this invention pertains to compounds of Formula 1 including all geometric and stereoisomers, iV-oxides, and salts thereof; provided that (b) when A is NR 1 ⁇ 5 X is X 1 or X 2 , Z 1 is a direct bond, and J is phenyl, then J is substituted with at least one R 5 other than H, F, Cl, CN, OCH 3 , CF 3 and CH 3 .
  • This invention also relates to a compound of Formula IA
  • each R 4al and R 4a2 is independently Ci-C 3 alkyl, C 2 -C 3 alkenyl, C 2 -C 3 alkynyl, cyclopropyl, C 1 -C 3 haloalkyl, C 2 -C 3 haloalkenyl, C 2 -C 3 haloalkynyl, halocyclopropyl, halogen, cyano, nitro, C 1 -C 2 alkoxy, C 1 -C 2 haloalkoxy, C 1 - C 2 alkylthio, C 1 -C 2 haloalkylthio, C 2 -C 3 alkoxyalkyl, C 2 -C 3 alkylcarbonyl, C 2 -C 3 alkoxycarbonyl, C 2 -C 3 alkylaminocarbonyl or C 3 -C 4 dialkylaminocarbonyl;
  • This invention also relates to a compound of Formula IB
  • each R 4al and R 4a2 is independently C 1 -C 3 alkyl, C 2 -C 3 alkenyl, C 2 -C 3 alkynyl, cyclopropyl, C 1 -C 3 haloalkyl, C 2 -C 3 haloalkenyl, C 2 -C 3 haloalkynyl, halocyclopropyl, halogen, cyano, nitro, C 1 -C 2 alkoxy, Cj-C 2 haloalkoxy, C 1 -
  • This invention further relates to a compound of Formula 1C
  • M is C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, hydroxy, C 1 -C 4 alkoxy, C 1 -C 2 haloalkoxy, C 1 -C 4 alkylamino, C 2 -C 8 dialkylamino, 1-piperidinyl, 1-pyrrolidinyl or 4-morpholinyl; and
  • J 1 is J-29-1 through J-29-58 depicted in Exhibit A as described below. More particularly, this invention pertains to compounds of Formulae IA, IB and 1C, including all geometric and stereoisomers, an JV-oxide or salt thereof (except that the compounds of Formula 1C of this invention are limited to those stereoisomer embodiments depicted for J 1 in the Summary of Invention above).
  • This invention also relates to a fungicidal composition
  • a fungicidal composition comprising a fungicidally effective amount of a compound of Formula 1 and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents.
  • This invention also relates to a fungicidal composition
  • a fungicidal composition comprising a mixture of a compound of Formula 1 (including all geometric and stereoisomers, iV-oxides, and salts thereof) and at least one other fungicide (e.g., at least one other fungicide having a different site of action).
  • This invention further relates to a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of Formula 1 (including all geometric and stereoisomers, JV-oxides, and salts thereof) (e.g., as a composition described herein).
  • This invention additionally relates to fungicidal compositions and methods of controlling plant diseases as described above, except that proviso (a) is removed from the definition of the scope of Formula 1.
  • compositions comprising, “comprising,” “includes,” “including,” “has,” “having” or any other variation thereof, are intended to cover a non-exclusive inclusion.
  • a composition, process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, process, method, article, or apparatus.
  • “or” refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and Both A and B are true (or present).
  • plant includes members of Kingdom Plantae, particularly seed plants (Spermatopsida), at all life stages, including young plants (e.g., germinating seeds developing into seedlings) and mature, reproductive stages (e.g., plants producing flowers and seeds).
  • Portions of plants include geotropic members typically growing beneath of the surface of the growing medium (e.g., soil), such as roots, tubers, bulbs and corms, and also members growing above the growing medium, such as foliage (including stems and leaves), flowers, fruits and seeds.
  • alkyl used either alone or in compound words such as “alkylthio” or “haloalkyl” includes straight-chain or branched alkyl, such as, methyl, ethyl, H-propyl, /-propyl, or the different butyl, pentyl or hexyl isomers.
  • Alkenyl includes straight-chain or branched alkenes such as ethenyl, 1-propenyl, 2-propenyl, and the different butenyl, pentenyl and hexenyl isomers.
  • Alkenyl also includes polyenes such as 1,2-propadienyl and 2,4-hexadienyl.
  • Alkynyl includes straight-chain or branched alkynes such as ethynyl, 1-propynyl, 2-propynyl and the different butynyl, pentynyl and hexynyl isomers.
  • Alkynyl can also include moieties comprised of multiple triple bonds such as 2,5-hexadiynyl.
  • Alkylene denotes a straight-chain or branched alkanediyl.
  • alkylene examples include CH 2 , CH 2 CH 2 , CH(CH 3 ), CH 2 CH 2 CH 2 , CH 2 CH(CH 3 ) and the different butylene isomers.
  • Alkoxy includes, for example, methoxy, ethoxy, n-propyloxy, isopropyloxy and the different butoxy, pentoxy and hexyloxy isomers.
  • Alkoxyalkyl denotes alkoxy substitution on alkyl.
  • alkoxyalkyl examples include CH 3 OCH 2 , CH 3 OCH 2 CH 2 , CH 3 CH 2 OCH 2 , CH 3 CH 2 CH 2 CH 2 OCH 2 and CH 3 CH 2 OCH 2 CH 2 .
  • Alkylthio includes branched or straight-chain alkylthio moieties such as methylthio, ethylthio, and the different propylthio, butylthio, pentylthio and hexylthio isomers.
  • Alkylsulfinyl includes both enantiomers of an alkylsulfinyl group.
  • alkylsulfinyl examples include CH 3 S(O), CH 3 CH 2 S(O), CH 3 CH 2 CH 2 S(O), (CH 3 ) 2 CHS(O) and the different butylsulfinyl, pentylsulf ⁇ nyl and hexylsulfmyl isomers.
  • alkylsulfonyl examples include CH 3 S(O) 2 , CH 3 CH 2 S(O) 2 , CH 3 CH 2 CH 2 S(O) 2 , (CH 3 ) 2 CHS(O) 2 and the different butylsulfonyl, pentylsulfonyl and hexylsulfonyl isomers.
  • alkylcarbonyl examples include C(O)CH 3 , C(O)CH 2 CH 2 CH 3 and C(O)CH(CH 3 ) 2 .
  • Trialkylsilyl includes 3 branched and/or straight- chain alkyl radicals attached to and linked through a silicon atom, such as trimethylsilyl, triethylsilyl and tert-butyldimethylsilyl.
  • Cycloalkyl includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Examples of “cycloalkylalkyl” include cyclopropylmethyl, cyclopentylethyl, and other cycloalkyl moieties bonded to straight-chain or branched alkyl groups.
  • Alkylcycloalkyl denotes alkyl substitution on a cycloalkyl moiety. Examples include 4-methylcyclohexyl and 3-ethylcyclopentyl.
  • a "ring” or “ring system” as a component of Formula 1 is carbocyclic or heterocyclic.
  • the term “ring system” denotes two or more connected rings.
  • the term “spirocyclic ring system” denotes a ring system consisting of two rings connected at a single atom (so the rings have a single atom in commonality).
  • J-29-28 Illustrative of a J 1 moiety that is a spirocyclic ring system is J-29-28 depicted in the definition of Formula 1C.
  • the term "bicyclic ring system” denotes a ring system consisting of two rings sharing two or more common atoms. In a “fused bicyclic ring system” the common atoms are adjacent, and therefore the rings share two adjacent atoms and bond connecting them. In a “bridged bicyclic ring system” the common atoms are not adjacent (i.e. there is no bond between the bridgehead atoms).
  • a “bridged bicyclic ring system” is conceptually formed by bonding a segment of one or more atoms to nonadjacent ring members of a ring.
  • a ring, a bicyclic ring system or spirocyclic ring system can be part of an extended ring system containing more than two rings wherein substituents on the ring, bicyclic ring system or spirocyclic are taken together to form the additional rings, which may be in bicyclic and/or spirocyclic relationships with other rings in the extended ring system.
  • the particular J 1 moiety J-29-26 depicted in the definition of Formula 1C consists of a dihydro isoxazoline ring having one R 5 substituent as Z 2 Q, which is a cyclobutyl ring substituted with two methyl groups as R 7 and also one R 7 group taken together with another R 5 substituent on the dihydro isoxazoline ring as -CH 2 CH 2 - to form the additional six- membered ring component in the ring system.
  • carbocyclic ring denotes a ring wherein the atoms forming the ring backbone are selected only from carbon.
  • carbocyclic ring system denotes two or more fused rings wherein the atoms forming the backbone of the rings are selected only from carbon.
  • heterocyclic ring denotes a ring wherein at least one of the atoms forming the ring backbone is other than carbon.
  • heterocyclic ring system denotes two or more fused rings wherein at least one of the atoms forming the backbone of the rings is other than carbon.
  • “Aromatic” indicates that each of ring atoms is essentially in the same plane and has a p-orbital perpendicular to the ring plane, and in which (4n + 2) ⁇ electrons, where n is a positive integer, are associated with the ring to comply with H ⁇ ckel's rule.
  • heterocyclic ring refers to a heterocyclic ring that is aromatic.
  • saturated heterocyclic ring denotes a heterocyclic ring containing only single bonds between ring members.
  • the term “partially saturated heterocyclic ring” denotes a heterocyclic ring containing at least one double bond but which is not aromatic.
  • the dotted line in Formula 1 and in other rings depicted in the present description represents that the bond indicated can be a single bond or double bond.
  • heterocyclic rings and ring systems are attached to the remainder of Formula 1 through any available carbon or nitrogen by replacement of a hydrogen on said carbon or nitrogen, and all substituents on the heterocyclic rings and ring systems are attached through any available carbon or nitrogen by 5 replacement of a hydrogen on said carbon or nitrogen.
  • J is a 5-, 6- or 7-membered ring, a 8- to 11-membered bicyclic ring system or a 7- to 11-membered spirocyclic ring system, each ring or ring system containing ring members selected from carbon and optionally 1 to 4 heteroatoms selected from up to 2 O, up to 2 S and up to 4 N, and optionally including 1 to 3 ring members
  • the heteroatoms are optional, 0 to 4 heteroatoms may be present.
  • the heteroatoms selected from up to 2 S are atoms and not the moieties S(O) or S(O) 2 -
  • the heteroatoms selected from up to 4 N may be oxidized as iV-oxides, because the present
  • the total number of unoxidized sulfur atoms (i.e. S) and oxidized sulfur moieties (i.e. S(O) and S(O) 2 ) does not exceed 2, so that at most two
  • ring members selected from S, S(O) and S(O) 2 are present in the ring or ring system.
  • the ring or ring system is carbocyclic.
  • the R 5 substituents may be attached to carbon atom ring members and to nitrogen atom ring members having an available point of attachment.
  • R 5 and R 7 may be taken together with the atoms linking R 5 and R 7 to form
  • the heteroatoms are optional, 0 to 3 heteroatoms may be present. In this description the heteroatom selected from up to 1 S is an atom and not the
  • the total number of unoxidized sulfur atoms (i.e. S) and oxidized sulfur moieties (i.e. S(O) and S(O)2) does not exceed 1, so that at most one ring member selected from S, S(O) and S(O) 2 is present in the ring.
  • the ring is carbocyclic.
  • The. 5- to 7-membered ring is optionally substituted.
  • the substituents on the atoms linking R 5 and R 7 are described in the definition of the components linking R 5 and R 7 .
  • the substituent R 20 is defined to be H, C 1 -C 4 alkyl or C 1 -C 4 haloalkyl.
  • an optional substituent is a non-hydrogen substituent that does not extinguish fungicidal activity.
  • Optional substituents may be attached to carbon atom ring members and to nitrogen atom ring members having an available point of attachment.
  • the substituents R 17 and R 18 are otherwise separately defined, and these ring members cannot be further substituted.
  • halogen either alone or in compound words such as “haloalkyl” includes fluorine, chlorine, bromine or iodine. Furthermore, when used in compound words such as “haloalkyl”, said alkyl may be partially or fully substituted with halogen atoms which may be the same or different. Examples of “haloalkyl” include F 3 C, ClCH 2 , CF 3 CH 2 and CF 3 CCl 2 .
  • haloalkenyl “haloalkynyl”, “halocycloalkyl”, “haloalkoxy", “haloalkylthio”, and the like, are defined analogously to the term “haloalkyl".
  • haloalkoxy examples include CF 3 O, CCl 3 CH 2 O, HCF 2 CH 2 CH 2 O and CF 3 CH 2 O.
  • haloalkylthio examples include CCl 3 S, CF 3 S, CCl 3 CH 2 S and ClCH 2 CH 2 CH 2 S.
  • haloalkylsulfmyl examples include CF 3 S(O), CCl 3 S(O), CF 3 CH 2 S(O) and CF 3 CF 2 S(O).
  • haloalkylsulfonyl examples include CF 3 S(O) 2 , CCl 3 S(O) 2 , CF 3 CH 2 S(O) 2 and CF 3 CF 2 S(O) 2 .
  • C 1 -C 4 alkylsulfonyl designates methylsulfonyl through butylsulfonyl
  • C 2 alkoxyalkyl designates CH 3 OCH 2
  • C 3 alkoxyalkyl designates, for example, CH 3 CH(OCH 3 ), CH 3 OCH 2 CH 2 or CH 3 CH 2 OCH 2
  • C 4 alkoxyalkyl designates the various isomers of an alkyl group substituted with an alkoxy group containing a total of four carbon atoms, examples including CH 3 CH 2 CH 2 OCH 2 and CH 3 CH 2 OCH 2 CH 2 .
  • substituents may be selected from the integers between i and j inclusive.
  • a group e.g., J
  • R 5 a substituent which can be hydrogen
  • this substituent is taken as hydrogen, it is recognized that this is equivalent to said group being unsubstituted.
  • a variable group is shown to be optionally attached to a position, for example (R 2 ) n wherein n may be 0, or as a further example (R 4 ) k wherein k may be 0 in Exhibit 1 , then hydrogen may be at the position even if not recited in the definition of the variable group (e.g., R 2 and R 4 ).
  • the phrase "optionally substituted with 1 to 5 substituents” means that 0, 1, 2, 3, 4 or 5 substituents can be present if the number of available connection points allows.
  • the term "unsubstituted” in connection with a group such as a ring or ring system means the group does not have any substituents other than its one or more attachments to the remainder of Formula 1.
  • the term "meta-substituted phenyl” means a phenyl ring substituted with a non-hydrogen substituent at a meta position relative to attachment of the phenyl ring to the remainder of Formula 1.
  • R 1 is an optionally substituted phenyl, naphthalenyl or 5- or 6- membered heteroaromatic ring
  • G is an optionally substituted 5-membered heteroarorhatic ring or 5-membered saturated or partially saturated heterocyclic ring
  • substituted in connection with the definitions of R 1 , G, R 5 and R 7 refers to groups that have at least one non-hydrogen substituent that does not extinguish fungicidal activity. Since these groups are optionally substituted, they need not have any non-hydrogen substituents. As these groups are "optionally substituted” without the number of substituents indicated, these groups may be substituted with as many optional substituents as can be accommodated by replacing a hydrogen atom with a non-hydrogen substituent on any available carbon or nitrogen atom. Naming of substituents in the present disclosure uses recognized terminology providing conciseness in precisely conveying to those skilled in the art the chemical structure.
  • pyrazol-1-yl means "lH-pyrazol-l-yl” according to the Chemical Abstracts system of nomenclature.
  • pyridyl is synonymous with “pyridinyl”. The order of listing substituents may be different from the Chemical Abstracts system if the difference does not affect the meaning.
  • Compounds of this invention can exist as one or more stereoisomers.
  • the various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers.
  • one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomers). Additionally, the skilled artisan knows how to separate, enrich, and/or to selectively prepare said stereoisomers.
  • the compounds of the invention may be present as a mixture of stereoisomers, individual stereoisomers, or as an optically active form.
  • Formula 1 when J is J-29 (see Exhibit 3) bonded at the 3 -position to the remainder of Formula 1 and J-29 has one R 5 substituent other than H at the 5-position, then Formula 1 possesses a chiral center at the carbon atom to which R 5 is bonded.
  • the two enantiomers are depicted as Formula 1' and Formula 1" with the chiral center identified with an asterisk (*).
  • This invention comprises racemic mixtures, for example, equal amounts of the enantiomers of Formulae l f and 1".
  • this invention includes compounds that are enriched compared to the racemic mixture in an enantiomer of Formula 1.
  • Also included are the essentially pure enantiomers of compounds of Formula 1, for example, Formula 1' and Formula 1".
  • enantiomeric excess which is defined as (2x-l) 100 %, where x is the mole fraction of the dominant enantiomer in the mixture (e.g., an ee of 20 % corresponds to a 60:40 ratio of enantiomers).
  • compositions of this invention have at least a 50 % enantiomeric excess; more preferably at least a 75 % enantiomeric excess; still more preferably at least a 90 % enantiomeric excess; and the most preferably at least a 94 % enantiomeric excess of the more active isomer.
  • enantiomerically pure embodiments of the more active isomer are enantiomerically pure embodiments of the more active isomer.
  • Compounds of Formula 1 can comprise additional chiral centers.
  • substituents and other molecular constituents such as R 4 , R 5 , R 7 , G, J, Q and X 1 through X 9 may themselves contain chiral centers.
  • This invention comprises racemic mixtures as well as enriched and essentially pure stereoconfigurations at these additional chiral centers.
  • Compounds of this invention can exist as one or more conformational isomers due to restricted rotation about the amide bond (e.g., C(W)-N) in Formula 1.
  • This invention comprises mixtures of conformational isomers.
  • this invention includes compounds that are enriched in one conformer relative to others.
  • Some of the unsaturated rings and ring systems depicted in Exhibits 1, 2, 3 and 4 can have an arrangement of single and double bonds between ring members different from that depicted. Such differing arrangements of bonds for a particular arrangement of ring atoms correspond to different tautomers.
  • the particular tautomer depicted is to be considered representative of all the tautomers possible for the arrangement of ring atoms shown.
  • the tables listing particular compounds incorporating, the ring and ring systems depicted in the Exhibits may involve a tautomer different from the tautomer depicted in the Exhibits.
  • the compounds of the invention include TV-oxide derivatives.
  • nitrogen-containing heterocycles can form iV-oxides since the nitrogen requires an available lone pair of electrons for oxidation to the oxide; one skilled in the art will recognize those nitrogen containing heterocycles which can form iV-oxides.
  • tertiary amines can form .V-oxides.
  • the present compounds of Formula 1 can be in the form of agriculturally suitable salts.
  • salts of chemical compounds are in equilibrium with their corresponding nonsalt forms, salts share the biological utility of the nonsalt forms.
  • the salts of the compounds of Formula 1 include acid-addition salts with inorganic or organic acids such as hydrobromic, hydrochloric, nitric, phosphoric, sulfuric, acetic, butyric, fumaric, lactic, maleic, malonic, oxalic, propionic, salicylic, tartaric, 4-toluenesulfonic or valeric acids.
  • salts also include those formed with organic or inorganic bases such as pyridine, triethylamine or ammonia, or amides, hydrides, hydroxides or carbonates of sodium, potassium, lithium, calcium, magnesium or barium. Accordingly, the present invention comprises compounds selected from Formulae 1, IA, IB and 1C, iV-oxides and salts thereof.
  • Embodiments of the present invention include: Embodiment 1. A compound of Formula 1 wherein A is CHR 15 .
  • Embodiment Ib A compound of Embodiment Ia wherein R 15 is H, cyano, hydroxy, methyl or methoxycarbonyl.
  • Embodiment Ic A compound of Embodiment Ib wherein R 15 is H. Embodiment 2. A compound of Formula 1 wherein A is NR 16 .
  • Embodiment 2a A compound of Embodiment 2 wherein R 16 is H, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 ⁇ C 4 alkylcarbonyl, C 2 -C 4 haloalkylcarbonyl or C 2 -C 4 alkoxycarbonyl.
  • Embodiment 2b A compound of Embodiment 2a wherein R 1 ⁇ i s H, methyl, methylcarbonyl or methoxycarbonyl.
  • Embodiment 2c A compound of Embodiment 2b wherein R 16 is H.
  • Embodiment 3 A compound of Formula 1 wherein W is O.
  • Embodiment 4. A compound of Formula 1 wherein W is S.
  • Embodiment 5. A compound of Formula 1 wherein each R 2 is independently C 1 - ⁇ alkyl, C 1 -C 2 haloalkyl, Cj-C 2 alkoxy, halogen, cyano or hydroxy.
  • Embodiment 5a A compound of Embodiment 5 wherein each R 2 is independently methyl, methoxy, cyano or hydroxy.
  • Embodiment 5b A compound of Embodiment 5a wherein each R 2 is methyl.
  • Embodiment 6. A compound of Formula 1 wherein n is 0 or 1.
  • Embodiment 7. A compound of Embodiment 6 wherein n is 0.
  • Embodiment 8. A compound of Formula 1 wherein X is X 1 , X 2 or X 3 .
  • Embodiment 9. A compound of Embodiment 8 wherein X is X 1 or X 2 .
  • Embodiment 10 A compound of Embodiment 9 wherein X is X 1 .
  • Embodiment I L A compound of Formula 1 wherein the ring comprising X is saturated
  • R 1 is a phenyl or 5- or 6- membered heteroaromatic ring optionally substituted with 1—2 substituents independently selected from R 4a on carbon ring members and R 4b on nitrogen ring members; each R 4a is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 4 -Cj O cycloalkylalkyl, C 4 -C] o alkylcycloalkyl, C ⁇ -C IQ alkylcycloalkylalkyl, C]-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C3— C 6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C 1 -
  • each R 4b is independently C 1 -C 6 alkyl, C 3 -C 6 alkenyl, C 3 -C 6 alkynyl, C
  • Embodiment 13 A compound of Embodiment 12 wherein R 1 is one of U-I through . U-50 depicted in Exhibit 1 ;
  • Embodiment 14 A compound of Embodiment 13 wherein R 1 is selected from U-I through U-5, U-8, U-I l, U- 13, U-15, U-20 through U-28, U-31, U-36 through U-39 and U-50.
  • Embodiment 15 A compound of Embodiment 14 wherein R 1 is selected from U-I through U-3, U-5, U-8, U-11, U-13, U-20, U-22, U-23, U-25 through U-28, U-36 through U-39 and U-50.
  • Embodiment 16 A compound of Embodiment 15 wherein R 1 is selected from U-I through U-3, U-I l, U-13, U-20, U-22, U-23, U-36 through U-39 and U-50.
  • Embodiment 17 A compound of Embodiment 16 wherein R 1 is U-I or U-50.
  • Embodiment 18 A compound of Embodiment 17 wherein R 1 is U-I.
  • Embodiment 19 A compound of Embodiment 17 wherein R 1 is U-50.
  • Embodiment 20 A compound of any one of Embodiments 12 and 13 wherein each R 4a is independently C 1 -C 3 alkyl, C 2 -C 3 alkenyl, C 2 -C 3 alkynyl, cyclopropyl, Cj- C 3 haloalkyl, C 2 -C 3 haloalkenyl, C 2 -C 3 haloalkynyl, halocyclopropyl, halogen, cyano, nitro, C 1 -C 2 a lkoxy, Cj-C 2 haloalkoxy, Cj-C 2 alkylthio, C]-C 2 haloalkylthio, C2-C3 alkoxyalkyl, C 2 -C3 alkylcarbonyl, C 2 -C 3 alkoxycarbonyl,
  • Embodiment 21 A compound of Embodiment 20 wherein each R 4a is independently C 1 -C 3 alkyl, C 2 -C 3 alkenyl, C 2 -C 3 alkynyl, cyclopropyl, Cj-C 3 haloalkyl, C 2 -
  • Embodiment 22 A compound of Embodiment 21 wherein each R 4a is independently halogen, C 1 -C 3 alkyl, C 1 ⁇ -C 3 haloalkyl. C 1 -C 2 alkoxy or C 1 -C 2 haloalkoxy.
  • Embodiment 23 A compound of Embodiment 21 wherein each R 4a is independently halogen, Cj-C 2 alkyl, C 1 -C 2 haloalkyl or C 1 -C 2 alkoxy.
  • Embodiment 24 A compound of Embodiment 23 wherein each R 4a is independently
  • Embodiment 25 A compound of Embodiment 24 wherein each R 4a is independently C J-C 2 alkyl, trifluoromethyl, Cl or Br.
  • Embodiment 26 A compound of any one of Embodiments 12 and 13 wherein each R 4b is independently C 1 -C 3 alkyl, C 3 alkenyl (e.g., allyl), C 3 alkynyl (e.g., propargyl), cyclopropyl, C 1 -C 3 haloalkyl, C 3 haloalkenyl, C 3 haloalkynyl, halocyclopropyl or C 2 -C 3 alkoxyalkyl.
  • Embodiment 27 A compound of Embodiment 26 wherein each R 4b is independently
  • Embodiment 28 A compound of Embodiment 27 wherein each R 4b is independently
  • Embodiment 29 A compound of Embodiment 28 wherein each R 4b is independently
  • Embodiment 30 A compound of Embodiment 29 wherein each R 4b is independently
  • Embodiment 31 A compound of Embodiment 13 wherein k is 1 or 2 and at least one R 4 is Cl.
  • Embodiment 32 A compound of Embodiment 13 wherein k is 1 or 2 and at least one
  • R 4 is Br.
  • Embodiment 33 A compound of Embodiment 13 wherein k is 1 or 2 and at least one
  • R 4 is methyl.
  • Embodiment 34 A compound of Embodiment 13 wherein k is 1 or 2 and at least one
  • R 4 is ethyl.
  • Embodiment 35 A compound of Embodiment 13 wherein k is 1 or 2 and at least one
  • R 4 is trifluoromethyl.
  • Embodiment 36 A compound of Embodiment 13 wherein k is 1 or 2 and at least one
  • R 4 is methoxy.
  • Embodiment 37 A compound of Embodiment 18 wherein k is 1 and R 4 is connected to the 3- or 5-position of U-I.
  • Embodiment 38 A compound of Embodiment 18 wherein k is 2 and one R 4 is connected to the 3-position and the other R 4 is connected to the 5-position of U-I.
  • Embodiment 39 A compound of Embodiment 19 wherein k is 1 and R 4 is connected to the 2- or 3-position of U-50.
  • Embodiment 40 A compound of Embodiment 19 wherein k is 2 and one R 4 is connected to the 2-position and the other R 4 is connected to the 5-position of U-50.
  • Embodiment 41 A compound of Embodiment 19 wherein k is 2 and one R 4 is connected to the 2-position and the other R 4 is connected to the 5-position of U-50.
  • Embodiment 42 A compound of Embodiment 41 wherein G is one of G-I through G-59 depicted in Exhibit 2;
  • each R 3a is independently selected from H or R 3 ; and R 1 la is selected from H and R* *; provided that: when G is G-6, G-16 or G-42, and each R 3a is other than H, then R 1 la is H; when G is G-25 or G-31, then at least one R 3a is H; and when G is one of G-31 through G-35, then Z 1 is a direct bond or CHR 20 .
  • Embodiment 43 Embodiment 43.
  • G is selected from G-I through G-3, G-7, G-8, G-IO, G-Il 5 G-14, G-15, G-23, G-24, G-26 through G-28, G-30, G-36 through G-38 and G-49 through G-55.
  • Embodiment 44 A compound of Embodiment 43 wherein G is selected from G-I, G-2, G-7, G-8, G-14, G-15, G-23, G-24, G-26, G-27, G-36, G-37, G-38, G-49, G-50 and G-55.
  • Embodiment 45 A compound of Embodiment 44 wherein G is selected from G-I, G-2, G-15, G-26, G-27, G-36, G-37 and G-38.
  • Embodiment 46 A compound of Embodiment 45 wherein G is selected from G-I, G-2,
  • Embodiment 47 A compound of Embodiment 46 wherein G is G-I.
  • G is G-I.
  • Embodiment 48 A compound of Embodiment 46 wherein G is G-2. Of note are embodiments of these compounds within Embodiments 1 through 40, Embodiments 52 through 83, and Embodiments Al through A5.
  • Embodiment 49 A compound of Embodiment 46 wherein G is G- 15. Of note are embodiments of these compounds within Embodiments 1 through 40, Embodiments 52 through 83, and Embodiments Al through AS.
  • Embodiment 50 A compound of Embodiment 46 wherein G is G-26.
  • G is G-26.
  • Embodiment 51 A compound of Embodiment 46 wherein G is G-36. Of note are embodiments of these compounds within Embodiments 1 through 40, Embodiments 52 through 83, and Embodiments Al through A5.
  • Embodiment 52 A compound of any one of Embodiments 41 through 51 wherein R 3a is H, C 1 -C 3 alkyl or halogen.
  • Embodiment 53 A compound of Embodiment 52 wherein R 3a is H or methyl.
  • Embodiment 54 A compound of any one of Embodiments 41 through 51 wherein R 3a is H and R 1 ] a is H or methyl.
  • Embodiment 55 A compound of any one of Formula 1 and Embodiments 41 through
  • Embodiment 56 A compound of Formula 1 wherein J is one of J-I through J-82 depicted in Exhibit 3;
  • Embodiment 56a A compound of Embodiment 56 wherein J is one of J-29-1 through J- 29-58 depicted in Exhibit A;
  • Embodiment 57 A compound of Embodiment 56 wherein J is selected from J-I, J-2,
  • Embodiment 58 A compound of Embodiment 57 wherein J is selected from J-4, J-5, J-8, J-11, J-15, J-16, J-20, J-29, J-30, J-37, J-38, and J-69.
  • Embodiment 59 A compound of Embodiment 58 wherein J is selected from J-4, J-5,
  • Embodiment 60 A compound of Embodiment 59 wherein J is J-11.
  • Embodiment 61 A compound of Embodiment 59 wherein J is J-29.
  • Embodiment 61a A compound of Embodiment 61 wherein J is any one of J-29- 1 to J-29-58 (depicted with Table 8).
  • Embodiment 62 A compound of Embodiment 59 wherein J is J-69.
  • Embodiment 63 A compound of Embodiment 60 wherein the 3-position of J-11 is connected to Z 1 and the 5-position of J-11 is connected to R 5 other than H.
  • Embodiment 63a A compound of Embodiment 63 wherein the 3-position of J-11 is connected to Z 1 and the 5-position of J-11 is connected to Z 2 Q.
  • Embodiment 64 A compound of Embodiment 61 wherein the 3-position of J-29 is connected to Z 1 and the 5-position of J-29 is connected to R 5 other than H.
  • Embodiment 64a A compound of Embodiment 65 wherein the 3-position of J-29 is connected to Z 1 and the 5-position of J-29 is connected to Z 2 Q.
  • Embodiment 65 A compound of Formula 1 or Embodiment 56 wherein each R 5 is independently H, cyano, C 1 -Cg alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -Cg haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C 3 -C 8 cycloalkyl, C 3 -C 8 halocycloalkyl, C 4 -C 10 alkylcycloalkyl, C 4 -C 10 cycloalkylalkyl, C 2 -C 6 alkoxyalkyl, C 4 -C 10 cycloalkoxyalkyl, C 3 -Cg alkoxyalkoxyalkyl, C 2 -C 6 alkylthioalkyl, C 2 -C 6 alkoxycarbonyl, C 1 -C 6 alkoxy, C 1 -C 6 hal
  • each R ⁇ is independently H, cyano, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -Cg cycloalkyl, C 3 -C 8 halocycloalkyl, C 2 -C 6 alkoxyalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 3 -C 8 cycloalkoxy, C 2 - C 6 alkenyloxy, C 2 -C 6 haloalkenyloxy, C 2 -C 6 alkynyloxy, C 2 -C 6 alkoxyalkoxy, C 2 -C 6 alkylcarbonyloxy, C 2 -C 6 haloalkylcarbonyloxy, C 1 -C 6 alkylthio, C 1 -C 6 haloalkylthio, C 3 -C 10 trialkylsilyl, -NR 25 R 2 ⁇ or Z
  • Embodiment 67 A compound of Embodiment 66 wherein each R 5 is independently H, cyano, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, -NR 2 5R 2 6 or Z 2 Q.
  • Embodiment 68 A compound of Formula 1 or Embodiment 56 wherein one instance of R 5 is Z 2 Q and other instances of R 5 are independently selected from H, cyano, C 1 -C ⁇ alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkylcarbonyl and halogen.
  • Embodiment 69 A compound of Embodiment 68 wherein the other instances of R 5 are independently selected from H and C ⁇ - C 3 alkyl.
  • Embodiment 70 A compound of Embodiment 56 wherein x is 1 or 2.
  • Embodiment 71 A compound of Embodiment 70 wherein x is 1.
  • Embodiment 72 A compound of Embodiment 71 wherein R 5 is Z 2 Q.
  • Embodiment 73 A compound of Formula 1 wherein Z 1 is direct bond.
  • Embodiment 74 A compound of Formula 1 wherein Z 2 is direct bond.
  • Embodiment 75 A compound of Formula 1 wherein Q is one of Q-I through Q- 102 depicted in Exhibit 4;
  • Embodiment 76 A compound of Embodiment 75 wherein Q is selected from Q-I, Q-20, Q-32 through Q-34, Q-45 through Q-47, Q-60 through Q-73, Q-76 through Q-79, Q-84 through Q-94 and Q-98 through Q-102.
  • Embodiment 77 A compound of Embodiment 76 wherein Q is Q-I, Q-45, Q-63, Q-64,
  • Embodiment 78 A compound of Embodiment 77 wherein Q is Q-45, Q-63, Q-64, Q-65,
  • Embodiment 78a A compound of Embodiment 78 wherein Q is Q-45, Q-63, Q-65,
  • Embodiment 78b A compound of Embodiment 78 wherein Q is Q-45, Q-63, Q-65 or
  • Embodiment 79 A compound of Formula 1 or Embodiment 75 wherein each R 7 is independently C 1 -C 3 alkyl, C 1 - ⁇ haloalkyl, halogen, hydroxy, amino, cyano, nitro, C 1 -C 2 alkoxy or C 1 -C 2 haloalkoxy.
  • Embodiment 80 A compound of Embodiment 79 wherein each R 7 is independently
  • Embodiment 81 A compound of Embodiment 80 wherein each R 7 is independently methyl, F, Cl, Br, hydroxy, cyano or methoxy.
  • Embodiment 82c A compound of Formula 1 wherein when R 5 and R 7 are taken together with the atoms linking R 5 and R 7 to form an optionally substituted 5- to 7-membered ring, then R 5 and R 7 are taken together with the atoms linking R 5 and R 7 to form a 5- to 7-membered ring containing as ring members 2 to 7 carbon atoms and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 .
  • each R 8 is independently C 1 -C 6 alkyl, C 2 -Cg alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 0 4 -C 10 cycloalkylalkyl, C4-C 1 0 alkylcycloalkyl, C ⁇ -C I Q alkylcycloalkylalkyl, C 1 -Cg haloalkyl, C 2 -C 6 haloalkenyl, C 2 ⁇ Cg haloalkynyl, C3-C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C 1 -C 4 alkoxy, C 1 -C4 haloalkoxy, C 1 -C 4 alkylthio,
  • Embodiment 82d A compound of Embodiment 82b or 82c wherein the ring is optionally substituted on ring members other than the atoms linking R 5 and R 7 with up to 4 substituents selected from R 8 .
  • Embodiment 82e A compound of Embodiment 82d wherein the ring is optionally substituted on ring members other than the atoms linking R 5 and R 7 with up to 2 substituents selected from R 8 .
  • Embodiment 82f A compound of Embodiment 82b or 82c wherein each R 8 is independently C 1 -C 3 alkyl.
  • Embodiment 82h A compound of Embodiment 82c wherein when R 5 and R 7 are taken together with the atoms linking R 5 and R 7 to form an optionally substituted 5- to 7-membered ring, then R 5 and R 7 are taken together with the atoms linking R 5 and R 7 to form a 5- to 7-membered ring containing as ring members 2 to 7 carbon atoms and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1
  • each R 8 is C 1 -C 3 alkyl.
  • Embodiment 83 A compound of Formula 1 or Embodiment 75 wherein p is 0, 1 , 2 or 3.
  • Embodiment 84. A compound of Formula 1 wherein R 1 is an optionally substituted phenyl or 5- or 6-membered heteroaromatic ring.
  • Embodiment 85. A compound of Formula 1 wherein A is CH 2 or NH.
  • Embodiment 86. A compound of Formula 1 wherein X is selected from X 1 , X 2 , X 3 , X 4 ,
  • Embodiment 88 A compound of Formula 1 wherein J is a phenyl or 5- or 6-membered heteroaromatic ring, or a naphthalenyl or 8- to 11-membered heteroaromatic bicyclic ring system, each ring or ring system optionally substituted with 1 to 5 substituents independently selected from R 5 ; or J is a 5-, 6- or 7-membered nonaromatic ring, an 8- to 11-membered nonaromatic bicyclic or a 7- to 11- menibered spirocyclic ring system, each ring or ring system optionally including
  • each R 5 is independently H, C 1 - C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 4 -C 10 cycloalkylalkyl, C 4 -C 10 alkylcycloalkyl, Cs-C 10 alkylcycloalkylalkyl, C 1 -C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C 3 -C 6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfmyl, C 1 -C 6 alkylsulfonyl, C 1 -C 6 hal
  • each Q is independently an optionally substituted phenyl, benzyl, naphthalenyl, C 3 -Cg cycloalkyl, C 3 -Cg cycloalkenyl or 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents selected from R 7 on carbon ring members and R 12 on nitrogen ring members.
  • Embodiment 90a is independently an optionally substituted phenyl, benzyl, naphthalenyl, C 3 -Cg cycloalkyl, C 3 -Cg cycloalkenyl or 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents selected from R 7 on carbon ring members and R 12 on nitrogen ring members.
  • Embodiment 95 A compound of Formula 1 wherein when G is an optionally substituted thiazole ring connected at its 2-position to X and at its 4-position to Z 1 in Formula 1, A is C
  • Z 1 in Formula 1 A is CHR 15 , Z 1 is a direct bond, and J is an optionally substituted isoxazole ring, then J is connected to the remainder of the Formula 1 at the 3- or 5-position of the isoxazole ring.
  • Embodiment 96 A compound of Formula 1 wherein when G is an optionally substituted thiazole ring connected at its 2-position to X and at its 4-position to
  • Z 1 in Formula 1 A is CHR 15 , Z 1 is a direct bond, and J is an optionally substituted isoxazole ring, then J is connected to the remainder of the Formula 1 at the 3-position of the isoxazole ring.
  • Embodiment 97 A compound of Formula 1 wherein when G is an optionally substituted thiazole ring connected at its 2-position to X and at its 4-position to Z 1 in Formula 1, Z 1 is a direct bond, and J is an optionally substituted isoxazole ring, then J is connected to the remainder of the Formula 1 at the 3 -position of the isoxazole ring.
  • Embodiment 98 A compound of Formula 1 wherein when X is X 2 and the ring containing X is saturated, A is CHR 15 , G is an optionally substituted 5- membered heteroaromatic ring, Z 1 is a direct bond, and J is a phenyl or 5- or 6- membered heteroaromatic ring or a naphthalenyl or 8- to 11-membered heteroaromatic bicyclic ring system, then the J ring or ring system is substituted with at least one R 5 that is other than H.
  • Embodiment 99 A compound of Formula 1 wherein when X is X 2 and the ring containing X is saturated, A is CHR 15 , G is an optionally substituted 5- membered heteroaromatic ring, Z 1 is a direct bond, and J is a phenyl or 5- or 6- membered heteroaromatic ring or a naphthalenyl or 8- to 11-membered heteroaromatic bicyclic ring system, then the J ring or ring system is substituted with at least one R 5 that is Z 2 Q.
  • Embodiment 100 Embodiment 100.
  • a compound of Formula 1 wherein when X is X 1 and the ring containing X is saturated, A is NH, G is an optionally substituted thiazole ring connected at its 2-position to X and at its 4-position to Z 1 in Formula 1, and J is an optionally substituted imidazole ring connected at its 2-position to the remainder of Formula 1, then Z 1 is O, C( O), S(O) 1n , CHR 20 or NR 21 .
  • a compound of Formula 1 wherein when X is X 1 and the ring containing X is saturated, A is NR 16 , G is an optionally substituted thiazole ring connected at its 2-position to X and at its 4-position to Z 1 in Formula 1, and J is an optionally substituted imidazole ring connected at its 2-position to the remainder of Formula 1, then Z 1 is O, C( O), S(O) m , CHR 20 or NR 21 .
  • Embodiment 102 A compound of Formula 1 wherein when G is an optionally substituted thiazole ring connected at its 2-position to X and at its 4-position to Z 1 in Formula 1, then J is other than optionally substituted imidazolyl.
  • Embodiment 103 A compound of Formula 1 wherein each Z 4 is independently C( 111 O) or S(O) 2 -
  • Embodiment 105. A compound of Formula 1 wherein each R 2 is independently C 1 -C 4 alkyl, C 1 -C 4 alkenyl, C 1 -C 4 haloalkyl, C 1 -
  • Embodiment Al A compound of Formula 1 wherein
  • G is a 5-membered heteroaromatic ring or 5-membered saturated or partially saturated heterocyclic ring, each ring optionally substituted with up to 2 substituents selected from R 3 on carbon ring members and selected from R 11 on nitrogen ring members;
  • R 1 is a phenyl or 5- or 6-membered heteroaromatic ring optionally substituted with 1 to 2 substituents independently selected from R 4a on carbon ring members and R 4b on nitrogen ring members; each R 2 is independently C 1 -C 2 alkyl, C 1 -C 2 haloalkyl, C 1 -C 2 alkoxy, halogen, cyano or hydroxy; each R 3 is independently C 1 -C 3 alkyl, C 1 -C 3 haloalkyl or halogen; each R 4a is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 - C 6 cycloalkyl, C 4 -C 10 cycloalkylalkyl, C 4 -C 10 alkylcycloalkyl, C 5 - C 10 alkylcycloalkylalkyl, C 1 -C 6 haloalkyl, C 2 ⁇ -
  • -C 6 haloalkyl C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C 3 -C 6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C 4 alkoxy, C 1 -C 4 haloalkoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, C 1 -C 4 haloalkylthio, C 1 -C 4 haloalkylsulfinyl, C 1 -C 4 haloalkylsulfonyl, C ] -C 4 alkylamino, C 2 -Cg dialkylamino, C 3 -C 6 cycloalkylamino, C 2 -C 4 alkoxyalkyl, C 1 - ⁇ hydroxyalkyl, C
  • Embodiment A2 A compound of Embodiment Al wherein
  • G is one of G-I through G-59 (as depicted in Exhibit 2) wherein the band projecting to the left is bonded to X, and bond projecting to the right is bonded to Z 1 ;
  • J is one of J-I through J-82 (as depicted in Exhibit 3) wherein the bond shown projecting to the left is bonded to Z 1 ;
  • Q is one of Q-I through Q- 102 (as depicted in Exhibit 4);
  • each R 5 is independently H, cyano, C 1 -C 6 aUkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, C 2 -C 6 haloalkeny
  • R 15 is H, cyano, hydroxy, methyl or methoxycarbonyl
  • R 16 is H, methyl, methylcarbonyl or methoxycarbonyl
  • k is 0, 1 or 2
  • p is 0, 1, 2 or 3
  • x is an integer from 0 to 5; provided that:
  • R 4 when R 4 is attached to a carbon.ring member, said R 4 is selected from R4a ; (b) when R 4 is attached to a nitrogen ring member (e.g., in U-4, U-I l through
  • R 4 is selected from R 4b ;
  • Embodiment A3 A compound of Embodiment A2 wherein
  • G is selected from G-I, G-2, G-7, G-8, G-14, G-15, G-23, G-24, G-26, G-27,
  • G-36 G-37. G-38, G-49, G-50 and G-55;
  • J is selected from J-I, J-2 S J-3, J-4, J-5, J-7, J-8, J-9, J-10, J-Il, J-12, J-14, J- • 15, J-16, J-20, J-24, J-25, J-26, J-29, J-30, J-37, J-38, J-45 and J-69; each Q is independently Q-I, Q-20, Q-32 through Q-34, Q-45 through Q-47, Q-60 through Q-73, Q-76 through Q-79, Q-84 through Q-94 and Q-98 through Q-102; A is CH 2 or NH; W is O;
  • each R 5 is independently H, cyano, Cj-Cg alkyl, C 1 -Cg haloalkyl, C 3 -Cg cycloalkyl, C 3 -C 8 halocycloalkyl, C 2 -C 6 alkoxyalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 3 -Cg cycloalkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 haloalkenyloxy, C 2 -Cg alkynyloxy, C 2 -C 6 alkoxyalkoxy, C 2 -C 6 alkylcarbonyloxy, C 2 -C 6 haloalkylcarbonyloxy, C 1 -C 6 alkylthio, C 1 - C 6 haloalkylthio, C 3 -C 10 trialkylsilyl, -NR 2
  • Rl is selected from U-I through U-3, U-11, U-13, U-20, U-22, U-23, U-36 through U-39 and U-50; each R 3 is independently methyl or halogen; each R 4a is independently C 1 -C 2 alkyl, C1-C2 haloalkyl, halogen, C 1 -C 2 alkoxy or C 1 -C 2 haloalkoxy; each R 4b is independently C 1 -C 2 alkyl or C 1 -C 2 haloalkyl; each R 7 is independently halogen, cyano, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, hydroxy, C 1 -C 2 alkoxy or C 1 -C 2 haloalkoxy; k is l or 2; and n is 0.
  • Embodiment A3 compounds wherein one R 5 is Z 2 Q and any other R 5 substituents are independently selected from H, C 1 -C6 alkyl, C 1 -Cg haloalkyl, C 3 -Cg cycloalkyl, C 3 -Cg halocycloalkyl, C 2 -Cg alkoxyalkyl, C 1 -Cg alkoxy, C 1 -Cg haloalkoxy, C 3 -Cs cycloalkoxy, C 2 -Cg alkenyloxy, C 2 -Cg haloalkenyloxy, C 2 -Cg alkynyloxy, C 2 -Cg alkoxyalkoxy, C 2 -Cg alkylcarbonyloxy, C 2 -Cg haloalkylcarbonyloxy, C 1 -Cg alkylthio, C 1 - C 6 haloalkylthio, C 3 -C 10 trialkylsily
  • Embodiment A3 compounds wherein all R 5 substituents are other than Z 2 Q are independently selected from H, C 1 -Cg alkyl, C 1 -Cg haloalkyl, C 3 -Cg cycloalkyl, C 3 -Cg halocycloalkyl, C 2 -C 6 alkoxyalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 3 -C 8 cycloalkoxy, C 2 -C 6 alkenyloxy, C 2 -Cg haloalkenyloxy, C 2 -Cg alkynyloxy, C 2 -Cg alkoxyalkoxy, C 2 -Cg alkylcarbonyloxy, C 2 -Cg haloalkylcarbonyloxy, C 1 -Cg alkylthio, C 1 -Cg haloalkylthio, C 3 -
  • Embodiment A4 A compound of Embodiment A3 wherein A is CH 2 ;
  • G is selected from G-I, G-2, G-15, G-26, G-27, G-36, G-37 and G-38; and G is unsubstituted;
  • J is selected from J-4, J-5, J-8, J-Il, J-15, J-16, J-20, J-29, J-30, J-37, J-38, . and 3-69;
  • Q is selected from Q-I, Q-45, Q-63, Q-64, Q-65, Q-68, Q-69, Q-70, Q-71, Q-
  • X is X 1 or X 2 ; and the ring comprising X is saturated; RUs U-I or U-50; each R 4a is independently C 1 -C 2 alkyl, trifluoromethyl, Cl, Br 3 1 or methoxy; each R 4b is independently C 1 -C 2 alkyl or trifluoromethyl; and each R 5 is independently H, cyano, C 1 -Cg alkyl, C 1 -Cg haloalkyl, C 1 -Cg alkoxy, C 1 -C 6 haloalkoxy, -NR 25 R 26 or Z 2 Q.
  • G is selected from G-I, G-2, G-15, G-26 and G-36; J is selected from J-4, J-5. J-I l, J-20, J-29, J-37, J-38, and J-69; Q is selected from Q-45, Q-63, Q-64, Q-65, Q-68, Q-69, Q-70, Q-71, Q-72 and Q-85; and
  • X is X 1 .
  • Embodiment A6 A compound of Formula 1 wherein
  • R 1 is an optionally substituted phenyl or 5- or 6-membered heteroaromatic ring;
  • A is CH 2 or NH;
  • R2 1 is H or C 1 -C 3 alkyl.
  • Embodiment A7 A compound of Embodiment A6 wherein
  • G is a 5 -membered heteroaromatic ring or 5 -membered saturated or partially saturated heterocyclic ring, each ring optionally substituted with up to 2 substituents selected from R 3 on carbon ring members and selected from R 1 J on nitrogen ring members;
  • R 1 is a phenyl or 5- or 6-membered heteroaromatic ring optionally substituted with 1 to 2 substituents independently selected from R 4a on carbon ring members and R 4b on nitrogen ring members; each R 3 is independently C 1 -C 3 alkyl, C 1 -C 3 haloalkyl or halogen; each R 4a is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 - C 6 cycloalkyl, C 4 -C 10 cycloalkylalkyl, C 4 -C 10 alkylcycloalkyl, C 5 - C 10 alkylcycloalkylalkyl, C 1 -C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C3-C5 halocycloalkyl, halogen, hydroxy, amino, cyan
  • Embodiment A8 A compound of Embodiment A7 wherein
  • G is one of G-I through G-55 (as depicted in Exhibit 2) wherein the bond projecting to the left is bonded to X, and bond projecting to the right is bonded to Z 1 ;
  • J is one of J-I through J-82 (as depicted in Exhibit 3) wherein the bond shown projecting to the left is bonded to Z 1 ;
  • Q is one of Q-I through Q-55 (as depicted in Exhibit 4);
  • R 1 is one of U-I through U-50 (as depicted in Exhibit 1); each R 3a is independently selected from H and R 3 ;
  • R 1 la is selected from H and R 11 ; k is 0, 1 or 2; p is 0, 1 or 2; and x is an integer from 0 to 5; provided that:
  • R 4 when R 4 is attached to a carbon ring member, said R 4 is selected from R 4a ; (b) when R 4 is attached to a nitrogen ring member (e.g., in U-4, U-I l through
  • R 4 is selected from R 4b ;
  • X is X 1 , X 2 or X 3 ; each Z 1 and Z 2 is a direct bond; RMs selected from U-I through U-3, U-Il, U-13, U-20, U-22, U-23, U-36 through U-39 and U-50; each R 3 is independently methyl or halogen; each R 4a is independently C 1 -C 2 alkyl, C 1 -C 2 haloalkyl, halogen or C 1 -C 2 alkoxy; each R 4b is independently C 1 -C 2 al ⁇ Y 1 or C l -Qz haloalkyl; one instance of R 5 is Z 2 Q and other instances of R 5 are independently selected from H, C J -C 4 alkyl, C J -C 4 haloalkyl and halogen; each R 7 is independently halogen, C 1 -C 3 alkyl, Cj-C 3 haloalkyl, hydroxy,
  • Embodiment Al 0. A compound of Embodiment A9 wherein A is CH 2 ;
  • G is selected from G-I, G-2, G-15, G-26, and G-36; and G is unsubstituted; J is selected from J-Il, J-25, J-26, J-29 and J-30;
  • Q is selected from Q-I and Q-45; X is X 1 or X 2 ; and the ring comprising X is saturated; Rl is U-I or U-50; each R 4a is independently C 1 -C 2 alkyl, trifluoromethyl, Cl, Br, I or methoxy; and each R 4b is independently Cj-C 2 alkyl or trifluoromethyl.
  • Embodiment Al 1. A compound of Embodiment AlO wherein J is selected from J-11 and J-29; X is Xl; and each R 4a is independently C 1 -C 2 alkyl, trifluoromethyl or Cl.
  • Embodiment A 12. A compound of Formula 1 wherein
  • R 1 is U-I or U-50 (as depicted in Exhibit 1) wherein when R 4 is attached to a carbon ring member, said R 4 is selected from R 4a , and when R 4 is attached to a nitrogen ring member, said R 4 is selected from R 4b ; each R 4a is independently C 1 -C2 alkyl, trifluoromethyl, Cl, Br, I or methoxy; each R 4b is independently C ] - C 2 alkyl or trifluoromethyl; A is CH 2 ; W is O;
  • X is X 1 or X 2 and ring comprising X is saturated; each R 2 is independently ethyl, methoxy, cyano or hydroxy;
  • G is selected from G-I, G-2, G- 15, G-26 and G-36 (as depicted in Exhibit 2) wherein the bond projecting to the left is bonded to X, and bond projecting to the right is bonded to Z 1 ; and G is unsubstituted; each R 3a is independently selected from H and R 3 ; each R 3 is independently methyl or halogen; J is selected from J-11, J-25, 3-26, J-29 and J-30 (as depicted in Exhibit 3); wherein the bond shown projecting to the left is bonded to Z 1 ; each R 5 is independently H, halogen, cyano, hydroxy, amino, nitro, -CHO,
  • R 25 is H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, C 2 -C 6 alkylcarbonyl, C 2 -C 6 haloalkylcarbonyl, C2-C 6 alkoxycarbonyl or C 2 - C 6 haloalkoxycarbonyl;
  • R 26 is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, C 2 -C 6 alkylcarbonyl, C 2 -C 6 haloalkylcarbonyl, C 2 -C 6 alkoxycarbonyl, C 2 -C 6 haloalkoxycarbonyl or -Z 4 Q; each Q is selected from Q-I, Q-45 and Q-63 (as depicted in Exhibit 4); each R 7 is independently C 1 -C 6 alkyl, C 2 -C 6 alkeny
  • each R 8 is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 4 -C 10 cycloalkylalkyl, C 4 -C 10 alkylcycloalkyl, C 5 -C 10 alkylcycloalkylalkyl, C 1 -C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C 3 -C 6 halocycloalkyl, halogen, hydroxy, amino, cyano
  • Embodiments of the present invention also include: Embodiment Bl.
  • Embodiment B2 A compound of Embodiment Bl wherein each R 4al and R 4a2 is independently C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, halogen, cyano, C 1 -C 2 alkoxy or ' C 1 -C 2 haloalkoxy.
  • Embodiment B3 A compound of Embodiment B2 wherein each R 4al and R 4a2 is independently C 1 -C 3 alkyl, C 1 -C 3 haloalkyl or halogen.
  • Embodiment B4 A compound of Formula IA wherein A a is H.
  • Embodiment B5. A compound of Formula IA wherein A a is CH 2 CO 2 H.
  • Embodiment B6 A compound of Formula IA wherein A a is CH 2 CO 2 R 30 .
  • Embodiment B7 A compound of Formula IA wherein A a is CH 2 C( ⁇ O)Cl.
  • each R 4al and R 4a2 is independently C 1 -C 3 alkyl, C 2 -C 3 alkenyl, C 2 -C 3 alkynyl, cyclopropyl, C 1 -C 3 haloalkyl, halocyclopropyl, halogen, cyano, nitro, C 1 -C 2 alkoxy or C 1 -C 2 haloalkoxy.
  • Embodiment B9 A compound of Embodiment B8 wherein each R 4al . and R 4a2 is independently C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, halogen, cyano, C 1 -C 2 alkoxy or
  • Embodiment BlO A compound of Embodiment B9 wherein each R 4al and R 4a2 is independently C 1 -C 3 alkyl, C 1 -C 3 haloalkyl or halogen.
  • Embodiment Bl 1. A compound of Formula IB wherein Z 3 is CN.
  • J-29 can be present in two or more enantiomeric forms.
  • the enantiomeric forms of J-29 embodiments for compounds of Formula 1C of this invention are those depicted about in the Exhibit A above. All J-29 enantiomers are included in the Formula 1C compounds in this invention for embodiments where no specific J-29 enantiomeric form is depicted (e.g., J-29-33 enantiomers and J-29-22 enantiomers based on the methyl group position).
  • Embodiment Bl 3 3.
  • Specific embodiments include compounds of Formula 1 selected from the group consisting of: 4-[4-[(5/.)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-l-[[5-methyl-3-
  • Specific embodiments also include compounds of Formula IB selected from the group consisting of: l-[2-[5-methyl-3-(trifluoromethyl)-lH-pyrazol-l-yl]acetyl]-4- piperidinecarbothioamide, l-[2-[3,5-bis(trifluoromemyl)-lH-pyrazol-l-yl]acetyl]-4-piperidmecarbotbioamide : , 1 -[2-[5-methyl-3-(trifluoromethyl)- l ⁇ f-pyrazol- 1 -yl]acetyl] -4-piperidinecarbonitrile, and l-[2-[3,5-bis(trifluoromethyl)-lH-pyrazol-l-yl]acetyl]-4-piperidinecarbonitrile.
  • R 1 is an optionally substituted phenyl or 5- or 6-membered heteroaromatic ring;
  • A is CH 2 or NH;
  • R 5 and R 7 are taken together with the atoms linking R ⁇ and R 7 to form an optionally substituted 5- to 7-membered ring containing as ring members 2 to 7 carbon atoms and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and up to 1 N;
  • R 12 is C 1 -C 3 alkyl; each Zl and Z 2 is independently a direct bond, O, S(O) m , CHR 20 or NR 21 ; R 21 is H or C 1 -C 3 alkyl; and m is 0, 1 or 2 (which is understood to mean that each m is independently 0, 1 or 2). Also of note are compounds of Formula 1, including all geometric and stereoisomers,
  • R 5 and R 7 are taken together with the atoms linking R 5 and R 7 to form an optionally substituted 5- to 7-membered ring containing as ring members 2 to 7 carbon atoms and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S, up to 1 Si and up to 1 N; and
  • R12 is C 1 -C 3 alkyl.
  • This invention provides a fungicidal composition comprising a compound of Formula 1 (including all geometric and stereoisomers, 2V-oxides, and salts thereof), and at least one other fungicide.
  • compositions comprising a compound corresponding to any of the compound embodiments described above.
  • This invention provides a fungicidal composition comprising a fungicidally effective amount of a compound of Formula 1 (including all geometric and stereoisomers, iV-oxides, and agriculturally suitable salts thereof), and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents.
  • embodiments of such compositions are compositions comprising a compound corresponding to any of the compound embodiments described above.
  • This invention provides a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of a compound of Formula 1 (including all geometric and stereoisomers, iV-oxides, and agriculturally suitable salts thereof).
  • a compound of Formula 1 including all geometric and stereoisomers, iV-oxides, and agriculturally suitable salts thereof.
  • embodiment of such methods are methods comprising applying a fungicidally effective amount of a compound corresponding to any of the compound embodiments describe above.
  • the compounds are applied as compositions of this invention.
  • the compounds of Formulae 1, IA, IB and 1C can be prepared by one or more of the following methods and variations as described in Schemes 1—20.
  • the definitions of A, G, J, W, X, Q, Z 1 , R 1 , R 2 , R 15 , R 16 and n in the compounds of Formulae 1-38 below are as defined above in the Summary of the Invention unless otherwise noted.
  • Formulae Ia-Ie and Formulae IBa and IBb are various subsets of Formula 1 and IB respectively.
  • compounds of Formula Ia (Formula 1 wherein A is CHR 15 ) wherein W is O can be prepared by coupling of an acid chloride of Formula 2 with an amine of Formula 3 in the presence of an acid scavenger.
  • Typical acid scavengers include amine bases such as triethylamine, N ⁇ -diisopropylethylamine and pyridine.
  • Other scavengers include hydroxides such as sodium and potassium hydroxide and carbonates such as sodium carbonate and potassium carbonate.
  • polymer-supported acid scavengers such as polymer-bound ⁇ V-diisopropylethylamine and polymerf bound 4-(dimethylamino)pyridine.
  • Acid salts of the Formula 3 amines can also be used in this reaction, provided that at least 2 equivalents of the acid scavenger is present.
  • Typical acids used to form salts with amines include hydrochloric acid, oxalic acid and trifluoroacetic acid.
  • amides of Formula Ia wherein W is O can be converted to thioamides of Formula Ia wherein W is S using a variety of standard thiating reagents such as phosphorus pentasulfide or 2,4-bis(4-methoxyphenyl)-l,3-dithia-2,4- diphosphetane-2,4-disulfide (Lawesson's reagent).
  • R 1 CB ⁇ COOH where R 1 is a heteroaromatic ring linked through nitrogen can be prepared by reacting the corresponding R 1 H compound with a haloacetic acid or ester in the presence of base; see, for example, U.S. Patent 4,084,955.
  • R 1 CBD 2 COOH wherein R 1 is a phenyl or a heteroaromatic ring linked through carbon can be prepared from the corresponding R 1 CH2-halogen compounds by displacement of the halogen with cyanide followed by hydrolysis; see, for example, K. Adachi, YuM Gosei Kagaku Kyokaishi 1969, 27, 875-876; from R 1 C( ⁇ O)CH 3 by the Willgerodt-Kindler reaction; see, for example, H. R. Darabi et al., Tetrahedron Letters 1999, 40, 7549-7552 and M. M. Alam and S. R. Adapa, Synthetic Communications 2003, 33, 59-
  • Certain compounds of Formula Ib (Formula 1 wherein A is CHR 15 and W is O) wherein R 1 is a 5-membered nitrogen-containing heteroaromatic ring linked through the nitrogen atom can be prepared by reaction of the parent heterocycle of Formula 5 and a haloacetamide of Formula 6 as shown in Scheme 3. The reaction is carried out in the presence of a base such as sodium hydride or potassium carbonate in a solvent such as tetrahydrofuran, iV ⁇ V-dimethylformamide or acetonitrile at 0 to 80 0 C.
  • a base such as sodium hydride or potassium carbonate
  • a solvent such as tetrahydrofuran, iV ⁇ V-dimethylformamide or acetonitrile at 0 to 80 0 C.
  • the haloacetamide of Formula 6 can be prepared by the reaction of an amine of Formula 3 with an ⁇ -halo carboxylic acid halide or an ⁇ -halo carboxylic acid or its anhydride, analogous to the amide- forming reactions described in Schemes 1 and 2, respectively.
  • Scheme 3
  • R 1 is a 5-membered nitrogen-containing heteroaromatic ring unsubstituted on N; and Y 1 is Cl, Br or I.
  • Compounds of Formulae Ic (Formula 1 wherein A is NH), wherein R 1 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, and W is O or S, can be prepared by reaction of an amine of Formula 3 with an isocyanate or isothiocyanate, respectively, of
  • the carbamoyl or thiocarbamoyl chlorides of Formula 9 can be prepared from amines of Formula 3 by treatment with phosgene or thiophosgene, respectively, or their equivalents, while carbamoyl or thiocarbamoyl imidazoles of Formula 9 (wherein Y is imidazol-1-yl) can be prepared from amines of Formula 3 by treatment with l,l'-carbonyldiimidazole or l,r-thiocarbonyldiimidazole, respectively, according to general methods known to one skilled in the art.
  • W is O or S; and Y is Cl or imidazol-1-yl.
  • Certain compounds of Formula Id can be prepared from compounds of Formula Ie where the ring containing X is unsaturated by catalytic hydrogenation as shown in Scheme 6.
  • Typical conditions involve exposing a compound of Formula Ie to hydrogen gas at a pressure of 70 to 700 kPa, preferably 270 to 350 kPa, in the presence of a metal catalyst such as palladium supported on an inert carrier such as activated carbon, in a weight ratio of 5 to 20 % of metal to carrier, suspended in a solvent such as ethanol at an ambient temperature.
  • a metal catalyst such as palladium supported on an inert carrier such as activated carbon
  • Certain compounds of Formula 1 wherein X is X 1 , X 5 , X 7 or X 9 , and G is linked to the ring containing X via a nitrogen atom, can be prepared by displacement of an appropriate leaving group Y 2 on the ring containing the X of Formula 10 with a nitrogen-containing heterocycle of Formula 11 in the presence of a base as depicted in Scheme 7.
  • Suitable bases include sodium hydride or potassium carbonate, and the reaction is carried out in a solvent such as iVjAT-dimethylfprmamide or acetonitrile at 0 to 80 0 C.
  • Suitable leaving groups in the compounds of Formula 10 include bromide, iodide, mesylate (OS(O) 2 CH 3 ), triflate
  • W is O or S;
  • X is X 1 , X 5 , X 7 or X 9 ; and
  • Y 2 is a leaving group such as Br, I, OS(O) 2 Me or OS(O) 2 CF 3 .
  • Compounds of Formula 1 wherein X is X 2 or X 8 can be prepared by reaction of a compound of Formula 12 with a heterocyclic halide or triflate (OS(O) 2 CF 3 ) of Formula 13 as shown in Scheme 8. The reaction is carried out in the presence of a base such as potassium carbonate in a solvent such as dimethylsulfoxide, Ny/V-dimethylformamide or acetonitrile at 0 to 80 °C.
  • a base such as potassium carbonate
  • a solvent such as dimethylsulfoxide, Ny/V-dimethylformamide or acetonitrile at 0 to 80 °C.
  • Compounds of Formula 13 wherein Y 2 is triflate can be prepared from corresponding compounds wherein Y 2 is OH by methods known to one skilled in the art. 14647
  • the amine compounds of Formula 3 can be prepared from the protected amine compounds of Formula 14 where Y 3 is an arnine-protecting group as shown in Scheme 9.
  • Y 3 is an arnine-protecting group as shown in Scheme 9.
  • a wide array of amine-protecting groups are available (see, for example, T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2nd ed.; Wiley: New York, 1991), and the use and choice of the appropriate protecting groups will be apparent to one skilled in chemical synthesis.
  • the protecting group can be removed and the amine isolated as its acid salt or the free amine by general methods known in the art.
  • the compounds of Formula 14 can also be prepared by reaction of a suitably functionalized compound of Formula 15 with a suitably functionalized compound of Formula 16 as shown in Scheme 10.
  • the functional groups Y 4 and Y 5 are selected from, but not limited to, moieties such as aldehydes, ketones, esters, acids, amides, thioamides, nitriles, amines, alcohols, thiols, hydrazines, oximes, amidines, amideoximes, olefins, acetylenes, halides, alkyl halides, methanesulfonates, trifluoromethanesulfonates, boronic acids, boronates, and the like, which under the appropriate reaction conditions, will allow the construction of the various heterocyclic rings G.
  • reaction of a compound of Formula 15 where Y 4 is a thioamide group with a compound of Formula 16 where Y 5 is a bromoacetyl group will give a compound of Formula 14 where G is a thiazole ring.
  • the synthetic literature describes many general methods for forming 5-membered heteroaromatic rings and 5-membered partially saturated heterocyclic rings (e.g., G-I through G-59); see, for example, Comprehensive Heterocyclic Chemistry, Vol. 4-6, A. R. Katritzky and C. W. Rees editors, Pergamon Press, New York, 1984; Comprehensive Heterocyclic Chemistry II, Vol. 2-4, A. R. Katritzky, C. W. Rees, and E. F.
  • Y 4 and Y 5 are functional groups suitable for construction of the desired heterocycle G.
  • Certain compounds of Formula 14 where Z 1 is O, S, or NR 21 can be prepared by displacement of an appropriate leaving group Y 2 on G of Formula 17 with a compound of Formula 18 in the presence of a base as depicted in Scheme 11.
  • Suitable bases include sodium hydride or potassium carbonate, and the reaction is carried out in a solvent such as ⁇ iV-dimethylformamide or acetonitrile at 0 to 80 0 C.
  • Suitable leaving groups in the compounds of Formula 17 include bromide, iodide, mesylate (OS(O) 2 CH 3 ), triflate (OS(O) 2 CF 3 ) and the like.
  • Compounds of Formula 17 can be prepared from corresponding compounds wherein Y 2 is OH by general methods known in the art. Many of the compounds of Formula 18 are known or can be prepared by general methods known in the art.
  • Y 2 is a leaving group such as Br, I, OS(O) 2 Me or OS(O) 2 CF 3 ; and Z 1 is O 5 S or NR 2 1.
  • Certain compounds of Formula 14 where Z 1 is O, S, or NR 21 can also be prepared by displacement of an appropriate leaving group Y 2 on J of Formula 20 with a compound of Formula 19 in the presence of a base as depicted in Scheme 12.
  • Suitable bases include sodium hydride or potassium carbonate, and the reaction is carried out in a solvent such as
  • Suitable leaving groups in the compounds of Formula 20 include bromide, iodide, mesylate (OS(O) 2 CH3), triflate
  • Y 2 is a leaving group such as Br, I, OS(O) 2 Me or OS(O) 2 CF 3 ; and Z 1 is O, S or NR 21 .
  • Compounds of Formula 14 can also be prepared by reaction of a suitably functionalized compound of Formula 21 with a suitably functionalized compound of Formula 22 as shown in Scheme 13.
  • the functional groups Y 6 and Y 7 are selected from, but not limited to, moieties such as aldehydes, ketones, esters, acids, amides, thioamides, nitriles, amines, alcohols, thiols, hydrazines, ⁇ ximes, amidines, amide oximes, olefins, acetylenes, halides, alkyl halides, methanesulfonates, trifluoromethanesulfonates, boronic acids, boronates, and the like, which, under the appropriate reaction conditions will allow the construction of the various heterocyclic rings J.
  • moieties such as aldehydes, ketones, esters, acids, amides, thioamides, nitriles, amines, alcohols, thiols, hydrazines, ⁇ ximes, amidines, amide oximes, olefins, acetylenes,
  • reaction of a compound of Formula 21 where Y 6 is a chloro oxime moiety with a compound of Formula 22 where Y 7 is a vinyl or acetylene group in the presence of base will give a compound of Formula 14 where J is an isoxazoline or isoxazole, respectively.
  • the synthetic literature includes .many general methods for the formation of carbocyclic and heterocyclic rings and ring systems (for example, J-I through J-82); see, for example, Comprehensive Heterocyclic Chemistry, Vol. 4-6, A. R. Katritzky and C. W. Rees editors, Pergamon Press, New York, 1984; Comprehensive Heterocyclic Chemistry II, Vol. 2—4, A. R. Katritzky, C. W.
  • Y 6 and Y 7 are functional groups suitable for construction of the desired heterocycle J.
  • An alternate preparation for the compounds of Formula 14 where Z 1 is a bond includes the well known Suzuki reaction involving Pd-catalyzed cross-coupling of an iodide or bromide of Formula 23 or 26 with a boronic acid of Formula 24 or 25, respectively, as shown in Scheme 14.
  • Many catalysts are useful for this type of transformation; a typical catalyst is tetrakis(triphenylphosphine)palladium.
  • Solvents such as tetrahydrofuran, acetonitrile, diethyl ether and dioxane are suitable.
  • the Suzuki reaction and related coupling procedures offer many alternatives for creation of the G-J bond.
  • Thioamides of Formula IBb are particularly useful intermediates for preparing compounds of Formula 1 wherein X is X 1 .
  • a thioamide of Formula IBb can be prepared by the addition of hydrogen sulfide to the corresponding nitrile of Formula IBa as shown in Scheme 15.
  • the method of Scheme 15 can be carried out by contacting a compound of Formula IBa with hydrogen sulfide in the presence of an amine such as pyridine, diethylamine or diethanolamine.
  • hydrogen sulfide can be used in the form of its bisulfide salt with an alkali metal or ammonia. This type of reaction is well documented in the literature (e.g., A. Jackson et al., EP 696,581 (1996)).
  • Certain compounds of Formula IBa wherein R 1 is a 5-rnembered nitrogen-containing heteroaromatic ring linked through a nitrogen atom can be prepared by reaction of the parent heterocycle of Formula 5 and a haloacetamide of Formula 27 as shown in Scheme 16. The reaction is carried out in the presence of a base such as sodium hydride or potassium carbonate in a solvent such as tetrahydrofuran, iV ⁇ -dimethylfo ⁇ narnide or acetonitrile at 0 to 80 0 C.
  • a base such as sodium hydride or potassium carbonate
  • a solvent such as tetrahydrofuran, iV ⁇ -dimethylfo ⁇ narnide or acetonitrile at 0 to 80 0 C.
  • R 1 is a 5-membered nitrogen-containing heteroaromatic ring unsubstituted on N (i.e. a 5-membered heteroaromatic ring comprising a ring member of the formula -(NH)-); and Y 1 is Cl, Br or I.
  • haloacetamides of Formula 27 can be prepared by the two methods shown rn Scheme 17.
  • 4-cyanopiperidine of Formula 29 is haloacetylated by contact with the appropriate haloacetyl chloride typically in the presence of a base according to standard methods.
  • Preferred conditions involve use of an aqueous solution of an inorganic base such as an alkali metal or alkaline-earth carbonate, bicarbonate, or phosphate, and a non-water- miscible organic solvent such as toluene, ethyl acetate or 1,2-dichloroethane.
  • a particularly preferred solvent for this transformation is an ⁇ V-dialkylamide such as iVyV-dimethylformamide.
  • the reaction is typically carried out by adding 0.9 to 2 equivalents, preferably 1.1 equivalents, of phosphorus oxychloride or thionyl chloride, to a mixture of a compound of Formula 28 and 0.5 to 10 parts by weight of solvent, at a temperature at which the reaction rapidly proceeds during the addition.
  • the addition time for this reaction is typically around 20 to 90 minutes at typical temperatures of around 35 to 55 0 C.
  • the compounds of Formula 28 can be prepared from the compound of Formula 30 by analogy with the haloacetylation reaction described for Scheme 17.
  • the compounds of Formula 30 are known or can be prepared from 4-cyanopyridine or isonicotinic acid using methods well-known in the art; see, for example, G. Marzolph, et al.,
  • Halomethyl isoxazole ketones of Formula 35 are particularly useful intermediates for preparing certain chiral compounds of Formula 1 wherein J is, for example, selected from J-29-1 through J-29-12 as depicted in Exhibit A.
  • Halomethyl isoxazole ketones of Formula 35 can be prepared by the multi-step reaction sequences shown in Scheme 19.
  • R 32 is C 2 — Cg dialkylamino, C2-C5 haloalkylamino, 1-piperidinyl, 1-pyr ⁇ olidinyl or 4-morpholinyl; and R 5 are as defined above in the Summary of the Invention.
  • the preparation of the racemic carboxylic acids of Formula 32 can be accomplished according to the well-known methods of basic or acidic hydrolysis of the corresponding compounds of Formula 31, preferably using a slight excess of sodium hydroxide in a water- miscible co-solvent such as methanol or tetrahydrofuran at about 25 to 45 0 C.
  • the product can be isolated by adjusting pH to about 1 to 3 and then filtration or extraction, optionally after removal of the organic solvent by evaporation.
  • the racemic carboxylic acids of Formula 32 can be resolved by classical fractional crystallization of diastereomeric salts of suitable chiral amine bases such as cinchonine, dihydrocinchonine or a mixture thereof.
  • a cinchonine-dihydrocinchonine mixture in about a 85:15 ratio is particularly useful, as it provides, for example, the (.Reconfigured carboxylic acids of Formula 33, wherein R 5 is a substituted phenyl group, as the less soluble salt. Furthermore, these chiral amine bases are readily available on a commercial scale.
  • the (/?)-conf ⁇ gured halomethyl ketone intermediates of Formula 35 afford the more fungicidaily active final products of Formula 1 after coupling with thioamides of Formula IBb.
  • the halomethyl ketones of Formula 35 can be prepared by first reacting the corresponding amides of Formula 31, either as pure enantiomers (i.e.
  • the isoxazole carboxamides of Formula 31 can be prepared by cycloaddition of the corresponding hydroxamoyl chlorides of Formula 36 with olefin derivatives of Formula 37, as shown in Scheme 20.
  • the base which can either be a tertiary amine base such as triethylamine or an inorganic base such as an alkali metal or alkaline- earth carbonate, bicarbonate or phosphate, is mixed with the olefin derivative of Formula 37, and the hydroxamoyl chloride of Formula 36 is added gradually at a temperature at which the cycloaddition proceeds at a relatively rapid rate, typically between 5 and 25 0 C.
  • the base can be added gradually to the other two components (the compounds of Formulae 36 and 37).
  • This alternative procedure is preferable when the hydroxamoyl chloride of Formula.36 is substantially insoluble in the reaction medium.
  • the solvent in the reaction medium can be water or an inert organic solvent such as toluene, hexane or even the olefin derivative used in excess.
  • the product can be separated from the salt co-product by filtration or washing with water, followed by evaporation of the solvent.
  • the crude product can be purified by crystallization, or the crude product can be used directly in the methods of Scheme 19.
  • Compounds of Formula 31 are useful precursors to the corresponding methyl ketones of Formula 34 and halomethyl ketones of Formula 35, and are also useful for preparing the resolved enantiomers of the compounds of Formulae 34 and 35 by hydrolysis, resolution, methyl ketone synthesis and halogenation, as shown in Scheme 19.
  • Step B Preparation of 4-[4-[4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-l-[[5- methyl-3-(trifluoromethyl)-lH-pyrazol-l-yl]acetyl]piperidine
  • Step A Preparation of 2-(4-piperidinyl)-4-thiazolecarboxaldehyde mono- hydrochloride
  • Step B Preparation of 4-(4-formyl-2-thiazolyl)- 1 -[[5-methyl r 3-(trifluoromethyl)-
  • Step C Preparation of 4-[4-[(hydroxyimino)methyl]-2-thiazolyl]-l-[[5-methyl- 3 -(trifh ⁇ oromethyl)- 1 i ⁇ T-pyrazol- 1 -yl] acetyl]piperidine
  • reaction mixture was concentrated under reduced pressure to give a yellow oil, which was purified by flash column chromatography on silica gel using 50 % ethyl acetate in hexanes as eluant to give 0.7 g of the title compound as a white solid.
  • Step D Preparation of l-[[5-methyl-3-(trifluoromethyl)-lH ' -pyrazol-l-yl]acetyl]-
  • the reaction mixture was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate.
  • the organic layer was separated, and the aqueous layer was extracted with ethyl acetate (3 x 30 mL).
  • the combined organic layers were washed with brine, dried (MgSC ⁇ ) and concentrated under reduced pressure to give an oil, which was purified by flash column chromatography on silica gel using 10 % methanol in ethyl acetate as eluant to give to give 70 mg of the title product, a compound of present invention, as a clear yellow oil.
  • Step B the product of Example 2, Step B) (0.8 g, 2.07 mmol) in tert-butanol (5 mL) was added N 1 -methy 1-1 -phenyl- 1 ,2-ethanediamine (43.57 mg, 0.29 mmol). The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 30 minutes, and then potassium carbonate (107.8 mg, 0.78 mmol) and iodine (43.57 mg, 0.33 mmol) were added. The reaction mixture was stirred at 70 0 C for 3 h and then quenched by addition of saturated aqueous sodium sulfite solution until the iodine color almost disappeared.
  • Step A Preparation of 1 , 1 -dimethylethyl 4-(4-ethenyl-2-thiazolyl)- 1 - piperidinecarboxylate To a cold (-50 0 C) suspension of methyltriphenylphosphonium bromide (1.2 g,
  • reaction mixture was allowed to stir for Ih, then filtered through Celite ® diatomaceous filter aid, and concentrated under reduced pressure to give an oil, which was purified by column chromatography on silica gel using 50 % ethyl acetate in hexane as eluant to give 73 mg of the title compound as a white foam, melting at 115—122 0 C (crystallized from methyl acetate/petroleum ether).
  • Step A Preparation of 1 , 1 -dimethylethyl 4-(aminothioxomethyl)- 1 -piperazine- carboxylate To a solution of thiocarbonyldiimidazole (2.1 g, 11.8 mmol) in tetrahydrofuran
  • Step B Preparation of 3-chloro-N-hydroxy-2-oxo-propanimidoyl chloride
  • 1,3-dichloroacetone 100 g, 0.79 mol
  • 2 M solution of hydrogen chloride in diethyl ether 400 mL
  • diethyl ether 400 mL
  • /-butyl nitrite 55 g, 0.534 mol
  • the reaction progress was monitored by 1 H NMR to obtain ⁇ 85 % conversion with no more than 3 % of the bis-nitrosation side product.
  • the reaction mixture was concentrated under reduced pressure to leave a semi-solid, which was then thoroughly rinsed with n-BuCl.
  • Step E Preparation of l-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]- piperazine hydrochloride .
  • Step F Preparation of l-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-l- piperazinyl]-2-[5-methyl-3-(trifluoromethyl)-lH/-pyrazol-l-yl]ethanone
  • l-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]piperazine hydrochloride i.e.
  • the reaction mixture was diluted with dichloromethane (30 mL), and washed with water (20 mL) and brine (20 mL). The organic layer was dried (Na 2 SO.;) and concentrated under reduced pressure. The crude residue was purified by column chromatography using 3 % methanol in chloroform as eluant to give 180 mg of the title product, a compound of the present invention as a white solid.
  • Step A 1 Alternative preparation of 1 -(2-chloroacetyl)-4-piperidinecarbonitrile
  • Step B Preparation of l-[2-[5-methyl-3-(trifluoromethyl)-lfl ' -pyrazol-l-yl]acetyl]-4- piperidinecarbonitrile
  • Step C Preparation of l-[2-[5-methyl-3-(trifluoromethyl)-lH-pyrazol-l-yl]acetyl]-4- piperidinecarbothioamide
  • Hydrogen sulfide gas was passed into a solution of l-[2-[5-methyl- 3-(trifluoromethyl)-lH-pyrazol-l-yl]acetyl]-4-piperidinecarbonitrile (i.e. the product of Example 8, Step B) (9.0 g, 30 mmol) and diethanolamine (3.15 g, 30 mmol) in TVyN-dimethylfo ⁇ namide (15 mL) at 50 0 C in a flask equipped with dry-ice condenser. The hydrogen sulfide feed was stopped when the reaction mixture became saturated with hydrogen sulfide, as indicated by condensation on the cold- finger. The reaction mixture was stirred for an additional 30 minutes at 50 0 C.
  • Step D Preparation of l-[4-[4-(3 I ,4'-dihydrospiro[isoxazole-5(4i ⁇ ),l ',(2 1 HO- naphthalen]-3-yl)-2-thiazolyl]-l-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)- 1 H-pyrazol- 1 -yl] ethanone
  • Example 8 the product of Example 8, Step C) (0.5 g, 1.5 mmol), 2-chloro-l-(3',4'- dihydrospiro[isoxazole-5(4H),r,(2'H)-naphthalen]-3-yl)ethanone (prepared by a method analogous to Example 7, Step C) (0.4 g, 1.5 mmol) and tetrabutylammonium bromide (0.030 g, 0.10 mmol) in tetrahydrofuran (15 mL) was stirred overnight at room temperature, and then heated at 55-60 0 C for 3 h. The reaction mixture was diluted with water and extracted with dichloromethane.
  • the extract was washed with brine, dried (MgSO ⁇ , and concentrated under reduced pressure.
  • the crude product was further purified by medium-pressure liquid chromatography using 50 % ethyl acetate in hexanes as eluant to give 260 mg of the title product, a compound of the present invention, as an off-white solid, melting at 81—84 0 C.
  • Step B Preparation of. S-chloro-NJV-dirnethyl-S- ⁇ fluoromethy ⁇ -li ⁇ -pyrazole-l- sulfonamide
  • Step D Preparation of ethyl 5-chloro-3-(trifluoromethyl)- lH-pyrazole- 1 -acetate
  • reaction mixture was diluted with water, and the aqueous layer was extracted with dichloromethane.
  • the organic layers were combined, dried (MgSC ⁇ ), and concentrated under reduced pressure to give 4,4-dichloro- 1,1,1- trifluoro-3-buten-2-one as an oil which was used for the next step without further purification.
  • Step E Preparation of 5-chloro-3-(trifluoromethyl)- lH-pyrazole- 1 -acetic acid
  • a solution of ethyl 5-chloro-3-(trifluoromethyl)-17 ⁇ ' -pyrazole-l-acetate (i.e. the product of Example 10, Step D or Dl) (218 mg, 0.85 mmol) in tetrahydrofuran (1 mL) was treated with a 50 wt. % aqueous solution of sodium hydroxide (0.2 mL) in water (0.6 mL).
  • reaction mixture was stirred at room temperature for 4 h.
  • the reaction mixture was treated with concentrated aqueous hydrochloric acid to lower the pH to 1, and then extracted with ethyl acetate.
  • the extract was dried (MgSC ⁇ ) and concentrated under pressure to give
  • Step F Preparation of 2-[5-chloro-3-(trifluoromethyl)-lH-pyrazol-l-yl]-l-[4-[4-(4,5- dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-l -piperidinyl]ethanone
  • reaction mixture was stirred overnight at room temperature, and then diluted with 1.0 N aqueous hydrochloric acid solution.
  • the organic layer was separated, washed with water, dried (MgSO 4 ), and concentrated under reduced pressure and purified by medium-pressure liquid chromatography using ethyl acetate in hexanes as eluant to give 40 mg of the title product, a compound of the present invention, as a solid, melting at 128—131 0 C.
  • Step A Preparation of 5-bromo-N ⁇ V-dimethyl-3-(trifluoromethyl)-lH/-pyrazole-l- sulfonamide
  • Step A Preparation of 4,5-dihydro- ⁇ ', ' -V-dimethyl-5-phenyl-3-isoxazolecarboxamide
  • Step B Preparation of 4,5-dihydro-5-phenyl-3-isoxazolecarboxylic acid
  • a solution of 4,5-dmydro-N//-dimethyl-5-phenyl-3-isoxazolecarboxamide i.e. the product of Example 12, Step A
  • methanol 300 mL
  • an aqueous sodium hydroxide solution 44 g of 50 wt. % aqueous NaOH in 50 mL of water
  • the reaction mixture was allowed to cool to room temperature and stirred overnight.
  • the resulting mixture was concentrated under reduced pressure, and treated with 200 mL of water.
  • the pH of the reaction mixture was adjusted using concentrated hydrochloric acid to about 1.0.
  • the crude product was extracted into ethyl acetate (200 mL).
  • the ethyl acetate solution was concentrated under reduced pressure, and the residue was triturated with hexanes.
  • the resulting precipitate was filtered, washed with hexanes (2 x 20 mL), and dried under vacuum to give 46.5 g of the title compound as a solid.
  • Step C Preparation of the cinchonine salt of (5R)-4,5-dihydro-5-phenyl-3-isoxazole- carboxylic acid
  • Step E Preparation of 2-bromo- 1 -[(5i?)-4,5-dihydro-5-phenyl-3-isoxazolyl]ethanone
  • Step F Preparation of l-[4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]- l-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-lH-pyrazol-l-yl]ethanone
  • l-[2-[5-methyl-3-(trifluoromethyl)-lH- ⁇ yrazol-l-yl]acetyl]-4-piperidine- carbothioamide (Le.
  • reaction mixture was diluted with water (50 mL) and brine (50 mL), and the organic layer was concentrated under reduced pressure and purified by medium-pressure liquid chromatography using 2 % of methanol in chloroform as eluant to give 0.7 g of the title compound as a brown solid.
  • Step B Preparation of 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-l,2,3,6- tetrahydro- 1 -(phenyhnethyl)pyridine
  • the reaction mixture was stirred at room temperature for 2 h, diluted with water (50 mL), neutralized with 1.5 N aqueous hydrochloric acid solution, and extracted with ethyl acetate (50 mL). The organic layer was separated, washed with brine (25 mL), and concentrated under reduced pressure. The residue was purified by medium-pressure liquid chromatography using 3 % of methanol in chloroform as eluant to give 0.4 g of the title compound as a white solid.
  • Step C Preparation of 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-l ,2,3,6- tetrahydropyridine hydrochloride To a solution of 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-l, 2,3,6- tetrahydro-l-(phenyhnethyl)pyridine (i.e.
  • Step D Preparation of 1 -[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-3,6- dmydro-l(2H)-pyridinyl]-2-[5-methyl-3-(trifluoromethyl)-lH-pyrazol-lyl]ethanone
  • the reaction mixture was stirred at room temperature for 24 h.
  • the reaction mixture was diluted with dichloromethane (30 mL) and washed with water (20 mL) and brine (20 mL).
  • the organic layer was separated, washed with water, dried (Na 2 SC> 4 ), and concentrated under reduced pressure and purified by medium-pressure liquid chromatography using 3 % methanol in chloroform as eluant to give 200 mg of the title product, a compound of the present invention, as a white solid.
  • the invention includes but is not limited to the following exemplary species.
  • a dash "-" in the (R 5 ) x column indicates no substitution on J.
  • a dash in each of the Z 2 and Q columns indicates that no Z 2 Q substituent is attached as R 5 to J.
  • a dash in the (R 7 ) p and/or R ⁇ 2 columns indicates no substitution on Q.
  • ** J-orientation refers to the attachment points for Z 1 and Z 2 (or another R 5 when Z 2 is not present) on ring J.
  • the first number refers to the ring position on J where Z* is attached
  • the second number refers to the ring position on J where Z 2 is attached or, when Z 2 is not present, the ring position on J where the substituent listed under (R ) x is attached.
  • R 5 and R 7 taken together to form a CH2CH2 bridge between position 4 of J-29 and position 2 of Q-45.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)

Abstract

Disclosed are compounds of Formulae 1, 1A, 1B and 1C including all geometric and stereoisomers, N oxides, and salts thereof, insert Formulae 1, 1A, 1B and 1C here wherein R1, R2, R4a1, R4a2, A, Aa, G, M, W, Z1, Z3, X, J, J1 and n are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

Description

TITLE FUNGICIDAL AZOCYCLIC AMIDES
FIELD OF THE INVENTION
This invention relates to certain carboxamides, their iV-oxides, salts and compositions, and methods of their use as fungicides.
BACKGROUND OF THE INVENTION
The control of plant diseases caused by fungal plant pathogens is extremely important in achieving high crop efficiency. Plant disease damage to ornamental, vegetable, field, cereal, and fruit crops can cause significant reduction in productivity and thereby result in increased costs to the consumer. Many products are commercially available for these purposes, but the need continues for new compounds which are more effective, less costly, less toxic, environmentally safer or have different sites of action.
World Patent Publication WO 05/003128 discloses thiazolylpiperidine derivatives of Formula i as MTP (Microsomal Triglyceride transfer Protein) inhibitors.
Figure imgf000002_0001
l wherein A is a radical selected from the radicals al and a2 below
Figure imgf000002_0002
al a2 and R1, R2, R2', R3, R4 and R5 are as defined in the disclosure. World Patent Publication WO 04/058751 discloses piperidinyl-thiazole carboxamide derivatives for altering vascular tone.
SUMMARY OF THE INVENTION
This invention relates to compounds of Formula 1 including all geometric and stereoisomers, N-oxides, and salts thereof, agricultural compositions containing them and their use as fungicides:
Figure imgf000003_0001
wherein
R1 is an optionally substituted phenyl, naphthalenyl or 5- or 6-membered heteroaromatic ring; A iS CHR15 Or NR1*;
R15 is H, halogen, cyano, hydroxy, -CHO, Cj- C4 alkyl, C2-C4 alkenyl, C2- C4 alkynyl, Cj-C4 haloalkyl, C2-C4 haloalkenyl, C2-C4 haloalkynyl, C2-C4 alkoxyalkyl, C2-C4 alkylthioalkyl, C2-C4 alkylsulfinylalkyl, C2-C4 alkylsulfbnylalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-Cs alkoxycarbonyl, C3-C5 alkoxycarbonylalkyl, C2-Cs alkylaminocarbonyl, C3-C5 dialkylaminocarbonyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1- C4 haloalkylthio, C1-C4 alkylsulfinyl, C1-C4 haloalkylsulfϊnyl, C1-C4 alkylsulfonyl or C1-C4 haloalkylsulfonyl;
R16 is H5 C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 haloalkenyl, C2-C4 haloalkynyl, C2-C4 alkoxyalkyl, C2-C4 alkylthioalkyl, C2-
C4 alkylsulfinylalkyl, C2-C4 alkylsulfonylalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-Cs alkoxycarbonyl, C3-C5 alkoxycarbonylalkyl, C2-Cs alkylaminocarbonyl, C3— C5 dialkylaminocarbonyl, Cj-C4 alkylsulfonyl or Cj- C4 haloalkylsulfonyl; W is O or S;
X is a radical selected from
X1 X^
Figure imgf000003_0002
Figure imgf000004_0001
X r8 Xy wherein the bond of X1, X2. X3, X4, X5, X6, X7, X8 or X9 which is identified with "t" is connected to the carbon atom identified with "q" of Formula 1, the bond which is identified with "u" is connected to the carbon atom identified with "r" of Formula 1, and the bond which is identified with "v" is connected to G; each R2 is independently C1-C4 alkyl, Ci- C4 alkenyl, Cj- C4 haloalkyl, Cp- C4 alkoxy, halogen, cyano or hydroxy; or two R2 are taken together as C1-C4 alkylene or C2-C4 alkenylene to form a bridged bicyclic or fused bicyclic ring system; or two R2 attached to adjacent ring carbon atoms joined by a double bond are taken together as -CH=CH-CH=CH- optionally substituted with 1 to 3 substituents selected from C1- C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, halogen, hydroxy, amino, cyano and nitro;
G is an optionally substituted 5-membered heteroaromatic ring or 5-membered saturated or partially saturated heterocyclic ring;
J is a 5-, 6- or 7-membered ring, a 8- to 11-membered bicyclic ring system or a 7- to 11-membered spirocyclic ring system, each ring or ring system containing ring members selected from carbon and optionally 1 to 4 heteroatoms selected from up to 2 O, up to 2 S and up to 4 N, and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O), S(O)2 and SiR17R18, each ring or ring system optionally substituted with 1 to 5 substituents independently selected from R5; each R5 is independently H, halogen, cyano, hydroxy, amino, nitro, -CHO, -C(=O)OH,
-C(=0)NH2, -NR25R26, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C4-C1Q alkylcycloalkyl, C4-C1QCyClOaIlSyIaIlCyI, C6-C14 cycloalkylcycloalkyl, C4-C1Q halocycloalkylalkyl, C5-C10 alkylcycloalkylalkyl, C3-C8 cycloalkenyl, C3-C8 halocycloalkenyl, C2-C6 alkoxyalkyl, C4-C10 cycloalkoxyalkyl, C3-C8 alkoxyalkoxyalkyl, C2-C6 alkylthioalkyl, C2-C6 alkylsulfinylalkyl, C2-C6 alkylsulfonylalkyl, C2-C6 alkylaminoalkyl, C3-C8 dialkylarninoalkyl, C2-C6 haloalkylaminoalkyl, C4-C10 cycloalkylaminoalkyl, C2-C6 alkylcarbonyl, C2-C6 haloalkylcarbony], C4-Cg cycloalkylcarbonyl, C2- C6 alkoxycarbonyl, C4-Cg cycloalkoxycarbonyl, C5-C10 cycloalkylalkoxycarbonyl, C2-C6 alkylaminocarbonyl, C3-C8 dialkylaminocarbonyl, C4-Cg cycloalkylaminocarbonyl, C2-Cg haloalkoxyalkyl, Ci-Cg hydroxyalkyl, C1-Cg alkoxy, C1-Cg haloalkoxy, C3-Cg cycloalkoxy, C3-C8 halocycloalkoxy, C4-C10 cycloalkylalkoxy, C2-Cg alkenyloxy, C2-Cg haloalkenyloxy, C2-Cg alkynyloxy, C2-Cg haloalkynyloxy, C2-Cg alkoxyalkoxy, C2-Cg alkylcarbonyloxy, C2-Cg haloalkylcarbonyloxy, C4-C8 cycloalkylcarbonyloxy, C3-Cg alkylcarbonylalkoxy, C1-Cg alkylthio, C1-Cg haloalkylthio, C3-Cg cycloalkylthio, C1-Cg alkylsulfinyl, C1-Cg haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C3-C8 cycloalkylsulfonyl, C3-C10 trialkylsilyl, C1-C6 alkylsulfonylamino, C1-C6 haloalkylsulfonylamino or -Z2Q;
R25 is H5 C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, C2-C6 alkylcarbonyl, C2-
C6 haloalkylcarbonyl, C2-C6 alkoxycarbonyl or C2-Cg haloalkoxycarbonyl; R26 is C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, C2-C6 alkylcarbonyl, C2-C6 haloalkylcarbonyl, C2-Cg alkoxycarbonyl, C2-Cg haloalkoxycarbonyl or -Z4Q; each R17 and R18 is independently C1-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl, C3-
C5 cycloalkyl, C3-Cg halocycloalkyl, C4-C1Q cycloalkylalkyl, C4-C7 alkylcycloalkyl, C5-C7 alkylcycloalkylalkyl, C1-C5 haloalkyl, C1-C5 alkoxy or C1-C5 haloalkoxy; each Q is independently phenyl, benzyl, naphthalenyl, a 5- or 6-membered heteroaromatic ring or an 8- to 11-membered heteroaromatic bicyclic ring system, each optionally substituted with 1 to 5 substituents independently selected from R7 on carbon atom ring members and R12 on nitrogen atom ring members; or each Q is independently a 3- to 7-membered nonaromatic carbocyclic ring, a 5-, 6- or 7-membered nonaromatic heterocyclic ring or an 8- to 11-membered nonaromatic bicyclic ring system, each optionally including ring members selected from the group consisting of C(=O), C(=S), S(O), S(O)2 and SiR17Rl8, and optionally substituted with 1 to 5 substituents independently selected from R7 on carbon atom ring members and R12 on nitrogen atom ring members; each R7 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl, C4-C10 alkylcycloalkyl, C5-C10 alkylcycloalkylalkyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3-C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylthio, C1-C4 haloalkylsulfinyl, C1-C4 haloalkylsulfonyl, C1-C4 alkylamino, C2-Cg dialkylamino, C3-C6 cycloalkylamino, C2-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C2-C4 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-C6 alkylcarbonylthio, C2-Cβ alkylaminocarbonyl, C3-C8 dialkylaminocarbonyl or C3-C6 trialkylsilyl; or R5 and R7 are taken together with the atoms linking R5 and R7 to form an optionally substituted 5- to 7-membered ring containing ring members selected from carbon and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and up to 1
N and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O), S(O)2 and SiR17R1S;
R12 is H5 C1-C3 alkyl, C1-C3 alkylcarbonyl, C1-C3 alkoxy or C1-C3 alkoxycarbonyl; each Z1 and Z2 is independently a direct bond, O, C(=O), S(O)m, CHR20 or NR21; each Z4 is independently O, C(=0), S(O)m or CHR20; each R20 is independently H, C1-C4 alkyl or C1- C4 haloalkyl; each R21 is independently H, C1-Cg alkyl, C1-Cg haloalkyl, C3-C8 cycloalkyl, C2-Cg alkylcarbonyl, C2-Cg haloalkylcarbonyl, C2-Cg alkoxycarbonyl or C2-Cg haloalkoxycarbonyl; each m is independently 0, 1 or 2; and n is O5 1 or 2; provided that:
(a) when R1 is unsubstituted thienyl, X is X1 and the ring containing X is saturated, G is an unsubstituted thiazole ring connected at its 2-position to X and at its 4-position to Z1 in Formula 1, A is CHR15, R15 is H, and J is an isoxazole ring connected at its 4-position to Z1 and substituted at its 5-position with methyl and at its 3-position with meta-substituted phenyl, then Z1 is O, C(=O), S(O)m, CHR20 orNR21.
More particularly, this invention pertains to compounds of Formula 1 including all geometric and stereoisomers, iV-oxides, and salts thereof; provided that (b) when A is NR1^5 X is X1 or X2, Z1 is a direct bond, and J is phenyl, then J is substituted with at least one R5 other than H, F, Cl, CN, OCH3, CF3 and CH3.
This invention also relates to a compound of Formula IA
Figure imgf000006_0001
1A wherein each R4al and R4a2 is independently Ci-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, cyclopropyl, C1-C3 haloalkyl, C2-C3 haloalkenyl, C2-C3 haloalkynyl, halocyclopropyl, halogen, cyano, nitro, C1-C2 alkoxy, C1-C2 haloalkoxy, C1- C2 alkylthio, C1-C2 haloalkylthio, C2-C3 alkoxyalkyl, C2-C3 alkylcarbonyl, C2-C3 alkoxycarbonyl, C2-C3 alkylaminocarbonyl or C3-C4 dialkylaminocarbonyl;
Aa is H, CH2CO2H, CH2CO2R30 or CH2C(=O)C1; and R30 is C1-C3 alkyl.
This invention also relates to a compound of Formula IB
Figure imgf000007_0001
IB wherein each R4al and R4a2 is independently C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, cyclopropyl, C1-C3 haloalkyl, C2-C3 haloalkenyl, C2-C3 haloalkynyl, halocyclopropyl, halogen, cyano, nitro, C1-C2 alkoxy, Cj-C2 haloalkoxy, C1-
C2 alkylthio, C1-C2 haloalkylthio, C2-C3 alkoxyalkyl, C2-C3 alkylcarbonyl, C2-C3 alkoxycarbonyl, C2-C3 alkylaminocarbonyl or C3-C4 dialkylaminocarbonyl; and Z3 is CN or C(=S)NH2. This invention further relates to a compound of Formula 1C
Figure imgf000007_0002
1C wherein
M is C1-C3 alkyl, C1-C3 haloalkyl, hydroxy, C1-C4 alkoxy, C1-C2 haloalkoxy, C1-C4 alkylamino, C2-C8 dialkylamino, 1-piperidinyl, 1-pyrrolidinyl or 4-morpholinyl; and
J1 is J-29-1 through J-29-58 depicted in Exhibit A as described below. More particularly, this invention pertains to compounds of Formulae IA, IB and 1C, including all geometric and stereoisomers, an JV-oxide or salt thereof (except that the compounds of Formula 1C of this invention are limited to those stereoisomer embodiments depicted for J1 in the Summary of Invention above).
This invention also relates to a fungicidal composition comprising a fungicidally effective amount of a compound of Formula 1 and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents.
This invention also relates to a fungicidal composition comprising a mixture of a compound of Formula 1 (including all geometric and stereoisomers, iV-oxides, and salts thereof) and at least one other fungicide (e.g., at least one other fungicide having a different site of action). This invention further relates to a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of Formula 1 (including all geometric and stereoisomers, JV-oxides, and salts thereof) (e.g., as a composition described herein).
This invention additionally relates to fungicidal compositions and methods of controlling plant diseases as described above, except that proviso (a) is removed from the definition of the scope of Formula 1.
DETAILS OF THE INVENTION
As used herein, the terms "comprises," "comprising," "includes," "including," "has," "having" or any other variation thereof, are intended to cover a non-exclusive inclusion. For example, a composition, process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, process, method, article, or apparatus. Further, unless expressly stated to the contrary, "or" refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and Both A and B are true (or present).
Also, use of "a" or "an" are employed to describe elements and components of the invention. This is done merely for convenience and to give a general sense of the invention. This description should be read to include one or at least one and the singular also includes the plural unless it is obvious that it is meant otherwise.
As referred to in the present disclosure and claims, "plant" includes members of Kingdom Plantae, particularly seed plants (Spermatopsida), at all life stages, including young plants (e.g., germinating seeds developing into seedlings) and mature, reproductive stages (e.g., plants producing flowers and seeds). Portions of plants include geotropic members typically growing beneath of the surface of the growing medium (e.g., soil), such as roots, tubers, bulbs and corms, and also members growing above the growing medium, such as foliage (including stems and leaves), flowers, fruits and seeds. In the above recitations, the term "alkyl", used either alone or in compound words such as "alkylthio" or "haloalkyl" includes straight-chain or branched alkyl, such as, methyl, ethyl, H-propyl, /-propyl, or the different butyl, pentyl or hexyl isomers. "Alkenyl" includes straight-chain or branched alkenes such as ethenyl, 1-propenyl, 2-propenyl, and the different butenyl, pentenyl and hexenyl isomers. "Alkenyl" also includes polyenes such as 1,2-propadienyl and 2,4-hexadienyl. "Alkynyl" includes straight-chain or branched alkynes such as ethynyl, 1-propynyl, 2-propynyl and the different butynyl, pentynyl and hexynyl isomers. "Alkynyl" can also include moieties comprised of multiple triple bonds such as 2,5-hexadiynyl. "Alkylene" denotes a straight-chain or branched alkanediyl. Examples of "alkylene" include CH2, CH2CH2, CH(CH3), CH2CH2CH2, CH2CH(CH3) and the different butylene isomers. "Alkenylene" denotes a straight-chain or branched alkenediyl containing one olefmic bond. Examples of "alkenylene" include CH=CH, CH2CH=CH, CH=C(CH3), CH2CH=CH and CH2CH=CHCH2. "Alkoxy" includes, for example, methoxy, ethoxy, n-propyloxy, isopropyloxy and the different butoxy, pentoxy and hexyloxy isomers. "Alkoxyalkyl" denotes alkoxy substitution on alkyl. Examples of "alkoxyalkyl" include CH3OCH2, CH3OCH2CH2, CH3CH2OCH2, CH3CH2CH2CH2OCH2 and CH3CH2OCH2CH2. "Alkylthio" includes branched or straight-chain alkylthio moieties such as methylthio, ethylthio, and the different propylthio, butylthio, pentylthio and hexylthio isomers. "Alkylsulfinyl" includes both enantiomers of an alkylsulfinyl group. Examples of "alkylsulfinyl" include CH3S(O), CH3CH2S(O), CH3CH2CH2S(O), (CH3)2CHS(O) and the different butylsulfinyl, pentylsulfϊnyl and hexylsulfmyl isomers. Examples of "alkylsulfonyl" include CH3S(O)2, CH3CH2S(O)2, CH3CH2CH2S(O)2, (CH3)2CHS(O)2 and the different butylsulfonyl, pentylsulfonyl and hexylsulfonyl isomers. Examples of "alkylcarbonyl" include C(O)CH3, C(O)CH2CH2CH3 and C(O)CH(CH3)2. Examples of "alkoxycarbonyl" include CH3OC(=O), CH3CH2OC(=O), CH3CH2CH2OC(=O), (CH3)2CHOC(=O) and the different butoxy- or pentoxycarbonyl isomers. Examples of "alkylaminocarbonyl" include CH3NHC(=O)-, CH3CH2NHC(=O)-,
CH3CH2CH2NHC(=O)-, (CH3)2CHNHC(=O)- and the different butylamino- or pentylaminocarbonyl isomers. Examples of "dialkylaminocarbonyl" include (CH3)2NC(=O)-, (CH3CH2)2NC(=O)-, CH3CH2(CH3)NC(=O)-, (CH3)2CHN(CH3)C(=O)- and CH3CH2CH2(CH3)NC(=O)-. "Alkylamino", "dialkylamino" and the like, are defined analogously to the above examples. "Trialkylsilyl" includes 3 branched and/or straight- chain alkyl radicals attached to and linked through a silicon atom, such as trimethylsilyl, triethylsilyl and tert-butyldimethylsilyl. "Cycloalkyl" includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Examples of "cycloalkylalkyl" include cyclopropylmethyl, cyclopentylethyl, and other cycloalkyl moieties bonded to straight-chain or branched alkyl groups. "Alkylcycloalkyl" denotes alkyl substitution on a cycloalkyl moiety. Examples include 4-methylcyclohexyl and 3-ethylcyclopentyl. Unless otherwise indicated, a "ring" or "ring system" as a component of Formula 1 (e.g., substituent J and Q) is carbocyclic or heterocyclic. The term "ring system" denotes two or more connected rings. The term "spirocyclic ring system" denotes a ring system consisting of two rings connected at a single atom (so the rings have a single atom in commonality). Illustrative of a J1 moiety that is a spirocyclic ring system is J-29-28 depicted in the definition of Formula 1C. The term "bicyclic ring system" denotes a ring system consisting of two rings sharing two or more common atoms. In a "fused bicyclic ring system" the common atoms are adjacent, and therefore the rings share two adjacent atoms and bond connecting them. In a "bridged bicyclic ring system" the common atoms are not adjacent (i.e. there is no bond between the bridgehead atoms). A "bridged bicyclic ring system" is conceptually formed by bonding a segment of one or more atoms to nonadjacent ring members of a ring.
A ring, a bicyclic ring system or spirocyclic ring system can be part of an extended ring system containing more than two rings wherein substituents on the ring, bicyclic ring system or spirocyclic are taken together to form the additional rings, which may be in bicyclic and/or spirocyclic relationships with other rings in the extended ring system. For example, the particular J1 moiety J-29-26 depicted in the definition of Formula 1C consists of a dihydro isoxazoline ring having one R5 substituent as Z2Q, which is a cyclobutyl ring substituted with two methyl groups as R7 and also one R7 group taken together with another R5 substituent on the dihydro isoxazoline ring as -CH2CH2- to form the additional six- membered ring component in the ring system.
The term "ring member" refers to an atom (e.g., C, O, N or S) or other moiety (e.g., C(=O), C(=S), S(O) or S(O)2) forming the backbone of a ring or ring system. The term "carbocyclic ring" denotes a ring wherein the atoms forming the ring backbone are selected only from carbon. The term "carbocyclic ring system" denotes two or more fused rings wherein the atoms forming the backbone of the rings are selected only from carbon. The term "heterocyclic ring" denotes a ring wherein at least one of the atoms forming the ring backbone is other than carbon. The term "heterocyclic ring system" denotes two or more fused rings wherein at least one of the atoms forming the backbone of the rings is other than carbon. "Aromatic" indicates that each of ring atoms is essentially in the same plane and has a p-orbital perpendicular to the ring plane, and in which (4n + 2) π electrons, where n is a positive integer, are associated with the ring to comply with Hϋckel's rule. The term "heteroaromatic ring" refers to a heterocyclic ring that is aromatic. The term "saturated heterocyclic ring" denotes a heterocyclic ring containing only single bonds between ring members. The term "partially saturated heterocyclic ring" denotes a heterocyclic ring containing at least one double bond but which is not aromatic.
The dotted line in Formula 1 and in other rings depicted in the present description (e.g., J-44, J-45, J-48 and J-49 in Exhibit 3) represents that the bond indicated can be a single bond or double bond. Unless otherwise indicated, heterocyclic rings and ring systems are attached to the remainder of Formula 1 through any available carbon or nitrogen by replacement of a hydrogen on said carbon or nitrogen, and all substituents on the heterocyclic rings and ring systems are attached through any available carbon or nitrogen by 5 replacement of a hydrogen on said carbon or nitrogen.
As already described, J is a 5-, 6- or 7-membered ring, a 8- to 11-membered bicyclic ring system or a 7- to 11-membered spirocyclic ring system, each ring or ring system containing ring members selected from carbon and optionally 1 to 4 heteroatoms selected from up to 2 O, up to 2 S and up to 4 N, and optionally including 1 to 3 ring members
10 selected from the group consisting of C(=O), C(=S), S(O), S(O)2 and SiR17R18, each ring or ring system optionally substituted with 1 to 5 substituents independently selected from R5. As the heteroatoms are optional, 0 to 4 heteroatoms may be present. In this description the heteroatoms selected from up to 2 S are atoms and not the moieties S(O) or S(O)2- The heteroatoms selected from up to 4 N may be oxidized as iV-oxides, because the present
15 invention also relates to iV-oxide derivatives of the compounds of Formula 1. Therefore the optional 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O), S(O)2 and SiR17R18 are in addition to the optional 1 to 4 heteroatoms selected from up to 2 O, up to 2 S and up to 4 N. Of note is when the total number of unoxidized sulfur atoms (i.e. S) and oxidized sulfur moieties (i.e. S(O) and S(O)2) does not exceed 2, so that at most two
20 ring members selected from S, S(O) and S(O)2 are present in the ring or ring system. When none of the optional heteroatoms and none of the optional ring members selected from S(O), S(O)2 and SiR17R18 are present, the ring or ring system is carbocyclic. The R5 substituents may be attached to carbon atom ring members and to nitrogen atom ring members having an available point of attachment. The carbon-based ring members C(=O) and C(^S) do not
25 have available points of attachment. Furthermore in SiR17R18 ring members, the substituents R17 and R18 are otherwise separately defined, and these ring members cannot be further substituted with R5. As the R5 substituents are optional, 0 to 5 substituents may be present, limited by the number of available points of attachment.
Similarly, R5 and R7 may be taken together with the atoms linking R5 and R7 to form
30 an optionally substituted 5- to 7-membered ring containing ring members selected from carbon and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and up to 1 N and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O), S(O)2 and SiR17R18. As the heteroatoms are optional, 0 to 3 heteroatoms may be present. In this description the heteroatom selected from up to 1 S is an atom and not the
35. moieties S(O) or S(O)2. The heteroatom selected from up to 1 N may be oxidized as an iV-oxide, because the present invention also relates to iV-oxide derivatives of the compounds
• of Formula 1. Therefore the optional 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O), S(O)2 and SiR17R18 are in addition to the optional 1 to 3 heteroatoms selected from. up to 1 O, up to 1 S and up to 1 N. Of note is when the total number of unoxidized sulfur atoms (i.e. S) and oxidized sulfur moieties (i.e. S(O) and S(O)2) does not exceed 1, so that at most one ring member selected from S, S(O) and S(O)2 is present in the ring. When none of the optional heteroatoms and none of the optional ring members selected from S(O), S(O)2 and SiR17R18 are present, the ring is carbocyclic. The. 5- to 7-membered ring is optionally substituted. The substituents on the atoms linking R5 and R7 are described in the definition of the components linking R5 and R7. For example, when linking component Z2 is CHR20, the substituent R20 is defined to be H, C1-C4 alkyl or C1-C4 haloalkyl. Regarding optional substituents attached to the portion of the ring consisting of R5 and R7 taken together, an optional substituent is a non-hydrogen substituent that does not extinguish fungicidal activity. Optional substituents may be attached to carbon atom ring members and to nitrogen atom ring members having an available point of attachment. The carbon-based ring members C(=O) and C(=S) do not have available points of attachment. Furthermore in SiR17R18 ring members, the substituents R17 and R18 are otherwise separately defined, and these ring members cannot be further substituted.
The term "halogen", either alone or in compound words such as "haloalkyl", includes fluorine, chlorine, bromine or iodine. Furthermore, when used in compound words such as "haloalkyl", said alkyl may be partially or fully substituted with halogen atoms which may be the same or different. Examples of "haloalkyl" include F3C, ClCH2, CF3CH2 and CF3CCl2. The terms "haloalkenyl", "haloalkynyl", "halocycloalkyl", "haloalkoxy", "haloalkylthio", and the like, are defined analogously to the term "haloalkyl". Examples of "haloalkenyl" include (Cl)2C=CHCH2 and CF3CH2CH=CHCH2. . Examples of "haloalkynyl" include HC=CCHCl, CF3CsC, CC13C≡C and FCH2OCCH2. Examples of "haloalkoxy" include CF3O, CCl3CH2O, HCF2CH2CH2O and CF3CH2O. Examples of "haloalkylthio" include CCl3S, CF3S, CCl3CH2S and ClCH2CH2CH2S. Examples of "haloalkylsulfmyl" include CF3S(O), CCl3S(O), CF3CH2S(O) and CF3CF2S(O). Examples of "haloalkylsulfonyl" include CF3S(O)2, CCl3S(O)2, CF3CH2S(O)2 and CF3CF2S(O)2.
The total number of carbon atoms in a substituent group is indicated by the "Cj-Cj" prefix where i and j are numbers from 1 to 10. For example, C1-C4 alkylsulfonyl designates methylsulfonyl through butylsulfonyl; C2 alkoxyalkyl designates CH3OCH2; C3 alkoxyalkyl designates, for example, CH3CH(OCH3), CH3OCH2CH2 or CH3CH2OCH2; and C4 alkoxyalkyl designates the various isomers of an alkyl group substituted with an alkoxy group containing a total of four carbon atoms, examples including CH3CH2CH2OCH2 and CH3CH2OCH2CH2. When a compound is substituted with a substituent bearing a subscript that indicates the number of said substituents can vary, then when the number of said substituents is greater than 1, said substituents are independently selected from the group of defined substituents. Furthermore when a range is indicated (e.g., i-j substituents), then the number US2007/014647
12 of substituents may be selected from the integers between i and j inclusive. When a group (e.g., J) contains a substituent (e.g., R5) which can be hydrogen, then when this substituent is taken as hydrogen, it is recognized that this is equivalent to said group being unsubstituted. When a variable group is shown to be optionally attached to a position, for example (R2)n wherein n may be 0, or as a further example (R4)k wherein k may be 0 in Exhibit 1 , then hydrogen may be at the position even if not recited in the definition of the variable group (e.g., R2 and R4). When a position on a group is said to be "not substituted" or "unsubstituted", then hydrogen atoms are attached to take up any free valency. The term "optionally substituted" in connection with groups listed for R1, R2, R5, R7, G, J and Q refers to groups that are unsubstituted or have at least 1 non-hydrogen substituent. Unless otherwise indicated, these groups may be substituted with as many optional substituents as can be accommodated by replacing a hydrogen atom with a non-hydrogen substituent on any available carbon or nitrogen atom. Commonly, the number of optional substituents (when present) ranges from 1 to 3. When a range specified for the number of substituents (e.g., x being an integer from 0 to 5 in Exhibit 3) exceeds the number of positions available for substituents on a ring (e.g., 2 positions available for (R5)x on J-I in Exhibit 3), the actual higher end of the range is recognized to be the number of available positions. The term "optionally substituted" means that the number of substituents can be zero. For example, the phrase "optionally substituted with up to 2 substituents selected from R3 on carbon ring members and selected from R1 J on nitrogen ring members" means that 0, 1 or 2 substituents can be present (if number of potential connection points allows), and thus the number of R3 and R11 substituents can be zero. Similarly, the phrase "optionally substituted with 1 to 5 substituents" means that 0, 1, 2, 3, 4 or 5 substituents can be present if the number of available connection points allows. The term "unsubstituted" in connection with a group such as a ring or ring system means the group does not have any substituents other than its one or more attachments to the remainder of Formula 1. The term "meta-substituted phenyl" means a phenyl ring substituted with a non-hydrogen substituent at a meta position relative to attachment of the phenyl ring to the remainder of Formula 1.
As noted above, R1 is an optionally substituted phenyl, naphthalenyl or 5- or 6- membered heteroaromatic ring; G is an optionally substituted 5-membered heteroarorhatic ring or 5-membered saturated or partially saturated heterocyclic ring; and R5 and R7 may be taken together with the atoms linking R5 and R7 to form an optionally substituted 5- to 7- membered ring containing ring members selected from carbon and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and up to 1 N and optionally including 1 to 3 ring members selected from the group; consisting of C(=O), C(=S), S(O), S(O)2 and SiR17R1S. The term "substituted" in connection with the definitions of R1, G, R5 and R7 refers to groups that have at least one non-hydrogen substituent that does not extinguish fungicidal activity. Since these groups are optionally substituted, they need not have any non-hydrogen substituents. As these groups are "optionally substituted" without the number of substituents indicated, these groups may be substituted with as many optional substituents as can be accommodated by replacing a hydrogen atom with a non-hydrogen substituent on any available carbon or nitrogen atom. Naming of substituents in the present disclosure uses recognized terminology providing conciseness in precisely conveying to those skilled in the art the chemical structure. For sake of conciseness, locant descriptors may be omitted; "pyrazol-1-yl" means "lH-pyrazol-l-yl" according to the Chemical Abstracts system of nomenclature. The term "pyridyl" is synonymous with "pyridinyl". The order of listing substituents may be different from the Chemical Abstracts system if the difference does not affect the meaning.
Compounds of this invention can exist as one or more stereoisomers. The various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers. One skilled in the art will appreciate that one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomers). Additionally, the skilled artisan knows how to separate, enrich, and/or to selectively prepare said stereoisomers. The compounds of the invention may be present as a mixture of stereoisomers, individual stereoisomers, or as an optically active form. For example, when J is J-29 (see Exhibit 3) bonded at the 3 -position to the remainder of Formula 1 and J-29 has one R5 substituent other than H at the 5-position, then Formula 1 possesses a chiral center at the carbon atom to which R5 is bonded. The two enantiomers are depicted as Formula 1' and Formula 1" with the chiral center identified with an asterisk (*).
Figure imgf000014_0001
1' 1"
This invention comprises racemic mixtures, for example, equal amounts of the enantiomers of Formulae lf and 1". In addition, this invention includes compounds that are enriched compared to the racemic mixture in an enantiomer of Formula 1. Also included are the essentially pure enantiomers of compounds of Formula 1, for example, Formula 1' and Formula 1".
When enantiomerically enriched, one enantiomer is present in greater amounts than the other, and the extent of enrichment can be defined by an expression of enantiomeric excess ("ee"), which is defined as (2x-l) 100 %, where x is the mole fraction of the dominant enantiomer in the mixture (e.g., an ee of 20 % corresponds to a 60:40 ratio of enantiomers). Preferably the compositions of this invention have at least a 50 % enantiomeric excess; more preferably at least a 75 % enantiomeric excess; still more preferably at least a 90 % enantiomeric excess; and the most preferably at least a 94 % enantiomeric excess of the more active isomer. Of particular note are enantiomerically pure embodiments of the more active isomer.
Compounds of Formula 1 can comprise additional chiral centers. For example, substituents and other molecular constituents such as R4, R5, R7, G, J, Q and X1 through X9 may themselves contain chiral centers. This invention comprises racemic mixtures as well as enriched and essentially pure stereoconfigurations at these additional chiral centers. Compounds of this invention can exist as one or more conformational isomers due to restricted rotation about the amide bond (e.g., C(W)-N) in Formula 1. This invention comprises mixtures of conformational isomers. In addition, this invention includes compounds that are enriched in one conformer relative to others.
Some of the unsaturated rings and ring systems depicted in Exhibits 1, 2, 3 and 4 can have an arrangement of single and double bonds between ring members different from that depicted. Such differing arrangements of bonds for a particular arrangement of ring atoms correspond to different tautomers. For these unsaturated rings and ring systems, the particular tautomer depicted is to be considered representative of all the tautomers possible for the arrangement of ring atoms shown. The tables listing particular compounds incorporating, the ring and ring systems depicted in the Exhibits may involve a tautomer different from the tautomer depicted in the Exhibits.
The compounds of the invention include TV-oxide derivatives. One skilled in the art will appreciate that not all nitrogen-containing heterocycles can form iV-oxides since the nitrogen requires an available lone pair of electrons for oxidation to the oxide; one skilled in the art will recognize those nitrogen containing heterocycles which can form iV-oxides. One skilled in the art will also recognize that tertiary amines can form .V-oxides. Synthetic , methods for the preparation of //-oxides of heterocycles and tertiary amines are very well known by one skilled in the art including the oxidation of heterocycles and tertiary amines with peroxy acids such as peracetic and /n-chloroperbenzoic acid (MCPBA), hydrogen peroxide, alikyl hydroperoxides such as tert-butyl hydroperoxide, sodium perborate, and dioxiranes such as dimethyldioxirane. These methods for the preparation of N-oxides have been extensively described and reviewed in the literature, see for example: T. L. Gilchrist in Comprehensive Organic Synthesis, vol. 7, pp 748-750, S. V. Ley, Ed., Pergamon Press; M. Tisler and B. Stanovnik in Comprehensive Heterocyclic Chemistry, vol. 3, pp 18—20, A. J. Boulton and A. McKillop, Eds., Pergamon Press; M. R. Grimmett and B. R. T. Keene in Advances in Heterocyclic Chemistry, vol. 43, pp 149-161, A. R. Katritzky, Ed., Academic Press; M. Tisler and B. Stanovnik in Advances in Heterocyclic Chemistry, vol. 9, pp 285— 291, A. R. Katritzky and A. J. Boulton, Eds., Academic Press; and G. W. H. Cheeseman and W 2
15
E. S. G. Werstiuk • in Advances in Heterocyclic Chemistry, vol. 22, pp 390-392, A. R. Katritzky and A. J. Boulton, Eds., Academic Press.
The present compounds of Formula 1 can be in the form of agriculturally suitable salts.
One skilled in the art recognizes that because in the environment and under physiological conditions salts of chemical compounds are in equilibrium with their corresponding nonsalt forms, salts share the biological utility of the nonsalt forms. Thus a wide variety of salts of the compounds of Formula 1 are useful for control of plant diseases caused by fungal plant pathogens (i.e. are agriculturally suitable). The salts of the compounds of Formula 1 include acid-addition salts with inorganic or organic acids such as hydrobromic, hydrochloric, nitric, phosphoric, sulfuric, acetic, butyric, fumaric, lactic, maleic, malonic, oxalic, propionic, salicylic, tartaric, 4-toluenesulfonic or valeric acids. When a compound of Formula 1 contains an acidic moiety such as a carboxylic acid or phenol, salts also include those formed with organic or inorganic bases such as pyridine, triethylamine or ammonia, or amides, hydrides, hydroxides or carbonates of sodium, potassium, lithium, calcium, magnesium or barium. Accordingly, the present invention comprises compounds selected from Formulae 1, IA, IB and 1C, iV-oxides and salts thereof.
Embodiments of the present invention include: Embodiment 1. A compound of Formula 1 wherein A is CHR15. Embodiment Ia. A compound of Embodiment 1 wherein R15 is H, halogen, cyano, hydroxy, -CHO, C1-C4 alkyl, C1-C4 haloalkyl or C2-C5 alkoxycarbonyl.
Embodiment Ib. A compound of Embodiment Ia wherein R15 is H, cyano, hydroxy, methyl or methoxycarbonyl.
Embodiment Ic A compound of Embodiment Ib wherein R15 is H. Embodiment 2. A compound of Formula 1 wherein A is NR16. Embodiment 2a. A compound of Embodiment 2 wherein R16 is H, C1-C4 alkyl, C1-C4 haloalkyl, C2~C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl or C2-C4 alkoxycarbonyl. Embodiment 2b. A compound of Embodiment 2a wherein R1^ is H, methyl, methylcarbonyl or methoxycarbonyl. Embodiment 2c. A compound of Embodiment 2b wherein R16 is H.
Embodiment 3. A compound of Formula 1 wherein W is O. Embodiment 4. A compound of Formula 1 wherein W is S. Embodiment 5. A compound of Formula 1 wherein each R2 is independently C1-^ alkyl, C1-C2 haloalkyl, Cj-C2 alkoxy, halogen, cyano or hydroxy. Embodiment 5a. A compound of Embodiment 5 wherein each R2 is independently methyl, methoxy, cyano or hydroxy.
Embodiment 5b. A compound of Embodiment 5a wherein each R2 is methyl. Embodiment 6. A compound of Formula 1 wherein n is 0 or 1. Embodiment 7. A compound of Embodiment 6 wherein n is 0. Embodiment 8. A compound of Formula 1 wherein X is X1, X2 or X3. Embodiment 9. A compound of Embodiment 8 wherein X is X1 or X2. Embodiment 10. A compound of Embodiment 9 wherein X is X1. Embodiment I L A compound of Formula 1 wherein the ring comprising X is saturated
(i.e. contains only single bonds). Embodiment 12. A compound of Formula 1 wherein R1 is a phenyl or 5- or 6- membered heteroaromatic ring optionally substituted with 1—2 substituents independently selected from R4a on carbon ring members and R4b on nitrogen ring members; each R4a is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-CjO cycloalkylalkyl, C4-C] o alkylcycloalkyl, C^-C IQ alkylcycloalkylalkyl, C]-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3— C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl,
C1-C4 haloalkylthio, C1-C4 haloalkylsulfmyl, C1-C4 haloalkylsulfonyl, C1-C4 alkylamino, C2-Cg dialkylamino, C3-C6 cycloalkylamino, C2-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C2-C4 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-C6 alkylcarbonylthio, C2-Ce alkylaminocarbonyl, C3-Cg dialkylamuiocarbonyl or C3-C6 trialkylsilyl; and each R4b is independently C1-C6 alkyl, C3-C6 alkenyl, C3-C6 alkynyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C3-C6 haloalkenyl, C3-C6 haloalkynyl, C3-C6 halocycloalkyl or C2-C4 alkoxyalkyl.
Embodiment 13. A compound of Embodiment 12 wherein R1 is one of U-I through . U-50 depicted in Exhibit 1 ;
Exhibit 1
Figure imgf000017_0001
U-I U-2 U-3 U-4
Figure imgf000017_0002
U-5 υ-6 U-7 U-8
Figure imgf000018_0001
U-9 U-IO U-I l U-12
Figure imgf000018_0002
U-13 U-14 U-15 U-16
Figure imgf000018_0003
U-17 U-18 U-19 U-20
Figure imgf000018_0004
U-21 U-22 U-23 U-24
Figure imgf000018_0005
U-25 U-26 U-27 U-28
Figure imgf000018_0006
U-33 U-34 U-35 U-36
Figure imgf000019_0001
U-41 U-42 U-43 U-44
Figure imgf000019_0002
U-45 U-46 U-47 U-48
Figure imgf000019_0003
U-49 U-50 wherein when R4 is attached to a carbon ring member, said R4 is selected from R4a, and when R4 is attached to a nitrogen ring member (e.g., in U-4, U-Il through U- 15, U-24 through U-26, U-31 or U-35), said R4 is selected from R4b; and k is 0, 1 or 2.
Embodiment 14. A compound of Embodiment 13 wherein R1 is selected from U-I through U-5, U-8, U-I l, U- 13, U-15, U-20 through U-28, U-31, U-36 through U-39 and U-50.
Embodiment 15. A compound of Embodiment 14 wherein R1 is selected from U-I through U-3, U-5, U-8, U-11, U-13, U-20, U-22, U-23, U-25 through U-28, U-36 through U-39 and U-50.
Embodiment 16. A compound of Embodiment 15 wherein R1 is selected from U-I through U-3, U-I l, U-13, U-20, U-22, U-23, U-36 through U-39 and U-50. Embodiment 17. A compound of Embodiment 16 wherein R1 is U-I or U-50. Embodiment 18. A compound of Embodiment 17 wherein R1 is U-I.
Embodiment 19. A compound of Embodiment 17 wherein R1 is U-50. Embodiment 20. A compound of any one of Embodiments 12 and 13 wherein each R4a is independently C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, cyclopropyl, Cj- C3 haloalkyl, C2-C3 haloalkenyl, C2-C3 haloalkynyl, halocyclopropyl, halogen, cyano, nitro, C1-C2 alkoxy, Cj-C2 haloalkoxy, Cj-C2 alkylthio, C]-C2 haloalkylthio, C2-C3 alkoxyalkyl, C2-C3 alkylcarbonyl, C2-C3 alkoxycarbonyl,
C2-C3 alkylaminocarbonyl or C3-C4 dialkylamϊnocarbonyl.
Embodiment 21. A compound of Embodiment 20 wherein each R4a is independently C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, cyclopropyl, Cj-C3 haloalkyl, C2-
C3 haloalkenyl, C2-C3 haloalkynyl, halocyclopropyl, halogen, cyano, nitro, C1-
C2 alkoxy or C1-C2 haloalkoxy. Embodiment 22. A compound of Embodiment 21 wherein each R4a is independently halogen, C1-C3 alkyl, C1^-C3 haloalkyl. C1-C2 alkoxy or C1-C2 haloalkoxy. Embodiment 23. A compound of Embodiment 21 wherein each R4a is independently halogen, Cj-C2 alkyl, C1-C2 haloalkyl or C1-C2 alkoxy. Embodiment 24. A compound of Embodiment 23 wherein each R4a is independently
C1-C2 alkyl, trifluoromethyl, Cl, Br, I or methoxy.
Embodiment 25. A compound of Embodiment 24 wherein each R4a is independently C J-C2 alkyl, trifluoromethyl, Cl or Br.
Embodiment 26. A compound of any one of Embodiments 12 and 13 wherein each R4b is independently C1-C3 alkyl, C3 alkenyl (e.g., allyl), C3 alkynyl (e.g., propargyl), cyclopropyl, C1-C3 haloalkyl, C3 haloalkenyl, C3 haloalkynyl, halocyclopropyl or C2-C3 alkoxyalkyl. Embodiment 27. A compound of Embodiment 26 wherein each R4b is independently
C1-C3 alkyl, C3 alkenyl, C3 aUcynyl, cyclopropyl, C1-C3 haloalkyl, C3 haloalkenyl or halocyclopropyl. Embodiment 28. A compound of Embodiment 27 wherein each R4b is independently
C J-C2 alkyl or C !-C2 haloalkyl. Embodiment 29. A compound of Embodiment 28 wherein each R4b is independently
C1-C2 alkyl or trifluoromethyl. Embodiment 30. A compound of Embodiment 29 wherein each R4b is independently
C1-C2 alkyl.
Embodiment 31. A compound of Embodiment 13 wherein k is 1 or 2 and at least one R4 is Cl.
Embodiment 32. A compound of Embodiment 13 wherein k is 1 or 2 and at least one
R4 is Br. Embodiment 33. A compound of Embodiment 13 wherein k is 1 or 2 and at least one
R4 is methyl. Embodiment 34. A compound of Embodiment 13 wherein k is 1 or 2 and at least one
R4 is ethyl. Embodiment 35. A compound of Embodiment 13 wherein k is 1 or 2 and at least one
R4 is trifluoromethyl. Embodiment 36. A compound of Embodiment 13 wherein k is 1 or 2 and at least one
R4 is methoxy. Embodiment 37. A compound of Embodiment 18 wherein k is 1 and R4 is connected to the 3- or 5-position of U-I. Embodiment 38. A compound of Embodiment 18 wherein k is 2 and one R4 is connected to the 3-position and the other R4 is connected to the 5-position of U-I. Embodiment 39. A compound of Embodiment 19 wherein k is 1 and R4 is connected to the 2- or 3-position of U-50. Embodiment 40. A compound of Embodiment 19 wherein k is 2 and one R4 is connected to the 2-position and the other R4 is connected to the 5-position of U-50. Embodiment 41. A compound of Formula 1 wherein G is a 5-membered heteroaromatic ring or 5-membered saturated or partially saturated heterocyclic ring, each ring optionally substituted with up to 2 substituents selected from E? on carbon ring members and selected from R11 on nitrogen ring members; each R3 is independently C1-C3 alkyl, Cj-C3 haloalkyl or halogen; and each R11 is independently C1- C3 alkyl.
Embodiment 42. A compound of Embodiment 41 wherein G is one of G-I through G-59 depicted in Exhibit 2;
Exhibit 2
Figure imgf000021_0001
G-I G-2 G-3 G-4
Figure imgf000021_0002
G-5 G-6 G-7 G-8
Figure imgf000022_0001
G-17 G-18 G-19 G-20
Figure imgf000022_0002
G-25 G-26 G-27 G-28
Figure imgf000023_0001
G-32
G-29 G-30 G-31
Figure imgf000023_0002
G-45 G-46 G-47 G-48
Figure imgf000023_0003
Figure imgf000024_0001
G-57 G-58 G-59 wherein the bond projecting to the left is bonded to X, and the bond projecting to the right is bonded to Z1; each R3a is independently selected from H or R3; and R1 la is selected from H and R* *; provided that: when G is G-6, G-16 or G-42, and each R3a is other than H, then R1 la is H; when G is G-25 or G-31, then at least one R3a is H; and when G is one of G-31 through G-35, then Z1 is a direct bond or CHR20. Embodiment 43. A compound of Embodiment 42 wherein G is selected from G-I through G-3, G-7, G-8, G-IO, G-Il5 G-14, G-15, G-23, G-24, G-26 through G-28, G-30, G-36 through G-38 and G-49 through G-55.
Embodiment 44. A compound of Embodiment 43 wherein G is selected from G-I, G-2, G-7, G-8, G-14, G-15, G-23, G-24, G-26, G-27, G-36, G-37, G-38, G-49, G-50 and G-55.
Embodiment 45. A compound of Embodiment 44 wherein G is selected from G-I, G-2, G-15, G-26, G-27, G-36, G-37 and G-38.
Embodiment 46. A compound of Embodiment 45 wherein G is selected from G-I, G-2,
G-15, G-26 and G-36. Embodiment 47. A compound of Embodiment 46 wherein G is G-I. Of note are embodiments of these compounds within Embodiments 1 through 40, Embodiments 52 through 83, and Embodiments Al through A5.
Embodiment 48. A compound of Embodiment 46 wherein G is G-2. Of note are embodiments of these compounds within Embodiments 1 through 40, Embodiments 52 through 83, and Embodiments Al through A5. Embodiment 49. A compound of Embodiment 46 wherein G is G- 15. Of note are embodiments of these compounds within Embodiments 1 through 40, Embodiments 52 through 83, and Embodiments Al through AS.
Embodiment 50. A compound of Embodiment 46 wherein G is G-26. Of note axe embodiments of these compounds within Embodiments 1 through 40,
Embodiments 52 through 83, and Embodiments Al through A5.
Embodiment 51. A compound of Embodiment 46 wherein G is G-36. Of note are embodiments of these compounds within Embodiments 1 through 40, Embodiments 52 through 83, and Embodiments Al through A5. Embodiment 52. A compound of any one of Embodiments 41 through 51 wherein R3a is H, C1-C3 alkyl or halogen.
Embodiment 53. A compound of Embodiment 52 wherein R3a is H or methyl.
Embodiment 54. A compound of any one of Embodiments 41 through 51 wherein R3a is H and R1 ] a is H or methyl. Embodiment 55. A compound of any one of Formula 1 and Embodiments 41 through
51 wherein G is unsubstituted.
Embodiment 56. A compound of Formula 1 wherein J is one of J-I through J-82 depicted in Exhibit 3;
Exhibit 3
Figure imgf000025_0001
J-I J-2 J-3 J-4
Figure imgf000025_0002
J-5 J-6 J-7 J-8
Figure imgf000025_0003
J-9 J-IO J-I l J-12
Figure imgf000026_0001
Figure imgf000027_0001
J-37 J-38 J-39 J-40
Figure imgf000027_0002
J-41 J-42 J-43 J-44
Figure imgf000027_0003
J-49 J-50 J-51 J-52
Figure imgf000027_0004
Figure imgf000028_0001
J-73 J-74 J-75 J-76"
Figure imgf000028_0002
J-81 J-82 wherein the bond shown projecting to the left is bonded to 7λ ; and x is an integer from
O to 5.
Embodiment 56a. A compound of Embodiment 56 wherein J is one of J-29-1 through J- 29-58 depicted in Exhibit A;
Exhibit A
Figure imgf000029_0001
J-29-10 J-29-11 J-29-12
Figure imgf000029_0002
J-29-13 J-29-14 J-29-15
Figure imgf000030_0001
J-29-19 J-29-20 J-29-21
Figure imgf000030_0002
J-29-25 J-29-26 J-29-27
Figure imgf000030_0003
J-29-28 J-29-29 J-29-30
Figure imgf000031_0001
J-29-43 J-29-44 J-29-45
Figure imgf000032_0001
Embodiment 57. A compound of Embodiment 56 wherein J is selected from J-I, J-2,
J-3, J-4, J-5, J-7, J-8, J-9, J-IO, J-Il, J-12, J-14, J-15, J-16, J-20, J-24, J-25, J-26, J-29, J-30, J-37, J-38, J-45 and J-69. Embodiment 58. A compound of Embodiment 57 wherein J is selected from J-4, J-5, J-8, J-11, J-15, J-16, J-20, J-29, J-30, J-37, J-38, and J-69.
Embodiment 59. A compound of Embodiment 58 wherein J is selected from J-4, J-5,
J-11, J-20, J-29, J-37, J-38, and J-69. Embodiment 60. A compound of Embodiment 59 wherein J is J-11.
Embodiment 61. A compound of Embodiment 59 wherein J is J-29.
Embodiment 61a. A compound of Embodiment 61 wherein J is any one of J-29- 1 to J-29-58 (depicted with Table 8).
Embodiment 62. A compound of Embodiment 59 wherein J is J-69. Embodiment 63. A compound of Embodiment 60 wherein the 3-position of J-11 is connected to Z1 and the 5-position of J-11 is connected to R5 other than H.
Embodiment 63a. A compound of Embodiment 63 wherein the 3-position of J-11 is connected to Z1 and the 5-position of J-11 is connected to Z2Q.
Embodiment 64. A compound of Embodiment 61 wherein the 3-position of J-29 is connected to Z1 and the 5-position of J-29 is connected to R5 other than H.
Embodiment 64a. A compound of Embodiment 65 wherein the 3-position of J-29 is connected to Z1 and the 5-position of J-29 is connected to Z2Q.
Embodiment 65. A compound of Formula 1 or Embodiment 56 wherein each R5 is independently H, cyano, C1-Cg alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-Cg haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C4-C10 alkylcycloalkyl, C4-C10 cycloalkylalkyl, C2-C6 alkoxyalkyl, C4-C10 cycloalkoxyalkyl, C3-Cg alkoxyalkoxyalkyl, C2-C6 alkylthioalkyl, C2-C6 alkoxycarbonyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C8 cycloalkoxy, C3-C8 halocycloalkoxy, C4-C1o cycloalkylalkoxy, C2-C6 alkenyloxy, C2-C6 haloalkenyloxy, C2-C6 alkynyloxy, C2-C6 haloalkynyl oxy,
C2-C6 alkoxyalkoxy, C2-C6 alkylcarbonyloxy, C2-C6 haloalkylcarbonyloxy, C4-C8 cycloalkylcarbonyloxy, C3-C6 alkylcarbonylalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C3-C8 cycloalkylthio, C3-C10 trialkylsilyl, -NR25R26 or Z2Q. Embodiment 66. A compound of Embodiment 65 wherein each R^ is independently H, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C3-Cg cycloalkyl, C3-C8 halocycloalkyl, C2-C6 alkoxyalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C8 cycloalkoxy, C2- C6 alkenyloxy, C2-C6 haloalkenyloxy, C2-C6 alkynyloxy, C2-C6 alkoxyalkoxy, C2-C6 alkylcarbonyloxy, C2-C6 haloalkylcarbonyloxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C3-C10 trialkylsilyl, -NR25R2^ or Z2Q.
Embodiment 67. A compound of Embodiment 66 wherein each R5 is independently H, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -NR25R26 or Z2Q. Embodiment 68. A compound of Formula 1 or Embodiment 56 wherein one instance of R5 is Z2Q and other instances of R5 are independently selected from H, cyano, C1-C^ alkyl, C1-C4 haloalkyl, C1-C4 alkylcarbonyl and halogen.
Embodiment 69. A compound of Embodiment 68 wherein the other instances of R5 are independently selected from H and Cγ- C3 alkyl.
Embodiment 70. A compound of Embodiment 56 wherein x is 1 or 2.
Embodiment 71. A compound of Embodiment 70 wherein x is 1.
Embodiment 72. A compound of Embodiment 71 wherein R5 is Z2Q.
Embodiment 73. A compound of Formula 1 wherein Z1 is direct bond. Embodiment 74. A compound of Formula 1 wherein Z2 is direct bond.
Embodiment 75. A compound of Formula 1 wherein Q is one of Q-I through Q- 102 depicted in Exhibit 4;
Exhibit 4
Figure imgf000034_0001
Q-I Q-2 Q-3 Q-4
Figure imgf000034_0002
Q-5 Q-6 Q-7 Q-8
Figure imgf000034_0003
Q-9 Q-10 Q-I l Q-12
Figure imgf000034_0004
Figure imgf000035_0001
Q-28 Q-25 Q-26 Q-27
Figure imgf000035_0002
Q-41 Q-42 Q-43 Q-44
Figure imgf000036_0001
Q-52 Q-49 Q-50 Q-51
Figure imgf000036_0002
Q-56 Q-57 Q-58
Figure imgf000036_0003
Q-59 Q-60 Q-61
Figure imgf000036_0004
Figure imgf000037_0001
Q-66 Q-67
Q-65
Figure imgf000037_0002
Q-71 Q-72 Q-73
Figure imgf000037_0003
Q-74 Q-75 Q-76
Figure imgf000037_0004
-79
Q-77 Q-78 Q
Figure imgf000038_0001
Q-80 Q-81 Q-82
Figure imgf000038_0002
Q-83 Q-84 Q-85
Figure imgf000038_0003
Figure imgf000039_0001
Q-IOl Q-102 wherein p is 0, 1, 2, 3, 4 or 5.
Embodiment 76. A compound of Embodiment 75 wherein Q is selected from Q-I, Q-20, Q-32 through Q-34, Q-45 through Q-47, Q-60 through Q-73, Q-76 through Q-79, Q-84 through Q-94 and Q-98 through Q-102. Embodiment 77. A compound of Embodiment 76 wherein Q is Q-I, Q-45, Q-63, Q-64,
Q-65, Q-68, Q-69, Q-70, Q-71, Q-72, Q-73, Q-76, Q-78, Q-79, Q-84, Q-85, Q-98, Q-99, Q-100, Q-101 or Q-102. Embodiment 78. A compound of Embodiment 77 wherein Q is Q-45, Q-63, Q-64, Q-65,
Q-68, Q-69, Q-70, Q-71, Q-72 or Q-85. Embodiment 78a. A compound of Embodiment 78 wherein Q is Q-45, Q-63, Q-65,
Q-70, Q-71, Q-72 or Q-85. Embodiment 78b. A compound of Embodiment 78 wherein Q is Q-45, Q-63, Q-65 or
Q-70.
Embodiment 79. A compound of Formula 1 or Embodiment 75 wherein each R7 is independently C1-C3 alkyl, C1-^ haloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C2 alkoxy or C1-C2 haloalkoxy. Embodiment 80. A compound of Embodiment 79 wherein each R7 is independently
Cj- C3 alkyl, halogen, hydroxy, cyano or Cj-C2 alkoxy.
Embodiment 81. A compound of Embodiment 80 wherein each R7 is independently methyl, F, Cl, Br, hydroxy, cyano or methoxy.
Embodiment 82. A compound of Formula 1 wherein when R5 and R7 are taken together with the atoms linking R5 and R7 to form an optionally substituted 5- to 7- membered ring, the ring members are selected from carbon and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and up to 1 N and optionally include 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O), S(O)2 and SiRl7R18. Embodiment 82a. A compound of Embodiment 82 wherein when R5 and R7 are taken together with the atoms linking R5 and R7 to form an optionally substituted 5- to 7-membered ring, then R5 and R7 are taken together with the atoms linking R5 and R7 to form a 5- to 7-membered ring containing as ring members carbon atoms and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and up to 1 N, and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O), S(O)2 and SiR17R18, optionally substituted with up to 2 substituents selected from R8; and each R8 is independently C1-C3 alkyl. Embodiment 82b. A compound of Formula 1 wherein when R5 and R7 are taken together with the atoms linking R5 and R7 to form an optionally substituted 5- to 7-membered ring, then R5 and R7 are taken together with the atoms linking R5 and R7 to form a 5- to 7-membered ring containing ring members selected from carbon and optionally 1 to 3 heteroatoms selected from up to 1 0, up to 1 S and up to 1 N, and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O), S(O)2 and SiR17R18, the ring optionally substituted on ring members other than the atoms linkiog R5 and R7 with substituents selected from R8; and each R8 is independently Ci-C6 alkyl, C2-Cg alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C1Q cycloalkylalkyl, C4-C1Q alkylcycloalkyl, C5-C10 alkylcycloalkylalkyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3-C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylthio, C1-C4 haloalkylsulfinyl, C1-C4 haloalkylsulfonyl, C1-C4 alkylamino, C2-Cg dialkylamino, C3-C6 cycloalkylamino, C2-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C2-C4 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-C6 alkylcarbonyltbio, C2-C6 alkylaminocarbonyl, C3^-Cg dialkylaminocarbonyl or C3-C6 trialkylsilyl.
Embodiment 82c. A compound of Formula 1 wherein when R5 and R7 are taken together with the atoms linking R5 and R7 to form an optionally substituted 5- to 7-membered ring, then R5 and R7 are taken together with the atoms linking R5 and R7 to form a 5- to 7-membered ring containing as ring members 2 to 7 carbon atoms and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 .
S, up to 1 Si and up to 1 N, the ring optionally substituted on ring members other than the atoms linking R^ and R7 with substituents selected from R8; and each R8 is independently C1-C6 alkyl, C2-Cg alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 04-C10 cycloalkylalkyl, C4-C10 alkylcycloalkyl, C^-C IQ alkylcycloalkylalkyl, C1-Cg haloalkyl, C2-C6 haloalkenyl, C2~Cg haloalkynyl, C3-C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylthio, Cj-C4 haloalkylsulfinyl, C1-C4 haloalkylsulfonyl, C1-C4 alkylamino, C2— Cg dialkylamino, C3— Cg cycloalkylamino, C2— C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C2-C4 alkylcarbonyl, C2-Cg alkoxycarbonyl, C2-Cg alkylcarbonyloxy, CJ-CQ alkylcarbonylthio, C2— Cg alkylaminocarbonyl, C3— Cg dialkylaminocarbonyl or C3— Cg trialkylsilyl. Embodiment 82d. A compound of Embodiment 82b or 82c wherein the ring is optionally substituted on ring members other than the atoms linking R5 and R7 with up to 4 substituents selected from R8. Embodiment 82e. A compound of Embodiment 82d wherein the ring is optionally substituted on ring members other than the atoms linking R5 and R7 with up to 2 substituents selected from R8.
Embodiment 82f. A compound of Embodiment 82b or 82c wherein each R8 is independently C1-C3 alkyl.
Embodiment 82g. A compound of Embodiment 82b wherein when R5 and R7 are taken together with the atoms linking R5 and R7 to form an optionally substituted 5- to 7-membered ring, then R5 and R7 are taken together with the atoms linking R5 and R7 to form a 5- to 7-membered ring containing ring members selected from carbon and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and up to 1 N, and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O), S(O)2 and SiR17R18, optionally substituted . . with up to 2 substituents selected from R8; and each R8 is C1—C3 alkyl.
Embodiment 82h. A compound of Embodiment 82c wherein when R5 and R7 are taken together with the atoms linking R5 and R7 to form an optionally substituted 5- to 7-membered ring, then R5 and R7 are taken together with the atoms linking R5 and R7 to form a 5- to 7-membered ring containing as ring members 2 to 7 carbon atoms and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1
S and up to 1 N, optionally substituted with up to 2 substituents selected from R8; and each R8 is C1-C3 alkyl.
Embodiment 83. A compound of Formula 1 or Embodiment 75 wherein p is 0, 1 , 2 or 3. Embodiment 84. A compound of Formula 1 wherein R1 is an optionally substituted phenyl or 5- or 6-membered heteroaromatic ring. Embodiment 85. A compound of Formula 1 wherein A is CH2 or NH. Embodiment 86. A compound of Formula 1 wherein X is selected from X1 , X2, X3, X4,
X5, X6, X7 and X8. Embodiment 87. A compound of Formula 1 wherein J is a 5- or 6-membered ring, a 8- to 11-membered bicyclic ring system or a 7- to 11 -merribered spirocyclic ring system, each ring or ring system containing ring members selected from carbon and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and up to 3 N5 and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O) and S(O)2, each ring or ring system optionally substituted with 1 to 5 sύbstituents independently selected from R5. Embodiment 88. A compound of Formula 1 wherein J is a phenyl or 5- or 6-membered heteroaromatic ring, or a naphthalenyl or 8- to 11-membered heteroaromatic bicyclic ring system, each ring or ring system optionally substituted with 1 to 5 substituents independently selected from R5; or J is a 5-, 6- or 7-membered nonaromatic ring, an 8- to 11-membered nonaromatic bicyclic or a 7- to 11- menibered spirocyclic ring system, each ring or ring system optionally including
1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O), S(O)2 and SiR17R18, and optionally substituted with 1 to 5 substituents independently selected from R5. Embodiment 89. A compound of Formula 1 wherein each R5 is independently H, C1- C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl, C4-C10 alkylcycloalkyl, Cs-C10 alkylcycloalkylalkyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3-C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 alkylsulfmyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylthio, C1-C6 haloalkylsulfinyl, C1-C6 haloalkylsulfonyl, C1-C6 alkylamino, C2-Cg dialkylamino, C3-C6 cycloalkylamino, C2-C6 alkoxyalkyl, C2-C6 haloalkoxyalkyl, C1-C6 hydroxyalkyl, C2-C6 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-C6 alkylcarbonylthio, C2-C6 alkylaminocarbonyl, C3-Cg dialkylaminocarbonyl, C3-C6 trialkylsilyl, or -Z2Q; each R7 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl, 04-C10 alkylcycloalkyl, Cs-C10 alkylcycloalkylalkyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3-C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfmyl, C1-C4 alkylsulfonyl, . C1-C4 haloalkylthio, C1-C4 haloalkylsulfinyl, C1-C4 haloalkylsulfonyl, C1-C4 alkylamino, C2-Cs dialkylamino, C3-C6 cycloalkylamino, C2-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C2-C4 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-C6 alkylcarbonylthio, C2-C6 alkylaminocarbonyl, C3-Cg 2007/014647
42 dialkylaminocarbonyl or C3-Cg trialkylsilyl; or R5 and R7 are taken together with the atoms linking R5 and R7 to form an optionally substituted 5- to 7- membered ring containing as ring members 2 to 7 carbon atoms and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and up to 1 N. Embodiment 90. A compound of Formula 1 wherein each Q is independently an optionally substituted phenyl, benzyl, naphthalenyl, C3-Cg cycloalkyl, C3-Cg cycloalkenyl or 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents selected from R7 on carbon ring members and R12 on nitrogen ring members. Embodiment 90a. A compound of Formula 1 wherein each Q is independently a 3- to 7- membered nonaromatic carbocyclic ring, a 5-, 6- or 7-membered nonaromatic heterocyclic ring or an 8- to 11-membered nonaromatic bicyclic ring system, each optionally including ring members selected from the group consisting of C(=O), C(=S), S(O), S(O)2 and SiR17R18, and optionally substituted with 1 to 5 substituents independently selected from R7 on carbon atom ring members and
R12 on nitrogen atom ring members; Embodiment 91. A compound of Formula 1 wherein each Z1 and Z2 is independently a direct bond, O, C(=O), S(O)m, CHR20 or NR21; Embodiment 92. A compound of Formula 1 wherein R21 is H, C1-C3 alkyl, C1-C3 alkylcarbonyl or C2-C3 alkoxycarbonyl.
Embodiment 93. A compound of Formula 1 wherein when G is an optionally substituted thiazole ring connected at its 2-position to X and at its 4-position to Z1 in Formula 1, A is CHR15, and J is an optionally substituted isoxazole ring connected at its 4-position to Z1, then Z1 is O, C(=O), S(O)1n, CHR20 or NR21. Embodiment 94. A compound of Formula 1 wherein when G is an optionally substituted thiazole ring connected at its 2-position to X and at its 4-position to Z1 in Formula 1, and J is an optionally substituted isoxazole ring connected at its 4-position to Zl, then Z1 is O. C(=O), S(0)m, CHR20 or NR21. Embodiment 95. A compound of Formula 1 wherein when G is an optionally substituted thiazole ring connected at its 2-position to X and at its 4-position to
Z1 in Formula 1, A is CHR15, Z1 is a direct bond, and J is an optionally substituted isoxazole ring, then J is connected to the remainder of the Formula 1 at the 3- or 5-position of the isoxazole ring. Embodiment 96. A compound of Formula 1 wherein when G is an optionally substituted thiazole ring connected at its 2-position to X and at its 4-position to
Z1 in Formula 1, A is CHR15, Z1 is a direct bond, and J is an optionally substituted isoxazole ring, then J is connected to the remainder of the Formula 1 at the 3-position of the isoxazole ring. Embodiment 97. A compound of Formula 1 wherein when G is an optionally substituted thiazole ring connected at its 2-position to X and at its 4-position to Z1 in Formula 1, Z1 is a direct bond, and J is an optionally substituted isoxazole ring, then J is connected to the remainder of the Formula 1 at the 3 -position of the isoxazole ring.
Embodiment 98. A compound of Formula 1 wherein when X is X2 and the ring containing X is saturated, A is CHR15, G is an optionally substituted 5- membered heteroaromatic ring, Z1 is a direct bond, and J is a phenyl or 5- or 6- membered heteroaromatic ring or a naphthalenyl or 8- to 11-membered heteroaromatic bicyclic ring system, then the J ring or ring system is substituted with at least one R5 that is other than H.
Embodiment 99. A compound of Formula 1 wherein when X is X2 and the ring containing X is saturated, A is CHR15, G is an optionally substituted 5- membered heteroaromatic ring, Z1 is a direct bond, and J is a phenyl or 5- or 6- membered heteroaromatic ring or a naphthalenyl or 8- to 11-membered heteroaromatic bicyclic ring system, then the J ring or ring system is substituted with at least one R5 that is Z2Q. Embodiment 100. A compound of Formula 1 wherein when X is X1 and the ring containing X is saturated, A is NH, G is an optionally substituted thiazole ring connected at its 2-position to X and at its 4-position to Z1 in Formula 1, and J is an optionally substituted imidazole ring connected at its 2-position to the remainder of Formula 1, then Z1 is O, C(=O), S(O)1n, CHR20 or NR21. Embodiment 101. A compound of Formula 1 wherein when X is X1 and the ring containing X is saturated, A is NR16, G is an optionally substituted thiazole ring connected at its 2-position to X and at its 4-position to Z1 in Formula 1, and J is an optionally substituted imidazole ring connected at its 2-position to the remainder of Formula 1, then Z1 is O, C(=O), S(O)m, CHR20 or NR21. Embodiment 102. A compound of Formula 1 wherein when G is an optionally substituted thiazole ring connected at its 2-position to X and at its 4-position to Z1 in Formula 1, then J is other than optionally substituted imidazolyl.
Embodiment 103. A compound of Formula 1 wherein each Z4 is independently C(111O) or S(O)2-
Embodiment 104. A compound of Embodiment 103 wherein each Z4 is C(=O). Embodiment 105. A compound of Formula 1 wherein each R2 is independently C1-C4 alkyl, C1-C4 alkenyl, C1-C4 haloalkyl, C1-
C4 alkoxy, halogen, cyano or hydroxy; or two R2 are taken together as Ct-Cβ alkylene or C2-C3 alkenyl ene to form a bridged bicyclic ring system; or two R2 attached to adjacent ring carbon atoms joined by a double bond are taken together as -CH=CH-CH=CH- optionally substituted with 1 to 3 substituents selected from C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1- C4 haloalkoxy, halogen, hydroxy, amino, cyano and nitro. Combinations of Embodiments 1—105 are illustrated by:
Embodiment Al. A compound of Formula 1 wherein
G is a 5-membered heteroaromatic ring or 5-membered saturated or partially saturated heterocyclic ring, each ring optionally substituted with up to 2 substituents selected from R3 on carbon ring members and selected from R11 on nitrogen ring members;
R1 is a phenyl or 5- or 6-membered heteroaromatic ring optionally substituted with 1 to 2 substituents independently selected from R4a on carbon ring members and R4b on nitrogen ring members; each R2 is independently C1-C2 alkyl, C1-C2 haloalkyl, C1-C2 alkoxy, halogen, cyano or hydroxy; each R3 is independently C1-C3 alkyl, C1-C3 haloalkyl or halogen; each R4a is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3- C6 cycloalkyl, C4-C10 cycloalkylalkyl, C4-C10 alkylcycloalkyl, C5- C10 alkylcycloalkylalkyl, C1-C6 haloalkyl, C2^-C6 haloalkenyl, C2-C6 haloalkynyl, C3-C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C4 alkoxy, Ci-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylthio, C1-C4 haloalkylsulfinyl, C1-C4 haloalkylsulfonyl, C1-C4 alkylamino, C2-C8 dialkylamino, C3-C6 cycloalkylamino, C2-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C2-C4 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-C6 alkylcarbonylthio, C2-C6 alkylaminocarbonyl, C3-Cg dialkylaminocarbonyl or C3-C6 trialkylsilyl; each R4b is independently C1-C6 alkyl, C3-C6 alkenyl, C3-C6 alkynyl, C3- C6 cycloalkyl, C1-C6 haloalkyl, C3-C6 haloalkenyl, C3-C6 haloalkynyl, C3-C6 halocycloalkyl or C2-C4 alkoxyalkyl; each R11 is independently C1-C3 alkyl; R15 is H, halogen, cyano, hydroxy, -CHO, C1-C4 alkyl, C1-C4 haloalkyl or
C2-C5 alkoxycarbonyl; R16 is H, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl or C2-C4 alkoxycarbonyl; when R5 and R7 are taken together with the atoms linking R5 and R7 to form an optionally substituted 5- to 7-membered ring, then R5 and R7 are taken together with the atoms linking R5 and R7 to form a 5- to 7-membered ring containing ring members selected from carbon and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and up to 1 N, and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O), S(O)2 and SiR17R18, the ring optionally substituted on ring members other than the atoms linking R5 and R7 with up to 4 substituents selected from R8; each R8 is independently C J-C6 alkyl, C2-Cg alkenyl, C2-C6 alkynyl, C3-Cs cycloalkyl, C4-C10 cycloalkylalkyl, C4-C10 alkylcycloalkyl, C5-C10 alkylcycloalkylalkyl, C !-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3-C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylthio, C1-C4 haloalkylsulfinyl, C1-C4 haloalkylsulfonyl, C]-C4 alkylamino, C2-Cg dialkylamino, C3-C6 cycloalkylamino, C2-C4 alkoxyalkyl, C1-^ hydroxyalkyl, C2-C4 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-C6 alkylcarbonylthio, C2-C6 alkylaminocarbonyl, C3-Cg dialkylaminocarbonyl or C3-C6 trialkylsilyl; and each Z4 is independently C(=O) or S(O)2.
Embodiment A2. A compound of Embodiment Al wherein
G is one of G-I through G-59 (as depicted in Exhibit 2) wherein the band projecting to the left is bonded to X, and bond projecting to the right is bonded to Z1; J is one of J-I through J-82 (as depicted in Exhibit 3) wherein the bond shown projecting to the left is bonded to Z1; Q is one of Q-I through Q- 102 (as depicted in Exhibit 4); R1 is one of U-I through U-50 (as depicted in Exhibit 1); each R2 is independently methyl, methoxy, cyano or hydroxy; each R3a is independently selected from H and R3; each R5 is independently H, cyano, C1-C6 aUkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3- Cg cycloalkyl, C3-Cg halocycloalkyl, C4-C1Q alkylcycloalkyl, C4-C1Q : cycloalkylalkyl, C2-C6 alkoxyalkyl, C4-C10 cycloalkoxyalkyl, C3-Cg alkoxyalkoxyalkyl, C2-C6 alkylthioalkyl, C2-C6 alkoxycarbonyl, C1-
C6 alkoxy, C1-C6 haloalkoxy, C3-C8 cycloalkoxy, C3-C8 halocycloalkoxy, C4-C10 cycloalkylalkoxy, C2-C6 alkenyloxy, C2-C6 haloalkenyloxy, C2-C6 alkynyloxy, C2-C6 haloalkynyloxy, C2-C6 alkoxyalkoxy, C2-Cg alkylcarbonyloxy, C2-C6 haloalkylcarbonyloxy, C4-C8 cycloalkylcarbonyloxy, C3-C6 alkylcarbonylalkoxy, Ci-Cg alkylthio, C1-C6 haloalkylthio, C3-C8 cycloalkylthio, C3-C10 trialkylsilyl, -NR25R26 or Z2Q; R11 a is selected from H and R11 ;
R15 is H, cyano, hydroxy, methyl or methoxycarbonyl; R16 is H, methyl, methylcarbonyl or methoxycarbonyl; each Z4 is C(=O); k is 0, 1 or 2; p is 0, 1, 2 or 3; and x is an integer from 0 to 5; provided that:
(a) when R4 is attached to a carbon.ring member, said R4 is selected from R4a; (b) when R4 is attached to a nitrogen ring member (e.g., in U-4, U-I l through
U-15, U-24 through U-26, U-31 or U-35), said R4 is selected from R4b;
(c) when G is G-6, G-16 or G-42, and each R3a is other than H, then R1 la is
H;
(d) when G is G-25 or G-31, then at least one R3a is H; and (e) when G is one of G-31 through G-35, then Z1 is a direct bond or CHR20.
Embodiment A3. A compound of Embodiment A2 wherein
G is selected from G-I, G-2, G-7, G-8, G-14, G-15, G-23, G-24, G-26, G-27,
G-36, G-37. G-38, G-49, G-50 and G-55;
J is selected from J-I, J-2S J-3, J-4, J-5, J-7, J-8, J-9, J-10, J-Il, J-12, J-14, J- • 15, J-16, J-20, J-24, J-25, J-26, J-29, J-30, J-37, J-38, J-45 and J-69; each Q is independently Q-I, Q-20, Q-32 through Q-34, Q-45 through Q-47, Q-60 through Q-73, Q-76 through Q-79, Q-84 through Q-94 and Q-98 through Q-102; A is CH2 or NH; W is O;
X iS X^ X2 Or X3; each R5 is independently H, cyano, Cj-Cg alkyl, C1-Cg haloalkyl, C3-Cg cycloalkyl, C3-C8 halocycloalkyl, C2-C6 alkoxyalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-Cg cycloalkoxy, C2-C6 alkenyloxy, C2-C6 haloalkenyloxy, C2-Cg alkynyloxy, C2-C6 alkoxyalkoxy, C2-C6 alkylcarbonyloxy, C2-C6 haloalkylcarbonyloxy, C1-C6 alkylthio, C1- C6 haloalkylthio, C3-C10 trialkylsilyl, -NR2^R2S or Z2Q; Z1 is a direct bond; Z2 is a direct bond or NR21;
Rl is selected from U-I through U-3, U-11, U-13, U-20, U-22, U-23, U-36 through U-39 and U-50; each R3 is independently methyl or halogen; each R4a is independently C1-C2 alkyl, C1-C2 haloalkyl, halogen, C1-C2 alkoxy or C1-C2 haloalkoxy; each R4b is independently C1-C2 alkyl or C1-C2 haloalkyl; each R7 is independently halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, hydroxy, C1-C2 alkoxy or C1-C2 haloalkoxy; k is l or 2; and n is 0.
Of note are Embodiment A3 compounds wherein one R5 is Z2Q and any other R5 substituents are independently selected from H, C1-C6 alkyl, C1-Cg haloalkyl, C3-Cg cycloalkyl, C3-Cg halocycloalkyl, C2-Cg alkoxyalkyl, C1-Cg alkoxy, C1-Cg haloalkoxy, C3-Cs cycloalkoxy, C2-Cg alkenyloxy, C2-Cg haloalkenyloxy, C2-Cg alkynyloxy, C2-Cg alkoxyalkoxy, C2-Cg alkylcarbonyloxy, C2-Cg haloalkylcarbonyloxy, C1-Cg alkylthio, C1- C6 haloalkylthio, C3-C10 trialkylsilyl and -NR25R26. Also of note are Embodiment A3 compounds wherein all R5 substituents are other than Z2Q (e.g., each R5 is independently selected from H, C1-Cg alkyl, C1-Cg haloalkyl, C3-Cg cycloalkyl, C3-Cg halocycloalkyl, C2-C6 alkoxyalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C8 cycloalkoxy, C2-C6 alkenyloxy, C2-Cg haloalkenyloxy, C2-Cg alkynyloxy, C2-Cg alkoxyalkoxy, C2-Cg alkylcarbonyloxy, C2-Cg haloalkylcarbonyloxy, C1-Cg alkylthio, C1-Cg haloalkylthio, C3- C10 trialkylsilyl and -NR25R26).
Embodiment A4. A compound of Embodiment A3 wherein A is CH2;
G is selected from G-I, G-2, G-15, G-26, G-27, G-36, G-37 and G-38; and G is unsubstituted; J is selected from J-4, J-5, J-8, J-Il, J-15, J-16, J-20, J-29, J-30, J-37, J-38, . and 3-69; Q is selected from Q-I, Q-45, Q-63, Q-64, Q-65, Q-68, Q-69, Q-70, Q-71, Q-
72, Q-73, Q-76, Q-78, Q-79, Q-84, Q-85, Q-98, Q-99, Q-100, Q-101 and Q-102;
X is X1 or X2; and the ring comprising X is saturated; RUs U-I or U-50; each R4a is independently C1-C2 alkyl, trifluoromethyl, Cl, Br3 1 or methoxy; each R4b is independently C1-C2 alkyl or trifluoromethyl; and each R5 is independently H, cyano, C1-Cg alkyl, C1-Cg haloalkyl, C1-Cg alkoxy, C1-C6 haloalkoxy, -NR25R26 or Z2Q. Embodiment A5. A compound of Embodiment A4 wherein G is selected from G-I, G-2, G-15, G-26 and G-36; J is selected from J-4, J-5. J-I l, J-20, J-29, J-37, J-38, and J-69; Q is selected from Q-45, Q-63, Q-64, Q-65, Q-68, Q-69, Q-70, Q-71, Q-72 and Q-85; and
X is X1. Embodiment A6. A compound of Formula 1 wherein
R1 is an optionally substituted phenyl or 5- or 6-membered heteroaromatic ring; A is CH2 or NH;
X is Xl , X2, X3, χ45 χ5? χ65 χ7 or χ8; each R2 is independently C1- C4 alkyl, C1-C4 alkenyl, C1- C4 haloalkyl, C1- C4 alkoxy, halogen, cyano or hydroxy; or two R2 are taken together as C1- C3 alkylene or C2- C3 alkenylene to form a bridged bicyclic ring system; or two R2 attached to adjacent ring carbon atoms joined by a double bond are taken together as -CH=CH-CH=CH- optionally substituted with 1 to 3 substituents selected from Cj-C4 alkyl, Cj-C4 haloalkyl, Cj-C4 alkoxy, C1-C4 haloalkoxy, halogen, hydroxy, amino, cyano and nitro; G is an optionally substituted 5-membered heteroaromatic ring or 5- membered saturated or partially saturated heterocyclic ring;
J is a 5- or 6-membered ring or a 8- to 11-membered bicyclic ring system, each ring or ring system containing ring members selected from carbon and optionally 1 to 3 hetefoatoms selected from up to 1 O, up to 1 S and up to 3 N, and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O), or S(O)2, each ring or ring system optionally substituted with 1 to 5 substituents independently selected from R5; each R5 is independently H, Cj-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3- C6 cycloalkyl, C4-C10 cycloalkylalkyl, C4-C10 alkylcycloalkyl, C5-
C10 alkylcycloalkylalkyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C^ haloalkynyl, C3— C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 alkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylthio, C1-C6 haloalkylsulfinyl, C1-C6 haloalkylsulfonyl, Cj-C6 alkylamino, C2-Cg dialkylamino, C3~C6 cycloalkylamino, C2-C6 alkoxyalkyl, C2-C6 haloalkoxyalkyl, C1-C6 hydroxyalkyl, C2-C6 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-C6 alkylcarbonylthio, C2— Cg alkylaminocarbonyl, C3-C8 dialkylarαinocarbonyl, C3— Cg trialkylsilyl, or -Z2Q; each Q is independently an optionally substituted phenyl, benzyl, naphthalenyl, C3-Cg cycloalkyl, C3-Cg cycloalkenyl or 5- or 6- membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents selected from R7 on carbon ring members and R12 on nitrogen ring members; each R7 is independently C1-Cg alkyl, C2-C6 alkenyl, C2-Cg alkynyl, C3-Cg cycloalkyl, C4-C1Q cycloalkylalkyl, C4-C10 alkylcycloalkyl, C5-C10 alkylcycloalkylalkyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3-Cg halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C4 alkoxy, C1-C4 haloalkoxy, Q-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylthio, C1-C4 haloalkylsulfinyl, C1-C4 haloalkylsulfonyl, C1-C4 alkylamino, C2-Cg dialkylamino, C3-C6 cycloalkylamino, C2-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C2-C4 alkylcarbonyl, C2-Cg alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-C6 alkylcarbonylthio, C2-C6 alkylaminocarbonyl, C3-Cg dialkylaminocarbonyl or C3-C6 trialkylsilyl; or R5 and R7 are taken together with the atoms linking R5 and R7 to form an optionally substituted 5- to 7-membered ring containing as ring members 2 to 7 carbon atoms and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and up to 1 N; Rl2 is C1-C3 alkyl; each Z1 and Z2 are independently a direct bond, O. S(O)m, CHR20 or NR21 ; and
R21 is H or C1-C3 alkyl. Embodiment A7. A compound of Embodiment A6 wherein
G is a 5 -membered heteroaromatic ring or 5 -membered saturated or partially saturated heterocyclic ring, each ring optionally substituted with up to 2 substituents selected from R3 on carbon ring members and selected from R1 J on nitrogen ring members;
R1 is a phenyl or 5- or 6-membered heteroaromatic ring optionally substituted with 1 to 2 substituents independently selected from R4a on carbon ring members and R4b on nitrogen ring members; each R3 is independently C1-C3 alkyl, C1-C3 haloalkyl or halogen; each R4a is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3- C6 cycloalkyl, C4-C10 cycloalkylalkyl, C4-C10 alkylcycloalkyl, C5- C10 alkylcycloalkylalkyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3-C5 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfrnyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylthio, C1-C4 haloalkylsulfinyl, C1-C4 haloalkylsulfonyl, C1-C4 alkylamino, C2-C8 dialkylamino, C3~C6 cycloalkylamino, C2-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C2- C4 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-C6 alkylcarbonylthio, C2-C6 alkylaminocarbonyl, C3-C8 dialkylaminocarbonyl or C3-C6 trialkylsilyl; each R4b is independently C1-C6 alkyl, C3-C6 alkenyl, C3-C6 alkynyl, C3- C6 cycloalkyl, C1-C6 haloalkyl, C3-C6 haloalkenyl, C3-C6 haloalkynyl, C3-C6 halocycloalkyl or C2- C4 alkoxyalkyl; each R11 is independently C1-C3 alkyl; and when R5 and R7 are taken together with the atoms linking R5 and R7 to form an optionally substituted 5- to 7-membered ring, then R5 and R7 are taken together with the atoms linking R5 and R7 to form a 5- to 7-membered ring containing as ring members 2 to 7 carbon atoms and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and up to 1 N, optionally substituted with up to 2 substituents selected from R8;
• and each R8 is independently C1-C3 alkyl. Embodiment A8. A compound of Embodiment A7 wherein
G is one of G-I through G-55 (as depicted in Exhibit 2) wherein the bond projecting to the left is bonded to X, and bond projecting to the right is bonded to Z1;
J is one of J-I through J-82 (as depicted in Exhibit 3) wherein the bond shown projecting to the left is bonded to Z1; Q is one of Q-I through Q-55 (as depicted in Exhibit 4); R1 is one of U-I through U-50 (as depicted in Exhibit 1); each R3a is independently selected from H and R3;
R1 la is selected from H and R11; k is 0, 1 or 2; p is 0, 1 or 2; and x is an integer from 0 to 5; provided that:
(a) when R4 is attached to a carbon ring member, said R4 is selected from R4a; (b) when R4 is attached to a nitrogen ring member (e.g., in U-4, U-I l through
U-15, U-24 through U-26, U-31 or U-35), said R4 is selected from R4b;
(c) when G is G-6, G-16 or G-42, and each R3a is other than H, then R1 la is
H; (d) when G is G-25 or G-31 , then at least one R3a is H; and
(e) when G is one of G-31 through G-35, then Z1 is a direct bond or CHR20. Embodiment A9. A compound of Embodiment A8 wherein
G is selected from G-I, G-2, G-15, G-26, G-27, G-36, G-37 and G-38; J is selected from J-I, J-2, J-3, J-4, J-5, J-7, J-8, J-9, J-IO, J-I l, J-12, J-14, J-15, J-16, J-20, J-24, J-25, J-26, J-29, J-30, J-45 and J-69; each Q is independently Q-I, Q-20, Q-32 to 34, Q-45 Q-46 or Q-47; W is O;
X is X1, X2 or X3; each Z1 and Z2 is a direct bond; RMs selected from U-I through U-3, U-Il, U-13, U-20, U-22, U-23, U-36 through U-39 and U-50; each R3 is independently methyl or halogen; each R4a is independently C1-C2 alkyl, C1-C2 haloalkyl, halogen or C1-C2 alkoxy; each R4b is independently C1-C2 al^Y1 or Cl-Qz haloalkyl; one instance of R5 is Z2Q and other instances of R5 are independently selected from H, CJ-C4 alkyl, CJ-C4 haloalkyl and halogen; each R7 is independently halogen, C1-C3 alkyl, Cj-C3 haloalkyl, hydroxy,
C1-C2 alkoxy or C1-C2 haloalkoxy; k is 1 or 2; and n is 0.
Embodiment Al 0. A compound of Embodiment A9 wherein A is CH2;
G is selected from G-I, G-2, G-15, G-26, and G-36; and G is unsubstituted; J is selected from J-Il, J-25, J-26, J-29 and J-30;
Q is selected from Q-I and Q-45; X is X1 or X2; and the ring comprising X is saturated; Rl is U-I or U-50; each R4a is independently C1-C2 alkyl, trifluoromethyl, Cl, Br, I or methoxy; and each R4b is independently Cj-C2 alkyl or trifluoromethyl. Embodiment Al 1. A compound of Embodiment AlO wherein J is selected from J-11 and J-29; X is Xl; and each R4a is independently C1-C2 alkyl, trifluoromethyl or Cl. Embodiment A 12. A compound of Formula 1 wherein
R1 is U-I or U-50 (as depicted in Exhibit 1) wherein when R4 is attached to a carbon ring member, said R4 is selected from R4a, and when R4 is attached to a nitrogen ring member, said R4 is selected from R4b; each R4a is independently C1-C2 alkyl, trifluoromethyl, Cl, Br, I or methoxy; each R4b is independently C]- C2 alkyl or trifluoromethyl; A is CH2; W is O;
X is X1 or X2 and ring comprising X is saturated; each R2 is independently ethyl, methoxy, cyano or hydroxy;
G is selected from G-I, G-2, G- 15, G-26 and G-36 (as depicted in Exhibit 2) wherein the bond projecting to the left is bonded to X, and bond projecting to the right is bonded to Z1 ; and G is unsubstituted; each R3a is independently selected from H and R3; each R3 is independently methyl or halogen; J is selected from J-11, J-25, 3-26, J-29 and J-30 (as depicted in Exhibit 3); wherein the bond shown projecting to the left is bonded to Z1 ; each R5 is independently H, halogen, cyano, hydroxy, amino, nitro, -CHO,
-C(=O)OH, -CO=O)NH2, -NR25R26, C1-C6 alkyl, C2-C6 alkenyl, C2- C6 alkynyl, Cj-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C4-C10 alkylcycloalkyl, C4- Cio cycloalkylalkyl, C6- C14 cycloalkylcycloalkyl, C4— CJQ halocycloalkylalkyl, C5-C10 alkylcycloalkylalkyl, C3-C8 cycloalkenyl,
C3-Cg halocycloalkenyl, C2-C6 alkoxyalkyl, C4-C10 cycloalkoxyalkyl, C3-C8 alkoxyalkoxyalkyl, C2-C6 alkylthioalkyl, C2-C6 alkylsulfinylalkyl, C2-C6 alkylsulfonylalkyl, C2-C6 alkylaminoalkyl, C3-Cg dialkylaminoalkyl, C2-C6 haloalkylaminoalkyl, C4-C10 cycloalkylaminoalkyl, C2-C6 alkylcarbonyl, C2-C6 haloalkylcarbonyl,
C4-Cg cycloalkylcarbonyl, C2-C^ alkoxycarbonyl, C4-Cg cycloalkoxycarbonyl, C5-CJ0 cycloalkylalkoxycarbonyl, C2-C6 alkylaminocarbonyl, C3-Cg dialkylaminocarbonyl, C4-C8 cycloalkylaminocarbonyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-Cg cycloalkoxy, C^-Cs halocycloalkoxy, C4— C1Q cycloalkylalkoxy, C2-C6 alkenyloxy, C2-C6 haloalkenyloxy, C2-C6 alkynyloxy, C2-C6 haloalkynyloxy, C2-C6 alkoxyalkoxy, C2-C^ alkylcarbonyloxy, C2-C^ haloalkylcarbonyloxy, C4-C8 cycloalkylcarbonyloxy, C3-C6 alkylcarbonylalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C3-C8 cycloalkylthio, C1-C6 alkylsulfinyl, C1-Cg haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C3-Cg cycloalkylsulfonyl, C3- C10 trialkylsilyl, C1-C6 alkylsulfonylamino, C1-C6 haloalkylsulfonylamino or -Z2Q;
R25 is H, C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, C2-C6 alkylcarbonyl, C2-C6 haloalkylcarbonyl, C2-C6 alkoxycarbonyl or C2- C6 haloalkoxycarbonyl; R26 is C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, C2-C6 alkylcarbonyl, C2-C6 haloalkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 haloalkoxycarbonyl or -Z4Q; each Q is selected from Q-I, Q-45 and Q-63 (as depicted in Exhibit 4); each R7 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl, C4-C1o alkylcycloalkyl, C5-CJQ alkylcycloalkylalkyl, C ^6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3-C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsuifinyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylthio, C1-C4 haloalkylsulfinyl, C1-C4 haloalkylsulfonyl, C1-C4 alkylamino, C2-C8 dialkylamino, C3-C6 cycloalkylamino, C2-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C2- C4 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-C6 alkylcarbonylthio, C2-C6 alkylaminocarbonyl, C3-Cg dialkylaminocarbonyl or C3-C6 trialkylsilyl; or R5 and R7 are taken together with the atoms linking R5 and R7 to form a 5- to
7-membered ring containing as ring members 2 to 7 carbon atoms and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S, up to 1 Si and up to 1 N, the ring optionally substituted on ring members other than the atoms linking R5 and R7 with up to 4 substituents selected from R8; each R8 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl, C4-C10 alkylcycloalkyl, C5-C10 alkylcycloalkylalkyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3-C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylthio, C1-C4 haloalkylsulfinyl, C1-C4 haloalkylsulfonyl, C1-C4 alkylamino, C2-C8 dialkylamino, C3-C6 cycloalkylamino, C2-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C2-C4 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-C6 alkylcarbonylthio, C2-C6 alkylaminocarbonyl, C3— Cg dialkylaminocarbonyl or C3-C6 trialkylsilyl; R12 is C1-C3 alkyl; each Z1 and Z2 is a direct bond; each Z4 is independently C(=O) or S(O)2; n is 0. 1 or 2; k is 0, 1 or 2; p is 0, 1 or 2; and x is an integer from 0 to 5; provided that when R1 is unsubstituted thienyl, X is X1, G is an unsubstituted thiazole ring connected at its 2-position to X and at its 4-position to Z1 in Formula 1, and J is an isoxazole ring connected at its 4-position to Z1 and substituted at its 5-position with methyl, then J is not substituted and at its 3-position with meta-substituted phenyl.
Embodiments of the present invention also include: Embodiment Bl. A compound of Formula IA wherein each R4al and R4a2 is independently C1-C3 alkyl, C2-^-C3 alkenyl, C2-C3 alkynyl, cyclopropyl, Cj- C3 haloalkyl, halocyclopropyl, halogen, cyano, nitro, Cj-C2 alkoxy or C1-C2 haloalkoxy.
Embodiment B2. A compound of Embodiment Bl wherein each R4al and R4a2 is independently C1-C3 alkyl, C1-C3 haloalkyl, halogen, cyano, C1-C2 alkoxy or' C1-C2 haloalkoxy.
Embodiment B3. A compound of Embodiment B2 wherein each R4al and R4a2 is independently C1-C3 alkyl, C1-C3 haloalkyl or halogen.
Embodiment B4. A compound of Formula IA wherein Aa is H. Embodiment B5. A compound of Formula IA wherein Aa is CH2CO2H. Embodiment B6. A compound of Formula IA wherein Aa is CH2CO2R30. Embodiment B7. A compound of Formula IA wherein Aa is CH2C(^O)Cl. Embodiment B8. A compound of Formula IB wherein each R4al and R4a2 is independently C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, cyclopropyl, C1-C3 haloalkyl, halocyclopropyl, halogen, cyano, nitro, C1-C2 alkoxy or C1-C2 haloalkoxy.
Embodiment B9. A compound of Embodiment B8 wherein each R4al. and R4a2 is independently C1-C3 alkyl, C1-C3 haloalkyl, halogen, cyano, C1-C2 alkoxy or
C1-C2 haloalkoxy.
Embodiment BlO. A compound of Embodiment B9 wherein each R4al and R4a2 is independently C1-C3 alkyl, C1-C3 haloalkyl or halogen. Embodiment Bl 1. A compound of Formula IB wherein Z3 is CN. Embodiment B12. A compound of Formula IB wherein Z3 is C(=S)NH2-
With regards to the compounds of Formula 1C of this invention, it is noted that various embodiments of J-29 can be present in two or more enantiomeric forms. The enantiomeric forms of J-29 embodiments for compounds of Formula 1C of this invention are those depicted about in the Exhibit A above. All J-29 enantiomers are included in the Formula 1C compounds in this invention for embodiments where no specific J-29 enantiomeric form is depicted (e.g., J-29-33 enantiomers and J-29-22 enantiomers based on the methyl group position). Embodiment Bl 3. A compound of Formula 1C wherein M is Cj— C2 alkyl, Ci- C2 haloalkyl, hydroxy, C1-C4 alkoxy, CJ-C2 haloalkoxy, C1-C3 alkylamino, C2- Cs dialkylamino, 1-piperidinyl, l-pyrrolidinyl or 4-morpholinyl.
Specific embodiments include compounds of Formula 1 selected from the group consisting of: 4-[4-[(5/.)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-l-[[5-methyl-3-
(trifluoromethyl)-l/ϊ-pyrazol-l-yl]acetyl]piperidine and its enantiomer (Compound
1). l-[[5-methyl-3-(trifluoromethyl)-lH-pyrazol-l-yl]acetyl]-4-[4-(5-phenyl-3- isoxazolyl)-2-thiazolyl]piperidine (Compound 2), l-[4-[4-[(5R)-4,5-dihydro-5-methyl-5-phenyl-3-isoxazolyl]-2-thiazolyl]-l- piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-lH-pyrazol-l-yl]ethanone and its enantiomer (Compound 15),
2-[5-methyl-3-(trifluoromethyl)-lH-pyrazol-l-yl]-l-[4-[4-[(3a5,9bi?),3a,4,5,9b- tetrahydronaphth[2, 1 -fi(]isoxazol-3-yl]-2-thiazolyl]- 1 -piperidinyl]ethanone and its enantiomer (Compound 16), l-[4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-l-piperidinyl]-2-[5τ ethyl-3-(trifluoromethyl)-liϊ-pyra2ol-l-yl]ethanone and its enantiomer (Compound 19),
2-[3,5-bis(trifluoromethyl)-lH-pyrazol-l-yl]-l-[4-[4-[(5/?)-4,5-dihydro-5-phenyl-3- isoxazolyl]-2-thiazolyl]-l-piperidinyl]ethanone and its enantiomer (Compound 22), l_[4.[4-[(5JR)-3',41-dihydrospiro[isoxazole-5(4A!)5r,(2tH)-naphthalen3-3-yl]-2- thiazolyl]- 1 -piperidinyl] -2-[5-methyl-3-(trifluoromethyl)- liY-pyrazol- 1 -yl] ethanone and its enantiomer (Compound 37), 1 -[4-[4-[(5R)-2,3-dihydrospiro[lH-indene- 1 ,5'(4IH)-isoxazol]-3'-yl]-2-thiazolyl]-l - piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-li-T-pyrazol-l-yl]ethanone and its enantiomer (Compound 44), l-tS-chloro-S-CtrifluoromethyO-lH-pyrazol-l-yη-l-μ-μ-tCS^^^-dihydro-S- phenyl-3-isoxazoly]-2-thiazolyl]-l-piperidinyl]ethanone and its enantiomer
(Compound 107),
2-[(5R)-4,5-dihydro-3-[2-[l-[2-[5-methyl-3-(trifluoromethyl)-lH-pyrazol~l-. yl]acetyl]-4-piperidinyl]-4-thiazolyl-5-isoxazolyl]-l/f-isoindole-l,3(2H)-dione and its enantiomer (Compound 129), 2-[5-chloro-3-(trifluoromethyl)-lH;-pyrazol-l-yl]-l-[4-[4-[(lJR)-253-dihydrospiro[lH- indene-1 ,5 ' (4'Η)-isoxazol] -3 ' -yl] -2-thiazolyl] - 1 -piperidinyl] ethanone and its enantiomer (Compound 232),
2-[5-chloro-3-(trifluoromethyl)-lH"-pyrazol-l-yl]-l-[4-[4-[(l'i?)-3',4'- dihydrospiro[isoxazole-5(4H),r(2'H)-naphthalen]-3-yl]-2-thiazolyl]-l- piperidinyl] ethanone and its enantiomer (Compound 230),
2-[5-methyl-3-(trifluoromethyl)- 1 H-pyrazol- 1 -yl]- 1 -[4-[4-(3i?)-spiro[benzofuran- 3(2H),5'(4'H)-isoxazol]-3'-yl-2-thiazolyl]-l-piperidinyl]ethanone and its enantiomer (Compound 185), l_[4.[4-[(li?).2,3-dmydrospiro[lH-indene-l,5'(4'H)-isoxazol]-3'-yl]-2-thiazolyl]-l- piperidinyl-2-(355-dimethyl-li!ϊ-pyrazol-l-yl)ethanone and its enantiomer
(Compound 165),
2-[3,5-bis(trifluoromethyl)-lH-pyrazol-l-yl]-l-[4-[4-[(l'Λ)-3'.4'- dihydrospiro[isoxazole-5(4J?-0J 1 '(2'fl)-naphthalen]-3-yl]-2-thiazolyl]-l- piperidinyl] ethanone and its enantiomer (Compound 229), 2-[3,5-bis(trifluoromethyl)-lH;-ρyrazol-l -yl]-l -[4-[4-[(li,)-2,3-dihydrospiro[lH;- indene- 1 , 5 ' (4 'H)-isoxazol]-3 ' -yl] -2-thiazolyl] - 1 -piperidinyl] ethanone and its enantiomer (Compound 231),
1 -[4-[4-[(5R)-5-(2,6-dichlorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]- 1 - piperidinyl]-2-[5-methyl-3-(trifluoromethyl)- 1 H-pyrazol- 1 -yl]ethanone and its enantiomer (Compound 135), l-[4-[4-[(5R)-4,5-dihydro-5-[2-(trifluoromethyl)phenyl]-3-isoxazolyl]-2-thiazolyl]- l-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-li:f-pyrazol-l-yl]ethanone and its enantiomer (Compound 79), l-[4-[4-[(5R)-4,5-dihydro-5-(2-methylphenyl)-3-isoxazolyl]-2-thiazolyl]-l- piperidinyl]-2-[5-methyl-3-(1xifluoromethyl)-lH-pyrazol-l-yl]ethanone and its enantiomer (Compound 161), l-[4-[4-[(5R)-5-(2,6-diraethylphenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyI]-l- piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-liϊ-pyra2;ol-l-yl3ethanone and its enantiomer (Compound 178), l-[4-[4-[(5R)-4,5-dihydro-5:(2,4,6-trimethylphenyl)-3-isoxazolyl]-2-thiazolyl]-l- piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-liϊ-pyrazol-l -yljethanone and its enantiomer (Compound 179), l-[4-[4-[(l 'Λ)-3 %4'-dihydrospiro[isoxazole-5(4H),l '(2'H)-naphthalen]-3-yl]-2- thiazolyl]-l -piperidϊnyl]-2-(3,5-dimethyl-lJcZ"-pyrazol-l-yl)ethanone and its enantiomer (Compound 164), l_[4-[4_[(5dR)-4j5-dihydro-5-(2,4,6-trimethoxyphenyl)-3-isoxazolyl]-2-thiazolyl]-l- piperidmyl]-2-[5-methyl-3-(trifluoromethyl)-li^-pyrazol- 1 -yl]ethanone and its enantiomer (Compound 155),
3-[(5R)-4,5-dihydro-3-[2-[l-[2-[5-methyl-3-(trifluoromethyl)-lH-pyrazol-l- yl]acetyl] -4-piperidinyl]-4-thiazolyl]-5-isoxazolyl]-2(3H)-benzoxazolone and its enantiomer (Compound 225),
1 -[4-[4-[(5R)-5-(2,6-difluorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]- 1 - piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-lH-pyrazol- 1 -yl]ethanone and its enantiomer (Compound 214),
2-[(5R)-4,5-dihydro-3-[2-[l -[2-[5-methyl-3-(trifluoromethyl)-lH;-pyrazol- 1 - yl]acetyl]-4-piperidinyl]-4-thiazolyl]-5-isoxazolyl]benzonitrile and its enantiomer (Compound 220), 2-[5-cmoro-3<trifluoromethyl)-lH-pyrazol-l-yl]-l-[4-[4-[(5JR)-4,5-dihydro-5- methyl-5-phenyl-3-isoxazolyl]-2-thiazolyl]-l-piperidinyl]ethanone and its enantiomer (Compound 261),
2-[3,5-bis(triflyoromethyl)- lH-ρyrazol- 1 -yl]- 1 -[4-[4-[(5i-)-4,5-dihydro-5-methyl-5- phenyl-3-isoxazolyl]-2-thiazolyl]-l-piperidinyl]ethanone and its enantiomer (Compound 260), l-[4-[4-[(5R)-5-(2-chlorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-l- piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-lH;-pyrazol-l-yl]ethanone and its enantiomer (Compound 8), l_[4-[4-[(5R)-4,5-dihydτo-5-phenyl-3-isoxazolyl]-2-thiazolyl]-l-piperidinyl]-2-[3- methyl-5-(trifluoromethyl)-liϊ-pyrazol-l-yl]ethanone and its enantiomer (Compound 128),
. l-[4-[4-[(45)-2,3-dihydrospiro[4H-l-benzopyran-455'(4'H)-isoxazol]-3'-yl)-2- thiazolylJ-l-piperidinyll^-tS-methyl-S-CtrifluoromethyO-liϊ-pyrazol-l-ylletlianone and its enantiomer (Compound 137), and
(5R)-4,5-dihydro-3-[2-[l-[2-[5-methyl-3-(trifiuoromethyl)-liϊ-pyrazol-l-yl]acetyl]- 4-piperidinyl]-4-thiazolyl]-5-phenyl-5-isoxazolecarbonitrile and its enantiomer (Compound 265). Specific embodiments also include compounds of Formula IB selected from the group consisting of: l-[2-[5-methyl-3-(trifluoromethyl)-lH-pyrazol-l-yl]acetyl]-4- piperidinecarbothioamide, l-[2-[3,5-bis(trifluoromemyl)-lH-pyrazol-l-yl]acetyl]-4-piperidmecarbotbioamide:, 1 -[2-[5-methyl-3-(trifluoromethyl)- lϋf-pyrazol- 1 -yl]acetyl] -4-piperidinecarbonitrile, and l-[2-[3,5-bis(trifluoromethyl)-lH-pyrazol-l-yl]acetyl]-4-piperidinecarbonitrile.
Of note are compounds of Formula 1, including all geometric and stereoisomers, Λ/-oxides, and agriculturally suitable salts thereof, agricultural compositions containing them and their use as fungicides wherein
R1 is an optionally substituted phenyl or 5- or 6-membered heteroaromatic ring; A is CH2 or NH;
X is Xl, X2, X3, X4, X5, X6, X7 or X«; each R2 is independently C1-C4 alkyl, C1-C4 alkenyl, C1-C4 haloalkyl, C1-C4 alkoxy, halogen, cyano or hydroxy; or two R2 are taken together as C1-C3 alkylene or C2-C3 alkenylene to form a bridged bicyclic ring system; or two R2 attached to adjacent ring carbon atoms joined by a double bond are taken together as -CH=CH-CH=CH- optionally substituted with 1 to 3 substituents selected from C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, halogen, hydroxy, amino, cyano and nitro;
J is a 5- or 6-membered ring or a 8- to 11-membered bicyclic ring system, each ring or ring system containing ring members selected from carbon and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and up to 3 N, and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O), or S(O)2, each ring or ring system optionally substituted with 1 to 5 substituents independently selected from R5; each R5 is independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C1Q cycloalkylalkyl, C4-C1Q alkylcycloalkyl, C5-CiQ alkylcycloalkylalkyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl,
C3-C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, Cj-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 alkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylthio, C1-C6 haloalkylsulfinyl, C1-C6 haloalkylsulfonyl, C1-C6 alkylamino, C2-Cg dialkylarnino, C3-C6 cycloalkylamino, C2-C6 alkoxyalkyl, C2-C6 haloalkoxyalkyl, C1-C6 hydroxyalkyl, C2-C6 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-C6 alkylcarbonylthio, C2-C6 alkylaminocarbonyl, C3-C8 dialkylaminocarbonyl, C3-C6 trialkylsilyl, or -Z2Q; each Q is independently an optionally substituted phenyl, benzyl, naphthalenyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl or 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents selected from R7 on carbon ring members and R12 on nitrogen ring members; each R7 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl, C4-C10 alkylcycloalkyl, C5-C10 alkylcycloalkylalkyl, Cj-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3-C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C4 alkoxy,
C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfmyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylthio, C1-C4 haloalkylsulfinyl, C1-C4 haloalkylsulfonyl, C1-C4 alkylamino, C2-Cg dialkylamino, C3-C6 cycloalkylamino, C2-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C2-C4 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-C6 alkylcarbonylthio, C2-C6 alkylaminocarbonyl, C3-Cg dialkylaminocarbonyl or C3-C6 trialkylsilyl; or
R5 and R7 are taken together with the atoms linking R^ and R7 to form an optionally substituted 5- to 7-membered ring containing as ring members 2 to 7 carbon atoms and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and up to 1 N;
R12 is C1-C3 alkyl; each Zl and Z2 is independently a direct bond, O, S(O)m, CHR20 or NR21; R21 is H or C1-C3 alkyl; and m is 0, 1 or 2 (which is understood to mean that each m is independently 0, 1 or 2). Also of note are compounds of Formula 1, including all geometric and stereoisomers,
TV-oxides, and salts thereof, agricultural compositions containing them and their use as fungicides wherein each R5 is independently H, halogen, cyano, hydroxy, amino, nitro, -CHO, -C(=O)OH, -C(=0)NH2, -NR25R26, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3-C8 cycloalkyl, C3-Cg halocycloalkyl, C4-C10 alkylcycloalkyl, 04-C10 cycloalkylalkyl, C6-Ci4 cycloalkylcycloalkyl, 04-C1Q halocycloalkylalkyl, Cs-C1Q alkylcycloalkylalkyi,
C3-Cg cycloalkenyl, C3-Cg halocycloalkenyl, C2-C6 alkoxyalkyl, C4-C10 cycloalkoxyalkyl, C3-Cg alkoxyalkoxyalkyl, C2-C6 alkylthioalkyl, C2-C6 alkylsulfinylalkyl, C2-C6 alkylsulfonylalkyl, C2-C6 alkylaminoalkyl, C3-Cg dialkylaminoalkyl, C2-C6 haloalkylaminoalkyl, C4-C10 cycloalkylatninoalkyl, C2-C6 alkylcarbonyl, C2-C6 haloalkylcarbonyl, C4-C8 cycloalkylcarbonyl, C2-
C6 alkoxycarbonyl, C4-Cg cycloalkoxycarbonyl, Cs-C10 cycloalkylalkoxycarbonyl, C2-C6 alkylaminocarbonyl, C3-Cg dialkylaminocarbonyl, C4-Cg cycloalkylaminocarbonyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-Cg cycloalkoxy, C3-Cg halocycloalkoxy, C4-C10 cycloalkylalkoxy, C2-Cs alkenyloxy, C2-C^ haloalkenyloxy, C2-C6 alkynyloxy,
C2-C6 haloalkynyloxy, C2-C6 alkoxyalkoxy, C2-C6 alkylcarbonyloxy, C2-C6 haloalkylcarbonyloxy, C4-Cg cycloalkylcarbonyloxy, C3-C6 alkylcarbonylalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C3-C8 cycloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C3-Cg cycloalkylsulfonyl, C3-C10 trialkylsilyl, C1-C6 alkylsulfonylamino, C1-C6 haloalkylsulfonylamino or -Z2Q; each R7 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl, C4-C10 alkylcycloalkyl, 05-C10 alkylcycloalkylalkyi, C1-C6 haloalkyl, C2-C6 haloalkenyl. C2-C6 haloalkynyl, C3-C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro. C1-C4 alkoxy,
C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylthio, C1-C4 haloalkylsulfinyl, C1-C4 haloalkylsulfonyl, C1-C4 alkylamino, C2-Cg dialkylamino, C3-C6 cycloalkylamino, C2-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C2-C4 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-C6 alkylcarbonylthio, C2-C6 alkylaminocarbonyl, C3-Cg dialkylaminocarbonyl or C3-C6 trialkylsilyl; or
R5 and R7 are taken together with the atoms linking R5 and R7 to form an optionally substituted 5- to 7-membered ring containing as ring members 2 to 7 carbon atoms and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S, up to 1 Si and up to 1 N; and
R12 is C1-C3 alkyl. This invention provides a fungicidal composition comprising a compound of Formula 1 (including all geometric and stereoisomers, 2V-oxides, and salts thereof), and at least one other fungicide. Of note as embodiments of such compositions are compositions comprising a compound corresponding to any of the compound embodiments described above. This invention provides a fungicidal composition comprising a fungicidally effective amount of a compound of Formula 1 (including all geometric and stereoisomers, iV-oxides, and agriculturally suitable salts thereof), and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents. Of note as embodiments of such compositions are compositions comprising a compound corresponding to any of the compound embodiments described above.
This invention provides a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of a compound of Formula 1 (including all geometric and stereoisomers, iV-oxides, and agriculturally suitable salts thereof). Of note as embodiment of such methods are methods comprising applying a fungicidally effective amount of a compound corresponding to any of the compound embodiments describe above. Of particular notes are embodiments where the compounds are applied as compositions of this invention.
The compounds of Formulae 1, IA, IB and 1C can be prepared by one or more of the following methods and variations as described in Schemes 1—20. The definitions of A, G, J, W, X, Q, Z1, R1, R2, R15, R16 and n in the compounds of Formulae 1-38 below are as defined above in the Summary of the Invention unless otherwise noted. Formulae Ia-Ie and Formulae IBa and IBb are various subsets of Formula 1 and IB respectively.
As shown in Scheme 1, compounds of Formula Ia (Formula 1 wherein A is CHR15) wherein W is O can be prepared by coupling of an acid chloride of Formula 2 with an amine of Formula 3 in the presence of an acid scavenger. Typical acid scavengers include amine bases such as triethylamine, N^-diisopropylethylamine and pyridine. Other scavengers include hydroxides such as sodium and potassium hydroxide and carbonates such as sodium carbonate and potassium carbonate. In certain instances it is useful to use polymer- supported acid scavengers such as polymer-bound Λ^V-diisopropylethylamine and polymerf bound 4-(dimethylamino)pyridine. Acid salts of the Formula 3 amines can also be used in this reaction, provided that at least 2 equivalents of the acid scavenger is present. Typical acids used to form salts with amines include hydrochloric acid, oxalic acid and trifluoroacetic acid. In a subsequent step, amides of Formula Ia wherein W is O can be converted to thioamides of Formula Ia wherein W is S using a variety of standard thiating reagents such as phosphorus pentasulfide or 2,4-bis(4-methoxyphenyl)-l,3-dithia-2,4- diphosphetane-2,4-disulfide (Lawesson's reagent). Scheme 1
R15 i - 4-
R1CHCOCl +
Figure imgf000063_0001
Ia wherein W is O
An alternate procedure for the preparation of compounds of Formula Ia wherein W is O is depicted in Scheme 2 and involves coupling of an acid of Formula 4 with an amine of Formula 3 (or its acid salt) in the presence of a dehydrative coupling reagent such as dicyclohexylcarbodiimide (DCC), 1 -(3-dimemylarnmopropyl)-3-ethylcarbodiimide hydrochloride (EDC) or O-benzoMazol-l-yl-Λ^JV'^V'-tetramethyluronium hexafluoro- phosphate (HBTU). Polymer-supported reagents are again useful here, such as polymer- bound cyclohexylcarbodiimide. These reactions are typically run at 0-40 0C in a solvent such as dichloromethane or acetonitrile in the presence of a base such as triethylamine or NJV-diisopropylethylamine. The acids of Formula 4 are known or can be prepared by methods known to one skilled in the art. For example, R1CB^COOH where R1 is a heteroaromatic ring linked through nitrogen can be prepared by reacting the corresponding R1H compound with a haloacetic acid or ester in the presence of base; see, for example, U.S. Patent 4,084,955. R1CBD2COOH wherein R1 is a phenyl or a heteroaromatic ring linked through carbon can be prepared from the corresponding R1CH2-halogen compounds by displacement of the halogen with cyanide followed by hydrolysis; see, for example, K. Adachi, YuM Gosei Kagaku Kyokaishi 1969, 27, 875-876; from R1C(^O)CH3 by the Willgerodt-Kindler reaction; see, for example, H. R. Darabi et al., Tetrahedron Letters 1999, 40, 7549-7552 and M. M. Alam and S. R. Adapa, Synthetic Communications 2003, 33, 59-
63 and references cited therein; or from R1Br or R1I by palladium-catalyzed coupling with tert-bntyl acetate or diethyl malonate followed by ester hydrolysis; see, for example, W. A.
Moradi and S. L. Buchwald, J. Am. Chem. Soc. 2001, 123, 7996-8002 and J. F. Hartwig et
• al., J. Am. Chem. Soc. 2002, 124, 12557-12565. Scheme 2
Figure imgf000063_0002
4 3 Ia wherein W is O As the synthetic literature includes many amide-forming methods, the synthetic procedures of Schemes 1 and 2 are simply representative examples of. an wide variety of methods useful for the preparation of Formula 1 compounds. One skilled in the art also realizes that acid chlorides of Formula 2 can be prepared from acids of Formula 4 by numerous well-known methods.
Certain compounds of Formula Ib (Formula 1 wherein A is CHR15 and W is O) wherein R1 is a 5-membered nitrogen-containing heteroaromatic ring linked through the nitrogen atom can be prepared by reaction of the parent heterocycle of Formula 5 and a haloacetamide of Formula 6 as shown in Scheme 3. The reaction is carried out in the presence of a base such as sodium hydride or potassium carbonate in a solvent such as tetrahydrofuran, iV^V-dimethylformamide or acetonitrile at 0 to 80 0C. The haloacetamide of Formula 6 can be prepared by the reaction of an amine of Formula 3 with an α-halo carboxylic acid halide or an α-halo carboxylic acid or its anhydride, analogous to the amide- forming reactions described in Schemes 1 and 2, respectively. Scheme 3
Figure imgf000064_0001
wherein R1 is a 5-membered nitrogen-containing heteroaromatic ring unsubstituted on N; and Y1 is Cl, Br or I.
Compounds of Formulae Ic (Formula 1 wherein A is NH), wherein R1 is phenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, and W is O or S, can be prepared by reaction of an amine of Formula 3 with an isocyanate or isothiocyanate, respectively, of
Formula 7 as depicted in Scheme 4. This reaction is typically carried out at an ambient temperature in an aprotic solvent such as dichloromethane or acetonitrile.
Scheme 4
Figure imgf000064_0002
3 7 Ic wherein W is O or S, and , Rl6 is H Compounds of Formulae Ic can also be prepared by the reaction of an amine of Formula 8 with a carbamoyl or thiocarbamoyl chloride or imidazole of Formula 9 as shown in Scheme 5. When Y is chlorine, the reaction is typically carried out in the presence of an acid scavenger. Typical acid scavengers include amine bases such as triethylamine, i\yV-diisopropylethylamine and pyridine. Other scavengers include hydroxides such as sodium and potassium hydroxide and carbonates such as sodium carbonate and potassium carbonate. The carbamoyl or thiocarbamoyl chlorides of Formula 9 (wherein Y is Cl) can be prepared from amines of Formula 3 by treatment with phosgene or thiophosgene, respectively, or their equivalents, while carbamoyl or thiocarbamoyl imidazoles of Formula 9 (wherein Y is imidazol-1-yl) can be prepared from amines of Formula 3 by treatment with l,l'-carbonyldiimidazole or l,r-thiocarbonyldiimidazole, respectively, according to general methods known to one skilled in the art.
Scheme 5
Figure imgf000065_0001
wherein W is O or S; and Y is Cl or imidazol-1-yl.
Certain compounds of Formula Id (i.e. Formula 1 in which the ring containing X is saturated) can be prepared from compounds of Formula Ie where the ring containing X is unsaturated by catalytic hydrogenation as shown in Scheme 6. Typical conditions involve exposing a compound of Formula Ie to hydrogen gas at a pressure of 70 to 700 kPa, preferably 270 to 350 kPa, in the presence of a metal catalyst such as palladium supported on an inert carrier such as activated carbon, in a weight ratio of 5 to 20 % of metal to carrier, suspended in a solvent such as ethanol at an ambient temperature. This type of reduction is very well known; see, for example, Catalytic Hydrogenation, L. Cerveny, Ed., Elsevier Science, Amsterdam, 1986. One skilled in the art will recognize that other certain functionalities that may be present in compounds of Formula Ie can also be reduced under catalytic hydrogenation conditions, thus requiring a suitable choice of catalyst and conditions. Scheme 6
CatalySt
Figure imgf000066_0001
Figure imgf000066_0002
Ie Id wherein X is X1, X2, χ5, χ8 or χ9.
Certain compounds of Formula 1 wherein X is X1, X5, X7 or X9, and G is linked to the ring containing X via a nitrogen atom, can be prepared by displacement of an appropriate leaving group Y2 on the ring containing the X of Formula 10 with a nitrogen-containing heterocycle of Formula 11 in the presence of a base as depicted in Scheme 7. Suitable bases include sodium hydride or potassium carbonate, and the reaction is carried out in a solvent such as iVjAT-dimethylfprmamide or acetonitrile at 0 to 80 0C. Suitable leaving groups in the compounds of Formula 10 include bromide, iodide, mesylate (OS(O)2CH3), triflate
(OS(O)2CF3) and the like, and compounds of Formula 10 can be prepared from the corresponding compounds wherein Y2 is OH, using general methods known in the art.
Scheme 7
Figure imgf000066_0003
wherein W is O or S; X is X1, X5, X7 or X9; and Y2 is a leaving group such as Br, I, OS(O)2Me or OS(O)2CF3.
Compounds of Formula 1 wherein X is X2 or X8 can be prepared by reaction of a compound of Formula 12 with a heterocyclic halide or triflate (OS(O)2CF3) of Formula 13 as shown in Scheme 8. The reaction is carried out in the presence of a base such as potassium carbonate in a solvent such as dimethylsulfoxide, Ny/V-dimethylformamide or acetonitrile at 0 to 80 °C. Compounds of Formula 13 wherein Y2 is triflate can be prepared from corresponding compounds wherein Y2 is OH by methods known to one skilled in the art. 14647
66 Scheme 8
Figure imgf000067_0001
wherein W is O or S; X is X2 or X8; and Y2 is a leaving group such as Br, I OS(O^Me or OS(O)2CF3. The amine compounds of Formula 3 can be prepared from the protected amine compounds of Formula 14 where Y3 is an arnine-protecting group as shown in Scheme 9. A wide array of amine-protecting groups are available (see, for example, T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2nd ed.; Wiley: New York, 1991), and the use and choice of the appropriate protecting groups will be apparent to one skilled in chemical synthesis. The protecting group can be removed and the amine isolated as its acid salt or the free amine by general methods known in the art. One skilled in the art will also recognize that the protected amines of Formula 14 can be prepared by methods analogous to those described in Schemes 6, 7, and 8 above where the group R1 AC(=W) is replaced by Y3 to give useful intermediates of Formula 14 for the preparation of compounds of Formula 1. Scheme 9
Figure imgf000067_0002
14 wherein Y3 is an amine protecting group 3
The compounds of Formula 14 can also be prepared by reaction of a suitably functionalized compound of Formula 15 with a suitably functionalized compound of Formula 16 as shown in Scheme 10. The functional groups Y4 and Y5 are selected from, but not limited to, moieties such as aldehydes, ketones, esters, acids, amides, thioamides, nitriles, amines, alcohols, thiols, hydrazines, oximes, amidines, amideoximes, olefins, acetylenes, halides, alkyl halides, methanesulfonates, trifluoromethanesulfonates, boronic acids, boronates, and the like, which under the appropriate reaction conditions, will allow the construction of the various heterocyclic rings G. As an example, reaction of a compound of Formula 15 where Y4 is a thioamide group with a compound of Formula 16 where Y5 is a bromoacetyl group will give a compound of Formula 14 where G is a thiazole ring. The synthetic literature describes many general methods for forming 5-membered heteroaromatic rings and 5-membered partially saturated heterocyclic rings (e.g., G-I through G-59); see, for example, Comprehensive Heterocyclic Chemistry, Vol. 4-6, A. R. Katritzky and C. W. Rees editors, Pergamon Press, New York, 1984; Comprehensive Heterocyclic Chemistry II, Vol. 2-4, A. R. Katritzky, C. W. Rees, and E. F. Scriven editors, Pergamon Press, New York, 1996; and the series, The Chemistry of Heterocyclic Compounds, E. C. Taylor, editor, Wiley, New York. The use of intermediates of Formula 15 where X is X1 and Y4 is Br, I, methanesulfonate or trifluoromethanesulfonate to prepare organozinc reagents for use in cross-coupling reactions with aromatic rings has been described; see, for example, S. Bellotte, Synlett 1998, 379-380, and M. Nakamura et al., Synlett 2005, 1794-1798. One skilled in the art knows how to select the appropriate functional groups to construct the desired heterocyclic rings such as G. Compounds of Formula 15 and 16 are known or can be prepared by one skilled in the art.
Scheme 10
Figure imgf000068_0001
wherein Y4 and Y5 are functional groups suitable for construction of the desired heterocycle G.
Certain compounds of Formula 14 where Z1 is O, S, or NR21 can be prepared by displacement of an appropriate leaving group Y2 on G of Formula 17 with a compound of Formula 18 in the presence of a base as depicted in Scheme 11. Suitable bases include sodium hydride or potassium carbonate, and the reaction is carried out in a solvent such as ΛζiV-dimethylformamide or acetonitrile at 0 to 80 0C. Suitable leaving groups in the compounds of Formula 17 include bromide, iodide, mesylate (OS(O)2CH3), triflate (OS(O)2CF3) and the like. Compounds of Formula 17 can be prepared from corresponding compounds wherein Y2 is OH by general methods known in the art. Many of the compounds of Formula 18 are known or can be prepared by general methods known in the art.
Scheme 11
Figure imgf000068_0002
2007/014647
68 wherein Y2 is a leaving group such as Br, I, OS(O)2Me or OS(O)2CF3; and Z1 is O5 S or NR21.
Certain compounds of Formula 14 where Z1 is O, S, or NR21 can also be prepared by displacement of an appropriate leaving group Y2 on J of Formula 20 with a compound of Formula 19 in the presence of a base as depicted in Scheme 12. Suitable bases include sodium hydride or potassium carbonate, and the reaction is carried out in a solvent such as
N,JV-dimethylfoπnamide or acetonitrile at O to 80 0C. Suitable leaving groups in the compounds of Formula 20 include bromide, iodide, mesylate (OS(O)2CH3), triflate
(OS(O)2CF3) and the like. Compounds of Formula 20 can be prepared from corresponding compounds wherein Y2 is OH using general methods known in the art.
Scheme 12
Figure imgf000069_0001
wherein Y2 is a leaving group such as Br, I, OS(O)2Me or OS(O)2CF3; and Z1 is O, S or NR21. Compounds of Formula 14 can also be prepared by reaction of a suitably functionalized compound of Formula 21 with a suitably functionalized compound of Formula 22 as shown in Scheme 13. The functional groups Y6 and Y7 are selected from, but not limited to, moieties such as aldehydes, ketones, esters, acids, amides, thioamides, nitriles, amines, alcohols, thiols, hydrazines, όximes, amidines, amide oximes, olefins, acetylenes, halides, alkyl halides, methanesulfonates, trifluoromethanesulfonates, boronic acids, boronates, and the like, which, under the appropriate reaction conditions will allow the construction of the various heterocyclic rings J. As an example, reaction of a compound of Formula 21 where Y6 is a chloro oxime moiety with a compound of Formula 22 where Y7 is a vinyl or acetylene group in the presence of base will give a compound of Formula 14 where J is an isoxazoline or isoxazole, respectively. The synthetic literature includes .many general methods for the formation of carbocyclic and heterocyclic rings and ring systems (for example, J-I through J-82); see, for example, Comprehensive Heterocyclic Chemistry, Vol. 4-6, A. R. Katritzky and C. W. Rees editors, Pergamon Press, New York, 1984; Comprehensive Heterocyclic Chemistry II, Vol. 2—4, A. R. Katritzky, C. W. Rees, and E. F. Scriven editors, Pergamon Press, New York, 1996; the series, The Chemistry of Heterocyclic Compounds, E. C. Taylor, editor, Wiley, New York, and Rodd's Chemistry of Carbon Compounds, Vol. 2—4, Elsevier, New York. General procedures for cycloaddition of nitrile oxides with olefins are well documented in the chemical literature. For relevant references see Lee, Synthesis 1982, 6, 508-509 and Kanemasa et al., Tetrahedron 2000, 56, 1057—1064 as well as references cited within. One skilled in the art knows how to select the appropriate functional groups to construct the desired heterocyclic ring J. Compounds of Formula 22 are known or can be prepared by general methods known in the art.
Scheme 13
Figure imgf000070_0001
21 22 14 wherein Y6 and Y7 are functional groups suitable for construction of the desired heterocycle J. An alternate preparation for the compounds of Formula 14 where Z1 is a bond includes the well known Suzuki reaction involving Pd-catalyzed cross-coupling of an iodide or bromide of Formula 23 or 26 with a boronic acid of Formula 24 or 25, respectively, as shown in Scheme 14. Many catalysts are useful for this type of transformation; a typical catalyst is tetrakis(triphenylphosphine)palladium. Solvents such as tetrahydrofuran, acetonitrile, diethyl ether and dioxane are suitable. The Suzuki reaction and related coupling procedures offer many alternatives for creation of the G-J bond. For leading references see for example C. A. Zificsak and D. J. Hlasta, Tetrahedron 2004, 60, 8991-9016. For a thorough review of palladium chemistry applicable to the synthesis of G-J bonds see J. J. Li and G. W. Gribble, editors, Palladium in Heterocyclic Chemistry: A Guide for the Synthetic Chemist, Elsevier: Oxford, UK, 2000. Many variations of catalyst type, base and reaction conditions are known in the art for this general method. Scheme 14
Figure imgf000071_0001
One skilled in the art will recognize that many compounds of Formula 1 can be prepared directly by methods analogous to those described in Schemes 10 through 14 above where the group Y3 is replaced by R1AC(=W). Thus, compounds corresponding to Formulae 15, 17, 19, 21, 23 and 25 in which Y3 is replaced by R1ACC=W) are useful intermediates for the preparation of compounds of Formula 1.
Thioamides of Formula IBb are particularly useful intermediates for preparing compounds of Formula 1 wherein X is X1. A thioamide of Formula IBb can be prepared by the addition of hydrogen sulfide to the corresponding nitrile of Formula IBa as shown in Scheme 15.
.Scheme 15
Figure imgf000071_0002
IBa IBb wherein R1 as defined for Formula 1.
The method of Scheme 15 can be carried out by contacting a compound of Formula IBa with hydrogen sulfide in the presence of an amine such as pyridine, diethylamine or diethanolamine. Alternatively, hydrogen sulfide can be used in the form of its bisulfide salt with an alkali metal or ammonia. This type of reaction is well documented in the literature (e.g., A. Jackson et al., EP 696,581 (1996)).
Certain compounds of Formula IBa wherein R1 is a 5-rnembered nitrogen-containing heteroaromatic ring linked through a nitrogen atom can be prepared by reaction of the parent heterocycle of Formula 5 and a haloacetamide of Formula 27 as shown in Scheme 16. The reaction is carried out in the presence of a base such as sodium hydride or potassium carbonate in a solvent such as tetrahydrofuran, iV^-dimethylfoπnarnide or acetonitrile at 0 to 80 0C.
Scheme 16
Figure imgf000072_0001
27 IBa wherein R1 is a 5-membered nitrogen-containing heteroaromatic ring unsubstituted on N (i.e. a 5-membered heteroaromatic ring comprising a ring member of the formula -(NH)-); and Y1 is Cl, Br or I.
The haloacetamides of Formula 27 can be prepared by the two methods shown rn Scheme 17.
Scheme 17
Figure imgf000072_0002
28 27 29 wherein YMs Cl3 Br, or I; and R31 is a tertiary alkyl group such as -C(Me)3.
In one method, 4-cyanopiperidine of Formula 29 is haloacetylated by contact with the appropriate haloacetyl chloride typically in the presence of a base according to standard methods. Preferred conditions involve use of an aqueous solution of an inorganic base such as an alkali metal or alkaline-earth carbonate, bicarbonate, or phosphate, and a non-water- miscible organic solvent such as toluene, ethyl acetate or 1,2-dichloroethane. In the second method depicted in Scheme 17, a l-(haloacetyl)-iV-substituted isonipecotamide derivative of Formula 28, wherein R31 is tertiary alkyl such as C(Me)3, is dehydrated using a standard amide dehydrating agent such as thionyl chloride or phosphorus oxychloride in a suitable solvent. A particularly preferred solvent for this transformation is an Λ^V-dialkylamide such as iVyV-dimethylformamide. The reaction is typically carried out by adding 0.9 to 2 equivalents, preferably 1.1 equivalents, of phosphorus oxychloride or thionyl chloride, to a mixture of a compound of Formula 28 and 0.5 to 10 parts by weight of solvent, at a temperature at which the reaction rapidly proceeds during the addition. The addition time for this reaction is typically around 20 to 90 minutes at typical temperatures of around 35 to 55 0C.
As shown in Scheme 18, the compounds of Formula 28 can be prepared from the compound of Formula 30 by analogy with the haloacetylation reaction described for Scheme 17.
Scheme 18
Figure imgf000073_0001
30 28
The compounds of Formula 30 are known or can be prepared from 4-cyanopyridine or isonicotinic acid using methods well-known in the art; see, for example, G. Marzolph, et al.,
DE 3,537,762 (1986) for preparation of JV-/-butyl pyridinecarboxamides from cyanopyridines and /-butanol and S. F. Nelsen, et al., J. Org. Chem., 1990, 55, 3825 for hydrogenation of JV-methylisonicotinamide with a platinum catalyst.
Halomethyl isoxazole ketones of Formula 35 are particularly useful intermediates for preparing certain chiral compounds of Formula 1 wherein J is, for example, selected from J-29-1 through J-29-12 as depicted in Exhibit A. Halomethyl isoxazole ketones of Formula 35 can be prepared by the multi-step reaction sequences shown in Scheme 19.
Scheme 19
Figure imgf000073_0002
Grignard rreeaaggeenntt
Figure imgf000073_0003
Figure imgf000073_0004
31a 34 35 47
73 wherein R32 is C2— Cg dialkylamino, C2-C5 haloalkylamino, 1-piperidinyl, 1-pyrτolidinyl or 4-morpholinyl; and R5 are as defined above in the Summary of the Invention.
The preparation of the racemic carboxylic acids of Formula 32 can be accomplished according to the well-known methods of basic or acidic hydrolysis of the corresponding compounds of Formula 31, preferably using a slight excess of sodium hydroxide in a water- miscible co-solvent such as methanol or tetrahydrofuran at about 25 to 45 0C. The product can be isolated by adjusting pH to about 1 to 3 and then filtration or extraction, optionally after removal of the organic solvent by evaporation. The racemic carboxylic acids of Formula 32 can be resolved by classical fractional crystallization of diastereomeric salts of suitable chiral amine bases such as cinchonine, dihydrocinchonine or a mixture thereof. A cinchonine-dihydrocinchonine mixture in about a 85:15 ratio is particularly useful, as it provides, for example, the (.Reconfigured carboxylic acids of Formula 33, wherein R5 is a substituted phenyl group, as the less soluble salt. Furthermore, these chiral amine bases are readily available on a commercial scale. The (/?)-confϊgured halomethyl ketone intermediates of Formula 35 afford the more fungicidaily active final products of Formula 1 after coupling with thioamides of Formula IBb. The halomethyl ketones of Formula 35 can be prepared by first reacting the corresponding amides of Formula 31, either as pure enantiomers (i.e. Formula 31a) or in enantiomerically enriched or racemic mixtures, with one molar equivalent of a methylmagnesium halide (Grignard reagent) in a suitable solvent or solvent mixture such as tetrahydrofuran and toluene at about 0 to 20 °C, and the crude ketone products of Formula 34 can be isolated by quenching with aqueous acid, extraction, and concentration. Then the crude ketones of Formula 34 are halogenated with a reagent such as sulfuryl chloride to afford the chloromethyl ketones of Formula 35 wherein Y1 is Cl or molecular bromine to afford the corresponding bromomethyl ketones of Formula 35 wherein Y1 is Br. The halomethyl ketones of Formula 35 can be purified by crystallization from a solvent such as hexanes or methanol, or can be used without further purification in the condensation reaction with thioamides.
The isoxazole carboxamides of Formula 31 can be prepared by cycloaddition of the corresponding hydroxamoyl chlorides of Formula 36 with olefin derivatives of Formula 37, as shown in Scheme 20.
Scheme 20
Figure imgf000074_0001
In this method, all three reacting components (the compounds of Formulae 36 and 37, and the base) are contacted so as to minimize hydrolysis or dimerization of the hydroxamoyl chloride of Formula 36. Ih one typical procedure, the base, which can either be a tertiary amine base such as triethylamine or an inorganic base such as an alkali metal or alkaline- earth carbonate, bicarbonate or phosphate, is mixed with the olefin derivative of Formula 37, and the hydroxamoyl chloride of Formula 36 is added gradually at a temperature at which the cycloaddition proceeds at a relatively rapid rate, typically between 5 and 25 0C. Alternatively, the base can be added gradually to the other two components (the compounds of Formulae 36 and 37). This alternative procedure is preferable when the hydroxamoyl chloride of Formula.36 is substantially insoluble in the reaction medium. The solvent in the reaction medium can be water or an inert organic solvent such as toluene, hexane or even the olefin derivative used in excess. The product can be separated from the salt co-product by filtration or washing with water, followed by evaporation of the solvent. The crude product can be purified by crystallization, or the crude product can be used directly in the methods of Scheme 19. Compounds of Formula 31 are useful precursors to the corresponding methyl ketones of Formula 34 and halomethyl ketones of Formula 35, and are also useful for preparing the resolved enantiomers of the compounds of Formulae 34 and 35 by hydrolysis, resolution, methyl ketone synthesis and halogenation, as shown in Scheme 19.
It is recognized that some reagents and reaction conditions described above for preparing compounds of Formulae 1, IA, IB and 1C may not be compatible with certain functionalities present in the intermediates. In these instances, the incorporation of protection/deprotection sequences or functional group interconversions into the synthesis will aid in obtaining the desired products. The use and choice of the protecting groups will be apparent to one skilled in chemical synthesis (see, for example, T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2nd ed.; Wiley: New York, 1991). One skilled in the art will recognize that, in some cases, after the introduction of a given reagent as it is depicted in any individual scheme, it may be necessary to perform additional routine synthetic steps not described in detail to complete the synthesis of compounds of Formulae 1, IA, IB and 1C. One skilled in the art will also recognize that it may be necessary to perform a combination of the steps illustrated in the above schemes in an order other than that implied by the particular sequence presented to prepare the compounds of Formulae 1, IA, IB and 1C.
One skilled in the art will also recognize that compounds of Formulae 1, IA, IB and 1C and the intermediates described herein can be subjected to various electrophilic, nucleophilic, radical, organometallic, oxidation, and reduction reactions to add substituents or modify existing substituents.
Without further elaboration, it is believed that one skilled in the art using the preceding description can utilize the present invention to its fullest extent. The following Examples are, therefore, to be construed as merely illustrative, and not limiting of the disclosure in any way whatsoever. Steps in the following Examples illustrate a procedure for each step in an overall synthetic transformation, and the starting material for each step may not have necessarily been prepared by a particular preparative run whose procedure is described in other Examples or Steps. Percentages are by weight except for chromatographic solvent mixtures or where otherwise indicated. Parts and percentages for chromatographic solvent mixtures are by volume unless otherwise indicated. 1HNMR spectra are reported in ppm downfield from tetramethylsilane; "s" means singlet, "d" means doublet, "t" means triplet, "m" means multiplet, "q" means quartet, "dd" means doublet of doublet, "br s" means broad singlet, "br d" means broad doublet, "br t" means broad triplet, "br m" means broad multiplet.
EXAMPLE 1 .
Preparation of 4-[4-[4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-l-[[5-methyl- 3-(trifluoromethyl)-lH/-pyrazol-l-yl]acetyl]piperidine (Compound 1) Step A: Preparation of 1,1 -dimethylethyl 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-
2-thiazolyl] - 1 -piperidinecarboxylate
To a suspension of 1,1-dimethylethyl 4-(4-formyl-2-thiazolyl)-l -piperidinecarboxylate (1.0 g, 3.4 mmol) in ethanol (5 mL) was added an aqueous solution of hydroxylamine (50 wt. %, 0.25 mL, 4.0 mmol). The reaction mixture was heated at 60 °C for 1 h, during which time the reaction mixture became homogeneous. The resulting solution was cooled to room temperature and diluted with tetrahydrofuran (10 mL). To the reaction mixture was added styrene (0.57 mL, 5 mmol), followed by portionwise addition of Clorox® aqueous sodium hypochlorite solution (10.5 mL) over 3 h. The reaction mixture was stirred overnight at room temperature, and the resulting solid was filtered, washed with water and diethyl ether, and air dried to give the title compound as a white powder (610 mg). The filtrate was diluted with saturated aqueous sodium bicarbonate solution and extracted with diethyl ether. The extract was dried (MgSO4) and concentrated under reduced pressure to give 850 mg of the title compound as a yellow oil. The oil was diluted with diethyl ether (4 mL) and allowed to stand to give additional 233 mg of the product as a white solid. 1H NMR (CDCl3) δ 1.47 (s, 9H), 1.7 (m, 2H)3 2.1 (m, 2H), 2.85 (m, 2H), 3.2 (m,. IH), 3.45 (m, IH), 3.84 (m, IH) 4.2 (br s, 2H), 5.75 (m, IH), 7.25-7.40 (m, 5H), 7.61 (s, IH).
Step B: Preparation of 4-[4-[4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-l-[[5- methyl-3-(trifluoromethyl)-lH-pyrazol-l-yl]acetyl]piperidine
To a solution of 1,1-dimethylethyl 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)- 2-thiazolyl]-l -piperidinecarboxylate (i.e. the product of Example 1, Step A) (0.815 g,
1.97 mmol) in dichloromethane (50 mL) was added a solution of hydrogen chloride in diethyl ether (2 M, 10 mL, 20 mmol). The reaction mixture was stirred at room temperature for 1 h to give a gummy precipitate. Methanol was added to dissolve the precipitate, and the reaction mixture was stirred for an additional 1 h. The reaction mixture was concentrated under reduced pressure and partitioned between ethyl acetate and saturated aqueous sodium bicarbonate solution, and the organic layer was dried (MgSC^) and concentrated to give the free amine as a clear oil (0.31 g), which solidified on standing. A mixture of the resulting free amine (0.31 g, 1.0 mmol), 5-methyl-3-(trifluoromethyl)-liϊ-pyrazole-l -acetic acid (0.208 g, 1.0 mmol), l-[3-(dimemylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.25 g, 1.3 mmol), triethylamine (150 μL, 1.08 mmol) and a catalytic amount of 1-hydroxy- benzotriazole hydrate (~1 mg) in dichloromethane (5 mL) was swirled to form a vortex and held at room temperature for 16 h. The reaction mixture was diluted with dichloromethane (10 mL), and washed with 1 N aqueous hydrochloric acid and saturated aqueous sodium bicarbonate solution. The organic layer was dried (MgSC>4) and concentrated under reduced pressure to give 0.47 g of the title product, a compound of present invention, as a white foam. 1H NMR (CDCl3) δ 1.8 (m, 2H), 2.2 (m, 2H), .2.32 (s, 3H), 2.9 (m, IH), 3.3 (m, 2H), 3.42 (m, IH), 3.85 (m, IH) 4.05 (m, IH)5 4.55 (m, IH)5 4.98 (m, 2H), 5.75 (m, IH), 6.33 (s, IH), 7.25-7.42 (m, 5H), 7.63 (s, IH).
The following compounds were prepared by procedures analogous to Step B of Example 1: 1 -[4-[4-(455-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]- 1 -piperidinyl]-2-[3-methyl-
5-(trifluoromethyl)-liϊ-pyrazol-l-yl]ethanone (Compound 128); 1H NMR (CDCl3) 5 1.7- 1.9 (m, 2H), 2.16 (m, IH), 2.24 (m, IH), 2.29 (s, 3H), 2.84-2.92 (br t, IH), 3.30 (m, 2H), 3.43 (m, IH)5 3.86 (m, 2H), 4.59 (br d, IH)5 5.04 (s, 2H)5 5.75 (m, IH), 6.47 (s, IH), 7.29- 7.39 (m, 5H), 7.64 (s, IH). l-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-l-piperidinyl]-2-[5-ethyl-
3-(trifluoromethyl)-lif-pyrazol-l-yl]ethanone (Compound 19); m.p. 128-133 0C (crystallized from methyl acetate/petroleum ether); 1H NMR (CDCl3) δ 1.28 (t5 3H)5 1.8 (m, 2H), 2.2 (m, 2H), 2.62 (q, 2H)5 2.9 (m, IH), 3.3 (m, 2H), 3.42 (m, IH), 3.85 (m, IH) 4.05 (ms IH), 4.55 (m, IH), 4.98 (m, 2H), 5.75 (m, IH), 6.33 (s, IH), 7.25-7.42 (m, 5H), 7.63 (s, IH).
2-[3,5-bis(trifluoromethyl)-l/f-pyrazol-l-yl]-l-[4-[4-(4,5-dihydro-5-phenyl- 3-isoxazolyl)-2-thiazolyl]-l-piperidinyl]ethanone (Compound 22); m.p. 130-133 0C (crystallized from methyl acetate/petroleum ether); 1H NMR (CDCl3) δ 1.8 (m, 2H)5 2.2 (m5 2H), 2.9 (m5 IH), 3.3 (m5 2H), 3.42 (m, IH), 3.85 (m, 2H)5 4.55 (m, IH), 5.10 (s, 2H), 5.77 (m, IH), 6.95 (s, IH)5 7.25-7.42 (m, 5H), 7.64 (s, IH).
144-[4-(2,3-dihydrosρiro[4Hr-l-berizopyran-4,5l(4'Hr)-isoxazol]-3l-yl)-2-thiazolyl]- 1 -piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-lH-pyrazol-l -yl]ethanone (Compound 137); 1H NMR (CDCl3) δ 1.83 (m, 2H), 2.18 (m, 3H)5 2.33 (s, 3H), 2.42 (m, IH), 2.90 (m, IH)5 3.31 (Bi7 2H), 3.47 (d, IH), 3.S3 (d, IH), 4.05 (m, IH), 4.27 (m, IH), 4.40 (m, IH), 4.58 (d, IH), 4.97 (m, 2H), 6.33 (s, IH), 6.87 (d, IH), 6.95 (dd, IH), 7.21 (dd, IH), 7.38 (d, IH), 7.67 (s, IH). l-[4-[4-(2,3-dihydrospko[4-f?-l-benzothiopyran-4,5X4'H)-isoxazol]-3'-yl)-2-thiazolyl]- l-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-lH-pyrazol-l-yl]ethanone (Compound 102);
1H NMR (CDCl3) δ 1.82 (m, 2H), 2.23 (m, 2H)3 2.31 (s, 3H), 2.37 (m, IH), 2.50 (m, IH),
2.90 (m, IH), 3.14 (m, IH), 3.17 (m, IH), 3.27 (m, 2H), 3.48 (d, IH), 3.66 (d, IH), 4.05 (m,
IH), 4.57 (d, IH), 4.97 (m, 2H), 6.33 (s, IH), 7.06 (m, 3H), 7.45 (d, IH), 7.65 (s, IH).
EXAMPLE 2 Preparation of l-[[5-methyl-3-(trifluoromethyl)-lH-pyrazol-l-yl]acetyl]-4-[4-(5-phenyl-3- isoxazolyl)-2-thiazolyl]piperidine (Compound 2)
Step A: Preparation of 2-(4-piperidinyl)-4-thiazolecarboxaldehyde mono- hydrochloride
To a solution of 1,1 -dimethyl ethyl 4-(4-formyl-2-thiazolyl)-l-piperidinecarboxylate (1.0 g, 3.4 mmol) in dichloromethane (20 mL) was added a solution of hydrogen chloride in diethyl ether (2.0 mL, 15 ml, 30 mmol). The reaction mixture was stirred under nitrogen at room temperature for 2 h and then evaporated under reduced pressure to give 1.2 g of the title compound as a white solid.
1H NMR (CDCl3) 62.31-2.38 (m, 2H), 2.44-2.50 (m, 2H), 3.11-3.20 (m, 2H), 3.36-3.44 (m, IH), 3.57-3.65 (m, 2H), 8.14 (s, IH), 10.01 (s, IH).
Step B: Preparation of 4-(4-formyl-2-thiazolyl)- 1 -[[5-methylr3-(trifluoromethyl)-
1 H-pyrazol- 1 -yl]acetyl]piperidine
To a solution of 5-methyl-3-(trifluoromethyl)-lH-pyrazole-l -acetic acid (0.8 g, 3.8 mmol) in dichloromethane (10 mL) was added oxalyl chloride (2.4 g, 19.2 mmol) and two drops of iV.TV-dimethylformamide, resulting in slight exothermicity. The reaction mixture was then heated at reflux for 15 minutes. The reaction mixture was concentrated in vacuo, and the residue was suspended in tetrahydrofuran (10 mL) and treated with a solution of 2-(4-piperidinyl)-4-thiazolecarboxaldehyde' monohydrochloride (i.e. the product of Example 2, Step A) (1.1 g, 5.1 mmol) in tetrahydrofuran (10 mL), followed by dropwise addition of triethylamine (1.2 g, 11.9 mmol). The reaction mixture was stirred overnight at room temperature and then partitioned between 1 N aqueous hydrochloric acid and ethyl acetate. The organic layer was separated, and the aqueous layer was extracted with additional ethyl acetate (2 x 30 mL). The combined organic layers were washed with 1 N aqueous hydrochloric acid, saturated aqueous sodium bicarbonate solution, and brine. The organic layer was dried (MgSC^) and evaporated under reduced pressure to give 0.8 g of the title compound as a yellow oil. IH NMR (CDCl3) δ 1.79-1.90 (m, 2H)5 2.18-2.29 (m, 2H), 2.33 (s, 3H), 2.87-2.94 (m, IH)5 3.28-3.40 (m, 2H), 4.05-4.15 (m, IH), 4.56-4.64 (m, IH), 4.99-5.02 (m, 2H), 6.35 (s, IH), 8.12 (s, IH)5 IO-Ol (s, IH).
Step C: Preparation of 4-[4-[(hydroxyimino)methyl]-2-thiazolyl]-l-[[5-methyl- 3 -(trifhαoromethyl)- 1 iϋT-pyrazol- 1 -yl] acetyl]piperidine
To a solution of 4-(4-formyl-2-thiazolyl)-l-[[5-methyl-3-(trifluoτomethyl)-liϊ-pyrazol- l-yl]acetyl]piperidine (Le. the product of Example 2, Step B) (0.8 g, 2.07 mmol) in ethyl alcohol (15 mL) was added hydroxylamine (50% aqueous solution, 0.136 g, 4.1 rnmol), and the reaction mixture was stirred at room temperature for 10 minutes. The reaction mixture was concentrated under reduced pressure to give a yellow oil, which was purified by flash column chromatography on silica gel using 50 % ethyl acetate in hexanes as eluant to give 0.7 g of the title compound as a white solid.
IH NMR (CDCl3) δ 1.72-1.85 (m, 2H), 2.17-2.27 (m, 2H), 2.32 (s, 3H), 2.82-2.91 (m, IH), 3.25-3.37 (m, 2H), 4.02-4.09 (m, IH), 4.58^.63 (m, IH), 4.95-5.03 (m, 2H), 6.35 (s, IH), 7.43 (s, IH), 7.71 (s, IH), 8.19 (s, IH).
Step D: Preparation of l-[[5-methyl-3-(trifluoromethyl)-lH'-pyrazol-l-yl]acetyl]-
4-[4-(5-phenyl-3-isoxazolyl)-2-thiazolyl]piperidine
4-[4-[(Hydroxyimino)memyl]-2-thiazolyl]-l-[[5-memyl-3-(trifluoroinethyl)-l/ϊ- pyrazol-l-yl]acetyl]piperidine (i.e. the product of Example 2, Step C) (0.2 g, 0.5 mmol) was suspended in tetrahydrofuran (20 mL), and phenylacetylene (1.1 mL, 1 mmol) was added, followed by a slow dropwise addition of Clorox® bleach solution (6.15 wt. % sodium hypochlorite, 10 mL) over 1 h. The reaction mixture was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine, dried (MgSC^) and concentrated under reduced pressure to give an oil, which was purified by flash column chromatography on silica gel using 10 % methanol in ethyl acetate as eluant to give to give 70 mg of the title product, a compound of present invention, as a clear yellow oil. IH NMR (CDCl3) δ 1.80-1.92 (m, 2H), 2.22-2.32 (m, 2H), 2.34 (s, 3H), 2.90-2.98 (m, IH), 3.31-3.41 (m, 2H), 4.05-4.11 (m, IH), 4.58-4.65 (m, IH)5 4.97-5.07 (m, 2H), 6.36 (s, IH), 6.98 (s, IH), 7.47-7.53 (m, 3H), 7.84 (s, 2H), 7.88 (m, IH).
EXAMPLE 3
Preparation of 4-[4-(4,5-dmydro-l-methyl-5-phenyl-lH"-imidazol-2-yl)-2-thiazolyl]- l-[[5-methyl-3-(trifiuoromethyl)-lH-pyrazol-l-yl]acetyl]piperidine (Compound 7) To a solution of 4-(4-formyl-2-1hiazolyl)-l-[[5-methyl-3-(trifluoromethyl)-li-r-pyrazol- l-yl]acetyl]piperidine (i.e. the product of Example 2, Step B) (0.8 g, 2.07 mmol) in tert-butanol (5 mL) was added N1 -methy 1-1 -phenyl- 1 ,2-ethanediamine (43.57 mg, 0.29 mmol). The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 30 minutes, and then potassium carbonate (107.8 mg, 0.78 mmol) and iodine (43.57 mg, 0.33 mmol) were added. The reaction mixture was stirred at 70 0C for 3 h and then quenched by addition of saturated aqueous sodium sulfite solution until the iodine color almost disappeared. The reaction mixture was extracted with chloroform, and the organic layer was washed with saturated aqueous sodium bicarbonate solution and brine, dried (Na2SC>4), filtered and concentrated. The residue was purified by preparative thin-layer chromatography on silica gel using a mixture of 94 % ethyl acetate, 5 % methanol and 1 % triethylamine as eluant to give 64 mg of the title product, a compound of the present invention, as an oil. 1HNMR (CDCl3) δ 1.72-1.87 (m, 2H), 2.15-2.28 (m, 2H), 2.31 (s, 3H), 2.86-2.92 (m, IH),
2.97 (s, 3H), 3.26-3.37 (m, 2H), 3.62-4.39 (m, 2H), 4.0-4.6 (m, 2H), 4.93-5.05 (m, 2H),
6.31 (s, IH), 7.30-7.41 (m, 5H), 7.88 (s, IH). EXAMPLE 4
Preparation of 4-[4-(4,5-dihydro-3-phenyl-5-isoxazolyl)-2-thiazolyl]-l-[(5-methyl- 3-(trifluoromethyl)-lH-pyrazol-l-yl)acetyl]piperidine (Compound 6)
Step A: Preparation of 1 , 1 -dimethylethyl 4-(4-ethenyl-2-thiazolyl)- 1 - piperidinecarboxylate To a cold (-50 0C) suspension of methyltriphenylphosphonium bromide (1.2 g,
3.3 mmol) in tetrahydrofuran (5 mL) was added a solution of sodium bis(trimethylsilyl)- amide (3.4 mL, 3.4 mmol), and the resulting mixture was stirred for 1 h at room temperature. The resulting cloudy yellow solution was re-cooled to —30 °C, and 1,1 -dimethylethyl 4-(4-formyl-2-thiazolyl)-l -piperidinecarboxylate (0.5 g, 1.68 mmol) was added. The resulting slightly yellow solution was stirred at room temperature for 3 h, then diluted with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried (MgSθ4), filtered, and purified by column chromatography on silica gel using 15-30 % ethyl acetate in hexanes as eluant to give 471 mg of the title compound as a colorless oil. 1H NMR (CDCl3) δ 1.47 (s, 9H), 1.68 (m, 2H), 2.10 (m, 2H), 2.88 (m, 2H), 3.15 (m, IH), 4.18 (m, 2H), 5.34 (d, IH), 6.02 (d, IH), 6.68 (dd, IH), 6.99 (s, IH).
Step B: Preparation of 4-(4-ethenyl-2-thiazolyl)piperiduie
To a solution of 1,1 -dimethylethyl 4-(4-ethenyl-2-thiazolyl)-l -piperidinecarboxylate (i.e. the product of Example 4, Step A) (471 mg, 1.6 mmol) in dichloromethane (5 mL) was added a solution of hydrogen chloride in diethyl ether (2.0 M, 7 mL, 14 mmol). The reaction mixture was stirred under nitrogen at room temperature for 4 h, and then 1 N aqueous sodium hydroxide solution was added until pH of the reaction mixture increased to about 10. The resulting mixture was extracted with dichloromethane (2 x). The organic layers were 2007/014647
80 combined, washed with brine, dried (MgSO^, filtered and concentrated in vacuo to give 302 mg of the title compound as an oil.
1H NMR (CDCl3) δ 1.70 (m, 2H), 1.82 (br s, IH), 2.12 (br d, 2H), 2.76 (br t, 2H), 3.11 (m, IH), 3.18 (m, 2H), 5.32 (d, IH), 6.02 (d, IH), 6.70 (dd, IH), 6.99 (s, IH). Step C: Preparation of 4-(4-ethenyl-2-thiazolyl)-l-[[5-methyl-3-(trifluoromethyl)- lH-pyrazol-1 -yl]acetyl]piperidine
To a solution of 5-methyl-3-(trifluoromethyl)-liϊ'-pyrazole-l -acetic acid (0.5 g,
2.4 mmol) in dichloromethane (4 mL) was added oxalyl chloride (0.3 mL, 3.6 mmol) and one drop of N,ΛT-dimethylformamide, resulting in slight exothermicity. The reaction mixture was then heated at reflux for 15 minutes. The reaction mixture was evaporated, and the resulting residue was suspended in dichloromethane (4 mL) and treated with a solution of 4-(4-ethenyl-2-thiazolyl)piperidine (i.e. the product of Example 4, Step B) (302 mg,
1.5 mmol) in dichloromethane (2 mL), followed by addition of triethylamine (0.32 mL, 2.3 mmol). The reaction mixture was stirred overnight at room temperature, then concentrated, and purified by column chromatography on silica gel using 30-40 % ethyl acetate in hexanes as eluant to give 414 mg of the title compound as a white solid. IH NMR (CDCl3) 6 1.78 (m, 2H), 2.18 (m, 2H), 2.32 (s, 3H), 2.90 (br t, IH), 3.30 (m, 2H),
4.03 (d, IH), 4.55 (d, IH), 5.00 (m, 2H), 5.35 (d, IH), 6.02 (d, IH), 6.33 (s, IH), 6.68 (dd,
IH)5 7.01 (s, IH). Step D: Preparation of 4-[4-(4,5-dihydro-3-phenyl-5-isoxazolyl)-2-thiazolyl]-
^[(S-methyl-S-^ifluoromethy^-lH-pyrazol-l-y^acetyljpiperidine
To a solution of benzaldehyde oxime (49 mg, 0.4 mmol) in iVijV-dimethylformamide
(3 mL) was added. N-cMorosuccinimide (54 mg, 0.4 mmol), followed by addition of
4-(4-ethenyl-2-thiazolyl)-l-[[5--methyl-3-(trifluoromethyl)-lH-pyrazol-l-yl]acetyl]piperidine (i.e. the product of Example 4, Step C) (103 mg, 0.27 mmol) and triethylamine (41 mg,
0.4 mmol). The resulting mixture was stirred at room temperature for 5 h, then diluted with water, extracted with dichloromethane (2 x). The organic layers were combined and dried
(MgS O4), and filtered. The filtrate was concentrated, and the residue was purified by column chromatography on silica gel using 55-70 % ethyl acetate in hexanes as eluant to give 90 mg of the title product, a compound of the present invention as a white solid.
1H NMR (CDCl3) δ 1.76 (m, 2H), 2.17 (m, 2H), 2.31 (s, 3H), 2.88 (br t, IH), 3.25 (m, 2H), 3.65 (m, IH), 3.78 (m, IH), 4.02 (br d, IH), 4.56 (br d, IH), 4.99 (m, 2H), 5.84 (dd, IH), 6.32 (s, IH), 7.28 (s, IH), 7.40-7.42 (m, 3H), 7.69-7.71 (m, 2H).
EXAMPLE 5 Preparation of l-[4-[4-[5-(2-chlorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl3-l- piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-licir-pyrazol-l -yl]ethanone (Compound 8) 14647
81
To a solution of l-chloro-2-ethenylbenzene (0.035g, 0.25 mmol), triethylamine (2.5 mg, 0.025 mmol) and Clorox® aqueous sodium hypochlorite solution (1 mL, 16.1 mmol) in dichloromethane (5 mL) was added 4-[4-[(hydroxyimino)methyl]-2-thiazolyl]-l-[[5-methyl-
3-(trifluoromethyl)-lH-pyrazol-l-yl]acetyl]piperidine (i.e. the product of Example 2, Step C) (0.10 g, 0.25 mmol) in dichloromethane (5 mL) dropwise over 1 h at 0 °C. The reaction mixture was allowed to stir for Ih, then filtered through Celite® diatomaceous filter aid, and concentrated under reduced pressure to give an oil, which was purified by column chromatography on silica gel using 50 % ethyl acetate in hexane as eluant to give 73 mg of the title compound as a white foam, melting at 115—122 0C (crystallized from methyl acetate/petroleum ether).
1H NMR (CDCl3) δ 1.74-1.80 (m, 2H), 2.14-2.22 (m, 2H)* 2.32 (s, 3H), 2.85-2.91 (m, IH), 3.26-3.30 (m, 2H), 3.31-3.32 (m, IH), 4.05^.07 (m, IH), 4.55-4.58 (m, IH), 4.93-5.03 (q, 2H), 6.01-6.06 (m, IH)5 6.331(s5 IH)5 7.25-7.29 (m, 2H)5 7.38-7.40 (m, IH), 7.56-7.58 (m, IH), 7.62 (s, IH). . EXAMPLE 6
Preparation of 1 -[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-l-piperidinyl]-2-[5- methyl-3-(trifluoromethyl)-lH-pyrazol-l-yl]ethanethione (Compound 130)
A solution of 4-[4-[4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-l-[[5- methyl-3-(trifluoromethyl)-li?-pyrazol-l-yl]acetyl]piperidine (i.e. the product of Example 1, Step B) (235 mg, 0.47 mmol) and phosphorus pentasulfide (104.5 mg, 0.235 mmol) in pyridine (5 ml) was heated under reflux for 2 h. The reaction mixture was then concentrated under reduced pressure, and the residue was distributed between dichloromethane (10 mL) and water (10 mL). The organic layer was washed with 1 N hydrochloric acid, water, saturated aqueous sodium bicarbonate solution and brine, dried (MgSO.4), and concentrated under reduced pressure to give 240 mg of the title product, a compound of the present invention, as a white foam.
1HNMR (CDCl3) δ 1.80-2.00 (m, 2H), 2.20-2.28 (m, 2H), 2.45 (s, 3H), 3.35-3.46 (3H, m), 3.50-3.61 (m, IH), 3.80-3.88 (m, IH), 4.70-4.80 (m, IH), 5.30-5.33 (m, 2H), 5.35-5.40 (m, IH), 5.74-5.80 (m, IH), 6.32 (s, IH), 7.30-7.40 (m, 5H), 7.65 (s5 IH). EXAMPLE 7
Preparation of 1 -[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]- 1 -piperazinyl]- 2-[5-methyl-3-(trifluoromethyl)-l/ϊ-pvrazol-l-yl]ethanone (Compound 154)
Step A: Preparation of 1 , 1 -dimethylethyl 4-(aminothioxomethyl)- 1 -piperazine- carboxylate To a solution of thiocarbonyldiimidazole (2.1 g, 11.8 mmol) in tetrahydrofuran
(3O mL) at room temperature, was added 1,1 -dimethylethyl 1-piperazinecarboxylate (2. g, 10.75 mmol). The reaction mixture was stirred at room temperature for 2 h and then heated to 55 0C for additional 2 h. The reaction mixture was cooled to room temperature, and concentrated under reduced pressure until approximately 20 mL of tetrahydrofuran remained. The residue was then treated with a 2 M solution of ammonia in methanol (10 mL) and stirred at room temperature for 24 h. The reaction mixture was concentrated under reduced pressure, and the residue was triturated with diethyl ether (25 mL) to give a white precipitate. The precipitate was filtered and dried to give 1.5 g of the title compound as a white solid. 1H NMR (CDCl3) δ 1.39 (s, 9H), 3.32 (m, 4H), 3.73 (rn, 4H), 7.49 (br s, 2H).
Step B: Preparation of 3-chloro-N-hydroxy-2-oxo-propanimidoyl chloride To a solution of 1,3-dichloroacetone (100 g, 0.79 mol) in 2 M solution of hydrogen chloride in diethyl ether (400 mL) at 15 0C was added /-butyl nitrite (55 g, 0.534 mol) over 10 minutes. The reaction progress was monitored by 1H NMR to obtain ~85 % conversion with no more than 3 % of the bis-nitrosation side product. The reaction mixture was concentrated under reduced pressure to leave a semi-solid, which was then thoroughly rinsed with n-BuCl. The resulting solid was collected under filtration to give a 77 g of the title compound as a white solid. The filtrate was further concentrated under reduced pressure to give a semi-solid residue, which was rinsed with additional n-BuCl. The resulting solid was collected under filtration to give additional 15 g of the title compound as a white solid. 1H NMR (DMSO-^6) 84.96 (s, 2H), 13.76 (s, IH). Step C: Preparation of 2-chloro-l-(4,5-dihydro-5-phenyl-3-isoxazolyl)ethanone
To a mixture of styrene (6.79 g, 65.3 mmol) and sodium bicarbonate (32.1 g, powder) in acetonitrile (100 mL), 3-chloro--V-hydroxy-2-oxo-propanimidoyl chloride (i.e. the product of Example 7, Step B) (10 g, 64.1 mmol) was added in 10 portions over 20 minutes. The reaction mixture was then stirred for additional 1 h and filtered. The filtered solid was rinsed with acetonitrile, and the combined filtrates were concentrated under reduced pressure to leave an oil, which was triturated first with hexanes and then with 1-chlorobutane to give 13.6 g of the title compound as a white solid.
1H NMR (CDCl3) 5 3.13 (m, IH), 3.66 (m, IH), 4.96 (s, 2H), 5.83 (m, IH), 7.34-7.44 (m, 5H). Step D: Preparation of 1,1-dimethylethyl 4-[4-(4,5-dihydro-5-phenyl-3-isqxazolyl)- 2-thiazolyl] - 1 -piperazineacetate
To a solution of 2-chloro-l-(4,5-dihydro-5-phenyl-3-isoxazolyl)ethanone (i.e. the product of Example 7, Step C) (0.450 g, 2.018 mmol) and 1,1-dimethylethyl 4-(amino- thioxomethyl)-l-piperazinecarboxylate (i.e. the product of Example 7, Step A) (0.5 g, 2.04 mmol) in ethanol (10 mL) was added triethylamine (0.204 g, 2.013 mmol), and the reaction mixture was stirred at room temperature for 12 h. The reaction mixture was concentrated 014647
83 under reduced pressure, and the residue was partitioned between, ethyl acetate (30 mL) and water (30 mL). The organic layer was separated and washed with brine (25 mL), dried (Na2SO4), and. concentrated under reduced pressure. The crude residue was purified by column chromatography using 20 % ethyl acetate in petroleum ether as eluant to give 700 mg of the title compound as a white solid.
1H NMR (CDCl3) δ 1.48 (s, 9H), 3.30 (m. IH), 3.54 (m, 8H)5 3.74 (m, IH)5 5.71 (m, IH)3 6.91 (s, IH), 7.40-7.29 (m, 5H).
Step E: Preparation of l-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]- piperazine hydrochloride . To a solution of 1,1-dimethylethyl 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-
2-thiazolyl]-l-piperazineacetate (i.e. the product of Example 7, Step D) (0.7 g, 1.686 mmol) in diethyl ether (10 mL) was added a 2 M solution of hydrogen chloride in methanol (10 mL) at room temperature. The reaction mixture was stirred at room temperature for 8 h. The resulting white precipitate was filtered, and dried to give 500 mg of the title compound as a white solid.
1H NMR (CDCl3) δ 3.21 (m, 4H)5 3.27 (m, IH), 3.68 (m, 4H), 3.79 (m, IH), 5.68 (m, IH),
7.41-7.29 (m, 6H), 9.49 (br s, 2H).
Step F: Preparation of l-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-l- piperazinyl]-2-[5-methyl-3-(trifluoromethyl)-lH/-pyrazol-l-yl]ethanone To a solution of l-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]piperazine hydrochloride (i.e. the product of Example 7, Step E) (200 mg, 0.57 mmol) and 5-methyl-3- (trifluoromethyl)-l.H-pyrazole-l -acetic acid (0.120 g, 0.57 mmol) in dichloromethane (10 mL) at room temperature was added l-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.110 g, 0.57 mmol), triethylamine (0.086 g, 0.85 mmol) and 1-hydroxy- benzotriazole hydrate (0.020 g, 0.14 mmol). The reaction mixture was stirred at room temperature for 24 h. The reaction mixture was diluted with dichloromethane (30 mL), and washed with water (20 mL) and brine (20 mL). The organic layer was dried (Na2SO.;) and concentrated under reduced pressure. The crude residue was purified by column chromatography using 3 % methanol in chloroform as eluant to give 180 mg of the title product, a compound of the present invention as a white solid.
1Η NMR (CDCl3) δ 2.32 (s, 3Η), 3.29 (m, IH), 3.52 (m, 2H), 3.61 (m, 2H), 3.79-3.72 (m,
5H), 4.98 (m, 2H), 5.69 (m,lH), 6.33 (s, IH), 6.93 (s, IH), 7.38-7.28 (m, 5H). Mass spectrum at 505.5 (M+l). 2007/014647
84
EXAMPLE 8
Preparation of l-[4-[4-(3',41-dihydrospiro[isoxazole-5(4H),l',(2IH)-naphthalen]-3-yl)-2- thiazolyl]-l -piperidinyl]-2-[5-methyl-3-(trifl\ioromethyl)- lH-pyrazol- 1 -yl]ethanone
(Compound 37) Step A: Preparation of l-(2-chloroacetyl)-4-piperidinecarbonitrile
A mixture of 4-piperidinecarbonitrile (200 g, 1.80 mol) and 40 % aqueous potassium carbonate solution (342g, 0.99 mol) in dichloromethane (1 L) was cooled to —10 0C, and a solution of chloroacetyl chloride (21O g, 1.86 mol) in dichloromethane (300 mL) was added over about 75 minutes while maintaining the reaction mixture at —10 to 0 0C. After the addition was complete, the reaction mixture was separated, the upper aqueous phase was extracted with dichloromethane (2 x 300 mL), and the combined organic phases were concentrated under reduced pressure to give 312 g of the title compound as a liquid which slowly crystallized on standing. This compound was of sufficient purity to use in subsequent reactions. 1H NMR (CDCl3) δ 1.8-2.1 (m, 4H), 2.95 (m, IH)3 3.5-3.8 (m, 4H), 4.08 (q, 2H).
Step A 1 : Alternative preparation of 1 -(2-chloroacetyl)-4-piperidinecarbonitrile
A solution of N-(l,l-dimethylethyl)-4-piperidinecarboxamide (201 g, 1.0 mol) in dichloromethane (1 L) was cooled under nitrogen to —5 0C, and chloroacetyl chloride (124 g, 1.1 mol) in 300 mL of dichloromethane was added dropwise over 30 minutes while maintaining the reaction mixture at 0 to 5 0C. Then 20 % aqueous potassium carbonate solution (450 g, 0.65 mol) was added dropwise over 30 minutes while keeping reaction temperature between 0 and 5 °C. The reaction mixture was stirred for an additional 30 minutes at 0 0C, and then allowed to warm to room temperature. The layers were separated, and the aqueous layer was extracted with dichloromethane (200 mL). The combined dichloromethane layers were concentrated under reduced pressure to yield a solid, which was triturated with 400 mL of hexanes. The slurry was filtered, and the filter cake was washed with 100 mL of hexanes and dried in a vacuum oven overnight at 50 0C to give 185.5 g of l-(2-chloroacetyl)-iV-(l,l-dimethylethyl)-4-piperidinecarboxamide as a solid, melting at 140.5-141.5 0C. 1H NMR (CDCl3) 6 1.35 (s, 9H), 1.6-2.0 (m, 4H), 2.25 (m, IH), 2.8 (t, IH), 3.2 (t, IH)5 3.9 (d, IH), 4.07 (s, 2H), 4.5 (d, IH), 5.3 (br s, IH).
To a solution of l-(2-chloroacetyl)-iV-(l,l-diinethylethyl)-4-piperidinecarboxamide (26.1 g, 0.10 mol) in JV^-dimethylformamide (35 mL) was added phosphorus oxychloride (18.8 g, 0.123 mol) dropwise over 30 minutes while allowing the temperature of the reaction mixture to rise to 37 0C. The reaction mixture was heated at 55 0C for 1 h and then was slowly added to water (about 150 g) cooled with ice to maintain a temperature of about 10 0C. The pH of the reaction mixture was adjusted to 5.5 with 50 % NaOH aqueous 07/014647
85 solution. The mixture was extracted with dichloromethane (4 x 100 mL), and the combined extract was concentrated under reduced pressure to give 18.1 g of the title compound as a solid. This compound was of sufficient purity to use in subsequent reactions.
Step B: Preparation of l-[2-[5-methyl-3-(trifluoromethyl)-lfl'-pyrazol-l-yl]acetyl]-4- piperidinecarbonitrile
A solution of 3-methyl-5-trifluoromethylpyrazole (9.3 g, 62 mmol) and 45 % aqueous potassium hydroxide solution (7.79 g, 62 mmol) in .VJV-dimethylformamide (25 mL) was cooled to 5 0C, and l-(2-chloroacetyl)-4-piperidinecarbonitrile (i.e. the product of Example 8, Step A or Al) (11.2 g, 60 mmol) was added. The reaction mixture was stirred for 8 h at 5— 10 0C5 then diluted with water (100 mL), and filtered. The filter cake was washed with water and dried at 50 0C in a vacuum-oven to give 15 g of the title compound as a solid containing 3 % of its regioisomer, i.e. l-[2-[3-methyl-5-(trifluoromethyl)-liϊ-pyrazol- l-yl]acetyl]-4-piperidinecarbonitrile. 1H NMR (CDCl3) 5 1.88 (m, 4H), 2.32 (s, 3H), 2.95 (m, IH), 3.7 (m, 4H), 5.0 (q, 2H), 6.34 (s, IH).
Step C: Preparation of l-[2-[5-methyl-3-(trifluoromethyl)-lH-pyrazol-l-yl]acetyl]-4- piperidinecarbothioamide
Hydrogen sulfide gas was passed into a solution of l-[2-[5-methyl- 3-(trifluoromethyl)-lH-pyrazol-l-yl]acetyl]-4-piperidinecarbonitrile (i.e. the product of Example 8, Step B) (9.0 g, 30 mmol) and diethanolamine (3.15 g, 30 mmol) in TVyN-dimethylfoπnamide (15 mL) at 50 0C in a flask equipped with dry-ice condenser. The hydrogen sulfide feed was stopped when the reaction mixture became saturated with hydrogen sulfide, as indicated by condensation on the cold- finger. The reaction mixture was stirred for an additional 30 minutes at 50 0C. Then excess hydrogen sulfide gas was sparged into the scrubber by a subsurface nitrogen flow, and water (70 mL) was gradually added. The reaction mixture was cooled to 5 0C, filtered, and washed with water (2 x 30 mL). The filter cake was dried at 50 0C in a vacuum-oven to give 8.0 g of the title compound as a solid, melting at 185-186 0C. IH NMR (CDCl3) δ 1.7 (m, 2H), 2.0 (m, 2H), 2.29 (m, 3H), 2.65 (t, IH), 3.0 (m, 3H), 3.2 (t, IH), 4.0 (d, IH), 4.6 (d, IH), 4.96 (d, IH)5 5.4 (d, IH)5 6.35 (s, IH), 7.4 (br s, IH), 7.5 (br s, IH).
Step D: Preparation of l-[4-[4-(3I,4'-dihydrospiro[isoxazole-5(4iϊ),l ',(21HO- naphthalen]-3-yl)-2-thiazolyl]-l-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)- 1 H-pyrazol- 1 -yl] ethanone A solution of l-[2-[5-methyl-3-(trifluoromethyl)-lHr-pyrazol-l-yl]acetyl]-4-piperidine- carbothioamide (i.e. the product of Example 8, Step C) (0.5 g, 1.5 mmol), 2-chloro-l-(3',4'- dihydrospiro[isoxazole-5(4H),r,(2'H)-naphthalen]-3-yl)ethanone (prepared by a method analogous to Example 7, Step C) (0.4 g, 1.5 mmol) and tetrabutylammonium bromide (0.030 g, 0.10 mmol) in tetrahydrofuran (15 mL) was stirred overnight at room temperature, and then heated at 55-60 0C for 3 h. The reaction mixture was diluted with water and extracted with dichloromethane. The extract was washed with brine, dried (MgSO^, and concentrated under reduced pressure. The crude product was further purified by medium-pressure liquid chromatography using 50 % ethyl acetate in hexanes as eluant to give 260 mg of the title product, a compound of the present invention, as an off-white solid, melting at 81—840C. 1H NMR (CDCl3) δ 1.76-1.86 (m, 3H)5 2.04-2.08 (m, 2H), 2.16-2.26 (m, 2H), 2.32 (s, 3H), 2.83-2.87 (m, 2H), 2.88-2.93 (m, IH), 3.27-3.35 (m, 2H), 3.48-3.65 (m, 2H), 4.02-4.06 (m, IH), 4.55-4.59 (m, IH), 4.94-5.04 (q, 2H), 6.33 (s, IH)57.10-7.12 (m, IH), 7.19-7.21 (m, 2H), 7.40-7.43 (m, IH), 7.62 (s, IH).
The following compounds were prepared by procedures analogous to Step D of Example 8: l-[4-[4-(4,5-dihydro-5-methyl-5-phenyl-3-isoxazolyl)-2-thiazolyl]-l-piperidinyl]-
2-[5-methyl-3-(trifluoromethyl)-lH-pyrazol-l-yl]ethanone (Compound 15); m.p. 97-100 0C (crystallized from methyl acetate/petroleum ether); 1H NMR (CDCl3) δ 1.74-1.80 (m, IH), 1.81 (s, 3H), 2.14-2.20 (m, 2H), 2.32 (s, 3H), 2.85-2.91 (m, IH), 3.26-3.32 (m, 2H), 3.52- 3.62 (m, 2H), 4.01-4.05 (m, IH), 4.54-4.58 (m, IH), 4.94-5.04 (q, 2H), 6.33 (s, IH), 7.26- 7.29 (m, IH), 7.35-7.38 (m, 2H), 7.48-7.50 (m, 2H), 7.58 (s, IH).
2-[5-memyl-3-(trifluoromethyl)-liϊ-pyrazol-l-yl]-l-[4-[4-(3α,4,5,96-tetrahydro- naphth[2,l-£f]isoxazol-3-yl)-2-thiazolyl]-l-piperidinyl]ethanone (Compound 16); m.p. 162- 165 0C (crystallized from methyl acetate/petroleum ether); 1H NMR (CDCl3) δ 1.79-1.85 (m, 2H), 2.00-2.05 (m, 2H), 2.20-2.26 (m, 2H), 2.33 (s, 3H), 2.68-2.72 (m, 2H), 2.88-2.94 (m, IH), 3.30-3.35 (m, 2H), 3.92-3.98 (m, IH), 4.06-4.10 (m, IH), 4.58-4.60 (m, IH), 4.94-5.06 (m, 2H), 5.58-5.60 (d, IH), 6.34 (s, IH), 7.17-7.20 (m, IH), 7.28-7.30 (m, 2H), 7.47-7.49 (m> IH), 7.72 (s, IH). l-[4-[4-(2,3-dihydrosρiro[liϊ-indene-l,5l(4Η)-isoxazol]-3'-yl)-2-thiazolyl]- 1 -piperidinyl] -2-[5-methyl-3 -(trifluoromethyl)- 1 H-pyrazol- 1 -yl] ethanone (Compound 44); 1H NMR (CDCl3) δ 1.77-1.84 (m, 2H), 2.17-2.25 (m, 2H), 2.33 (s, 3H), 2.61-2.68 (m, IH), 2.90-2.96 (m, 2H), 3.12-3.20 (m, lH),.3.31-3.35 (m, 2H), 3.54-3.75 (m, 2H), 4.04-4.10 (m, IH), 4.56-4.60 (m, IH), 4.94-5.04 (q, 2H), 6.34 (s, IH), 7.28-7.30 (m, 3H), 7.37-7.38 (m, IH), 7.64 (s, IH). l-[4-[4-[4,5-dihydro-5-(4-methoxyphenyl)-3-isoxazolyl]-2-thiazolyl]-l-piρeridinyl]-2- [5-methyl-3-(trifluoromethyl)-liϊ-pyrazol-l-yl]ethanone (Compound 18); m.p.t 119-124 0C (crystallized from methyl acetate/petroleum ether); 1H NMR (CDCl3) δ 1.76-1.82 (m, 2H), 2.16-2.24 (m, 2H), 2.32 (s, 3H), 2.86-2.92 (m, IH), 3.28-3.34 (m, 2H), 3.37-3.43 (m, IH), 14647
87
3.76-3.83 (m, IH), 3.81 (s, 3H), 4.03-4.06 (m5 IH), 4.56-459 (m, IH), 4.94-5.04 (q, 2H), 5.67-5.72 (m, IH), 6.33 (s, IH)5 6.89-6.91 (d, 2H)5 7.31-7.33 (d, 2H), 7.62 (s, IH).
EXAMPLE 9
Preparation, of 1 -[4-[4-(4,5-dihydro-5-(2-pyridinyl)-3-isoxazolyl)-2-thiazolyl]-l -piperidinyl]- 2-[5-methyl-3-(trifluoromethyl)-lH/-pyrazol-l-yl]ethanone (Compound 98 )
To a solution of l-[2-[5-methyl-3-(trifluoromethyl)-lH/-pyrazol-l-yl]acetyl]-4- piperidinecarbothioamide (i.e. the product of Example 8, Step C) (200 mg, 0.6 mmol) in tetrahydrofuran (8 mL) was added 3-chloro-iV-hydroxy-2-oxopropanimidoyl chloride (i.e. the product of Example 7, Step B) (93 mg, 0.6 mmol), followed by tetrabutylammonium bromide (15 mg, 0.05 mmol). The reaction mixture was heated at 50 0C for 4 h. The reaction mixture was cooled and concentrated under reduced pressure. To the resulting residue, acetonitrile (8 mL) and finely powdered sodium bicarbonate (151 mg, 1.0 mmol) were added followed by 2-ethenylpyridine (63 mg, 0.6 mmol), and the resulting mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure and purified by flash chromatography on a silica gel (20 g), Varian Bond Elute SI® column using 0 to 75 % ethyl acetate in hexanes as eluant to give 80 mg of the title product, a compound of the present invention, as a yellow semi-solid.
1HNMR (CDCl3) 5 1.47-1.62 (m, IH), 1.70-1.85 (m, IH), 2.01-2.18 (m, 2H), 2.49 (s. 3H)5 2.82 (t5 IH)5 3.20-3.42 (m, 2H), 3.73 (dd, IH), 3.82 (dd, IH), 3.98 (d, IH), 4.38 (d, IH), 5.26 (m, 2H), 5.80 (dd, IH), 6.50 (s, IH), 7.38 (dd, IH), 7.50 (d, IH), 7.82 (t, IH)5 8.05 (s, IH)5 8.60 (d, IH).
EXAMPLE 10
Preparation of 2-[5-chloro-3-(trifluoromethyl)-ljF-r-pyrazol- 1 -yl]-l -[4-[4-(4,5 -dihydro-5- phenyl-3-isoxazolyl)-2-thiazolyl]-l-piperidinyl]ethanone (Compound 107) Step A: Preparation of Λ^V-dimethyl-3-(trifluoromethyl)-liϊ-pyra2ole-l -sulfonamide
To a solution of 3-trifluoromethylpyrazole (5.0 g, 36 mmol), triethylamine (7.0 mL, 50 mmol) in dichloromethane (40 mL) was added dimethylsulfamoyl chloride (5.5 mL, 51 mmol), and the reaction mixture was heated at reflux for 2 days. The resulting mixture was cooled to ambient temperature and filtered through a pad of silica gel using dichloromethane as eluent. The filtrate was then concentrated under reduced pressure to give an amber residue. The resulting residue was dissolved in diethyl ether. The ether solution was washed with water, dried (MgSC^), and concentrated under reduced pressure to give 8.71 g of the title compound. 1HNMR (CDCl3) δ 3.01 (s, 6H), 6.65 (s, IH)5 8.03 (s, IH). Step B: Preparation of. S-chloro-NJV-dirnethyl-S-^fluoromethy^-liϊ-pyrazole-l- sulfonamide
A stirred solution of N^-dirnethyl-3-(trifluoromethyl)-lH-pyrazole-l -sulfonamide
(i.e. the product of Example 10, Step A) (4.0 g, 16 mmol) in tetrahydrofuran (25 mL) was cooled to —78 °C, and then treated dropwise with 2 M «-butyllithium in cyclohexane (8.6 mL, 17.2 mmol). The reaction mixture was stirred for a further 30 minutes, and then a solution of hexachloroethane (4.2 g, 18 mmol) in tetrahydrofuran (15 mL) was added dropwise. The reaction mixture was stirred for 1 h, warmed to room temperature, and quenched with water (50 mL). The resulting solution was extracted with dichloromethane, dried (MgSC^), and concentrated under reduced pressure to give 4.38 g of title compound.
This compound was of sufficient purity to use in subsequent reactions.
1HNMR (CDCl3) δ 3.15 (s, 6 H), 6.58 (s, 1 H).
Step C: Preparation 5-chloro-3-(trifluoromeΛyl)-lH-pyrazole
A solution of S-chloro-iV^^-dimethyl-S-^ifluoromethy^-liJ-pyrazole-l-sulfonamide (i.e. the product of Example 10, Step B) (4.38 g, 15.8 mmol) and trifluoroacetic acid (2.7 mL, 35 mmol) was stirred at 0 0C for 1.5 h. The reaction mixture was diluted with water (15 mL),and sodium carbonate was added to raise the pH to 12. The solution was extracted with diethyl ether, dried (MgSO^, and concentrated under reduced pressure to give 2.1 g of the title compound. This compound was of sufficient purity to use in subsequent reactions. l H NMR (CDCl3) δ 6.57 (m, 1 H).
Step D: Preparation of ethyl 5-chloro-3-(trifluoromethyl)- lH-pyrazole- 1 -acetate
To a suspension of 5-chloro-3-(trifluoromethyl)-lH-pyrazole (i.e. the product of Example 10, Step C) (2.1 g, 12.3 mmol) and potassium carbonate (3.6 g, 26.0 mmol) in 20 mL of Λr^-dimethylformamide was added ethyl bromoacetate (2.1 mL, 18.8 mmol), and the resulting mixture was stirred at room temperature for 12 h. The resulting mixture was diluted with ethyl acetate, washed with water, and dried (MgSC^). The reaction mixture was concentrated in vacuo and further purified by medium-pressure liquid chromatography using 0—50% of ethyl acetate in hexanes as eluant to give 940 mg of the title compound as an oil. 1H NMR (CDCl3) δ 1.29 (m, 3 H), 4.27 (q, 2 H), 4.96 (m, 2 H), 6.55 (s, 1 H). Step Dl : Alternative preparation of ethyl 5-chloro-3-(trifluoromethyl)-lH-pyra2ole-l- acetate
To a solution of aluminum chloride (3.0 g, 22.5 mmol) in dichloromethane (100 mL) was added dropwise a solution of trifluoroacetyl chloride (3 g, 22.6 mmol) in dichloromethane (5 mL) while keeping the temperature of the reaction mixture below —30 0C. The reaction mixture was stirred for 15 minutes at -50 0C. Then a solution of vinylidene chloride (2.2 g, 22.7 mmol) in dichloromethane (10 mL) was added dropwise over 2 h to the reaction mixture. The reaction mixture was stirred an additional 2 h at -50 0C and then warmed gradually to room temperature. The reaction mixture was diluted with water, and the aqueous layer was extracted with dichloromethane. The organic layers were combined, dried (MgSC^), and concentrated under reduced pressure to give 4,4-dichloro- 1,1,1- trifluoro-3-buten-2-one as an oil which was used for the next step without further purification.
1H NMR (CDCl3) δ 5.30 (s, IH). . 1^F NMR (CDCl3) δ -63.6.
To a mixture of ethyl hydrazinoacetate hydrochloride (2.8 g, 18.1 mmol) and triethylamine (9.2 g, 91 mmol) in a solution of ethanol (20 mL) and iV.N-dimemylforrnamide (1 mL), a solution of crude 4,4-dichloro- l,l,l-trifluoro-3-buten-2-one in dichloromethane (20 mL) was added dropwise while keeping the temperature of the reaction mixture below 10 0C. After stirring a further 2 h at below 10 0C, the reaction mixture was concentrated under reduced pressure. The residue was diluted with diethyl ether, and the mixture was filtered. The resulting filtrate was concentrated to give 4.34 g of the title compound as a solid. This compound was of sufficient purity to use in subsequent reactions. 1H NMR (CDCl3) δ 1.29 (t, 3H), 4.27 (q, 2H), 4.97 (s, IH), 6.55 (s, IH). 19F NMR (CDCl3) δ -63.4.
Step E: Preparation of 5-chloro-3-(trifluoromethyl)- lH-pyrazole- 1 -acetic acid A solution of ethyl 5-chloro-3-(trifluoromethyl)-17ϊ'-pyrazole-l-acetate (i.e. the product of Example 10, Step D or Dl) (218 mg, 0.85 mmol) in tetrahydrofuran (1 mL) was treated with a 50 wt. % aqueous solution of sodium hydroxide (0.2 mL) in water (0.6 mL).
The reaction mixture was stirred at room temperature for 4 h. The reaction mixture was treated with concentrated aqueous hydrochloric acid to lower the pH to 1, and then extracted with ethyl acetate. The extract was dried (MgSC^) and concentrated under pressure to give
140 mg of the title compound. This compound was of sufficient purity to use in subsequent reactions.
1H NMR (DMSO-d6) δ 5.41 (s, 2H), 7.09 (s, IH).
Step F: Preparation of 2-[5-chloro-3-(trifluoromethyl)-lH-pyrazol-l-yl]-l-[4-[4-(4,5- dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-l -piperidinyl]ethanone
To a solution of 1,1-dimethylethyl 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2- thiazolyl]-l-piperidrnecarboxylate (i.e. the product of Example 1, Step A) (1.026 g, 2.48 mmol) in ethanol (10 mL) was added a 2 M solution of hydrogen chloride in diethyl ether (4.2 mL, 12.6 mmol). The reaction mixture was stirred at room temperature overnight. Then the reaction mixture was heated at 60 0C for 2 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to give 0.710 g of 4-[4-(4,5-dihydro-5- phenyl-3-isoxazolyl)-2-thiazolyl]-l-piρeridine, hydrochloride as a white solid. To 5-chloro-3-(trifluoromethyl)-liϊ-pyrazole-l-acetic acid (i.e. the product of Example 10, Step E) (0.14 g, 0.61 mmol) in dichloromethane (5 mL) was added N,N- dimethylformamide (1 drop) followed by oxalyl chloride (0.07 mL, 0.80 mmol) at room temperature. The reaction mixture was stirred at room temperature for 1 h, and then concentrated under reduced pressure. The resulting crude 5-chloro-3-(trifluoromethyl)-lH- pyrazole-1 -acetyl chloride was taken up in 5 mL of dichloromethane, and the resulting solution was added dropwise to a mixture of 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2- thiazolyl]-l -piperidine, hydrochloride (0.20 g, 0.57 mmol) prepared above and triethylamine (0.40 mL, 2.85 mmol) in 10 mL of dichloromethane at 0 0C. The reaction mixture was stirred overnight at room temperature, and then diluted with 1.0 N aqueous hydrochloric acid solution. The organic layer was separated, washed with water, dried (MgSO4), and concentrated under reduced pressure and purified by medium-pressure liquid chromatography using ethyl acetate in hexanes as eluant to give 40 mg of the title product, a compound of the present invention, as a solid, melting at 128—131 0C. 1H NMR (CDCl3) δ 1.81 (m, 2H), 2.20 (m, 2H), 2.89 (m, IH), 3.31 (m, 2H), 3.46 (m, IH), 3.87 (m, 2H), 4.55 (m, IH), 5.08 (M, 2H), 5.75 (m, IH), 6.54 (s, IH), 7.25-7 '.42 (m, 5H), 7.63 (s, IH).
EXAMPLE I l
Preparation of 2-[5-bromo-3-(trifluoromethyl)-lH-pyrazol-l-yl]-l-[4-[4-(4,5-dihydro-5- phenyl-3-isoxazoly)-2-thiazolyl]-l-piperidinyl]ethanone (Compound 126)
Step A: Preparation of 5-bromo-N^V-dimethyl-3-(trifluoromethyl)-lH/-pyrazole-l- sulfonamide
A stirred solution of N^-dimethyl-3-(trifluoromethyl)-lH-pyrazole-l -sulfonamide (i.e. the product of Example 10, Step A) (4.25 g, 17.5 mmol) in tetrahydrofuran (50 mL) was cooled to -78 0C, and then 2 M n-butyllithium in cyclohexane (10.0 mL, 20.0 mmol) was added dropwise. The reaction mixture was stirred a further 30 minutes, and then bromine (1.0 mL, 3.1 g, 18.7 mmol) was added dropwise. The reaction mixture was stirred for 10 minutes, warmed to room temperature, and quenched with brine (50 mL). The resulting solution was extracted with diethyl ether, dried (MgSO4), and concentrated under reduced pressure to give 6.77 g of title compound as a light yellow oil. This compound was of sufficient purity to use in subsequent reactions. 1H NMR (CDCl3) δ 3.15 (s, 6H), 6.69 (s, IH).
Step B: Preparation 5-bromo-3-(trifluoromeΦyl)-l.H-pyrazole
A solution of 5 -bromo-Λ^V-' dimethyl-3-(trifluoromethyl)-liϊ'-pyrazole-l -sulfonamide (i.e. the product of Example 11, Step A) (4.50 g, 14.0 mmol) and trifluoroacetic acid (2.0 mL, 26 mmol) was stirred at 25 0C for 4 h. The reaction mixture was diluted with water (20 mL), and sodium hydroxide was added to raise the pH to 12. The solution was extracted with chloroform, dried (MgSO^), and concentrated under reduced pressure to give 2.73 g of the title compound as a yellow light oil. This compound was of sufficient purity to use in subsequent reactions. 1H NMR (CDCl3) δ 6.63 (m, IH). Step C: Preparation of ethyl 5-bromo-3-(trifluoromethyl)-liϊ-pyrazole-l-acetate
A suspension of 5-bromo-3-(trifluoromethyl)-lH-pyrazole (i.e. the product of Example 11, Step B) (2.73 g, 12.7 mmol) and potassium carbonate (2.0 g, 14.5 rnmol) in iVyN-dimethylformamide (20 mL) was treated with ethyl iodoacetate (3.0 ml, 25.3 mmol), and the resulting mixture was stirred at 95 0C for 3 h. The resulting mixture was diluted with ethyl acetate, washed with water, and dried (MgSO.4). The reaction mixture was concentrated in vacuo and further purified by medium-pressure liquid chromatography using 0-50 % of ethyl acetate in hexanes as eluant to give 2.84 g of the title compound as a brown oil. 1Η NMR (CDCl3) δ 1.29 (m, 3Η), 4.26 (q, 2H), 5.00 (m, 2H), 6.64 (s, IH). Step D: Preparation of 5-bromo-3-(trifluoromethyl)-lH-pyrazole-l-acetic acid
A solution of ethyl 5-bromo-3-(trifluoromethyl)-lH-pyrazole-l-acetate (i.e. the product of Example 11, Step C) (2.84 g, 9.4 mmol) in tetrahydrofuran (10 mL) was treated with a 50 wt. % aqueous solution of sodium hydroxide solution (1.0 mL). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was treated with concentrated aqueous hydrochloric acid to lower the pΗ to 1, and then extracted with ethyl acetate. The extract was dried (MgSC^) and concentrated under pressure to give 2.26 g of the title compound as a light brown solid. Recrystallization from 1-chlorobutane (20 mL) gave 0.68 g of the title compound as lustrous light pink plates. 1HNMR (CDCl3) δ 5.08 (s, 2H), 6.65 (s, IH). Step E: Preparation of 2-[5-bromo-3-(trifluoromethyI)-l/f-pyrazol-l-yl]-l-[4-[4-(4,5- dihydro-5-phenyl-3-isoxazoly)-2-thiazolyl]-ϊ-piperidinyl]ethanone To a solution of 5-bromo-3-(trifluoromethyl)-liϊ-pyrazole-l-acetic acid (i.e. the product of Example 11, Step D) (0.12 g, 0.61 mmol) in dichloromethane (5 mL) was added N,iV-dimethylformamide (1 drop) followed by oxalyl chloride (0.25 mL, 2.86 mmol). The reaction mixture was stirred at room temperature for 1 h and then concentrated under reduced pressure. The residue containing crude acid chloride was taken up in dichloromethane (5 mL), and the solution was added dropwise to a mixture of 4-[4-(4,5- dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-l-piperidine hydrochloride (i.e. the product of Example 10, Step F) (0.15 g, 0.43 mmol) and triethylamine (0.25 mL, 1.8 mmol) in dichloromethane (5 mL) at 0 0C. The reaction mixture was allowed to warm to room temperature, and then stirred overnight at room temperature. The mixture was then partitioned between 1.0 N aqueous hydrochloric acid solution and dichloromethane. The organic layer was washed with water, dried (MgSC^), concentrated under reduced pressure, and purified by medium-pressure liquid chromatography using ethyl acetate in hexanes as eluant to give 90 mg of the title product, a compound of the present invention, as an amorphous solid.
1H NMR (CDCl3) δ 1.84 (m, 2H), 2.20 (m, 2H), 2.89 (m, IH), 3.31 (m, 2H), 3.46 (m, IH), 3.89 (m, 2H), 4.58 (m, IH), 5.11 (m, 2H), 5.75 (m, IH), 6.63 (s, IH), 7.25-7.42 (m, 5H), 7.66 (s, IH).
EXAMPLE 12 Preparation of l-[4-[4-[(5.R)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-l-piperidinyl]- 2-[5-methyl-3-(trifiuoromethyl)-lH-pyrazol-l-yl]ethanone (Compound 3)
Step A: Preparation of 4,5-dihydro-Λ','-V-dimethyl-5-phenyl-3-isoxazolecarboxamide
To a solution of 2-(dimethylammo)-iV-hydroxy-2-oxoethanimidoyl chloride (prepared according to the procedure of E. Raleigh, U.S. Patent 3,557,089) (6.0 g, 40 mmol), styrene (6.0 g, 60 mmol) in toluene (15 mL) was added a solution of potassium hydrogen carbonate (5.0 g, 50 mmol) in water (25 mL) over 1 h, while keeping the reaction temperature between 7 and 10 0C. The reaction mixture was diluted with 10 mL of toluene, and stirred for an additional 10 minutes. The organic layer was separated and washed with water. The organic layer was concentrated under reduced pressure until no styrene remained to give 8.7 g of the title compound as a light yellow oil. This compound was of sufficient purity to use in subsequent reactions.
1H NMR (CDCl3) δ 3.08 (s, 3H), 3.32 (s, 3H), 3.35 (dd, IH), 3.71 (dd, IH), 5.65 (dd, IH), 7.35 (m, 5H).
Step B: Preparation of 4,5-dihydro-5-phenyl-3-isoxazolecarboxylic acid To a solution of 4,5-dmydro-N//-dimethyl-5-phenyl-3-isoxazolecarboxamide (i.e. the product of Example 12, Step A) (60.0 g, 275 mmol) in methanol (300 mL) was added an aqueous sodium hydroxide solution (44 g of 50 wt. % aqueous NaOH in 50 mL of water) dropwise over 30 minutes while maintaining the temperature of the reaction mixture at 45 0C.
The reaction mixture was allowed to cool to room temperature and stirred overnight. The resulting mixture was concentrated under reduced pressure, and treated with 200 mL of water. The pH of the reaction mixture was adjusted using concentrated hydrochloric acid to about 1.0. The crude product was extracted into ethyl acetate (200 mL). The ethyl acetate solution was concentrated under reduced pressure, and the residue was triturated with hexanes. The resulting precipitate was filtered, washed with hexanes (2 x 20 mL), and dried under vacuum to give 46.5 g of the title compound as a solid.
1HNMR (CDCl3) δ 3.25 (dd, IH), 3-75 (dd, IH), 5.85 (dd, IH), 7.35 (m, 5H), 8.1 (br s, IH). Step C: Preparation of the cinchonine salt of (5R)-4,5-dihydro-5-phenyl-3-isoxazole- carboxylic acid
A mixture of racemic 4,5-dihydro-5-phenyl-3-isoxazolecarboxylic acid (i.e. the product of Example 12, Step B) (9.5 g, 50 mmol) in methanol (70 mL) was heated to 55 0C5 and cinchonine (containing about 15 % dihydrocinchonine, 14.5 g, 50 mmol) was added over 20 minutes while keeping the temperature of the reaction mixture between 53 and 57 0C. The reaction mixture was allowed to cool to room temperature over 60 minutes, and then water (35 mL) was added dropwise over 30 minutes. The resulting slurry was cooled to 10 °C and filtered. The filter cake was washed twice with 10 mL of 25 % methanol in water, and air dried to give 8.52 g of the title compound as a solid. The diastereomeric ratio of the . product was determined using chiral high performance liquid chromatography (HPLC) analysis on a Daicel Chiralcel®, OD HPLC column to be about 99:1. 1HNMR (CDCl3) δ 3.25 (dd, IH), 3.75 (dd, IH), 5.85 (dd, IH), 7.35 (m, 5H), 8.1 (br s, IH).
Step D: Preparation of (5R)-4,5-dihydro-iV>N-dimethyl-5-phenyl-3-isoxazole- carboxamide
The cinchonine salt of (5R)-4,5-dihydro-5-phenyl-3-isoxazolecarboxylic acid (i.e. the product of Example 12, Step C) (98 % diastereomeric excess, 16.5 g, 34.3 mmol) was slurried in a mixture of 1 N hydrochloric acid (90 mL), cyclohexane (100 mL) and ethyl acetate (40 mL). After all the solids dissolved, the phases were separated, and the organic layer was washed with brine (20 mL) and concentrated under reduced pressure to give 5.6 g of white solid. To a solution of the resulting free acid (5.0 g, 26.2 mmol) in ethyl acetate (100 mL) at room temperature was added iV^V-dimethylformamide (1 drop) followed by thionyl chloride (4.25 g, 35.7 mmol). The reaction mixture was then heated under reflux for 3 h. The resulting mixture was cooled and concentrated under reduced pressure. The residue containing crude acid chloride was dissolved in ethyl acetate (25 mL), and this solution was added in portions to a pre-cooled (5 0C) mixture of dimethylamine in tetrahydrofuran (29 mL of a 2.0 M solution), while maintaining the temperature of the mixture at 5-10 0C. When the addition was complete, the reaction mixture was concentrated under reduced pressure, and diluted with water (50 mL). The resulting precipitate was filtered, washed with water and suction-dried overnight to give 4.1 g of the title compound as a light tan solid, melting at 59-61 °C. This compound was of sufficient purity to use in subsequent reactions.
Step E: Preparation of 2-bromo- 1 -[(5i?)-4,5-dihydro-5-phenyl-3-isoxazolyl]ethanone
A solution of (5R)-4,5-dmydro-iVr/V-dimethyl-5-phenyl-3-isoxazole-carboxamide (i.e. the product of Example 12, Step D) (3.5 g, 16.0 mmol) in a mixture of tetrahydrofuran (5 mL) and toluene (10 mL) was cooled to -15 0C, and methyl magnesium bromide (3.0 M solution in tetrahydrofuran, 8.8 mL, 26.4 mmol) was added over 1 h at -15 0C. Then the reaction mixture was poured over a mixture of 20 g of concentrated hydrochloric acid and 80 US2007/014647
94 g of ice, and the organic phase was separated. The aqueous phase was extracted with ethyl acetate (100 mL), and the combined extract was washed with brine (40 .mL) and concentrated under reduced pressure to give 3.2 g of l-[(5.R)-4,5-dihydro-5-phenyl-3- is oxazoyl] ethanone. 1H NMR (CDCl3) δ 2.55 (s, 3H), 3.17 (dd, IH), 3.54 (dd, IH), 5.75 (dd, IH)5 7.35 (m, 5H). l-[(5R)-4,5-dihydro-5-phenyl-3-isoxazoyl]ethanone (3.2 g, 16.7 mmol) was dissolved in 1,2-dichloroethane (15 mL), and a solution of bromine (2.13 g, 13.3 mmol) in dichloroethane (5 mL) was added over 30 minutes while maintaining the temperature of the reaction mixture at about 30 0C. The reaction mixture was diluted with water (10 mL), and the organic layer was concentrated under reduced pressure and purified by medium-pressure liquid chromatography using 35 % of dichloromethane in hexanes as eluant to give 2.6 g of the title compound as a white solid, melting at 31—33 0C. 1H NMR (CDCl3) 63.20 (dd, IH), 3.60 (dd, IH), 4.49 (s, 2H), 5.80 (dd, IH), 7.35 (m, 5H).
Step El: Alternative preparation of 2-bromo-l-(4,5-dihydro-5-phenyl-3-isoxazolyl)- ethanone
To a solution of 4,5-dihydro-iV)7V-dimethyl-5-phenyl-3-isoxazolecarboxamide (i.e. the product of Example 12, Step A) (17 g, 78.0 mmol) in a mixture of tetrahydrofuran (20 mL) and toluene (80 mL) was added methyl magnesium bromide (3.0 M solution in tetrahydrofuran, 28 mL, 84 mmol) over 1 h, while keeping the reaction temperature between -10 and —15 0C. The reaction mixture was poured over a mixture of concentrated hydrochloric acid (20 g) and ice (80 g), and the organic phase was separated. The aqueous phase was extracted with ethyl acetate (100 mL), and the combined organic extracts were washed with brine (40 mL) and concentrated under reduced pressure to give 14.4 g of l-(4,5- dihydro-5-phenyl-3-isoxazoyl)ethanone as a light yellow oil. 1H NMR (CDCl3) δ 2.55 (s, 3H), 3.17 (dd, IH), 3.54 (dd, IH), 5.75 (dd, IH), 7.35 (m, 5H). l-(4,5-Dihydro-5-phenyl-3-isoxazoyl)ethanone (11.5 g, 60 mmol) was dissolved in ethyl acetate (45 mL), and a solution of bromine (9.6 g, 60.0 mmol) in ethyl acetate (30 mL) was added over 30 minutes while maintaining the temperature of the reaction mixture at about 30 0C. After 1 h, the reaction mixture was diluted with water (10 mL), and the organic layer was concentrated under reduced pressure to give 16.7 g of reddish oil which contained about 10 % starting methyl ketone and ~10 % dibrominated ketone. IH NMR (CDCl3) δ 3.20 (dd, IH), 3.60 (dd, IH), 4.49 (s, 2H), 5.80 (dd, IH), 7.35 (m, 5H).
Step F: Preparation of l-[4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]- l-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-lH-pyrazol-l-yl]ethanone A mixture of l-[2-[5-methyl-3-(trifluoromethyl)-lH-ρyrazol-l-yl]acetyl]-4-piperidine- carbothioamide (Le. the product of Example 8, Step C) (1.7,g, 5.0 mmol) and 2-bromo-l- [(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]ethanone (i.e. the product of Example 12, Step E or El) (1.35 g, 5 mmol) in ethanol (15 mL) was heated at 50 0C for 30 minutes. The reaction mixture was diluted with water and extracted with dichloromethane. The extract was washed with brine, dried (MgSC^), and concentrated under reduced pressure to give the title product, a compound of the present invention, as a pale-yellow gum. High performance liquid chromatography (HPLC) analysis showed that the title product was about 95 % pure and contained the (i?)-enantiomer in about 98 % enantiomeric excess. 1H NMR (CDCl3) 8 1.8 (m, 2H), 2.2 (m, 2H), 2.32 (s, 3H), 2.9 (m, IH), 3.3 (m, 2H), 3.42
(dd, IH)5 3.82 (dd, IH), 4.05 (m, IH), 4.6 (m, IH), 5.0 (q, 2H), 5.78 (dd, IH), 6.35 (s, IH),
7.4 (m, 5H), 7.62 (s, IH). . EXAMPLE 13
Preparation of 1 -[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-3,6-dihydro-l (2H)- pyridinyl]-2-[5-methyl-3-(trifluoromethyl)-liϊ-pyrazol-lyl3ethanone (Compound 217) Step A: Preparation of 4-[4-(4,5-dihydro-5 -phenyl-3-isoxazolyl)-2-thiazolyl]pyridine
To a solution of thioisonicotinamide (0.5 g, 3.6 mmol) in l-methyl-2-pyrrolidinone (25 mL) was added 2-chloro-l-(4,5-dihydro-5-phenyl-3-isoxazolyl)ethanone (0.807 g, 3.6 mmol), at room temperature. The reaction mixture was then heated to 100 °C for 3 h. Then the reaction mixture was cooled to room temperature, quenched with water (100 mL), extracted with ethyl acetate (50 mL x 2). The reaction mixture was diluted with water (50 mL) and brine (50 mL), and the organic layer was concentrated under reduced pressure and purified by medium-pressure liquid chromatography using 2 % of methanol in chloroform as eluant to give 0.7 g of the title compound as a brown solid.
1H NMR (CDCl3) δ 3.5 (m, IH), 3.9 (m, IH), 5.8 (m, IH), 7.35 (m, 5H), 8.16 (s, IH), 8.3 (d, 2H), 8.8 (d, 2H). Step B: Preparation of 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-l,2,3,6- tetrahydro- 1 -(phenyhnethyl)pyridine
To a solution of 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]pyridine (i.e. the product of Example 13, Step A) (0.60 g, 1.95 mmol) in toluene (10 mL) was added benzyl bromide (0.670 g, 3.90 mmol), and the reaction mixture was heated to 100 0C for 12 h. Then the reaction mixture was cooled to room temperature. The solid that precipitated out was filtered and dried. The solid was dissolved in methanol (10 mL), and sodium borohydride (0.072 g, 1.95 mmol) was added in portions. The reaction mixture was stirred at room temperature for 2 h, diluted with water (50 mL), neutralized with 1.5 N aqueous hydrochloric acid solution, and extracted with ethyl acetate (50 mL). The organic layer was separated, washed with brine (25 mL), and concentrated under reduced pressure. The residue was purified by medium-pressure liquid chromatography using 3 % of methanol in chloroform as eluant to give 0.4 g of the title compound as a white solid. 1H NMR (CDCl3) δ 3.03-3.1 (m, 2H), 3.4-3.6 (m, 4H), 3.8-4.0 (m, 2H), 4.25-4.32 (m, 2H), 5.76-5.79 (m, IH), 6.47 (s, IH), 7.34-7.48 (m, 10H), 7.72 (s, IH).
Step C: Preparation of 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-l ,2,3,6- tetrahydropyridine hydrochloride To a solution of 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-l, 2,3,6- tetrahydro-l-(phenyhnethyl)pyridine (i.e. the product of Example 13, Step B) (0.400 g, 0.99 mmol) in dichloro ethane (10 mL) was added 1 -chloroethyl chloroformate (0.286 g, 1.99 mmol), and the reaction mixture was heated to 80 0C for 5 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. Methanol (10 mL) was added to the residue, and the resulting mixture was heated to 60 0C for 1 h, cooled to room temperature, and concentrated under reduced pressure. The residue was triturated with 50 % of petroleum ether in ethyl acetate, arid the solid formed was filtered and dried to give 0.25 g of the title compound as a white solid. 1H NMR (DMSO-cfø) 5 2.50-2.55 (m, 2H), 3.31-3.39 (m, 3H), 3.86-3.91 (m, 3H), 5.73- 5.78 (m, IH), 6.67 (s, IH), 7.34-7.39 (m, 5H), 7.68 (s, IH), 9.47 (s, 2H).
Step D: Preparation of 1 -[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-3,6- dmydro-l(2H)-pyridinyl]-2-[5-methyl-3-(trifluoromethyl)-lH-pyrazol-lyl]ethanone
To a solution of 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-l,2,3,6- tetrahydropyridine hydrochloride (i.e. the product of Example 13, Step C) (0.250 g, 0.720 mmol) and 5-methyl-3-(trifluoromethyl)-lH-pyrazole-l-acetic acid (0.150 g, 0.720 mmol) in dichloromethane (10 mL) was added N- (3-dimethylamuiopropyl)-Λ^-ethylcarbodiimide (0.138 g, 0.720 mmol), 1-hydroxybenzotriazole (0.024 g, 0.177 mmol), and triethylamine (0.145 g, 1.44 mmol) at room temperature. The reaction mixture was stirred at room temperature for 24 h. The reaction mixture was diluted with dichloromethane (30 mL) and washed with water (20 mL) and brine (20 mL). The organic layer was separated, washed with water, dried (Na2SC>4), and concentrated under reduced pressure and purified by medium-pressure liquid chromatography using 3 % methanol in chloroform as eluant to give 200 mg of the title product, a compound of the present invention, as a white solid. *Η NMR (CDCl3) 52.3 (s, 3Η), 2.71-2.75 (m, 2H), 3.42-3.46 (m, IH), 3.74-3.88 (m, 3H), 4.24-4.27 (m, 2H)5 5.02 (s, 2H), 5.71-5.76 (m, IH), 6.32 (s, IH), 6.57 (s, IH), 7.3-7.38 (m, 5H), 7.64 (s, IH).
By the procedures described herein, together with methods known in the art, the following compounds of Tables IA to 8 can be prepared. The following abbreviations are used in the Tables which follow: t means tertiary, s means secondary, n means normal, i means iso, c means cyclo, Ac means acetyl, Me means methyl, Et means ethyl, Pr means propyl (i.e. w-propyl), /-Pr means isopropyl, c-Pr means cyclopropyl, Bu means butyl, Pen means pentyl, Hex means hexyl, Am means amyl, CN means cyano. A dash (-) indicates no substituents.
The invention includes but is not limited to the following exemplary species.
TABLE IA
Figure imgf000098_0001
Figure imgf000099_0001
2-bromo-5-propylphenyl
2-bromo-5-isopropylρhenyl
2-bromo-5-(trifluoromethyl)phenyl
2-bromo-5-(2,2,2-trifluoroethyl)phenyl
2-bromo-5-(pentafluoroethyl)phenyl
2-bromo-5-cyanophenyl
2-bromo-5-nitrophenyl
5-chloro-2-methylphenyl
5-bromo-2-methylphenyl
5-iodo-2-methylphenyl
2,5-dimethylphenyl
5-ethyl-2-methylphenyl
2-methyl-5-propylphenyl
5-isopropyl-2-methylphenyl
2-methyl-5-(trifluoromethyl)phenyl
2-methyl-5-(2,2,2-trifluoroelhyl)phenyl
2-methyl-5 -(pentafluoroethyl)phenyl
5-cyano-2-methylphenyl -yl
2-methyl-5-nitrophenyl
5-chloro-2-methoxyphenyl
5-bromo-2-methoxyρhenyl
5 -iodo-2-methoxyρhenyl
2-methoxy-5-methylphenyl
3-iodo-5-methylpyrazol-l -yl
3-ethyl-5-methylpyrazol-l -yl
5-methyI-3-propylpyrazol- 1 -yl
3 -isopropyl-5 -methylpyrazol- 1 -yl
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl -methyl-3-(2,2,2-trifluoroethyl)pyra2ol- 1 -yl 3-bromo-5-ethy]pyrazol-l-yl
5-methyl-3-(pentafluoroethyl)pyrazol-l-yl
3-cyano-5 -methylpyrazol- 1 -yl
5-methyl-3-nitropyrazol-l -yl
S-chloro-S-methylpyrazol- 1 -yl
3,5-dichloropyrazol-l-yl 1 -yl
5 -chloro-3 -bromopyrazol- 1 -yl l
5-chloro-3-iodopyrazol-l-yl 1 -yl
5-chIoro-3-ethylpyrazol-l -yl
Figure imgf000099_0002
Figure imgf000100_0001
R* Rl
4-( trifluoromethyl)-2-oxazolyl 2,5-dimethyl-3-pyridyl
4-methyl-2-(trifluoromethyl)-5-oxazolyI 2,5-dimethyl-4-pyridyl
4-bromo-5-isothiazolyl 3 ,6-dichloro-2-pyridyl
4-bromo-5-isoxazolyl 2,5-dichloro-3-pyridyl l-methyl-5-ρyrazolyl 2,5-dichloro-4-pyridyI l-methyl-5-imidazolyl 4-bromo-3-pyridazinyl l-tnethyl-4-(trifluoromethyl)-2-imidazolyl 4-(trifluoromethyl)-2-pyrimidinyl
4-methyl-3-(l ,3,4-triazolyl) 3 ,6-dimethyl-2-pyrazinyl
2-methyl-3-(l ,2,4-triazolyl) 2,5-dimethyl-4-pyritnidinyl
5-(trifluoromethyl)-2-( 1 ,3 ,4-thiadiazolyl) 4-methoxy-5-pyrimidinyl
5-(trifluoromethyl)-2-( 1 ,3 ,4-oxadiazolyI) 3 ,6-dimethy]-4-pyridazinyl
3-(trifluoromethyl)-5-( 1 ,2,4-thiadiazolyl) 5-(trifluoromelhyI)-3-( 1 ,2,4-triazinyl)
3-(trifluoromethyl)-5-(l,2,4-oxadiazolyl) 5-methoxy-6-( 1 ,2,4-triazinyl)
3-(trifluoromethyl)-l-(l,2,4-triazolyl) 4-(trifluoromethyl)-2-( 1 ,3 ,5-triazinyl)
2,5-dimethyl- 1 -pyrrolyl 3 ,6-dimethyl-5-(l ,2,4-triazinyl) l-methyl-3-(trifluoromethyl)pyrazol-5-yl l-methyl-4-(trifluoromethyl)imidazol-2-yl
3 -bromo-5 -(trifluoro methy I)pyrazol- 1 -yl 3,5-bis-(trifluoromethyl)pyrazol-l-yl
3-iodo-5-(trifluoromethyl)pyrazol-l-yl 3-(2s2,2-trifluoroethyl)-5-(trifluoromethyl)pyrazol-l-yl
3-ethyl-5-(trifluoromethy])-pyrazol- 1 -yl 3-(pentafluoroethyl)-5 -(trifluoromethyl)pyrazol- 1 -yl
3-propyl-5-(trifluoromethyl)pyrazol-l-yl 3-cyano-5-(trifluoromethyl)pyrazol-l-yl
3-isoρropyl-5-(trifluoromethyl)pyrazol- 1 -yl 3-nitro-5-(trifluorømethyl)pyrazol-l-yl
3-methyl-5-(trifluoromethyl)-pyra2ol-l-yl 3-chloro-5-(trifluoromethyl)-pyrazol- 1 -yl •
3-methoxy-S-(trifluoromethyl)-pyrazol-l-yl 3,5-bis-(trichloromethyl)pyrazol-l-yl
5 -di fIuoromethoxy-3 -methy lpyrazol- 1 -yl 3-difluoromethoxy-5-methylpyrazol-l-yl
S-difluoroinethoxy-3-chloropyrazol-l-yl S-difluoromethoxy-S-chloropyrazol-l-yl
3,5-dibromopyrazol-l-yl 3-difluoromethoxy-5-bromopyrazol-l-yl
5-difluorometboxy-3-iodopyrazol- 1 -yl 3-difluoromethoxy-5-iodopyrazol- 1 -yl
5-difluoromethoxy-3-ethylpyrazol-l-yl 3-difluoromethoxy-5 -ethylpyrazol- 1 -yl
5-difluoromethoxy-3 -propylpyrazol-1 -yl 3-difluoromethoxy-5-(trifluoromethyl)ρyrazol-l-yl
5-difluoromethoxy-3-isopropylpyrazol-l-yl 3-difluoromethoxy-5-(2,2,2-trifluoroethyl)pyrazol-l-yl
5-difluoromethoxy-3-(trifluoromethyl)pyrazol-l-yl S-difluoromethoxy-S-Cpentafluoroethy^pyrazol- 1 -yl-difluoromethoxy-3-(2,2,2-trifluoroethyl)pyrazol-l-yl S-difluoromethoxy-S-cyanopyrazol- 1 -yl
5-difluoromethoxy-3-(pentafluoroethyl)pyrazol-l-yl 3-difluoromethoxy-5-nitropyrazol-l -yl
5 -difluoτomethoxy-3 -cyanopyrazol- 1 -yl 3,5-bis-(difluoromethoxy)pyrazol-l-yl
5 -difluoromethoxy-3 -nitropyrazol- 1 -yl 5-carbomethoxy-3-(trifluoromethyl)pyrazol- 1 -yl
3-carbomethoxy-5-(trifluoromethyl)pyrazol-l-yl 3 ,5-dimethoxypyrazol- 1 -yl
5-methoxy-3-methylρyrazol- 1-yl 5-ethoxy-3-methylpyrazol-l-yl
-yl •
1 -yl
Figure imgf000102_0001
TABLE IB
Figure imgf000102_0002
2-methoxyphenyl NH O
2,5-dichlorophenyl NH O
5-bromo-2-chlorophenyl NH O
2-chloro-5-methylphenyl NH O
2-chloro-5-(trifluoromethyl)phenyl NH O
2,5 -dibromophenyl NH O
2-bromo-5-methylphenyl NH O
2-bromo-5-(trifluoromethyl)phenyl NH O
5-chloro-2-methylphenyl NH O
5-bromo-2-methylphenyl NH O
2,5-dimethylphenyl NH O
5-ethyl-2-methylphenyl NH O
2-methyl-5-(trifluoromethyl)phenyl NH O
5-bromo-2-methoxyρhenyl NH O
2-methoxy-5-methylphenyl NH O
2-methoxy-5-(trifluoromethyl)phenyl NH O Rl A W
3-ethyl-5-methylpyrazol-l-yl CH2 S -methyl-S-CtrifluoromethylJpyrazol- 1 -yl CH2 S
3 ,5-dichloropyrazol- 1-yl CH2 S
S-chloro-S-CtrifluoromethyOpyrazol-l-yl CH2 S
3 ,5-bis-(trifluoromethy l)pyrazol-l -yl CH2 S
3 ,5-dimethylpyrazol- 1 -yl CH2 S
3,5-dibromopyrazol-l -yl CH2 S
5-bromo-3-(trifluoromethyl)pyrazol-l-yl CH2 S
3 ,5 -dicthylpyrazol- 1 -yl CH2 S
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl CH2 S
2-methoxyphenyl NH S
2,5-dichlorophenyl NH S
5-bromo-2-chlorophenyl NH S
2-cliloro-5-methylphenyl NH S
2-chIoro-5-(trifluoromethyl)phenyl NH S
2,5-dibromophenyI NH S
2-bromo-5-methylphenyl NH S
2-bromo-5-(trifluoromethyl)phenyl NH S
5-cMoro-2-methylphenyl NH S
5-bromo-2-methylphenyl NH S
2,5-dimethyIphenyl NH S
5-ethyl-2-methylphenyl NH S
2-methyl-5-(trifluoromethyl)phenyl NH S
5-bromo-2-methoxyρhenyl NH S
2-methoxy-5-methylphenyl NH S
2-methoxy-5-(trifluoromethyl)phenyl NH S
5-methyl-3-(trifluoromethyl)pyrazol-l-yl NCH3 O
5-methyl-3-(trifluoromethyl)pyrazol- 1-yl NAc O
3-methyl-5-(trifluoroinethyl)pyrazol- 1 -y 1 CH2 S
5-methyl-3-(trifluorornethyl)pyrazol-l-yl CHCH3 O
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl CHCOOCH3 O
5-methyl-3-(trifluoromethyl)pyrazol-l-yl CHCl O
5-methyl-3-(trifluoromethyl)ρyrazol- 1 -yl NCOOCH3 O
5-methyl-3-(trifluoromethyl)ρyrazol-l-yl NH S
3 ,5-dimethylpyrazol-l -yl NH O
3 ,5-dichloropyrazol- 1 -yl NH O
3 ,5-dibromopyrazol- 1 -yl NH O Ei A W
5-methyl-3-(trifluoromethyl)pyrazol-l-yl NH O
S-chloro-S-CtrifluoromethyOpyrazol-l-yl NH O
5-bromo-3-(trifluoromethyl)pyrazol- 1 -yl NH O
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl NH O
•3,5-bis-(trifluoromethyl)pyrazol-l-yl NH O
3-methyl-5-(trifluoromethyl)pyrazol-l-yl NH O
3-cWoro-5-(trifluoromethyl)pyrazol-l-yl NH O
3-bromo-5-(trifluoromethyl)pyrazol-l-yl NH O
5-methoxy-3-(trifluoromethyl)pyrazol- 1 -yl NH O
5-difluoromethoxy-3 -(trifluoromethyl)pyrazol- 1 -yl NH O
TABLE 2*
Figure imgf000104_0001
J (R5)x Z2 Q (R7)P R12 . J-orientation ** bond J-I — bond Q-45 — — 2/4 bond J-I - bond Q-45 - - 2/5 bond J-I - bond Q-45 - - 4/2 bond J-I - bond Q-45 - - 5/2 bond J-2 - bond Q-45 - - 2/4 bond J-2 - bond Q-45 - - 2/5 bond J-2 - bond Q-45 - - 4/2 bond J-2 - bond Q-45 - - 5/2 bond J-3 1-Me bond Q-45 - - 2/4 bond J-3 1-Me bond Q-45 - - 2/5 bond J-3 1-Me bond Q-45 - - 4/2 bond J-3 1-Me bond Q-45 - - 5/2
CH2 J-3 - bond Q-45 - - 1/4 bond J-3 bond Q-45 4/1 J (R5)x Z2 Q (R7)p R12 J-orientation ** bond J-4 — bond Q-45 - - 2/4 bond J-4 - bond Q-45 - - 2/5 bond J-4 - bond Q-45 - - 4/2 bond J-4 - bond Q-45 - - 5/2 bond J-4 . - bond Q-45 - - 3/5 bond J-4 - bond Q-45 - - 5/3 bond J-5 - bond Q-45 - - 2/4 bond J-5 - bond Q-45 - - 2/5 bond J-5 - bond Q-45 - • - 4/2 bond J-5 - bond Q-45 - - 5/2 bond J-5 - bond Q-45 - - 3/5 bond J-5 - bond Q-45 - - 5/3 bond J-6 - bond Q-45 - - 2/4 bond J-6 - bond Q-45 - - 2/5 bond J-6 - bond Q-45 - - 4/2 bond J-6 - bond Q-45 - - 5/2 bond J-6 - bond Q-45 - - 3/5 bond J-6 - bond Q-45 - - 5/3
CH2 J-6 - bond Q-45 - - 1/3 bond J-6 - bond Q-45 - - 3/1 bond J-7 - bond Q-45 - - ' 5/3 bond J-7 - bond Q-45 - - 3/5 bond J-8 - bond Q-45 - - 5/3 bond J-8 - bond Q-45 - - 3/5 bond J-9 1-Me bond Q-45 - - 5/3 bond J-9 1-Me bond Q-45 - - 3/5
CH2 J-9 - bond Q-45 - - 1/4 bond J-9 - bond Q-45 - - 4/1 bond J-10 - bond Q-45 - - 3/5 bond J-10 - bond Q-45 - - 5/3 bond J-Il - bond Q-45 - - 3/5 bond J-Il - bond Q-45 - - 5/3 bond J-12 1-Me bond Q-45 - 3/5 bond J-12 1-Me bond Q-45 - - 5/3
CH2 J-12 - bond Q-45 - - 1/3 bond J-12 bond Q-45 _ _ 3/1 (R5)x Z2 (RQp Rl2 J-orientation ** bond J-13 bond Q-45 1/4 bond J-13 bond Q-45 4/1 bond J-14 1-Me bond Q-45 3/5 bond J-14 bond Q-45 5/3 bond J-15 bond Q-45 2/5 bond J-16 bond Q-45 2/5
CH2 J-17 bond Q-45 2/4 bond J-17 bond Q-45 4/2
CH2 J-]8 bond Q-45 2/5 bond J-18 bond Q-45 5/2 bond J-19 bond Q-45 2/4 bond J-19 bond Q-45 4/2 bond J-20 bond Q-45 2/4 bond J-20 bond Q-45 2/5 bond J-20 bond Q-45 2/6 bond J-20 bond Q-45 3/5 bond J-20 bond Q-45 4/2 bond J-20 bond Q-45 5/2 bond J-21 bond Q-45 3/5 bond J-21 bond Q-45 3/6 bond J-21 bond Q-45 5/3 bond J-22 bond Q-45 2/4 bond J-22 bond Q-45 2/5 bond J-22 bond Q-45 4/6 bond J-22 bond Q-45 4/2 bond J-22 bond Q-45 5/2 bond J-23 bond Q-45 2/5 bond J-23 bond Q-45 2/6 bond J-24 bond Q-45 2/4 bond J-24 bond Q-45 2/5 bond J-24 bond Q-45 4/2 bond J-24 bond Q-45 5/2 bond J-25 bond Q-45 2/4 bond J-25 bond Q-45 2/5 bond J-25 bond Q-45 4/2 bond J-25 bond Q-45 5/2 J (R5)x Z2 Q (R7)p R12 J-orientation ** bond J-26 _ bond Q-45 - - 2/4 bond J-26 - bond Q-45 - - 2/5 bond J-26 - bond Q-45 - - 4/2 bond J-26 - bond Q-45 - - 5/2
CH2 J-26 - bond Q-45 - - 1/4 bond J-26 - bond Q-45 - - 4/1 bond J-27 • - bond Q-45 - - 2/4 bond J-27 - bond Q-45 - - 2/5 bond J-27 - bond Q-45 - - 3/5 bond J-27 - bond Q-45 - - 4/2 bond J-27 - bond Q-45 - - 5/2 bond J-27 - bond Q-45 - - 5/3 bond J-28 - bond Q-45 - - 3/5 bond J-28 - bond Q-45 - - 5/3 bond J-29 - bond Q-45 - - 3/5 bond J-29 - bond Q-45 - - 5/3 bond J-30 - bond Q-45 - - 3/5 bond J-30 - bond Q-45 - - 5/3
CH2 J-30 - bond Q-45 - - 1/3 bond J-30 - bond Q-45 - - 3/1
CH2 J-30 - bond Q-45 - - 1/4 bond J-30 - bond Q-45 - - 4/1
CH2 J-31 - bond Q-45 - - 1/3
CH2 J-31 - bond Q-45 - - 1/4 bond J-31 - bond Q-45 - - 2/4 bond J-31 - bond Q-45 - - 2/5 bond J-31 - bond Q-45 - - 3/5 bond J-31 - bond Q-45 - - 3/1 bond J-31 - bond Q-45 - - 4/1 bond J-31 - bond Q-45 - - 4/2 bond J-31 - bond Q-45 - - 5/2 bond J-32 - bond Q-45 - - 2/4 bond J-32 - bond Q-45 - - 2/5 bond J-32 - bond Q-45 - - 3/5 bond J-32 - bond Q-45 - - 5/3 bond J-32 bond Q-45 5/2 Zl (R5)x Z2 (R7)P Rl2 J-orientation : bond J-32 bond Q-45 4/2 bond J-33 bond Q-45 2/4 bond J-33 bond Q-45 2/5 bond J-33 bond Q-45 3/5 bond J-33 bond Q-45 5/3 bond J-33 bond Q-45 5/2 bond J-33 bond Q-45 4/2 bond J-34 bond Q-45 1/3 bond J-34 bond Q-45 1/4 bond J-34 bond Q-45 3/5 bond J-34 bond Q-45 3/1 bond J-34 bond- Q-45 4/1
CH2 J-35 bond Q-45 1/4 bond J-35 bond Q-45 4/1
CH2 J-36 bond Q-45 1/3 bond J-36 bond Q-45 3/1 bond J-36 bond Q-45 3/5 bond J-36 bond Q-45 5/3 bond J-37 bond Q-45 2/5 bond J-37 bond Q-45 5/2 bond J-37 bond Q-45 2/4 bond J-37 bond Q-45 4/2 bond J-38 bond Q-45 2/5 bond J-38 bond Q-45 5/2 bond J-38 bond Q-45 2/4 bond J-38 bond Q-45 4/2 bond J-39 4-Me bond Q-45 3/5 bond J-39 4-Me bond Q-45 5/3 bond J-40 bond Q-45 3/5 bond J-40 bond Q-45 5/3 bond J-41 bond Q-45 1/3 bond J-41 bond Q-45 1/4
CH2 J-42 bond Q-45 1/3
CH2 J-42 bond Q-45 1/4
CH2 J-43 bond Q-45 1/4 bond J-44 bond Q-45 1/3 Zl (R5)x Z2 Q (R7)D R12 J-orientation ** bond J-44 bond Q-45 — 2/4 bond J-44 bond Q-45 - 2/5 bond J-44 bond Q-45 - 2/6 bond J-45 bond Q-45 - 2/4 bond J-45 bond Q-45 - 2/5 bond J-45 bond Q-45 - 2/6 bond J-46 bond Q-45 • 2/4 bond J-46 bond Q-45 - 2/5 bond J-46 bond Q-45 - . 4/2 bond J-46 bond Q-45 - 5/2 bond J^7 bond Q-45 - 2/4 bond J-47 bond Q-45 - 2/5 bond J-47 bond Q-45 - 4/2 bond J-47 bond Q-45 - 5/2 bond J-48 bond Q-45 - 3/5 bond J-49 bond Q-45 - 2/4 bond J-49 bond Q-45 - 2/5 bond J-49 bond Q-45 - 4/2 bond J-49 bond Q-45 - 5/2 bond J-50 bond Q-45 - 2/6 bond J-51 bond Q-45 - 2/6 bond J-52 bond Q-45 _ 2/6 bond J-53 2/3 bond J-54 2/3 bond J-55 2/3 bond J-56 2/3 bond J-57 l-Me 2/4 bond J-58 1-Me 3/4 bond J-59 2/4 bond J-60 2/4 bond J-61 2/4 bond J-62 2/4 bond J-63 . 3/4 bond J-64 2/3 bond J-65 3/4 bond J-66 6/7 Z1 J (R5)χ Z2 Q (R7)p R12 J-orientation
— — 2/3 bond J-67 bond J-68 - - - 2/3 bond J-69 - bond Q-45 1/3 bond J-69 - bond Q-45 1/4 bond J-70 - bond Q-45 1/3 bond J-71 - bond Q-45 2/4 bond J-71 - bond Q-45 4/2 bond J-72 - bond Q-45 2/4 bond J-72 - bond Q-45 4/2 bond J-73 - bond Q-45 2/4 bond J-73 - bond Q-45 4/2 bond J-73 - bond Q-45 1/3 bond J-73 - bond Q-45 1/4 bond J-73 - bond Q-45 4/1 bond J-74 3-Me bond Q-45 2/4 bond J-74 3-Me bond Q-45 2/5 bond J-74 3-Me bond Q-45 4/2 bond J-74 3-Me bond Q-45 ".5/2 bond J-74 - bond Q-45 3/5 bond J-74 - bond Q-45 5/3 bond J-75 • - bond Q-45 3/5 bond J-75 - bond Q-45 5/3 bond J-75 - bond Q-45 2/4 bond J-75 - bond Q-45 2/5 bond J-75 2-Me bond Q-45 3/5 bond J-75 2-Me bond Q-45 5/3 bond J-76 - bond Q-45 3/6 bond J-76 - bond Q-45 6/3 bond J-77 - bond Q-45 3/5 bond J-77 - bond Q-45 5/3 bond J-78 - bond Q-45 1/3 bond J-79 - bond Q-45 1/3 3/1 bond J-79 - bond Q-45 bond J-80 - bond Q-45 1/3 bond J-80 - bond Q-45 3/1 bond J-81 _ bond Q-45 3/5 47
110 zi (R5). Z2 (R7)r R12 J-orientation ** bond J-81 — bond Q-45 5/3 bond J-82 - bond Q-45 3/5 bond J-82 - bond Q-45 3/6 bond J-82 - bond Q-45 5/3 bond J-82 - bond Q-45 6/3
CH2 J-83 - - _ 2/6
O J-29 - bond Q-45 3/5
S J-29 - bond Q-45 3/5
SO J-29 - bond Q-45 3/5
SO2 J-29 - bond Q-45 3/5
NH J-29 - bond Q-45 3/5
NMe J-29 - bond Q-45 3/5
NPr J-29 - bond Q-45 3/5
CH2 J-29 - bond Q-45 3/5
CH-i-
J-29 - bond Q-45 3/5 Bu bond J-29 4-Me bond Q-45 3/5 bond J-29 5-Me bond Q-45 3/5 bond J-29 4,5-di-Me bond Q-45 3/5 bond J-29 4,4-di-Me bond Q-45 3/5 bond J-29 [Note 1] bond Q-45 6-Me, [Note 1] 3/5 bond J-29 [Note 2] bond Q-45 6-Me, [Note 2] 3/5 bond J-29 5-Et bond Q-45 3/5 bond J-29 5-/-Bu - - 3/5 bond J-29 5-/-amyl - 3/5 bond J-29 5 -(4-Me-3 -penten- 1 -y 1) - 3/5 bond J-29 5-(3,3-di-Me-l -butyn-1 -yl) - 3/5 bond J-29 5-c-Pr bond Q-45 3/5 bond J-29 5-(4-Me-cyclohexyl) - - 3/5 bond J-29 5-CF3 bond Q-45 3/5 bond J-29 5-perfluoropropyl - - ' - 3/5 bond J-29 5-(3,3-di-Cl-2-propen-l-yl) - - 3/5 bond J-29 5-OMe bond Q-45 3/5 bond J-29 5-SiMe3 - - 3/5 bond J-69 4-F bond Q-45 1/3 bond J-69 4-Cl bond Q-45 1/3 J (R5)x Z2 Q (R% R12 J-orientation ** bond J-69 4-OH bond Q-45 — — 1/3 bond J-69 4-NH2 bond Q-45 - - 1/3 bond J-69 4-CN O Q-45 - - 1/3 bond J-69 4-NO2 NH Q-45 - - 1/3 bond J-69 4-CF3 S Q-45 - - 1/3 bond J-69 - O Q-45 - - 1/3 bond J-69 - S Q-45 - - 1/3 bond J-69 - so Q-45 - - 1/3 bond J-69 - SO2 Q-45 - - 1/3 bond J-69 - NH Q-45 - - 1/3 bond J-69 - N-Me Q-45 - - 1/3 bond J-69 - CH2 Q-45 - - 1/3 bond J-69 4-OEt bond Q-45 - - 1/3 bond J-69 4-OCF3 bond Q-45 - - 1/3 bond J-69 4-SMe bond Q-45 - - 1/3 bond J-69 4-SOMe bond Q-45 - - 1/3 bond J-69 4-SO2Me bond Q-45 - - 1/3 bond J-69 4-SO2-?-Bu - - - - 1/3 bond J-69 4-SCF3 bond Q-45 - - 1/3 bond J-69 4-SO2CH2CF3 - - - - 1/4 bond J-22 4-NH-ι-Bu - - - - 2/4 . bond J-22 4-di-E£N - - - - 2/4 bond J-22 4-NH-cyclohexyl - - - - 2/4 bond J-69 4-CH2O-I-Pr - - - - 1/4 bond J-69 4-CH2OCHF2 bond Q-45 - - 1/3 bond J-69 4-CH2OH bond Q-45 - - 1/3 bond J-74 3-acetyl bond Q-45 - - 2/5 bond J-69 4-CO2-Z-Pr - - - - 1/4 bond J-69 4-O-acetyl bond Q-45 - - 1/3 bond J-69 4-S-acetyl bond Q-45 - - 1/3 bond J-69 4-CONHMe bond Q-45 - - 1/3 bond J-69 4-CONEt2 - - - - 1/4 bond J-69 - O Q-45 - - 1/4 bond J-29 - bond Q-I - - 3/5 bond J-29 - bond Q-2 - - 3/5 bond J-29 _ bond Q-3 _ Me 3/5 J (R5)x Z2 Q (R% R12 J-orientation ** bond J-29 — bond Q-4 - — 3/5 bond J-29 - bond Q-5 - - 3/5 bond J-29 - bond Q-6 - - 3/5 bond J-29 - bond Q-7 - - 3/5 bond J-29 - bond Q-8 - - 3/5 bond J-29 - bond Q-9 - - 3/5 bond J-29 - bond Q-IO - Me 3/5 bond J-29 - bond Q-I l - Me 3/5 bond J-29 - bond Q-12 - Me 3/5 bond J-29 - bond Q-13 - Me 3/5 bond J-29 - bond Q-14 - Me 3/5 bond J-29 - bond Q-15 - - 3/5 bond J-29 - bond Q-16 - - 3/5 bond J-29 - bond Q-17 - - 3/5 bond J-29 - bond Q-18 - - 3/5 bond J-29 - bond Q-19 - - 3/5 bond J-29 - bond Q-20 - - 3/5 bond J-29 - bond Q-21 - Me 3/5 bond J-29 - bond Q-22 - Me 3/5 bond J-29 • - bond Q-23 - Me 3/5 bond J-29 - bond Q-24 - - 3/5 bond J-29 - bond Q-25 - - 3/5 bond J-29 - bond Q-26 - - 3/5 bond J-29 - bond Q-27 - - 3/5 bond J-29 - bond Q-28 - Me 3/5 bond J-29 - bond Q-29 - - 3/5 bond J-29 - bond Q-30 - - 3/5 bond J-29 - bond Q-31 - Me 3/5 bond J-29 - bond Q-32 - - 3/5 bond J-29 - bond Q-33 - - 3/5 bond J-29 - bond Q-34 - - 3/5 bond J-29 - bond Q-35 - - 3/5 bond J-29 - bond Q-36 - - 3/5 bond J-29 - bond Q-37 - - 3/5 bond J-29 - bond Q-38 - - 3/5 bond J-29 _ bond Q-39 _ 3/5 J (R5)x Z2 Q (R7)D R12 J-orientation ' bond J-29 — bond Q-40 - 3/5 bond J-29 - bond Q-41 - 3/5 bond J-29 - bond Q-42 - 3/5 bond J-29 - bond Q-43 - 3/5 bond J-29 - bond- Q-44 - 3/5 bond J-29 - bond Q-46 - 3/5 bond J-29 - CH2 Q-47 - 3/5 bond J-29 - bond Q-48 - 3/5 bond J-29 - bond Q-49 - 3/5 bond J-29 - bond Q-50 - 3/5 bond J-29 - bond Q-51 - 3/5 bond J-29 - bond Q-52 - 3/5 bond J-29 - bond Q-53 - 3/5 bond J-29 - bond Q-54 - 3/5 bond J-29 - bond Q-55 - 3/5 bond J-29 - bond Q-56 - 3/5 bond J-29 - bond Q-57 - 3/5 bond J-29 - bond Q-58 - 3/5 bond J-29 - bond Q-59 - 3/5 bond J-29 - bond Q-60 - 3/5 bond J-29 - bond Q-61 - 3/5 bond J-29 - bond Q-62 - 3/5 bond J-29 - bond Q-63 - 3/5 bond J-29 - bond Q-64 - 3/5 bond J-29 - bond Q-65 - 3/5 bond J-29 - bond Q-66 - 3/5 bond J-29 - bond Q-67 - 3/5 bond J-29 - bond Q-68 - 3/5 bond J-29 - bond Q-69 - 3/5 bond J-29 - bond Q-45 2-Me 3/5 bond J-29 - bond Q-45 3-Me 3/5 bond J-29 - bond Q-45 4-Me 3/5 bond J-29 - bond Q-45 2-Cl 3/5 bond J-29 - bond Q-45 3-Cl 3/5 bond J-29 - bond Q-45 4-Cl 3/5 bond J-29 bond Q-45 2-OMe 3/5 (R5)x Z2 (R% R12 J-orientation ** bond J-29 — bond Q-45 3-OMe 3/5 bond J-29 - bond Q-45 4-OMe 3/5 bond J-29 - bond Q-45 2-Et 3/5 bond J-29 - bond Q-45 3-f-Pr 3/5 bond J-29 - bond Q-45 2,6-di-Me 3/5 bond J-29 - bond Q-45 4-vmyl 3/5 bond J-29 - bond Q-45 4-ethynyl 3/5 bond J-29 - bond Q-45 4-c-Pr 3/5 bond J-29 - bond Q-45 3-CF3 3/5 bond J-29 - bond Q-45 3-OCF3 3/5 bond J-29 - bond Q-45 4-Br 3/5 bond J-29 - bond Q-45 3-OH 3/5 bond J-29 - bond Q-45 3-NH2 3/5 bond J-29 - bond Q-45 2-CN 3/5 bond J-29 - bond Q-45 2-NO2 3/5 bond J-29 - bond Q-45 4-O-r-Bu 3/5 bond J-29 - bond Q-45 4-SMe 3/5 bond J-29 - bond Q-45 4-SCF3 3/5 bond J-29 - bond Q-45 3-SO2Me 3/5 bond J-29 - bond Q-45 3-NHMe 3/5 bond J-29 - bond Q-45 4-NMe2 3/5 bond J-29 - bond Q-45 2-CH2OMe 3/5 bond J-29 - bond Q-45 3-COMe 3/5 bond J-29 - bond Q-45 3-CO2Me 3/5 bond J-29 - bond Q-45 3-CONHMe 3/5 bond J-29 - bond Q-45 4-OCOMe 3/5 bond J-29 - bond Q-45 4-SCOMe 3/5 bond J-29 - bond Q-45 3-CONMe2 3/5 bond J-29 - bond Q-45 4-SiMe3 3/5 bond J-29 - bond Q-45 2,6-di-F 3/5 bond J-29 - bond Q-45 2,6-di-Cl 3/5 bond J-29 - bond Q-45 2-OH 3/5 bond J-29 - bond Q-45 4-OCHF2 3/5 bond J-26 1-Me bond Q-45 - 2/5 bond J-26 [Note 3] bond Q-45 [Note 3] 2/5 bond J-26 1-Me, [Note 3] bond Q-45 [Note 3] 2/5 Zl (R5). Z2 (R7)t R12 J-orientation ** bond J-26 — bond Q-45 4-OH 2/5 bond J-26 - bond Q-45 4-OMe 2/5 bond J-26 - CH2 Q-45 4-OH 2/5 bond J-26 - CH2 Q-45 4-OMe 2/5 bond J-26 - bond Q-45 4-OH 2/4 bond J-26 - bond Q-45 4-OMe 2/4 bond J-26 - CH2 Q-45 4-OH 2/4 bond J-26 - CH2 Q-45 4-OMe - 2/4 bond J-25 - bond Q-45 4-OH 2/4 bond J-25 - bond Q-45 4-OMe 2/4 bond J-25 - CH2 Q-45 4-OH 2/4 bond J-25 - CH2 Q-45 4-OMe 2/4 bond J-I 5-Me bond Q-45 - 2/4 bond J-3 - bond Q-45 - 2/4 bond J-3 [Note 4] bond Q-45 [Note 4] 2/5 bond J-29 5-CO2Me bond Q-45 - 3/5 bond J-29 5-CO2Et bond Q-45 - 3/5 bond J-29 4,4-di-Me-5-CO2Me bond Q-45 - 3/5 bond J-29 5-CONEt2 bond Q-45 - 3/5 bond J-29 — NH Q-45 - 3/5 bond J-29 — NMe Q-45 - ' 3/5 bond J-29 — NEt Q-45 - 3/5 bond J-29 — NPr Q-45 - 3/5 bond J-29 5-NHAc - - - 3/5 bond J-29 5-NAc2 - - - 3/5 bond J-29 5-N(Me)Ac - - - 3/5 bond J-29 5-N(Me)C(=0)Ph - - - 3/5 bond J-29 5-N(Et)Ac - - - 3/5 bond J-29 5-N(Et)C(=O)Ph - - - 3/5 bond J-29 5-NHC(=O)OMe - - - 3/5 bond J-29 5-N(Me)C(=O)OMe - - - 3/5 bond J-29 5-NHC(=0)0Et - - - 3/5 bond J-29 5-N(Me)C(=O)OEt - - - 3/5 bond J-69 3-Cl - - - 1/3 bond J-69 3-Br - - - • 1/3 bond J-69 3-1 _ _ 1/3 Z1 J Z2 (R7)r R12 J-orientation ' bond J-69 3-Me 1/3 bond J-69 3-Et 1/3 bond J-69 3-Pr 1/3 bond J-69 3-/-Pr 1/3 bond J-69 3-Bu 1/3 bond J-69 3-/-Bu 1/3 bond J-69 3-5-Bu 1/3 bond J-69 3-f-Bu 1/3 bond J-69 3-Am . 1/3 bond J-69 3 -/-Am 1/3 bond J-69 3-/-Am 1/3 bond J-69 3-cyclopropyl 1/3 bond J-69 3-cyclobutyl 1/3 bond J-69 3-cyclopentyl 1/3 bond J-69 3-cyclohexyl 1/3 bond J-69 3-triflurometoxy 1/3 bond J-69 3-isoρropyoxy 1/3 bond J-69 3-isobutoxy 1/3 bond J-69 4-Cl 1/4 bond J-69 4-Br 1/4 bond J-69 4-1 1/4 bond J-69 4-Me 1/4 bond J-69 4-Et : i/4 bond J-69 4-Pr 1/4 bond J-69 4-/-Pr 1/4 bond J-69 4-Bu 1/4 bond J-69 4-/-Bu 1/4 bond J-69 4-s-Bu 1/4 bond J-69 4-/-Bu 1/4 bond J-69 4- Am 1/4 bond J-69 4-/-Am 1/4 bond J-69 4-r-Am 1/4 bond J-69 4-cyclopropyl 1/4 bond J-69 4-cyclobutyl 1/4 bond J-69 4-cyclopentyl 1/4 bond J-69 4-cyclohexyl 1/4 zi (R5)* Z2 (R7)t R12 J-orientation bond J-69 4-triilurometoxy - - 1/4 bond J-69 4-isopropyoxy - - 1/4 bond J-69 4-isobutoxy - - 1/4 bond J-69 3,4-di-Cl - - 1/4 bond J-69 3,4-di-Br - - 1/4 bond J-69 3,4-di-Me - - 1/4 bond J-69 3,4-di-Et - - 1/4 bond J-69 3,4-di-OMe - - 1/4 bond J-69 3,4-di-OEt - - 1/4 bond J-69 3-OMe-4-O-propargyl - - 1/4 bond J-4 5-i-Bu - - 2/5 bond J-4 5-(-Am - - 2/5 bond J-5 5-/-Bu - - 2/5 bond J-5 5-i-Am - - 2/5 bond J-Il 5-ϊ-Bu - 3/5 bond J-Il 5-ι-Ajtn - - 3/5 bond J-29 - bond Q-70 3/5 bond J-29 - bond Q-71 3/5 bond J-29 - bond Q-72 Me 3/5 bond J-29 - bond Q-73 3/5 bond J-29 - bond Q-74 3/5 bond J-29 - bond Q-75 Me 3/5 bond J-29 - bond Q-76 3/5 bond J-29 - bond Q-77 3/5 bond J-29 - bond Q-78 Me 3/5 bond J-29 - bond Q-79 Me 3/5 bond J-29 - bond Q-80 3/5 bond J-29 - bond Q-81 3/5 bond J-29 - bond Q-82 3/5 bond J-29 - bond Q-83 3/5 bond J-29 - bond Q-84 3/5 bond J-29 - bond Q-85 3/5 bond J-29 - bond Q-86 Me 3/5 bond J-29 - bond Q-87 3/5 bond J-29 - bond Q-88 Me 3/5 bond J-29 _ bond Q-89 3/5 Zl (R5)* Z2 Q (R7)p R12 J-orientation ♦♦
bond J-29 bond Q-90 - 3/5 bond J-29 bond Q-91 - 3/5 bond J-29 bond Q-92 - Me 3/5 bond J-29 bond Q-93 - 3/5 bond J-29 bond Q-94 - 3/5 bond J-29 bond Q-95 - Me 3/5 bond J-29 bond Q-96 - 3/5 bond J-29 bond Q-97 - 3/5 bond J-29 bond Q-98 - 3/5 bond J-29 bond Q-99 - 3/5 bond J-29 bond Q-100 - 3/5 bond J-29 bond Q-101 - 3/5 bond J-29 bond Q-102 - Me 3/5 bond J-29 bond Q-87 4-phenyl 3/5 bond J-29 bond Q-72 - acetyl 3/5 bond J-29 bond Q-72 - methoxycarbonyl 3/5 bond J-29 bond Q-72 - methoxy 3/5 bond J-29 bond Q-71 4-Cl 3/5 bond J-29 bond Q-71 5-Cl 3/5 bond J-29 bond Q-71 6-Cl 3/5 bond J-29 bond Q-71 7-Cl 3/5 bond J-29 bond Q-71 4-Me 3/5 bond J-29 bond Q-71 5-Me 3/5 bond J-29 bond Q-71 6-Me 3/5 bond J-29 bond Q-71 5-CF3 3/5 bond J-29 bond Q-71 5-NO2 3/5 bond J-29 bond Q-71 6-Br 3/5 bond J-29 bond Q-71 6-NO2 3/5 bond J-29 bond Q-71 6-NH2 3/5 bond J-29 bond Q-71 6-OMe 3/5 bond J-29 bond Q-71 5,6-di-OMe 3/5 bond J-29 bond Q-71 5,6-di-Cl 3/5 bond J-29 bond Q-70 • 5-Cl 3/5 bond J-29 bond Q-70 5-Me 3/5 bond J-29 bond Q-70 5-NO2 3/5 bond J-29 bond Q-70 5-NH2 3/5 Z1 J (R5)x Z2 Q J-onentation ' bond J-29 _ bond Q-70 .. 66--CCll 3/5 bond J-29 - bond Q-70 66--MMee 3/5 bond J-29 - bond Q-70 66--NNOO22 3/5 bond J-29 - bond Q-70 66--NNHH22 3/5 bond J-29 - bond Q-70 55,,66--ddii--CCll 3/5 bond J-29 - bond Q-70 55--CC11--66--OOHH 3/5 bond J-29 - bond Q-72 55--CCll Me 3/5 bond J-29 - bond Q-72 55--MMee Me 3/5 bond J-29 - bond Q-72 55--NNOO22 Me 3/5 bond J-29 - bond Q-72 55--NNHH22 Me 3/5 bond J-29 - bond Q-72 66--CCll Me 3/5 bond J-29 - bond Q-72 66--MMee Me 3/5 bond J-29 - bond Q-72 66--NNOO22 Me 3/5 bond J-29 - bond Q-72 66--NNHH22 Me 3/5 bond J-29 - bond Q-72 55,,66--ddii--CCll Me 3/5 bond J-29 - bond Q-63 44--MMee 3/5 bond J-29 - bond Q-63 44--NNOO22 3/5 bond J-29 - bond Q-63 44--NNHH22 3/5 bond J-29 - bond Q-63 55--CCll 3/5 bond J-29 - bond Q-63 55--MMee 3/5 bond J-29 - bond Q-63 55--CCNN 3/5 bond J-29 - bond Q-63 55--NNOO22 3/5 bond J-29 - bond Q-63 55--NNHH22 3/5 bond J-29 - bond Q-63 55--CCOOOOMMee 3/5 bond J-29 - bond Q-63 55,,66--ddii--CCll 3/5 bond J-29 5-N(Ac)C(=O)Ph bond - _- 3/5
J-29 5-N(Ac)C(=O)(2-
3/5 bond carbomethoxy-Ph) bond
Figure imgf000120_0001
the above Embodiments. A dash "-" in the (R5)x column indicates no substitution on J. A dash in each of the Z2 and Q columns indicates that no Z2Q substituent is attached as R5 to J. A dash in the (R7)p and/or R^2 columns indicates no substitution on Q.
** J-orientation refers to the attachment points for Z1 and Z2 (or another R5 when Z2 is not present) on ring J. The first number refers to the ring position on J where Z* is attached, and the second number refers to the ring position on J where Z2 is attached or, when Z2 is not present, the ring position on J where the substituent listed under (R )x is attached. [Note I]: R5 and R7 taken together to form a CH2CH2 bridge between position 4 of J-29 and position 2 of Q-45.
[Note 2]: R5 and R7 taken together to form a CH2 bridge between position 4 of J-29 and position 2 of Q-45.
[Note 3]: R5 and R7 taken together to form a CH2CH2 bridge between position 4 of J-26 and position 2 of Q- 45.
[Note 4]: R5 and R7 taken together to form a CH2CH2 bridge between position 1 of J-3 and position 2 of Q-45.
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000123_0001
Figure imgf000124_0001
Figure imgf000125_0001
Figure imgf000126_0001
007/014647
126
X R3a Rl Ia
(R2)r,
X9 - G-I H -
The definitions of X, G, R3a and R1 l a in the compounds of this table are as defined in the Summary of the Invention and Exhibit 2 in the above Embodiments.
A dash "-" in the (R^)n column indicates no substituents.
TABLE 4*
Figure imgf000127_0001
Rl X G** J*** (R5X R?a
2,5-dicblorophenyl χi G-I J-I (2/4) H 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-I (2/4) H
2,5-dimethylρhenyl χi G-I J-I (2/4) H 2-τnethyl-5-(trifluoromethyl)phenyl χi G-I J-I (2/4) H
3 ,5 -dimethylpyrazol- 1 -yl χi G-I J-I (2/4) H
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-I (2/4) H
5-chloro-3-(trifiuoromethyl)pyrazol-l-yl χi G-I J-I (2/4) H
5-bromo-3-(trifluoromethyl)pyrazol-l-yI χi G-I J-I (2/4) H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-I (2/4) H
3 ,5-bis-(trifluoromethyl)pyrazol-l -yl χi G-I J-I (2/4) H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-I (2/4) H -methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-l-<2/4) H
2,5-dichlorophenyl χi G-I J-2 (2/4) H 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-2 (2/4) H
2,5-dimethylphenyl χi G-I J-2 (2/4) H 2-methyl-5-(trifluoromethyl)phenyl χi G-I J-2 (2/4) H
3 , 5-dirnethylρyrazol- 1 -yl χi G-I J-2 (2/4) H 5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-2 (2/4) H 5-chloro-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-2 (2/4) H 5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-2 (2/4) H Rl X G** J*** R7a
(R5)v
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X1 G-I J-2 (2/4) - H
3 ,S-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-2 (2/4) - H l-methyl-3-(trifluoromethyl)pyrazol~5-yl χi G-I J-2 (2/4) - H l-methyl-4-(trifluoromethyl)imidazoI-2-yl χi G-I J-2 (2/4) - H
2,5-dichlorophenyl χi G-I J-3 (2/4) 1-Me H 2-chloro-5-(trifluoromethy])phenyl X1 G-I J-3 (2/4) 1-Me H
2,5-dimethylphenyl χi G-I J-3.(2/4) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl χi G-I J-3 (2/4) 1-Me H
3,5-dimethylpyrazol-l-yl χi G-I J-3 (2/4) 1-Me H
5-methyl-3-(trifluoromeihyl)pyrazol-l -yl χi G-I J-3 (2/4) 1-Me H
5 -chloro-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-I J-3 (2/4) 1-Me H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-3 (2/4) 1-Me H
5-ethyl-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-I J-3 (2/4) 1-Me H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-3 (2/4) 1-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-3 (2/4) 1-Me H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-3 (2/4) 1-Me H
2 , 5 -dichlorophenyl χi G-I J-4 (2/5) - H 2-chJoro-5-(trifluoromethyl)phenyl χi G-I J-4 (2/5) - H
2,5-dimethylphenyl χi G-I J-4 (2/5) - H 2-methyl-5-(trifluoromethyl)ρhenyl χi G-I J-4 (2/5) - H
3 ,5-dimethylpyrazol- 1 -yl χi G-I J-4 (2/5) - H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-4 (2/5) - H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-4 (2/5) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-4 (2/5) - H
5-ethyl-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-I J-4 (2/5) - H
3 ,5-bis-(trifluorometbyl)pyrazol- 1 -yl χi G-I J-4 (2/5) - . H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-4 (2/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-4 (2/5) - H
2,5-dichlorophenyl χi G-I J-8 (5/3) - H 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-8 (5/3) - H
2,5-dimethylphenyl χi G-I J-8 (5/3) - H
2-methyl-5-(trifluoromethyl)phenyl χi G-I J-8 (5/3) - H
3 ,5-dimethylpyrazol- 1 -yl χi G-I J-8 (5/3) H 7 014647
128
Rl X G** j *** (R5)v R7a
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-8 (5/3) - H
5-chloro-3 -(trifluoromethyl)pyrazbl-l -yl χi G-I J-8 (5/3) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-8 (5/3) - H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-8 (5/3) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-8 (5/3) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-8 (5/3) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-8 (5/3) - H
2,5-dichlorophenyl χi G-I J-9 (5/3) - H 2-chloro-5 -(trifluoromethyl) phenyl χi G-I J-9 (5/3) - H
2 ,5 -dimethylphenyl χi G-I J-9 (5/3) - H 2-methyl -5 -(trifluoromethyl)phenyl X1 G-I J-9 (5/3) - H
3 ,5-dimethylpyrazol- 1 -yl χi G-I J-9 (5/3) - H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi- G-I J-9 (5/3) - H
5-chloro-3-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-9 (5/3) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-9 (5/3) - H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-9 (5/3) - H
3 ,5 -bi s-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-9 (5/3) - H l-methyl-3-(trifluoromethyl)pyra2ol-5-yl χi G-I J-9 (5/3) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-9 (5/3) - H
2,5-dichlorophenyl χi G-I J-Il (3/5) - H 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-Il (3/5) - H
2,5-dimethylphenyl χi G-I J-Il (3/5) - H 2-methyl-5-(trifluoromethyl)phenyl χi G-I J-Il (3/5) - H
3,5-dimethylpyrazol- 1 -yl χi G-I J-Il (3/5) - H
5-methyl-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-I J-Il (3/5) - H
5-chloro-3-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-Il (3/5) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-Il (3/5) - H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-Il (3/5) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-Il (3/5) - H l-methyl-3-(trifluoromethy])pyrazol-5-yl χi G-I J-Il (3/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-Il (3/5) - H
2,5-dichlorophenyl χi G-I J-12 (3/5) - H 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-12 (3/5) — H R1 X G** j *** R7a
(R5)v
2,5 -dimethylphenyl χi G-I • J-I2 (3/5) - H 2-methyl-5 -(trifluoromethyl)phenyl χi G-I J-12 (3/5) - H
3,5-dimethylpyrazol- 1 -yl χi G-I J-I2 (3/5) - H
5-methyl-3-(trifluoromethy])pyrazol- 1 -yl χi G-I J-I2 (3/5) - H
5-chloro-3-(trifluoromethyl)pyτazol-l-yl χi G-I J-12 (3/5) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-12 (3/5) - H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-I2 (3/5) - H
3,5-bis-(trifluoromethyl)pyrazol-l -yl χi G-I J-12 (3/5) - H l-methyl-3-(trifluoromethyl)pyrazol-5~yl χi G-I J-12 (3/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-12 (3/5) - H
2 ,5 -dichloropheny 1 χi G-I J-12 (3/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-12 (3/5) 1-Me H
2,5-dimethylphenyl χi G-I J-12 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)ρhenyl χi G-I J-12 (3/5) 1-Me H
3 ,5-dimethylpyrazol- 1-yl x» G-I J-12 (3/5) 1-Me H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-12 (3/5) 1-Me H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-12 (3/5) 1-Me H
5-bromo-3-(trifluoroinethyl)pyra2ol-l-yl χi G-I J-12 (3/5) 1-Me H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-12 (3/5) 1-Me H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -y 1 χi G-I J-12 (3/5) 1-Me H l-inethyl-3-(trifluoroinethyl)pyrazol-5-yl χi G-I J-12 (3/5) 1-Me H l-methyl-4-(trifluoroinethyl)iinidazol-2-yl χi G-I J-12 (3/5) 1-Me H
2,5-dichlorophenyl χi G-I J-14 (3/5) - H 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-14 (3/5) - H
2,5-dimethylphenyl χi G-I J-14 (3/5) - H 2-methyl-5-(trifluoromethyl)phenyl χi G-I J-14 (3/5) - H
3 ,5-dimethylpyrazol- 1 -yl χi G-I J-14 (3/5) - H
5-methyl-3-(tτifluoromethyl)pyrazol-l-yl χi G-I J-14 (3/5) - H
5-chloro-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-I J-14 (3/5) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-14 (3/5) - H
5-ethyl-3-Ctrifluoromethyl)pyrazol-l-yl χi G-I J-14 (3/5) - H
3,5-bis-(trifluoromethyl)pyrazol-l -yl χi G-I J-14 (3/5) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-14 (3/5) H Rl X G** J*** (R5)y R7a l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-14 (3/5) - H
2,5-dichlorophenyl χi G-I J-15 (2/5) - H 2-chloro-5-(trifluoromethyl)ρhenyl χi G-I J-15 (2/5) - H
2,5-dimethylphenyl χi' G-I J-15 (2/5) - H 2-methyl-5-(trifluoromethyl)phenyl χi G-I J-15 (2/5) - H
3,5-dimethylpyrazol-l-yl χi G-I J-15 (2/5) - H
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-15 (2/5) - H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-15 (2/5) - H
5-bromo-3-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-15 (2/5) - H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-15 (2/5) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-15 (2/5) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-15 (2/5) - H l-methyl-4-(trifluoromethyl)irnidazol-2-yl χi G-I J-15 (2/5) - H
2,5-dichlorophenyl χi G-I J-16 (2/5) - H 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-16 (2/5) - H
2,5-dimethylphenyl χi G-I J-16 (2/5) - H 2-methyl-5-(trifluoromethyl)phenyl χi G-I J-16 (2/5) - H
3 ,5 -dimethylpyrazol- 1 -yl χi G-I J-16 (2/5) - H
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-16 (2/5) - H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-16 (2/5) - H
5-brorno-3-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-16 (2/5) - H
5-ethyl-3-(trifluoromethyl)pyrazol- 1-yl χi G-I J-16 (2/5) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-16 (2/5) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-16 (2/5) - H l-methyl-4-(trifluoromethyl)imida2ol-2-yl χi G-I J-16 (2/5) - H
2,5-dichlorophenyl χi G-I J-22 (2/4) - H 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-22 (2/4) - H
2,5-dimethylphenyl χi G-I J-22 (2/4) - H 2-methyl-5-(trifluoromethyl)ρhenyl χi G-I J-22 (2/4) - H
3,5-dimethylpyrazol-l-yl χi G-I J-22 (2/4) - H 5-methyl-3-(trifluoroinethyl)pyrazol-l-yl χi G-I J-22 (2/4) - H 5-chloro-3-(tri£luoromethyl)pyrazol- 1 -yl χi G-I J-22 (2/4) - H 5-bromo-3-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-22(2/4) H Rl X G** J*** R7a
(R5)v
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-22 (2/4) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-22 (2/4) - H 1 -methyl-3 -(trifluoromethyl)pyrazol-5-yl χi G-I J-22 (2/4) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-22 (2/4) - H
2 ,5-dichlorophenyl χi G-I J-24 (2/4) - H 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-24 (2/4) - H
2,5-dimethylphenyl χi G-I J-24 (2/4) - H 2-methyl-5-(trifluoromethyl)phenyl χi G-I J-24 (2/4) - H
3 ,5-dimethylpyrazol- 1 -yl χi G-I J-24 (2/4) - H
5-inethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-24 (2/4) - H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-24 (2/4) - H
5-bromo-3-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-24 (2/4) - H
5-ethyI-3-(triiluoromethyl)pyrazol- 1 -yl χi G-I J-24 (2/4) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-24 (2/4) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-24 (2/4) - H l-methyl-4-(trifluoroinethyl)imidazol-2-yl χi G-I J-24 (2/4) - H
2,5-dichlorophenyl χi G-I J-25 (2/4) - H 2-chloro-5-(lτifluoroπiethyl)phenyI χi G-I J-25 (2/4) - H
2 ,5 -dimethylphenyl χi G-I J-25 (2/4) - H 2-methyl-5-(trifluoromethyl)phenyl χi G-I J-25 (2/4) - H
3 ,5-dimethylρyrazol- 1 -yl χi G-I J-25 (2/4) - H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-25 (2/4) - H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-25 (2/4) - H
5-bromo-3 -(trifl uoromethyl)pyrazol- 1 -yl χi G-I J-25 (2/4) - H
5-ethyl-3-(trifluorometfayl)pyrazol-l-yl χi G-I J-25 (2/4) - H
3 ,5-bis-(trifluoromethyl)ρyrazol- 1 -yl χi G-I J-25 (2/4) - H l-methyl-3-(trifluoromethyl)pyra2ol-5-yl χi G-I J-25 (2/4) - H l-methyl-4-(trifluoroinethyl)imidazol-2-yl χi G-I J-25 (2/4) - H
2,5-dichlorophenyl X1 G-I J-26 (2/4) - H 2-chloro-5 -(trifluoromethyl)phenyl χi G-I J-26 (2/4) - H
2,5-dimethylphenyl χi G-I J-26 (2/4) - H
2-mcthyl-5 -(trifluoromethyl)phenyl χi G-I J-26 (2/4) - H
3 ,5 -dimethylpyrazol- 1 -yl χi G-I J-26 (2/4) H R X G** J*** (R5)v R7a
5-methyl-3-(tτifluoromethy1)pyrazol-l-yl χi G-I J-26 (2/4) - H
5-chJoro-3-(trifluoromethyl)pyrazol- 1-yl χi G-I J-26 (2/4) - H
5 -bromo-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-I J-26 (2/4) - H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-26 (2/4) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-26 (2/4) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-26 (2/4) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-26 (2/4) - H
2,5-dichlorophenyl χi G-I J-26 (2/4) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-26 (2/4) 1-Me H
2,5-dimethylphenyl χi G-I J-26 (2/4) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl χi G-I J-26 (2/4) 1-Me H
3 ,5-dimethylpyrazol- 1 -yl χi G-I J-26 (2/4) 1-Me H
5-methyl-3-(trifluoromethyl)pyrazol-]-yl χi G-I J-26 (2/4) 1-Me H
5-chloro-3-(trifluoromethyl)pyrazol- 1 -yl χi Q-I J-26 (2/4) 1-Me H
5-bromo-3-(tτifluoromethyl)ρyrazoI-l-yl χi G-I J-26 (2/4) 1-Me H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-26 (2/4) 1-Me H
3,5-bis-(trifluoromethyl)pyrazol-l-yl χi G-I J-26 (2/4) 1-Me H l-methyl-3-(trifluoromethyl)ρyrazol-5-yl χi G-I J-26 (2/4) 1-Me H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-26 (2/4) 1-Me H
2,5-dichlorophenyl X* G-I J-26 (2/5) 1-Me H 2-chloro-5 -(trifluoromethy l)pheny 1 χi G-I J-26 (2/5) 1-Me H
2,5-dimethylphenyl χi G-I J-26 (2/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X1 G-I J-26 (2/5) 1-Me H
3,5-dimethylpyτazol-l-yl χi G-I J-26 (2/5) 1-Me H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-26 (2/5) 1-Me H
5-chloro-3-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-26 (2/5) 1-Me H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-26 (2/5) 1-Me H
5-ethyl-3-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-26 (2/5) 1-Me H
3,5-bis-(trifluoromethyl)pyrazol-l-yl χi G-I J-26 (2/5) 1-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-26 (2/5) 1-Me H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-26 (2/5) 1-Me H
2,5-dichlorophenyl χi G-I J-28 (3/5) - H 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-28 (3/5) H Rl X G j * •* (R5)y R7a
2,5-dimethylphenyl χi G-I J-28 (3/5) _ H 2-methyl-5-(trifluoromethyl)phenyl χi G-I J-28 (3/5) - H
3 ,5-dimethylpyrazol- 1 -yl χi G-I J-28 (3/5) - H
5-methyl-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-I J-28 (3/5) - H
5~chloro-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-28 (3/5) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-28 (3/5) - H .
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-28 (3/5) - H
3,5-bis-(trifluoromethyl)pyrazol-l-yl χi G-I J-28 (3/5) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-28 (3/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-28 (3/5) - H
2,5-dichloroρhenyl χi G-I J-30 (3/5) - H 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-30 (3/5) - H
2,5-dimethylphenyl χi G-I J-30 (3/5) - H 2-methyl-5-(trifluororaethyl)phenyl χi G-I J-30 (3/5) - H
3 ,5-dimethylpyrazol- 1 -yl χi G-I J-30 (3/5) - H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-30 (3/5) - H
5-chloro-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-I J-30 (3/5) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-30 (3/5) - H
5-ethyl-3-(trifluoromethyl)pyrazoH-yl χi G-I J-30 (3/5) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-30 (3/5) . - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-30 (3/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-30 (3/5) - H
2,5-dichlorophenyl χi G-I J-30 (3/5) 1-Me H 2-chloro-5-(trifluoromethyl)pheπyl χi G-I J-30 (3/5) 1-Me H
2,5-dimethylphenyl χi G-I J-30 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)ρhenyl χi G-I J-30 (3/5) 1-Me H
3,5-dimethylpyrazol-l-yl χi G-I J-30 (3/5) 1-Me H
5-methyl-3-(trifluoromethyl)ρyrazol-l-yl χi G-I J-30 (3/5) 1-Me H
5-chioro-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-I J-30 (3/5) 1-Me • H
5-bromo-3-(trifluoromethyl)pyra2ol- 1 -yl χi G-I J-30 (3/5) 1-Me H
5-εthyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-30 (3/5) 1-Me H
3 ,5-bis-(trifluoromethyl)pyrazol- 1-yl χi G-I J-30 (3/5) 1-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-30 (3/5) 1-Me H Rl X G** J *** (R5)v R7a l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-30(3/5) 1-Me H
2,5-dichlorophenyl χi G-I J-36 (3/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-36 (3/5) 1-Me H
2,5-dimethylphenyl χi G-I J-36 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl χi G-I J-36(3/5) 1-Me H
3 ,5-dimethylpyrazol- 1 -yl χi G-I J-36(3/5) 1-Me H
5-methyl-3-(trifhioromethyl)pyrazol-l-yl χi G-I J-36 (3/5) 1-Me H
5 -chloro-3 -(trifluoromethy l)pyrazol- 1 -yl χi G-I J-36 (3/5) I-Me H
5-bromo-3-(trifluoroπiethyl)pyrazol- 1 -yl χi G-I J-36 (3/5) 1-Me H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-36 (3/5) 1-Me H
3,5-bis-(trifluoromethyl)pyrazol-l-yl χi G-I J-36 (3/5) 1-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-36 (3/5) 1-Me H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-36 (3/5) 1-Me H
2,5-dichlorophenyl χi G-I J-37 (2/5) - H 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-37 (2/5) - H
2,5-dimethylphenyl χi G-I J-37 (2/5) - H 2-methyl-5-(trifluoromethyl)phenyl X' G-I J-37 (2/5) - H
3 ,5-dimethylpyrazol- 1 -yl χi G-I J-37 (2/5) - H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X1 G-I J-37 (2/5) - H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-37 (2/5) H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-37 (2/5) H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-37 (2/5) H
3 ,5-bis-(trifluoromethyl)pyrazol-l -yl χi G-I J-37 (2/5) H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-37 (2/5) H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-37 (2/5) H
2,5-dichlorophenyl χi G-I J-38 (2/5) H 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-38 (2/5) H
2,5-dimethylphenyl χi G-I J-38 (2/5) H 2-methyl-5-(trifluoromethyl)phenyl X1 G-I J-38 (2/5) H
3 ,5 -dimethylpyrazol- 1 -yl χi G-I J-38 (2/5) H 5-methyl-3-(trifluoromethyl)pyra2pl-l-yl χi G-I J-38 (2/5) H S-chloro-3-(trifluoromethyl)pyrazol-l-yl X1 G-I J-38 (2/5) H 5-bromo-3-(trifluoroinethyl)ρyrazol-l-yl X1 G-I J-38 (2/5) H Rl J *** (R5X R7a
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl G-I J-38 (2/5) H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-38 (2/5) H
1 -methyl-3 -(trifluoromethyl)pyrazoi -5-yl χi G-I J-38 (2/5) H l-methyl-4-(trifluoromethyl)imidazol-2-yl x» G-I J-38 (2/5) H
2,5-dichlorophenyl χi G-I J-39 (3/5) H 2-chloro-5 -(trifluoromethyl)phenyl χi G-I J-39 (3/5) H
2,5-dimethylphenyl χi G-I J-39 (3/5) H 2-methyl-5-(trifluoromethyl)phenyl χi G-I J-39 (3/5) H
3 ,5 -dimethy lpyrazol- 1 -yl χi G-I J-39 (3/5) H
5-methyl-3 -(trifluoromethyl)pyrazol- 1 -y 1 χi G-I J-39 (3/5) H
5-chloro-3-(tτifluoromethyl)pyrazol-l-yl χi G-I J-39 (3/5) H .
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-39 (3/5) H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-39 (3/5) H
3,5-bis-(trifluoromethyl)pyrazol-l -yl χi G-I J-39 (3/5) H l-methyl-3-(trifluoromethyl)ρyrazol-5-yl χi G-I J-39 (3/5) H l-methyl-4-(trifluoroinethyl)itnidazol-2-yl χi G-I J-39 (3/5) H
2,5-dichlorophenyl x* G-I J-40 (3/5) H 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-40 (3/5) H
2,5-dimethylphenyl x* G-I J-40 (3/5) H 2-methyl-5-(trifluoromethyl)phenyl χi G-I J-40 (3/5) H
3 ,5-dimethylpyrazol- 1 -yl χi G-I J-40 (3/5) H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-40 (3/5) H
5-chloro-3-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-40 (3/5) H
5-bromo-3-(trifluoromethyl)pyrazol- 1-yl • χi G-I J-40 (3/5) H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-40 (3/5) H
3,5-bis-(trifluoromethyl)pyrazol-l-yl χi G-I J-40 (3/5) H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-40 (3/5) H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-40 (3/5) H
2,5-dichlorophenyl χi G-I J-69 (1/3) H 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-69 (1/3) H
2,5-dimethylphenyl χi G-I J-69 (1/3) H
2-methyl-5-(trifluoromethyl)phenyl χi G-I J-69 (1/3) H
3 ,5-dimethy lpyrazol- 1 -yl χi G-I J-69 (1/3) H Rl X G** J*** R7a
(R5)v
5-methyl-3-(trifluoromethy1)pyrazol-l-yl χi G-I J-69 (1/3) - H
5-chloro-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-I 3-69 (1/3) - H
5-bromo-3-(trifluorornethyl)pyrazol-l-yl χi G-I J-69 (1/3) - H
5-ethyl-3-(trifluoromethyl)pyτazol-l-yl χi G-I J-69 (1/3) - H
3 ,5-bis-(trifluorornethyl)pyrazol- 1 -yl χi G-I J-69 (1/3) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-69 (1/3) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-69 (1/3) - H
2,5-dicMorophenyl χi G-I J-69 (1/4) - H 2-chloro-5-(trifluorornethyl)phenyl χi G-I J-69 (1/4) - H
2,5-dimethylphenyl χi G-I J-69 (1/4) - H 2-methyl-5-(trifluoromethyI)phenyl χi G-I J-69 (1/4) - H
3 ,5-dimethylpyrazol- 1 -yl χi G-I J-69 (1/4) - H
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-69 (1/4) - H
5 -chloro-3 -(trifluoromethy l)pyrazol- 1 -y 1 χi G-I J-69 (1/4) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-69 (1/4) - H
5 -ethyl -3 -(trifluoromethy l)pyrazol- 1 -yl χi G-I J-69 (1/4) - H
3,5-bis-(trifluorornethyl)pyrazol-l-yl χi G-I J-69 (1/4) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-69 (1/4) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-69 (1/4) - H
2,5-dichlorophenyl χi G-I J-Il (3/5) - 2-Me 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-11 (3/5) - 2-Me
2,5-dimethylphenyl χi G-I J-11 (3/5) - 2-Me 2-methyl-5-(trifluoromethyl)phenyl χi G-I J-11 (3/5) - 2-Me
3,5-dimethylpyrazol- 1 -yl χi G-I J-11 (3/5) - 2-Me
5-methyl-3-(tri£luoromethyl)pyrazol-l-yl χi G-I J-Il (3/5) - 2-Me
5-chloro-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-11 (3/5) - 2-Me
5-bromo-3 -(trifluoromethy l)pyrazol~ 1 -yl χi G-I J-Il (3/5) - 2-Me
5-ethyl-3-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-11 (3/5) - 2-Me
3,5-bis-(trifluoromethyl)pyrazol-l-yl χi G-I J-Il (3/5) - 2-Me l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-11 (3/5) - 2-Me
1 -methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-Il (3/5) - 2-Me
2,5-dichlorophenyl χi G-I J-11 (3/5) - 3-Me 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-11 (3/5) 3-Me Rl X G** j *** (R5)v R7a
2,5-dimethylphenyl χi G-I J-11 (3/5) - 3-Me 2-methyl-5-(trifluoromethyl)phenyl χi G-I J-Il (3/5) - 3-Me
3 ,5-dimethylpyrazol- 1 -yl χi G-I J-Il (3/5) - 3-Me
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-Il (3/5) - 3-Me
5-chloro-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-Il (3/5) - 3-Me
5-bromo-3 -(trifluoromethyl)ρyrazol- 1 -yl χi G-I J-Il (3/5) - 3-Me
5-ethyl-3-(trifluoromethy])pyrazol-l -yl X1 G-I J-U (3/5) - 3-Me
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-Il (3/5) - 3-Me l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-H (3/5) - 3-Me l-methyl-4-(trifluoroinethyl)iinidazol-2-yl χi G-I J-Il (3/5) - 3-Me
2,5-dichlorophenyl χi G-I J-H (3/5) - 4-Me 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-Il (3/5) - 4-Me
2,5-dimethylphenyl χi G-I J-Il (3/5) - 4-Me 2-methyl-5-(trifluoromethyl)phenyl χi G-I J-Il (3/5) - 4-Me
3 ,5-dimethylpyrazol- 1 -yl χi G-I J-Il (3/5) - 4-Me
5 -methyl-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-I J-Il (3/5) - 4-Me
5-chloro-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-H (3/5) - 4-Me
5-broτno-3 -(trifluoromethyl)ρyrazol- 1 -yl χi G-I J-Il (3/5) - 4-Me
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-Il (3/5) - 4-Me
3,5-bis-(trifluoromethyl)ρyrazol-l-yl X1 G-I J-H (3/5) - 4-Me l-methyl-3-(trifluoromethyl)pyra2ol-5-yl χi G-I J-Il (3/5) - 4-Me l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-Il (3/5) - 4-Me
2,5-dichlorophenyl χi G-I J-Il (3/5) - 2-Cl 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-Il (3/5) - 2-Cl
2,5-dimethylphenyl χi G-I J-Il (3/5) - 2-Cl . 2-methyl-5-(trifluoromethyl)phenyl χi G-I J-Il (3/5) - 2-Cl
3 ,5-dimethylpyrazol- 1 -yl χi G-I J-11 (3/5) - 2-CI
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-Il (3/5) 2-Cl
5-chloro-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-I J-Il (3/5) - 2-Cl
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X* G-I J-H (3/5) - 2-Cl
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-H (3/5) - 2-Cl
3 ,5-bis-(trifluoromethyl)pyrazol- 1-yl χi G-I J-Il (3/5) - 2-Cl l-methyl-3-(trifluorornethyl)pyrazol-5-yl χi G-I J-Il (3/5) 2-Cl Rl X G** J*** R/a
(RD)v l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-Il (3/5) - 2-Cl
2,5-dichlorophenyl χi G-I J-Il (3/5) - 4-Cl 2-chloro-5-(trifluoromethyl)phenyl χi G-I .J-Il (3/5) - 4-Cl
2,5-dimethylphenyl χi G-I J-Il (3/5) - 4-Cl 2-methyl-5-(trifluoromethyl)phenyl χi G-I J-Il (3/5) - 4-Cl
3 ,5-dimethylpyrazol- 1 -y 1 χi G-I J-Il (3/5) - 4-Cl
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-Il (3/5) - 4-Cl
5-chloro-3-(trifluoromethyl)pyrazol-l-yl x* G-I J-Il (3/5) - 4-Cl
5-bromo-3-(trifluoromeihyl)pyrazol-l-yl χi G-I J-Il (3/5) - 4-Cl
5-ethyl-3 -(trifluoromethyl)pyra2θl- 1 -yl χi G-I J-I 1 (3/5) - 4-Cl
3,5-bis-(trifluoromethyl)pyrazol-l-yl χi G-I J-Il (3/5) - 4-Cl l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-Il (3/5) - 4-Cl l-methyl-4-(trifluoromethyl)iinidazol-2-yl χi G-I J-Il (3/5) - 4-Cl
2,5-dichlorophenyl χi G-I J-29 (3/5) 5-Me 2-Me 2-chJoro-5-(trifluoromethyl)phenyl χi G-I J-29 (3/5) 5-Me 2-Me
2,5-dimethylphenyl χi G-I J-29 (3/5) 5-Me 2-Me 2-methyl-5-(trifluoromethyl)ρhenyl χi G-I J-29 (3/5) 5-Me 2-Me
3 ,5-dimethylpyrazol- 1 -yl χi G-I J-29 (3/5) 5-Me 2-Me
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-29 (3/5) 5-Me 2-Me
5-chloro-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-29 (3/5) 5-Me 2-Me
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-29 (3/5) 5-Me 2-Me
5-ethyl-3-(trifluoromethyl)ρyrazol-l-yl χi G-I J-29 (3/5) 5-Me 2-Me
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-29 (3/5) 5-Me 2-Me l-raethyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-29 (3/5) 5-Me 2-Me l-methyl-4-(triflxioroπiethyl)irnidazol-2-yl χi G-I J-29 (3/5) 5-Me 2-Me
2,5-dichlorophenyl χi G-I J-29 (3/5) - 3-Me 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-29 (3/5) - 3-Me
2,5-dimethylphenyl χi • G-I J-29 (3/5) - 3-Me 2-methyl-5-(trifluoromethyl)phenyl χi G-I J-29 (3/5) - 3-Me
3 ,5-dimethylpyrazol- 1 -yl χi G-I J-29 (3/5) - 3-Me 5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-29 (3/5) - 3-Me S-chloro-S-CtrifluoromethylJpyrazol-l-yl χi G-I J-29 (3/5) - 3-Me 5-bromo-3-(trifluoroinethyl)pyτa2ol-l-yl χi G-I J-29 (3/5) _ 3-Me Rl X G** j **♦ (R5)v R7a
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-29 (3/5) - 3-Me
3.S-bis-CtrifluoromethyOpyrazol- 1 -yl χi G-I J-29 (3/5) - 3-Me l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-29 (3/5) - 3-Me l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I ■ J-29 (3/5) - 3-Me
2,5-dichlorophenyl X1 G-I J-29 (3/5) - 4-Me 2-chloro-5 -(trifluoromethyl)phenyl χi G-I J-29 (3/5) - 4-Me
2s5-dimethylphenyl χi G-I J-29 (3/5) - 4-Me 2-methyl-5-(trifluoroinethyl)phenyl χi G-I J-29 (3/5) - 4-Me
3 ,5-dimethylpyrazol-l -yl χi G-I J-29 (3/5) - 4-Me
5-methy 1-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-I J-29 (3/5) - 4-Me
5-chloro-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-29 (3/5) - 4-Me
5-bromo-3-(trifluoromethyl)pyra2ol-l-yl χi G-I J-29 (3/5) - 4-Me
5-ethyl-3-(trifluoromethyl)pyrazol- 1 -yl χi G-I J-29 (3/5) - 4-Me
3,5-bis-(trifluoromethyl)pyrazol-l-yl χi G-I J-29 (3/5) - 4-Me l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-I J-29 (3/5) - 4-Me l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-I J-29 (3/5) - 4-Me
2,5-dichlorophenyl χi G-I J-29 (3/5) 5-Me 2-Cl 2-chloro-5-(trifluoromethyI)phenyl χi G-I J-29 (3/5) 5-Me 2-Cl
2,5-dimethylphenyl χi G-I J-29 (3/5) 5-Me 2-Cl 2-methyl-5-(iτifluoromethyl)phenyl χi G-I J-29 (3/5) 5-Me 2-Cl
3,5-dimethylpyrazol-l-yl χi G-I J-29 (3/5) 5-Me 2-Cl
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-I J-29 (3/5) 5-Me 2-Cl
5-chloro-3-(trifluoromethyl)pyrazol-l-yI χi G-I J-29 (3/5) 5-Me 2-Cl
5-bromo-3-(trifluorometliyl)pyrazol-l-yl χi G-I J-29 (3/5) 5-Me 2-Cl
5-ethyl-3-(trifluorome1hyl)pyrazol-l-yl χi G-I J-29 (3/5) 5-Me 2-Cl
3,5-bis-(triJEluoromethyl)pyrazol-l-yl χi G-I J-29 (3/5) 5-Me 2-Cl l-methyl-3-(trifluoromethyl)pyrazόl-5-yl χi G-I J-29 (3/5) 5-Me 2-Cl l-metliyl-4-(trifluoromethyl)iiπidazol-2-yl χi G-I J-29 (3/5) 5-Me 2-Cl
2,5-dichlorophenyl χi G-I • J-29 (3/5) - 4-Cl 2-chloro-5-(trifluoromethyl)phenyl χi G-I J-29 (3/5) - 4-Cl
2,5-dimethylρhenyl χi G-I J-29 (3/5) - 4-Cl
2-methyl-5-(trifluoromethyl)phenyl χi G-I J-29 (3/5) - 4-Cl
3 ,5-dimethylpyrazol- 1 -yl χi G-I J-29 (3/5) 4-Cl
Figure imgf000141_0001
Figure imgf000142_0001
Rl X G** j *** R7a
(R5)v l-methyl-4-(trifluoromethyl)imidazol-2-yl X1 G-2 . J-2(2/4) - H
2,5-dichlorophenyl χi G-2 J-3 (2/4) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-3 (2/4) 1-Me H
2,5-dimethylphenyl χi G-2 J-3 (2/4) 1-Me H 2-methyl-5-(tri£luoromethyI)ρhenyl χi G-2 J-3 (2/4) 1-Me H
3 ,5-dimethylpyrazol-l-yl χi G-2 J-3 (2/4) 1-Me H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-3 (2/4) 1-Me H
5 -chloro-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-3 (2/4) 1-Me H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-3 (2/4) 1-Me H
5-ethyl-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-3 (2/4) 1-Me H
3,5-bis-(trifluoromethyl)pyrazol-l-yl χi G-2 J-3 (2/4) 1-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-2 J-3 (2/4) 1-Me H l-inethyl-4-(trifluoromethyl)iinidazol-2-yl χi G-2 J-3 (2/4) 1-Me H
2,5-dichlorophenyl χi G-2 J-4 (2/5) - H 2-chloro-5-(trifluoromethyl)phenyl x* G-2 J-4 (2/5) - H
2,5-dimethylphenyl χi G-2 J-4 (2/5) - H 2-methyl-5-{trifluoromethyl)phenyl χi G-2 J-4 (2/5) - H
3 ,5-dimethylpyrazol- 1 -yl χi G-2 J-4 (2/5) - H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-4 (2/5) - H
5-chloro-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-4 (2/5) - H
5 -bromo-3 -(tri fluoromethyl)pyrazol- 1 -yl χi G-2 J-4 (2/5) - H
5-ethyl-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-4 (2/5) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-4 (2/5) - H l-methyl-3-(trifluoromethyl)ρyτazol-5-yl χi G-2 J-4 (2/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-2 J-4 (2/5) - H
2,5-dichlorophenyl χi G-2 J-8 (5/3) - H 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-8 (5/3) - H
2,5-dimethylphenyl χi • G-2 J-8 (5/3) - H 2-methyl-5-(trifluoromethyl)phenyl χi G-2 J-8 (5/3) - H
3 ,5 -dimethylpyrazol- 1 -yl χi G-2 J-8 (5/3) - H 5-methyl-3-(trifluoromethyl)pyrazol-l-yl X1 G-2 J-8 (5/3) - H 5-chloro-3-(trifluoromethyl)pyrazol-l-yl X1 G-2 J-8 (5/3) - H 5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-8 (5/3) H Ri X G** j *** (R5)v R7a
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-8 (5/3) - . H
3,5-bis-(trifluoromethyl)pyrazol-l-yl χi G-2 J-8 (5/3) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-2 J-8 (5/3) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-2 J-8 (5/3) - H
2,5-dichlorophenyl χi G-2 3-9 (5/3) - H 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-9 (5/3) - H
2,5-dimethylphenyl χi G-2 J-9 (5/3) • - H 2-methyl-5-(trifluoromethyl)phenyl χi G-2 J-9 (5/3) - H
3 ,5-dimethylpyrazol-l -yl χi G-2 J-9 (5/3) - H
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-9 (5/3) - H
S-chloro-S-ørifluoromethy^pyrazol-l-yl χi G-2 J-9 (5/3) - H
5-bromo-3-(trifluoromethyI)pyrazol-l-yl χi G-2 J-9 (5/3) - H
5-ethyl-3-(trifluoromethyl)ρyrazol-l-yl χi G-2 J-9 (5/3) - H
3,5-bis-(trifluoromethyl)pyrazol-l-yl χi G-2 J-9 (5/3) - H l-methyl-3-(tτifluoromethyl)pyrazol-5-yl χi G-2 J-9 (5/3) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl X* G-2 J-9 (5/3) - H
2,5-dichlorophenyl χi G-2 J-H (3/5) - H 2-chloro-5 -(trifluoromethy l)ρheny 1 χi G-2 J-Il (3/5) - H
2,5-dimethylphenyl χi G-2 J-Il (3/5) - H 2-methyl-5-(trifluoromethyl)phenyl χi G-2 J-Il (3/5) - H
3,5-dimethylpyrazol-l-yl χi G-2 J-Il (3/5) - H
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-Il (3/5) - H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-Il (3/5) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-I 1 (3/5) - H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-Il (3/5) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-Il (3/5) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-2 J-I 1 (3/5) - H l-methyl-4-(trifluoromethyl)imida2ol-2-yl χi G-2 J-I 1 (3/5) - H
2,5-dichlorophenyl χi G-2 J-I2 (3/5) - H 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-12 (3/5) - H
2,5-dimethylphenyl χi G-2 J-12 (3/5) - H
2-methyl-5-(trifluoromethyI)phenyl χi G-2 J-12 (3/5) - H
3 ,5-dimethylpyrazol- 1 -yl χi G-2 J-12 (3/5) _ H Rl X G** j ♦** (R3)v R/a
5-methyl-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-12 (3/5) - H
5-chloro-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-12 (3/5) - H
5-bromo-3 -(trifluoromethy l)pyrazol- 1 -yl χi G-2 J-12 (3/5) - H
5-ethyl-3-(trifluoromethyl)pyrazol- 1 -yl X1 G-2 J-12 (3/5) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-12 (3/5) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-2 J-12 (3/5) - H l-methyl-4-(trifluoromethyl)imidazol~2-yl χi G-2 J-12 (3/5) - H
2,5-dichlorophenyl χi G-2 J-12 (3/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-12 (3/5) 1-Me H
2 ,5 -dimethylpheny 1 χi G-2 J-12 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl χi G-2 J-12 (3/5) 1-Me H
3 ,5-dimethylpyrazol- 1 -yl χi G-2 • J-12 (3/5) 1-Me H
5-methyl-3-(trifluoromethyl)pyrazol-l~yl χi G-2 J-12 (3/5) 1-Me H
5-chloro-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-12 (3/5) 1-Me H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-12 (3/5) 1-Me H
5-ethyl-3-(trifluoromethyI)pyrazol-l-yl χi G-2 J-12 (3/5) 1-Me H
3 ,5-bis-(trifluoromethyl)pyrazol- 1-yl χi G-2 J-12 (3/5) 1-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-2 J-12 (3/5) 1-Me H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-2 J-12 (3/5) 1-Me H
2,5-dichlorophenyl χi G-2 J-14 (3/5) - H 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-14 (3/5) - H
2,5-dimethylphenyl χi G-2 J-14 (3/5) - H 2-methyl-5-(trifluoromethyl)phenyl χi G-2 J-14 (3/5) - H
3 ,5-dimethylpyrazol- 1 -yl χi G-2 J-14 (3/5) - H
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-14 (3/5) - H
S-chloro-S-CtrifluoromethyOpyrazol-l-yl χi G-2 J-14 (3/5) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-14 (3/5) - H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-14 (3/5) - H
3,5-bis-(trifluoromethyl)pyra2ol-l-yl χi G-2 J-14 (3/5) - H l-methyl-3-(trifluoromethyl)ρyrazol-5-yl χi G-2 J-14 (3/5) - H l-methyl-4-(trifluoroinethyl)imidazol-2-yl χi G-2 J-14 (3/5) - H
2,5-dichlorophenyl χi G-2 J-15 (2/5) - H 2-chloro-5-(trifluoromethyl)phenyl x» G-2 J-15 (2/5) _ H R* X G** J *** (R5)v R7a
2,5-dimethylphenyl χi G-2 J-15 (2/5) - H 2-methyl-5-(trifluoromethyl)phenyl χi G-2 J-15 (2/5) - H
3 ,5 -dimethylpyrazol- 1 -yl χi G-2 J-15 (2/5) - H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-15 (2/5) - H
S-chloro-S-CtrifluoromethyOpyrazol- 1 -yl χi G-2 J-15 (2/5) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-15 (2/5) - H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-15 (2/5) - H
3,5-bis-(trifluoromethyl)pyrazol-l-yl χi G-2 J-15 (2/5) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-2 J-15 (2/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-2 J-15 (2/5) - H
2,5-dichlorophenyl χi G-2 J-16 (2/5) - H 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-16 (2/5) - H
2,5-dimethylphenyl χi G-2 J-16 (2/5) - H 2-methyl-5-(trifluoromethyl)ρhenyl χi G-2 J-16 (2/5) - H
3 ,5-dimethylpyrazol-l-yl χi G-2 J-16 (2/5) - H
5-methyl-3 -(trifluorotnethyl)pyrazol- 1-yl χi G-2 J-16 (2/5) - H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-16 (2/5) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-16 (2/5) - H
5-ethyl-3-(trifluoromethyI)pyrazol-l-yl χi G-2 J-16 (2/5) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-16 (2/5) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-2 J-16 (2/5) - H l-methyl-4-(trifluoroπiethyl)iinidazol-2-yl χi G-2 J-16 (2/5) - H
2,5-dichlorophenyl X1 G-2 J-22 (2/4) - H 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-22 (2/4) - H
2,5-dimethylphenyl χi G-2 J-22 (2/4) - H 2-methyl-5-(trifluoromethyl)phenyl X1 G-2 J-22 (2/4) - H
3 ,5-dimethylpyrazol- 1 -yl X1 G-2 J-22 (2/4) - H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X1 G-2 J-22 (2/4) - H
S-chloro-3-(trifIuoromethyl)pyrazol-l-yl X* G-2 J-22 (2/4) - H
5 -bromo-3-(trifluoroinethyl)pyrazol- 1 -yl X1 G-2 J-22 (2/4) - H
5-ethyl-3-(trijEluoromethyl)pyrazol- 1 -yl X1 G-2 J-22 (2/4) - H
3,5-bis-(trifluoromethyl)pyrazol-l -yl X1 G-2 J-22 (2/4) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X1 G-2 J-22 (2/4) H Rl X G** j ♦♦* R7a
(R5)v l-τnethyl-4-(trifluoromethyl)imidazol-2-yl χi G-2 J-22 (2/4) - H
2,5-dichlorophenyl χi G-2 J-24 (2/4) - H 2-chloro-5-(trifluoτomethyl)phenyl χi G-2 J-24 (2/4) - H
2 , 5 -dimethylphenyl χi G-2 J-24 (2/4) - H 2-methyl-5-(trifluoromethyl)phenyl χi G-2 J-24 (2/4) . - H
3 ,5-dimethylpyrazol- 1 -yl χi G-2 j-24 (2/4) - H
5 -methyl-3-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-24 (2/4) - H
S-chloro-S-CtrifluoromethyOpyrazol-l-yl χi G-2 J-24 (2/4) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-24 (2/4) - H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-24 (2/4) - H
3 ,5-bis-(trifluorometliyl)pyrazol- 1 -yl χi G-2 J-24 (2/4) - H
1 -methyl-3 -(trifluoromethyl)pyrazol-5-yl χi G-2 J-24 (2/4) - H l-methyl-4-(tτifluoroπiethyl)iinidazol-2-yl χi G-2 J-24 (2/4) - H
2,5-dichlorophenyl χi G-2 J-25 (2/4) - H 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-25 (2/4) - H
2,5-dimethylphenyl χi G-2 J-25 (2/4) - H 2 -methyl -5-(trifluoromethyl)phenyl χi G-2 J-25 (2/4) - H
3,5-dimethylpyrazol-l-yl χi G-2 J-25 (2/4) - H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-25 (2/4) - H
5-chloro-3 -(trifluoromethy l)pyrazol- 1 -yl χi G-2 J-25 (2/4) - H
5-bromo-3-(trifluoroinethyl)pyrazol-l-yl χi G-2 J-25 (2/4) - H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-25 (2/4) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-25 (2/4) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-2 J-25 (2/4) - H l-methyl-4-(.trifluoromethyl)imidazol-2-yl χi G-2 J-25 (2/4) - H
2,5-dichlorophenyl χi G-2 J-26 (2/4) - H 2-chloro-5-(trifluoroinethyl)phenyl χi G-2 J-26 (2/4) - H
2,5-dimethylphenyl χi G-2 J-26 (2/4) - H 2-methyl-5-(trifluoromethyl)phenyl χi G-2 J-26 (2/4) - H
3 ,5 -dimethylpyrazol- 1 -yl χi G-2 J-26 (2/4) - H 5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-26 (2/4) - H 5-chloro-3-(1xifluorornethyl)pyrazol-l-yl χi G-2 J-26 (2/4) - H 5 -bromo-3 -(trifluoromethy l)pyrazol- 1 -yl χi G-2 J-26 (2/4) _ H Rl X G** J *** (R5)γ R7a
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-26 (2/4) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1-yl χi G-2 J-26 (2/4) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-2 J-26 (2/4) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-2 J-26 (2/4) - H
2 ,5-dichlorophenyl χi G-2 J-26 (2/4) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-26 (2/4) 1-Me H
2,5-dimethylphenyl χi G-2 J-26 (2/4) 1-Me H 2-methyl-5-(trifluoromethyl)pheny] χi G-2 J-26 (2/4) 1-Me H
3,5-dimethylpyrazol-l-yl χi G-2 J-26 (2/4) 1-Me H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-26 (2/4) 1-Me . H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-26 (2/4) 1-Me H
5 -bromo-3-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-26 (2/4) 1-Me H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X^ G-2 J-26 (2/4) 1-Me H
3,5-bis-(trifluoromethyl)pyrazol-l-yl χi G-2 J-26 (2/4) 1-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-2 J-26 (2/4) 1-Me H l-methyl-4-(trifluoromethyl)iinidazol-2-yl χi G-2 J-26 (2/4) 1-Me H
2,5-dichlorophenyl χi G-2 J-26 (2/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-26 (2/5) 1-Me H
2,5-dimethylphenyl χi G-2 J-26 (2/5) 1-Me H 2-methyl-5-(trifluoromethyl)pheπyl χi G-2 J-26 (2/5) 1-Me H
3,5-dimethylpyrazol- 1 -yl χi G-2 J-26 (2/5) 1-Me H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-26 (2/5) 1-Me H
5-cMoro-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-26 (2/5) 1-Me H
5-bromo-3-(tτifluoromethyl)pyra2θl-l-yl χi G-2 J-26 (2/5) 1-Me H
5-ethyI-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-26 (2/5) 1-Me H
3,5-bis-(trifluoromethyl)pyrazol-l-yl χi G-2 J-26 (2/5) 1-Me H l-methyl-3-(trifluoromethy])pyra2ol-5-yl χi G-2 J-26 (2/5) 1-Me H l-methyl-4-(trifluoromethyl)imidazol-2-yl X1 G-2 J-26 (2/5) 1-Me H
2,5-dichlorophenyl x» G-2 J-28 (3/5) - H 2-chloro-5-(trifluoromethyl)phenyl X1 G-2 J-28 (3/5) - H
2,5-dimethylphenyl X1 G-2 J-28 (3/5) - H
2-methyl-5-(trifluoromethyl)phenyl X1 G-2 J-28 (3/5) - H
3 ,5-dimethylpyrazol- 1-yl χi G-2 J-28 (3/5) H Rl X G** j *** R7a
(R5)v
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-28 (3/5) - H
5-chloro-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-28 (3/5) - H
5-bromo-3-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-28 (3/5) - H
5-ethyl-3-(trifluoromethyl)pyraizol-l-yl χi G-2 J-28 (3/5) - H
3,5-bis-(trifluoromethyl)pyrazol-l-yl χi G-2 J-28 (3/5) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-2 J-28 (3/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl x» G-2 J-28 (3/5) - H
2,5-dichlorophcnyl χi G-2 J-30 (3/5) - H 2-chloro-5-(trifluoroπiethyl)phenyl χi G-2 J-30 (3/5) - H
2,5-dimethylphenyl χi G-2 J-30 (3/5) - H 2-methyl-5-(trifluoromethyl)phenyl χi G-2 J-30 (3/5) - H
3 ,5 -dimethylpyrazol- 1 -yl χi G-2 J-30 (3/5) - H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl x* G-2 J-30 (3/5) - H
5-chloro-3-(trifluoromethyl)pyra2;ol- 1 -yl χi G-2 J-30 (3/5) - H
5-bromo-3-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-30 (3/5) - H
5-ethyl-3-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-30 (3/5) - H
3,5-bis-(trifluoromethyl)pyrazol-l-yl χi G-2 J-30 (3/5) - H l-methyl-3-(trifluorometb.yl)pyrazol-5-yl χi G-2 J-30 (3/5) - H l-τnethyl-4-(trifluoromethyl)imi(ia2θl-2-yl χi G-2 J-30 (3/5) - H
2,5-dichlorophenyl χi G-2 J-30 (3/5) 1-Me H 2-chloro-5-(trifluorornethyl)phenyl χi G-2 J-30 (3/5) 1-Me H
2,5-dimethylphenyl χi G-2 J-30 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl χi G-2 J-30 (3/5) 1-Me H
3 ,5-dimethylpyrazol- 1 -yl χi G-2 J-30 (3/5) 1-Me H
5-raethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-30 (3/5) 1-Me H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-30 (3/5) 1-Me H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-30 (3/5) 1-Me H
5-ethyl-3-(trifluoromethyl)pyτazol- 1 -yl χi G-2 J-30 (3/5) 1-Me H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-30 (3/5) 1-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X* G-2 J-30 (3/5) 1-Me H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-2 J-30 (3/5) 1-Me H
2,5-dichlorophenyl X1. G-2 J-36 (3/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-36 (3/5) 1-Me H Rl X . G** j ♦** R7a
(R5)v
2,5-dimethylphenyl χi G-2 J-36 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl χi G-2 J-36(3/5) 1-Me H
3,5-dimethylpyrazol-l -yl χi G-2 J-36 (3/5) 1-Me H
5-methyI-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-36 (3/5) 1-Me H
S-chloro-S-CtrifluoromethyOpyrazol-l-yl χi G-2 J-36 (3/5) 1-Me H
5-bromo-3-(trifluoromethyI)pyrazol-l-yl χi G-2 J-36 (3/5) 1-Me H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-36 (3/5) 1-Me H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-36 (3/5) 1-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-2 J-36 (3/5) 1-Me H l-methyl-4-(trifluoromethyl)imidazol-2-yl Xl G-2 J-36 (3/5) 1-Me H
2,5-dichlorophenyl χi G-2 J-37 (2/5) - H 2-chloro-5-(trifluoroiπethyI)phenyl χi G-2 J-37 (2/5) - H
2 , 5 -dimethylphenyl χi G-2 J-37 (2/5) - H 2 -methyl-5 -(trifluoromethy I)phenyl χi G-2 J-37 (2/5) - H
3 ,5-dimethylpyrazol- 1 -yl χi G-2 J-37 (2/5) - H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-37 (2/5) - H
5-chloro-3-(trifluoromethyI)pyrazol- 1 -yl χi G-2 J-37 (2/5) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-37 (2/5) - H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-37 (2/5) - H
3 ,5-bis-(trifl uoromethyl)pyrazol- 1 -yl χi G-2 J-37 (2/5) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-2 J-37 (2/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-2 J-37 (2/5) - H
2,5-dichlorophenyl χi G-2 J-38 (2/5) - H 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-38 (2/5) - H
2,5-dimethylphenyl χi G-2 J-38 (2/5) - H 2-methyl-5-(trifluoromethyl)phenyl χi G-2 J-38 (2/5) - H
3 ,5-dimethylpyrazol- 1 -yl χi .G-2 J-38 (2/5) - H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-38 (2/5) - H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-38 (2/5) - H
5-bromo-3-(trifluoromethyl)pyra2ol-l-yl χi G-2 J-38 (2/5) - H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-38 (2/5) - H
3,5-bis-(trifluoromethyl)pyrazol-l-yl χi G-2 J-38 (2/5) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-2 J-38 (2/5) _ H Rl X G** j *** (R5)v R7a l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-2 J-38 (2/5) - H
2,5-dichlorophenyl χi G-2 J-39 (3/5) - H 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-39 (3/5) - H
2,5-dimethylphenyl χi G-2 J-39 (3/5) - H 2-methyl-5-(trifluoromethyl)phenyl χi G-2 J-39 (3/5) - H
3 ,5-dimethylpyrazol- 1 -yl χi G-2 J-39 (3/5) - H
5-methyI-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-39 (3/5) - H
5-chloro-3 -(trifluoromethyl)pyrazol-l -yl χi G-2 J-39 (3/5) - H
5 -bromo-3 -(trifl uoromethy l)pyrazol- 1 -yl χi G-2 J-39 (3/5) - H
5-ethyl-3-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-39 (3/5) - H
3 ,5-bis-(txifluoromethyl)pyrazol- 1 -yl χi G-2 J-39 (3/5) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-2 J-39 (3/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-2 J-39 (3/5) - H
2,5-dichlorophenyl χi G-2 J-40 (3/5) - H 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-40 (3/5) - H
2,5-dimethylphenyl χi G-2 J-40 (3/5) - H 2-methyl-5-(trifluoroπiethyl)ρhenyl X* G-2 J-40 (3/5) - H
3 ,5-dimethylpyrazol- 1 -yl χi G-2 J-40 (3/5) - H
5-methyl-3-(trifluorσmethy l)pyrazol- 1 -yl χi G-2 J-40 (3/5) - H
5-chloro-3-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-40(3/5) - H
5-bromo-3-(trifluorometliyl)pyrazol-l-yl X1 G-2 J-40 (3/5) - H
5 -ethyl-3 -(trifluoromethy l)pyrazol- 1 -y 1 χi G-2 J-40 (3/5) - H
3 ,5-bis-(trifluorometliyl)pyrazol- 1 -yl χi G-2 J-40(3/5) - H l-methyl-3-(trifluoromεthyl)pyrazol-5-yl χi G-2 J-40 (3/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-2 J-40 (3/5) . - H
2,5-dichlorophenyl χi G-2 J-69 (1/3) - H 2-chloro-5 -(trifluoromethyl)phenyl χi G-2 J-69 (1/3) - H
2,5-dimethylphenyl X1 G-2 J-69 (1/3) - H 2-methyl-5-(trifluoromethyl)phenyl ■ χi G-2 J-69 (1/3) - H
3 ,5-dimethylpyrazol- 1 -yl χi G-2 J-69 (1/3) - H 5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-69 (1/3) - H 5-chloro-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-69 (1/3) - H 5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-69 (1/3) _ H Rl X G** j *** R7a
(R5)v
5-ethyl-3-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-69 (1/3) - H
3,5-bis-(trifluoromethyl)pyrazol-l-yl χi G-2 J-69 (1/3) - H l-methyl-3-(trifluoromethyl)pyrazol-5-.yl χi G-2 J-69 (1/3) - H l-methyl-4-(trifluQromethyl)ϊmidazol-2-yl χi G-2 J-69 (1/3) - H
2,5-dicWorophenyl χi G-2 . J-69 (1/4) - H 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-69 (1/4) - H
2,5-dimethylρhenyl χi G-2 J-69 (1/4) - H 2-methyl-5-(trifluoromethyl)phenyl χi G-2 J-69 (1/4) - H
3 ,5-dimethylpyrazol- 1 -yl χi G-2 J-69 (1/4) - H
5-methyl-3-(trifIuoromethyl)pyrazol-l-yl χi G-2 J-69 (1/4) - H
S-chloro-S-CtrifluoromethyOpyrazol-l-yl χi G-2 J-69 (1/4) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-69 (1/4) - H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-69 (1/4) - H
3,5-bis-(trifluoromethyl)pyrazol- 1-yl χi G-2 J-69 (1/4) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-2 J-69 (1/4) - H l-methyl-4-(trifluoromethyl)imida2ol-2-yl χi G-2 J-69 (1/4) - H
2,5-dichlorophenyl .χi G-2 J-Il (3/5) - 2-Me 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-11 (3/5) - 2-Me
2,5-dimethylphenyl χi G-2 J-Il (3/5) . - 2-Me 2-methyl-5-(trifluoromethyl)phenyl χi G-2 J-Il (3/5) - 2-Me
3 ,5-dimethylpyrazol- 1 -yl χi G-2 J-I 1 (3/5) - 2-Me
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-H (3/5) - 2-Me
5-chloro-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-Il (3/5) - 2-Me
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-Il (3/5) - 2-Me
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-Il (3/5) - 2-Me
3,5-bis-(trifluoromethyl)pyrazol-l -yl χi G-2 J-I1 (3/5) - 2-Me l-methyl-3-(trifluoromethyl)ρyrazol-5-yl χi G-2 J-Il (3/5) - 2-Me
1 -methyl-4-(trifluorbmethyl)imidazol-2-yl χi G-2 J-11 (3/5) - 2-Me
2,5-dichlorophenyl χi G-2 J-Il (3/5) - 3-Me 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-I 1 (3/5) - 3-Me
2,5-dimethylphenyl χi G-2 J-Il (3/5) - 3-Me
2-methyl-5 -(trifluoromethyl)phenyl χi G-2 J-Il (3/5) - 3-Me
3,5-dimethylpyrazol- 1 -yl χi G-2 J-Il (3/5) _ 3-Me
Figure imgf000153_0001
Rl X G** J*** (R5)v R7a
2,5-dimethylphenyl χi G-2 J-Il (3/5) - 4-Cl 2-methyl-5-(trifluoromethyl)phenyl χi G-2 J-Il (3/5) - 4-Cl
3 ,5-dimetbylpyrazol- 1 -yl χi G-2 J-Il (3/5) - 4-Cl
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-Il (3/5) - 4-Cl
5-cUoro-3-(trifluoromethyl)ρyrazol-l-yl χi G-2 J-Il (3/5) - 4-Cl
5-bromo-3-(trifluoroπiethyl)pyrazol- 1 -yl χi G-2 J-Il (3/5) - 4-Cl
5-ethyl-3-(trifluorometbyl)pyrazol-l-yl χi G-2 J-Il (3/5) - 4-Cl
3,5-bis-(trifluoromethyl)pyrazol-] -yl χi G-2 J-Il (3/5) - 4-Cl l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-2 J-Il (3/5) - 4-Cl l-τnethyl-4-(trifluoromethyl)imidazol-2-yl χi G-2 J-Il (3/5) - 4-Cl
2,5-dichlorophenyl χi G-2 J-29 (3/5) - 2-Me 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-29 (3/5) - 2-Me
2,5-dimethylpheπyl χi G-2 J-29 (3/5) - 2-Me 2-methyl-5-(trifluoroπieihyl)phenyl χi G-2 J-29 (3/5) - 2-Me
3 ,5 -dimethylpyrazol- 1 -yl χi G-2 J-29 (3/5) - 2-Me
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-29 (3/5) - 2-Me
5-chloro-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-29 (3/5) - 2-Me
5-bromo-3-(trifluoromethyl)ρyrazol-l-yl χi G-2 J-29 (3/5) - 2-Me
5-ethyl-3-(trifluoromethyl)pyra2ol-l-yl χi G-2 J-29 (3/5) - 2-Me
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-29 (3/5) - 2-Me
1 -methy 1-3 -(trifluoromethy])pyrazol-5-yl χi G-2 J-29 (3/5) - 2-Me l-methyl-4-(tτifluoromethyl)imidazol-2-yl x* G-2 J-29 (3/5) - 2-Me
2,5-dichlorophenyl χi G-2 J-29 (3/5) - 3-Me 2-chloro-5 -(trifluoromethyl)pheny 1 χi G-2 J-29 (3/5) - 3-Me
2,5-dimethylphenyl χi G-2 J-29 (3/5) - 3-Me 2-methyl-5-(trifluoromethyl)phenyl χi G-2 J-29 (3/5) - 3-Me
3,5-dimethylpyrazol-l-yl x» . G-2 J-29 (3/5) - 3-Me
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl X1 G-2 J-29 (3/5) - 3-Me
5-chloro-3 -(trifluoromethyl)pyrazol- 1 -yl x» G-2 J-29 (3/5) - 3-Me
5-bromo-3-:(trifluoromethyl)pyrazol-l-yl χi G-2 J-29 (3/5) - 3-Me
5-ethyl-3-(trifluoromethyl)pyra2:ol-l-yl χi G-2 J-29 (3/5) - 3-Me
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X1 G-2 J-29(3/5) - 3-Me l-methyl-3-(trifluoromethyl)pyrazol-5-yl X1 G-2 J-29 (3/5) 3-Me Rl X G (R5X R7a l-methyl-4-(trifluorornethyl)iinidazol-2-yl χi G-2 J-29 (3/5) 3-Me
2,5-dichlorophenyl χi G-2 J-29 (3/5) 4-Me 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-29 (3/5) 4-Me
2,5-dimethylphenyl χi G-2 J-29 (3/5) 4-Me 2-methyl-5-(trifluoromethyl)pheπyl χi G-2 J-29 (3/5) 4-Me
3 ,5-dimethy lpyrazol- 1 -yl χi G-2 J-29 (3/5) 4-Me
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-29 (3/5) 4-Me
5-cMoro-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-29 (3/5) 4-Me
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-29 (3/5) 4-Me
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-29 (3/5) 4-Me
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-29 (3/5) 4-Me
1 -methyl-3 -(trifluoromethyl)pyrazol-5-yl χi G-2 J-29 (3/5) 4-Me l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-2 J-29 (3/5) 4-Me
2,5-dichlorophenyl χi G-2 J-29 (3/5) 2-Cl 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-29 (3/5) 2-Cl
2,5-dimethylphenyl χi G-2 J-29 (3/5) 2-Cl 2-methyl-5-(trifluoromethyl)phenyl χi G-2 J-29 (3/5) 2-Cl
3 ,5-dimethylpyrazol- 1 -yl χi G-2 J-29 (3/5) 2-Cl
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-29 (3/5) 2-Cl
5-chloro-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-29 (3/5) 2-Cl
5-bromo-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-29 (3/5) 2-Cl
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-29 (3/5) 2-Cl
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-29 (3/5) 2-Cl l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-2 J-29 (3/5) 2-Cl l-methyl-4-(trifluoromethyl)imidazol-2-yl χi G-2 J-29 (3/5) 2-Cl
2,5-dichlorophenyl χi G-2 J-29 (3/5) 4-Cl 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-29 (3/5) 4-Cl
2 ,5-dimethylphenyl χi G-2 J-29 (3/5) 4-Cl 2-methyl-5-(trifluoromethyl)phenyl χi G-2 J-29 (3/5) 4-Cl
3 ,5-dimethylpyrazol- 1 -yl χi G-2 J-29 (3/5) 4-Cl 5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-29 (3/5) 4-Cl S-chloro-S-Ctrifluorornethytypyrazol- 1 -yl χi G-2 J-29 (3/5) 4-Cl 5-bromo-3-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-29 (3/5) 4-Cl Rl X G** J*** (R5)v R7a
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-29 (3/5) - 4-Cl
3,5-bis-(trifluoromethyl)pyrazol-l -yl χi G-2 J-29 (3/5) - 4-Cl l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-2 J-29 (3/5) - 4-Cl l-methyl-4-(tri£luoromethyl)imidazol-2-yl χi G-2 J-29 (3/5) - 4-Cl
2,5-dichloropheπyl χi G-2 J-29 (3/5) 5-Me H 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-29 (3/5) 5-Me H
2,5-dimethylpheny] χi G-2 J-29 (3/5) 5-Me H 2-methyl-5-(tτifluoromethyl)phenyl χi G-2 J-29 (3/5) 5-Me H
3 ,5-diτnethylpyrazol- 1 -yl χi G-2 J-29 (3/5) 5-Me H
5-methyl-3 -(trifluoromethy I)pyrazol- 1 -yl χi G-2 J-29 (3/5) 5-Me H
5-chloro-3-(trifluoromethyl)pyτazol-l-yl χi G-2 J-29 (3/5) 5-Me H
5-bromo-3-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-29 (3/5) 5-Me H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-29 (3/5) 5-Me H
3,5-bis-(trifluoromethyl)pyrazol-l -yl χi G-2 J-29 (3/5) 5-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-2 J-29 (3/5) 5-Me H l-methyl-4-(trifluoromethyl)imida2ol-2-yl χi G-2 J-29 (3/5) 5-Me H
2,5-dichlorophenyl χi G-2 J-29 (3/5) 4-Me H 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-29 (3/5) 4-Me H
2,5-dimethylphenyl χi G-2 J-29 (3/5) 4-Me H 2-methyl-5-(trifluoromethyl)phenyl χi G-2 J-29 (3/5) 4-Me H
3,5-dimethylpyrazol-l-yl χi G-2 J-29 (3/5) 4-Me H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-29 (3/5) 4-Me H
5-chloro-3-(trifluoroπiethyl)pyrazol- 1 -yl χi G-2 J-29 (3/5) 4-Me H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-29 (3/5) 4-Me H
5-ethyl-3 -(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-29 (3/5) 4-Me H
3,5-bis-(trifluoromethyl)pyrazol-l-yl • χi G-2 J-29 (3/5) 4-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl χi G-2 J-29 (3/5) 4-Me H l-methyl-4-(tri£luoromethyl)imida2ol-2-yl χi G-2 J-29 (3/5) 4-Me H
2,5-dichlorophenyl χi G-2 J-29 (3/5) 4,4-di-Me H 2-chloro-5-(trifluoromethyl)phenyl χi G-2 J-29 (3/5) 4,4-di-Me H
2,5-dimethylphenyl χi G-2 J-29 (3/5) 4,4-di-Me H
2-methyl-5-(trifluoromethyl)phenyl χi G-2 J-29 (3/5) 4,4-di-Me H
3,5-dimethylpyrazol-l -yl χi G-2 J-29 (3/5) 4,4-di-Me H Rl X j *** (RJ)y R'a
5-methyl-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-29 (3/5) 4,4-di-Me H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-29 (3/5) 4,4-di-Me H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl χi G-2 J-29 (3/5) 4,4-di-Me H
5-ethyl-3-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-29 (3/5) 4,4-di-Me H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl χi G-2 J-29 (3/5) 4,4-di-Me H
1 -methyl-3 -(trifluoromethyl)pyrazol-5-yl χi G-2 J-29 (3/5) 4,4-di-Me H l-methyl-4-(trifluoromethyl)iinida2ol-2-yl χi G-2 J-29 (3/5) 4,4-di-Me H
2,5-dichlorophenyl X2 G-I J-I (2/4) - H 2-chloro-5-(trifluoromethyl)phenyl X2 G-I J-I (2/4) - H
2,5-dimethylphenyl X2 G-I J-I (2/4) - H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-I (2/4) - H
3 ,5-dimethylpyrazol- 1 -yl X2 G-I J-I (2/4) - H
5-me&yl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-I (2/4) - H
5-ch]oro-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-I (2/4) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-I (2/4) - H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-I (2/4) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-I (2/4) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-I (2/4) - H l-inethyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-I (2/4) - H
2,5-dichlorophenyl X2 G-I J-2 (2/4) - H 2-chloro-5-(trifluoromethyl)phenyl X2 G-I J-2 (2/4) - H
2,5-dimethylphenyl X2 G-I J-2 (2/4) - H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-2 (2/4) - H
3,5-dimethylpyra2ol-l-yl X2 G-I J-2 (2/4) - H
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-2 (2/4) - H
5-cMoro-3-(trifluorornethyl)pyrazol-l-yl X2 G-I J-2 (2/4) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-2 (2/4) - H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-2 (2/4) - H
3,5-bis-(trifluoromethyl)pyrazol-l -yl X2 G-I J-2 (2/4) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-2 (2/4) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-2 (2/4) - H
2,5-dichlorophenyl X2 G-I J-3 (2/4) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X2 G-I J-3 (2/4) 1-Me H R1 X G ** J *** (R5)v R7a
2,5-dimethylphenyl X2 G-I J-3 (2/4) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-3 (2/4) 1-Me H
3 ,5 -dimethylpyrazol- 1 -yl X2 G-I J-3 (2/4) 1-Me . H
5 -methyl-3 -(trifluoromethy l)pyrazol- 1 -y 1 X2 G-I J-3 (2/4) 1-Me H
5-chloro-3-(trifluoromethyl)pyrazol-l-yI X2 G-I J-3 (2/4) 1-Me H
5-bromo-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-3 (2/4) 1-Me H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-3 (2/4) 1-Me H
3 , 5-bis-(trifluoromethy l)pyrazol- 1 -yl X2 G-I J-3 (2/4) 1-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-3 (2/4) 1-Me H l-methyl-4-(trifluoroπiethyl)iπiidazol-2-yl X2 G-I J-3 (2/4) 1-Me H
2,5-dichlorophenyl X2 G-I J-4 (2/5) - H 2-chloro-5-(trifluoromethyl)phenyl X2 G-I J-4 (2/5) - H
2,5-dimethylphenyl X2 G-I J-4 (2/5) - H 2-methyl-5-(trifluoroinethyl)plienyl X2 G-I J-4 (2/5) - H
3,5-dimethylpyrazol-l -yl X2 G-I J-4 (2/5) - H
5-methyl-3 -(trifluoromethyl)pyτazol- 1 -yl X2 G-I J-4 (2/5) - H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-4 (2/5) - H
5-bromo-3-(trifluoromethyl)pyτazol- 1 -yl X2 G-I J-4 (2/5) - H
5-ethyl-3-(trifluoromethyl)ρyrazol-l-yl X2 G-I J-4 (2/5) - H
3,5-bis-(trifluoromethyl)pyrazol-l-yl X2 G-I J-4 (2/5) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-4 (2/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-4 (2/5) - H
2,5-dichlorophenyl X2 G-I J-8 (5/3) - H 2-chloro-5-(trifluoromethyl)phenyl X2 G-I J-8 (5/3) - H
2,5-dimethylphenyl X2 G-I J-8 (5/3) - H 2-methyl-5 -(trifluoromethyl)phenyl X2 G-I J-8 (5/3) - H
3 ,5 -dimethylpyrazol- 1 -yl X2 G-I J-8 (5/3) - H
5-methyl-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-8 (5/3) - H
5-chloro-3 -(trifluoroinethyl)pyrazol- 1 -yl X2 G-I J-8 (5/3) - H
5-bromo-3-(trifluoromethyl)pyτazol-l-yl X2 G-I J-8 (5/3) - H
5-ethyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-8 (5/3) - H
3,5-bis-(trifluoromethyl)pyrazol-l -yl X2 G-I J-8 (5/3) - H
1 -methyl-3 -(trifluoromethyl)pyrazol-5-yl X2 G-I J-8 (5/3) H R* X G** (RS)y R?a l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-8 (5/3) H
2,5-dichlorophenyl X2 G-I J-9 (5/3) H 2-chloro-5-(trifluoromethyl)phenyl X2 G-I J-9 (5/3) H
2,5-dimethylphenyl X2 G-I J-9 (5/3) H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-9 (5/3) H
3 ,5-dimethylpyrazol- 1 -yl X2 G-I J-9 (5/3) H
5 -methyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-9 (5/3) H
5-chloro-3-(trifluoromethyl)pyrazoI-l-yl X2 G-I J-9 (5/3) H
5-bromo-3-(trifluoroinethyl)pyrazol-l-yl X2 G-I J-9 (5/3) H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-9 (5/3) H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-9 (5/3) H
1 -methyl-3 -(trif!uoromethyl)pyrazol-5-yl X2 G-I J-9 (5/3) H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-9 (5/3) H
2,5-dichlorophenyl X2 G-I J-Il (3/5) H 2-chloro-5-(trifIuoroiπethyl)phenyl X2 G-I J-Il (3/5) H
2,5-dimethylphenyl X2 G-I J-Il (3/5) H 2-methyl-5-(trifluororπethyl)phenyl X2 G-I J-Il (3/5) H
3 ,5-dimethylpyrazol- 1 -yl X2 G-I J-Il (3/5) H
5-methyl-3-(trifluoromethyl)ρyrazol-l-yl X2 G-I J-Il (3/5) H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-Il (3/5) H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-Il (3/5) H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-Il (3/5) H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-Il (3/5) H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-Il (3/5) H l-methyl-4-(trifluorornethyl)imidazol-2-yl X2 G-I J-U (3/5) H
2,5-dichlorophenyl X2 G-I J-12 (3/5) H 2-chloro-5-(trifluoromethyl)phenyl X2 G-I J-12 (3/5) H
2,5-dimethylphenyl X2 G-I J-12 (3/5) H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-12 (3/5) H
3 ,5-dimethylpyrazol- 1 -yl X2 G-I J-12 (3/5) H 5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-12 (3/5) H 5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-12 (3/5) H 5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-12 (3/5) H Rl X G** J*** (R-')v R'a
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-12 (3/5) - H
3 ,5-bis-(1rifluoromethyl)pyrazol- 1-yl X2 G-I J-12 (3/5) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-12 (3/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-12 (3/5) - H
2,5-dichlorophenyl X2 G-I J-12 (3/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X2 G-I J-12 (3/5) 1-Me H
2,5-dimethylphenyl X2 G-I J-12 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-12 (3/5) 1-Me H
3 , 5 -dimethylpyrazol-1 -yl X2 G-I J-12 (3/5) 1-Me H
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-12 (3/5) 1-Me H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-12 (3/5) 1-Me H
5 -bromo-3 -(trifluoromethyl)pyrazol- 1 -y 1 X2 G-I J-12 (3/5) 1-Me H
5 -ethyl-3 -(tr ifluoromethy l)pyrazol- 1 -yl X2 G-I J-12 (3/5) 1-Me H
3,5-bis-(trifluoromethyl)pyrazol-l-yl X2 G-I J-12 (3/5) 1-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-12 (3/5) 1-Me H l-methyl-4-(trifluorornethyl)imidazol-2-yl X2 G-I J-12 (3/5) 1-Me H
2,5-dichlorophenyl X2 G-I J-14 (3/5) - H 2-chloro-5-(trifluoromethyl)phenyl X2 G-I J-14 (3/5) - H
2,5-dimethylphenyl X2 G-I J-14 (3/5) - H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-14 (3/5) - H
3 ,5-dimethylpyrazol- 1 -yl X2 G-I J-14 (3/5) - H
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-14 (3/5) - H
5-chloro-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-14 (3/5) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-14 (3/5) - H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-14 (3/5) - H
3,5-bis-(trifluoromethyl)pyrazol-l-yl X2 G-I J-14 (3/5) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-14 (3/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-14 (3/5) - H
2,5-dichlorophenyl X2 G-I J-15 (2/5) - H 2-chloro-5 -(trifluoromethyl)phenyl X2 G-I J-15 (2/5) - H
2,5-dimethylphenyl X2 G-I J-15 (2/5) - H
2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-15 (2/5) - H
3 ,5 -dimethylpyrazol- 1 -yl X2 G-I J-15 (2/5) H Rl X G** J*** (R5>v R7a
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-15 (2/5) - H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-15 (2/5) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-15 (2/5) - H
5-ethyl-3-(trifluoromethyI)pyrazol- 1 -yl X2 G-I J-15 (2/5) - H
3,5-bis-(trifluoromethyl)pyrazol-l-yl X2 G-I J-15 (2/5) - H l-methyl-3-(trifluoromethy])pyrazol-5-yl X2 G-I J-15 (2/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-15 (2/5) - H
2,5-dichloroρhenyl X2 G-I J-16 (2/5) - H 2-chloro-5-(trifluoromethyl)phenyl X2 G-I J-16 (2/5) - H
2,5-dimethylphenyl X2 G-I J-16 (2/5) - H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-16 (2/5) - H
3 ,5-dimethylpyrazol- 1 -yl X2 G-I J-16 (2/5) - H
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-16 (2/5) - H
5-chloro-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-16 (2/5) - H
5-bromo-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-16 (2/5) - H
5-ethyl-3 -(trifluoromethy l)pyrazol- 1 -yl X2 G-I J-16 (2/5) - H
355-bis-(trifluoromethyl)pyra2ol- 1 -yl X2 G-I J-16 (2/5) - H
1 -methyl-3 -(trifhiorornethyl)pyrazol-5-yl X2 G-I J-16 (2/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-16 (2/5) - H
2,5-dϊchlorophenyl X2 G-I J-22 (2/4) - H 2-chloro-5-(trifluoromethyl)phenyI X2 G-I J-22 (2/4) - H
2,5-dimethylphenyl X2 G-I J-22 (2/4) - H 2-raethyl-5-(trifluoroπieihyl)phenyl X2 G-I J-22 (2/4) - H
3 ,5-dimethylpyrazol- 1 -yl X2 G-I J-22 (2/4) - H
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-22 (2/4) - H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-22 (2/4) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-22 (2/4) - H
5 -ethyl-3 -(trifluoromethy I)pyrazol- 1 -yl X2 G-I J-22 (2/4) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-22 (2/4) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-22 (2/4) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-22 (2/4) - H
2,5-dichlorophenyl X2 G-I J-24 (2/4) - H 2-chloro-5-(trifluoromethyl)phenyl X2 G-I J-24 (2/4) H Rl X G** j *** (R5)y R7a
2,5-dimethylphenyl X2 G-I J-24 (2/4) H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-24 (2/4) H
3,5-dimethylρyrazol- 1 -yl X2 G-I J-24 (2/4) H
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-24 (2/4) H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-24 (2/4) H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-24 (2/4) H
5-ethyI-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-24 (2/4) H
3 jS-bis-CtrifluoromethyOpyrazol- 1 -yl X2 G-I J-24 (2/4) H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-24 (2/4) H l-methyl-4-(trifluoromethyl)iπiidazol-2-yl X2 G-I J-24 (2/4) H
2,5-dichlorophenyl X2 G-I J-25 (2/4) H 2-chloro-5-(trifluoromethyl)phenyl X2 G-I J-25 (2/4) H
2,5-dimethylphenyl X2 G-I J-25 (2/4) H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-25 (2/4) H
3 ,5-dimethylpyrazol- 1 -yl X2 G-I J-25 (2/4) H
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-25 (2/4) H
5-chloro-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-25 (2/4) H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-25 (2/4) H
5-ethyl-3-(trifluorornethyl)pyrazol- 1 -yl X2 G-I J-25 (2/4) H
3,5-bis-(trifluoromethyl)pyrazol-l-yl X2 G-I J-25 (2/4) H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-25 (2/4) H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-25 (2/4) H
2,5-dichlorophenyl X2 G-I J-26 (2/4) H 2-cbloro-5-(trifluoromethyl)phenyl X2 G-I J-26 (2/4) H
2,5-dimethylphenyl X2 G-I J-26 (2/4) H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-26 (2/4) H
3,5-dimethylpyrazol- 1 -yl X2 G-I J-26 (2/4) H
5-inethyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-26 (2/4) H
5-chloro-3 -(trifluoiOinethyl)pyrazol- 1 -yl X2 G-I J-26 (2/4) H
5-bromo-3-(trifluoromethyl)pyrazoI- 1 -yl X2 G-I J-26 (2/4) H
5-ethyl-3-(trifluoromethyl)pyrazol- 1-yl X2 G-I J-26 (2/4) H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-26 (2/4) H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-26 (2/4) H R1 X G ** J *** (R5)v R7a l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-26 (2/4) - H
2 ,5-dichlorophenyl X2 G-I J-26 (2/4) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X2 G-I J-26 (2/4) 1-Me H
2,5-dimethylphenyl X2 G-I J-26 (2/4) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-26 (2/4) 1-Me H
3,5-dimethylpyrazol-l-yl X2 G-I J-26 (2/4) 1-Me H
S-methyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-26 (2/4) 1-Me H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-26 (2/4) 1-Me H
5~bromo-3-(trifluoromethyl)ρyrazol- 1 -yl X2 G-I J-26 (2/4) 1-Me H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-26 (2/4) 1-Me H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-26 (2/4) 1-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-26 (2/4) 1-Me H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-26 (2/4) 1-Me H
2,5-dichlorophenyl X2 G-I J-26 (2/5) 1-Me H 2-chloro-5 -(trifluoromethyl)phenyl X2 G-I J-26 (2/5) 1-Me H
2,5-dimethylphenyl X2 G-I J-26 (2/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-26 (2/5) 1-Me H
3 ,5-dimethylpyrazol- 1 -yl X2 G-I J-26 (2/5) 1-Me H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-26 (2/5) 1-Me H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-26 (2/5) 1-Me H
5-bromo-3-(trifluoromethyl)pyra2;ol-l-yl X2 G-I J-26 (2/5) 1-Me H
5-ethyl-3-(trifluoromethyI)ρyrazol-l-yl X2 G-I J-26 (2/5) 1-Me H
3 ,5-bis-(trifluoromethyl)pyrazol-l -yl X2 G-I J-26 (2/5) 1-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-26 (2/5) 1-Me ' H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-26 (2/5) 1-Me H
2,5-dichlorophenyl X2 G-I J-28 (3/5) - H 2-chloro-5-(trifluoroiπethyl)phenyl X2 G-I J-28 (3/5) - H
2,5-dimethylphenyl X2 G-I J-28 (3/5) - H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-28 (3/5) - H
3 ,5-dimethylpyrazol-l -yl X2 G-I J-28 (3/5) - H 5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-28 (3/5) - H 5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-28 (3/5) - H 5-bromo-3-(trifluoromethyl)ρyrazol- 1 -yl X2 G-I J-28 (3/5) _ H Rl X G** J*** (R5)v R7a
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-28 (3/5) - H
3,5-bis-(trifluoromethyl)pyrazol-l -yl X2 G-I J-28 (3/5) - H l-raethyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-28 (3/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-28 (3/5) - H
2,5-dichlorophenyl X2 G-I J-30 (3/5) - H 2-chloro-5-(trifluoromethyl)phenyl X2 G-I J-30 (3/5) - H
2,5-dimethylphenyl X2 G-I J-30 (3/5) - H 2-methy 1-5 -(tri fluoromethyl)phenyl X2 G-I J-30 (3/5) - H
3,5-dimethylpyrazol-l-yl X2 G-I J-30 (3/5) - H
5-methyl-3-(trifluoromethyI)pyrazol- 1 -yl X2 G-I J-30 (3/5) - H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-30 (3/5) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-30 (3/5) - H
5-ethyl-3-(trifluoromethyl)pyrazol- 1 -yl χ2 G-I J-30 (3/5) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-30 (3/5) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-30 (3/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-30 (3/5) - H
2,5-dichlorophenyl X2 G-I J-30 (3/5) 1-Me H 2-chloro-5-(trifIuoroinethyl)phenyl X2 G-I J-30 (3/5) 1-Me H
2,5 -dimethylphenyl X2 G-I J-30 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-30 (3/5) 1-Me H
3 ,5 -dimethylpyrazol- 1 -yl X2 G-I J-30 (3/5) 1-Me H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-30 (3/5) 1-Me H
5-chloro-3-(trifluoromethyl)pyrazόl- 1 -yl X2 G-I J-30 (3/5) 1-Me H
5-bromo-3-(trifluoromethyl)pyτazol- 1 -yl X2 G-I J-30 (3/5) 1-Me H
5-ethyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-30 (3/5) 1-Me H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-30 (3/5) 1-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-30 (3/5) 1-Me H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-30 (3/5) 1-Me H
2,5-dichlorophenyl X2 G-I J-36 (3/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X2 G-I J-36 (3/5) 1-Me H
• 2,5-dimethylphenyl χ2 G-I J-36 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-36 (3/5) 1-Me H 3 ,5-dimeihylpyrazol- 1 -yl X2 G-I J-36 (3/5) 1-Me H Rl X G** J*** (R5)v R7a
5-methyl-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-36 (3/5) 1-Me H
5-chloro-3-(trifluoromethyl)pyra2θl-l-yl X2 G-I J-36 (3/5) 1-Me H
5-bromo-3-(trifluoromethyl)pyrazol-l-y] X2 G-I J-36 (3/5) 1-Me H
5-ethyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-36 (3/5) I-Me H
3,5-bJs-(trifluoromethyl)pyrazol-l-yl X2 G-I J-36 (3/5) 1-Me H l-methyl-3-(trifluoromethyl)pyrazoI-5-yl X2 G-I J-36 (3/5) 1-Me H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-36 (3/5) 1-Me H
2,5-dichlorophenyl X2 G-I J-37 (2/5) - H 2-chloro-5-(trifluoromethyl)phenyl χ2 G-I J-37 (2/5) - H
2,5-dimethylphenyl X2 G-I J-37 (2/5) - H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-37 (2/5) - H
3 ,5-dimethylpyrazol- 1 -yl X2 G-I J-37 (2/5) - H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-37 (2/5) - H
5-chloro-3-(trifluoromethy])pyrazol-l-yl X2 G-I J-37 (2/5) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-37 (2/5) - H
5-ethy l-3-(trifluoromethyl)pyra2ol- 1 -yl X2 G-I J-37 (2/5) - H
3,5-bis-(trifluoromethyl)pyrazol- 1-yl X2 G-I J-37 (2/5) - H l-tnethyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-37 (2/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-37 (2/5) - H
2,5-dichlorophenyl X2 G-I ' J-38 (2/5) - H 2-chIoro-5-(trifluoromethyl)pheπyl X2 G-I J-38 (2/5) - H
2,5 -dimethylphenyl X2 G-I J-38 (2/5) - H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-38 (2/5) - H
3 ,5-dimethylpyrazol- 1 -yl X2 G-I J-38 (2/5) - H
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-38 (2/5) - H
5-chloro-3-(trifluoromethyl)ρyrazol-l-yl X2 G-I J-38 (2/5) - H
5-bromo-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-38 (2/5) - H
5 -ethyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-38 (2/5) - H
3 ,5-bis-(trifluoromethy l)pyrazol- 1 -yl X2 G-I J-38 (2/5) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-38 (2/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-38 (2/5) - H
2,5-dichlorophenyl X2 G-I J-39 (3/5) - H 2-chloro-5 -(trifluoromethyl)phenyl X2 G-I J-39 (3/5) H Rl G ** (R5)y RTa
2,5-dimethylphenyl Gl J-39 (3/5) H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-39 (3/5) H
3 ,5-dimethylpyrazol- 1 -yl X2 G-I J-39 (3/5) H
5-methyl-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-39 (3/5) H
5-chloro-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-39 (3/% H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-39 (3/5) H
5-ethyl-3-(trifluoromethyl)ρyrazol-l-yl X2 G-I J-39 (3/5) H
3 , 5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-39 (3/5) H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-39 (3/5) H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-39 (3/5) H
2,5-dichlorophenyl X2 G-I J-40 (3/5) H 2-chloro-5-(trifluoromethyl)phenyl X2 G-I J-40 (3/5) H
2,5-dimethylphenyl X2 G-I J-40 (3/5) H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-40 (3/5) H
3 ,5 -dimethy lpyrazol- 1 -yl X2 G-I J-40 (3/5) H
5-methyl-3 -(trifluoroTOethyl)pyrazol- 1 -yl X2 G-I J-40 (3/5) H
5-chloro-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-40 (3/5) H
5-bromo-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-40 (3/5) H
5-ethyl-3 -(tri fluoromethy l)pyrazol- 1 -y 1 X2 G-I J-40 (3/5) H
3 , 5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-40 (3/5) H
1 -methyl-3 -(trifluoromethyl)pyrazol-5-yl X2 G-I J-40 (3/5) H l-methyl-4-(txifluoromethyl)imidazol-2-yl X2 G-I J-40 (3/5) H
2,5-dichlorophenyl X2 G-I J-69 (1/3) H 2-chIoro-5-(trifluoromethyl)phenyl X2 G-I J-69 (1/3) H
2,5-dimethylphenyl X2 G-I J-69 (1/3) H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-69 (1/3) H
3 , 5 -dimethy lpyrazol- 1 -yl X2 G-I J-69 (1/3) H
5-methyl-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-69 (1/3) H
5-chloro-3-(trifluoromethyl)pyra2ol-l-yl X2 G-I J-69 (1/3) H
5-bromo-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-69 (1/3) H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-69 (1/3) H
3,5-bis-(trifluoromethyl)pyrazol-l -yl X2 G-I J-69 (1/3) H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-69 (1/3) H Rl X G»* J *** (R5)v R7a l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-69 (1/3) - H
2 ,5-dichlorophenyl χ2 G-I J-69 (1/4) - H 2-chJoro-5-(trifluoromethyl)phenyl X2 G-I J-69 (1/4) - H
2,5-dimethylpheπyl X2 G-I J-69 (1/4) - H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-69 (1/4) - H
3 ,5-dimethylpyrazol- 1 -y 1 X2 G-I J-69 (1/4) - H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-69 (1/4) - H
5-chloro-3-(trifluoroinethyl)pyrazol-l-yl X2 G-I J-69 (1/4) - H-
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-69 (1/4) - H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-69 (1/4) - H
3 ,5-bis-(1rifluoroinethyl)pyrazol- 1 -yl X2 G-I J-69 (1/4) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-69 (1/4) - H l-methyl-4-(trifluoromethyl)iinida2ol-2-yl X2 G-I J-69 (1/4) - H
2,5-dichlorophenyl X2 G-I J-Il (3/5) - 2-Me 2-chJoro-5-(trifluoromethyl)phenyl X2 G-I J-Il (3/5) - 2-Me
2,5-dimethylphenyl X2 G-I J-I 1 (3/5) - 2-Me 2-methyl-5-(trifluoromethyI)phenyl X2 G-I J-11 (3/5) - 2-Me
3 ,5-dimethylpyrazol- 1 -yl X2 G-I J-Il (3/5) - 2-Me
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-Il (3/5) - 2-Me
5-chloro-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-Il (3/5) - 2-Me
5-bromo-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-Il (3/5) - 2-Me
5-ethyl-3-(trifluororaethyl)pyraz;ol- 1 -yl X2 G-I J-Il (3/5) - 2-Me
3,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-Il (3/5) - 2-Me
1 -methyl-3 -(trifluoromethyl)pyrazol-5-yl X2 G-I J-Il (3/5) - 2-Me l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-11 (3/5) - 2-Me
2,5-dichlorophenyl X2 G-I J-Il (3/5) - 3-Me 2-chloro-5-(trifhiorornethyl)phenyl X2 G-I J-Il (3/5) - 3-Me
2,5-dimethylphenyl X2 G-I J-Il (3/5) ■ - 3-Me 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-Il (3/5) - 3-Me
3 ,5-dimethylpyrazol- 1 -yl X2 G-I J-Il (3/5) - 3-Me 5-methyl-3-(trifluoromethy3)pyrazo]-l-yl X2 G-I J-11 (3/5) - 3-Me 5-chloro-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-11 (3/5) - • 3-Me 5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-Il (3/5) _ 3-Me Rl X G** J*** (R5)v R7a
5-ethyl-3-(trifluoromethyl)pyrazoI- 1 -yl X2 G-I J-Il (3/5) 3-Me
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-Il (3/5) 3-Me l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-Il (3/5) 3-Me l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-11 (3/5) 3-Me
2,5-dichlorophenyl X2 G-I J-Il (3/5) 4-Me 2-chloro-5-(trifluoromethyl)phenyl X2 G-I J-Il (3/5) 4-Me
2,5-dJmethylphenyl X2 G-I J-Il (3/5) 4-Me 2-methyl-5 -(trifluoromethyl)pheriyl X2 G-I J-Il (3/5) 4-Me
3 ,5-dimethylρyrazol- 1 -yl X2 G-I J-Il (3/5) 4-Me
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-Il (3/5) 4-Me
5-chlort>-3 -(trifluoτomethyl)pyrazol- 1 -yl X2 G-I J-Il (3/5) 4-Me
5-bromo-3-(trifluoromethyl)pyrazol-I-yl X2 G-I J-11 (3/5) .4-Me
5-ethyl-3-(tήfluoromethyl)pyrazol-l-yl X2 G-I J-Il (3/5) 4-Me
3,5-bis-(trifluoromethyl)pyrazol-l-yl X2 G-I J-11 (3/5) 4-Me
1 -methyl-3 -(trifluoromethyl)pyrazol-5-yl X2 G-I J-11 (3/5) 4-Me l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-11 (3/5) 4-Me
2,5-dichlorophenyl X2 G-I J-Il (3/5) 2-Cl 2-cbJoro-5-(trifluoromethyl)phenyl X2 G-I J-11 (3/5) 2-Cl
2 ,5 -dimethylphenyl X2 G-I J-Il (3/5) 2-Cl 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-Il (3/5) 2-Cl
3,5-dimethylpyrazol- 1 -yl X2 G-I J-Il (3/5) 2-Cl
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-11 (3/5) 2-Cl
5-chloro-3-(trifluoromethyI)pyrazol- 1 -yl X2 G-I J-Il (3/5) 2-Cl
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-Il (3/5) 2-Cl
5 -ethyl -3 -(tri fluoromethy l)pyrazol- 1 -y 1 X2 G-I J-Il (3/5) 2-Cl
3,5-bis-(trifluoromethyI)ρyτazol- 1 -yl X2 G-I J-I1 (3/5) 2-Cl l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-11(3/5) 2-Cl l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-Il (3/5) 2-Cl
2,5-dichlorophenyl X2 G-I J-Il (3/5) 4-Cl 2-chloro-5-(trifluoromethyl)ρhenyl X2 G-I J-Il (3/5) 4-Cl
2,5-dimethylphenyl X2 G-I J-Il (3/5) 4-Cl
2-methyl-5-(trifluoromethyI)ρhenyl X2 G-I J-Il (3/5) 4-Cl
3,5-dimethylpyrazol- 1 -yl X2 G-I J-Il (3/5) 4-Cl Rl X G** j ***
(R5)v R7a
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-Il (3/5) - 4-Cl
5-chloro-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-U (3/5) - 4-Cl
5-bromo-3-(trifluoromethyI)pyrazol- 1 -yl X2 G-I J-Il (3/5) - 4-Cl
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-Il (3/5) - 4-Cl
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-Il (3/5) - 4-Cl
- 1 -methyl-3-(trifluoromethyI)pyrazol-5-yl X2 G-I J-Il (3/5) - 4-Cl
1 -methy.-4-(trifluoromethyl)imϊdazol-2-yl X2 G-I J-Il (3/5) - 4-Cl
2,5-dichlorophenyl X2 G-I J-29 (3/5) - 2-Me 2-chloro-5-(trifluoromethyl)ρhenyl X2 G-I J-29 (3/5) - 2-Me
2,5-dimethylphenyl X2 G-I J-29 (3/5) - 2-Me 2-methy 1-5 -(trifluoroπiethyl)phenyl X2 G-I J-29 (3/5) - 2-Me
3,5-dimethylpyrazol-l -yl X2 G-I J-29 (3/5) - 2-Me
5-methyl-3-(trifluoromethyl)pyτazol-l-yl X2 G-I J-29 (3/5) - 2-Me
5-ch]oro-3-(trifluoromethyl)pyrazol-l-y] X2 G-I J-29 (3/5) - 2-Me
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-29 (3/5) - 2-Me
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-29 (3/5) - 2-Me
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-29 (3/5) - 2-Me l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-29 (3/5) - 2-Me l-rπethyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-29 (3/5) - 2-Me
2 , 5-d ichlorophenyl X2 G-I J-29 (3/5) - 3-Me 2-cbJoro-5-(trifluoromethyl)phenyl X2 G-I J-29 (3/5) - 3-Me
2,5-dimethylρhenyl X2 G-I J-29 (3/5) - 3-Me 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-29 (3/5) . - 3-Me
3 ,5-dimethylpyrazol- 1 -yl X2 G-I J-29 (3/5) - 3-Me
5-methyl-3-(trifluoromethyl)pyra2ol- 1 -yl X2 G-I J-29 (3/5) - 3-Me
5-chloro-3-(trifluoromethyl)pyra2ol- 1 -yl X2 G-I J-29 (3/5) - 3-Me
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-29 (3/5) - 3-Me
5-ethyl-3-(trifIuoromethyl)pyrazol- 1 -yl X2 G-I J-29 (3/5) - 3-Me
3 ,5-bis-(trifluoromethyl)pyra2θl- 1 -yl X2 G-I J-29 (3/5) - 3-Me l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-29 (3/5) - 3-Me l-methyl-4-(trifluoromethyl)imida2ol-2-yl X2 G-I J-29 (3/5) - 3-Me
2,5-dichlorophenyl X2 G-I J-29 (3/5) - 4-Me 2-chloro-5-(trifluoromethyl)phenyl X2 G-I J-29 (3/5) _ 4-Me Rl X G** J *** R7a
(R5)v
2,5-dimethylphenyl X2 G-I J-29 (3/5) - 4-Me 2-methyl-5-(trifluoromethyl)phenyl χ2 G-I J-29 (3/5) - 4-Me
3 ,5-dimethylpyrazol- 1 -yl X2 G-I J-29 (3/5) - 4-Me
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-29 (3/5) - 4-Me
5 -chloro-3 -(trifluoromethy l)pyrazol- 1 -yl X2 G-I J-29 (3/5) - 4-Me
5-brorno-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-29 (3/5) - 4-Me
5-ethyl-3 -(trifluoromethyi)pyrazol- 1 -yl X2 G-I J-29 (3/5) - 4-Me
3 ,5-bis-(trifluoromethy l)pyrazol- 1 -yl X2 G-I J-29 (3/5) - 4-Me l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-29 (3/5) - 4-Me l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-29 (3/5) - 4-Me
2,5-dichlorophenyl X2 G-I J-29 (3/5) - 2-Cl 2-chloro-5-(trifluoromethyl)phenyl X2 G-I J-29 (3/5) - 2-Cl
2,5-dimethylphenyl X2 G-I J-29 (3/5) - 2-Cl 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-29 (3/5) - 2-Cl
3 ,5-dimethylpyrazol- 1 -yl X2 G-I J-29 (3/5) - 2-Cl
5-methyl-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-29 (3/5) - 2-Cl
5-chloro-3-(trifluoromethyI)pyrazol- 1 -yl X2 G-I J-29 (3/5) - • 2-Cl
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-29 (3/5) - 2-Cl
5-ethyl-3-(trifluoromethyI)pyrazol-l-yl X2 G-I J-29 (3/5) - 2-Cl
3 ,5-bis-(trifluoromethy l)pyrazol- 1 -yl X2 G-I J-29 (3/5) - 2-Cl l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-29 (3/5) - 2-Cl l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-29 (3/5) - 2-Cl
2,5-dichlorophenyl X2 G-I J-29 (3/5) - 4-Cl 2-chloro-5-(trifluoromethyl)phenyl X2 G-I J-29 (3/5) - 4-Cl
2,5-dimethylphenyl X2 G-I J-29 (3/5) - 4-Cl 2-methyl-5-(trifluoromethyl)ρhenyl X2 G-I J-29 (3/5) - 4-Cl
3 ,5-dimethylpyrazol- 1 -yl X2 G-I J-29 (3/5) - 4-Cl
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-29 (3/5) - 4-Cl
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-29 (3/5) - 4-Cl
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-29 (3/5) - 4-Cl
5-ethyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-29 (3/5) - 4-Cl
3,5-bis-(trifluoromethyl)pyrazol-l-yl X2 G-I J-29 (3/5) - 4-Cl l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-29 (3/5) 4-Cl Rl X (R5)v R7a l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-I J-29 (3/5) - 4-Cl
2,5-dichlorophenyl X2 G-I J-29 (3/5) 5-Me H 2-chloro-5-(trifluoromethyl)phenyl χ2 G-I J-29 (3/5) 5-Me H
2,5-dimethylphenyl X2 G-I J-29 (3/5) 5-Me H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-29 (3/5) 5-Me H
3 , 5-dimethy lpyrazol- 1 -y 1 X2 G-I J-29 (3/5) 5-Me H
5-methy l-3-(trifIuoromethyl)pyrazol- 1 -yl X2 G-I J-29 (3/5) 5-Me H
5-chloro-3-(trifluoromethyl)pyrazol-l-yI X2 G-I J-29 (3/5) 5-Me H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-29 (3/5) 5-Me H
5-ethy]-3 -(trifluoromethyl)pyτazol- 1 -yl X2 G-I J-29 (3/5) 5-Me H
3,5-bis-(trifIuoromethyl)pyrazol-l-yl X2 G-I J-29 (3/5) 5-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-29 (3/5) 5-Me H l-methyl-4-(trifluoromethyI)itπidazol-2-yl X2 G-I J-29 (3/5) 5-Me H
2,5-dichlorophenyl X2 G-I J-29 (3/5) 4-Me H 2-chloro-5 -(trifluoromethyl)phenyl X2 G-I J-29 (3/5) 4-Me H
2,5-dimethylphenyl X2 G-I J-29 (3/5) 4-Me H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-29 (3/5) 4-Me H
3,5-dimethylpyrazol-l-yl X2 G-I J-29 (3/5) 4-Me H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-29 (3/5) 4-Me H
5-chloro-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-29 (3/5) 4-Me H
5-bromo-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-29 (3/5) 4-Me H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-I J-29 (3/5) 4-Me H
3,5-bis-(trifluoromethyl)pyrazol-l-yl X2 G-I J-29 (3/5) 4-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-29 (3/5) 4-Me H l-methyl-4-(trifluoromethyl)imida2;ol-2-yl X2 G-I J-29 (3/5) 4-Me H
2,5-dichlorophenyl X2 G-I J-29 (3/5) 4,4-di-Me H 2-chloro-5-(trifluoromethyl)phenyl X2 G-I J-29 (3/5) 4,4-di-Me H
2,5-dimethylphenyl X2 G-I J-29 (3/5) 4,4-di-Me H 2-methyl-5-(trifluoromethyl)phenyl X2 G-I J-29 (3/5) 4,4-di-Me H
3 ,5-dimethylpyrazol- 1 -yl X2 G-I J-29 (3/5) 4,4-di-Me H 5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-29 (3/5) 4,4-di-Me H 5-chloro-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-29 (3/5) 4,4-di-Me H 5-bromo-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-I J-29 (3/5) 4,4-di-Me H Rl X G** J*** <R5)v R7a
5-ethyl-3-(trifIuoromethyl)pyrazol-l-yl X2 G-I J-29 (3/5) 4,4-di-Me H
3 ,5-bis-(trifluoromethyl)ρyrazol- 1 -yl X2 G-I J-29 (3/5) 4,4-di-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-I J-29 (3/5) 4,4-di-Me H
1 -methyl-4-(trifluoromethy l)imidazol-2-yl X2 G-I J-29 (3/5) 4,4-di-Me H
2,5-dichlorophenyl X2 G-2 J-I (2/4) - H 2-chloro-5-(trifluoromethy])pheny] X2 G-2 J-I (2/4) - H
2,5-dimethylphenyl X2 G-2 J-I (2/4) - H 2-methy 1-5 -(tri fl uoromethy l)phenyl X2 G-2 J-I (2/4) - H
3 ,5-dimethylpyrazol- 1 -yl X2 G-2 J-I (2/4) - H
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-I (2/4) - H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-I (2/4) - H
5-bromo-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-I (2/4) - H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-I (2/4) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-I (2/4) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 ' J-I (2/4) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-I (2/4) - H
2,5-dichlorophenyl X2 G-2 J-2 (2/4) - H 2-chloro-5 -(trifluoromethyl)phenyl X2 G-2 J-2 (2/4) - H
2,5-dimethylphenyl X2 G-2 J-2 (2/4) - H 2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-2 (2/4) - H
3 ,5-dimethylpyrazol- 1 -yl X2 G-2 J-2 (2/4) - H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-2 (2/4) - H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-2 (2/4) - H
5-bromo-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-2 (2/4) - H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-2 (2/4) - H"
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-2 (2/4) - H l-methyI-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-2 (2/4) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-2 (2/4) - H
2,5-dichlorophenyl X2 G-2 J-3 (2/4) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-3 (2/4) 1-Me H
2,5-dimethylphenyl X2 G-2 J-3 (2/4) 1-Me H
2-methyl-5 -(trifluoromethyl)phenyl X2 G-2 J-3 (2/4) 1-Me H
3 ,5-dimethylpyrazol- 1 -yl X2 G-2 J-3 (2/4) 1-Me H Rl X G** J*** R7a
(R5)v
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-3 (2/4) 1-Me H
5-chloro-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-3 (2/4) 1-Me H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-3 (2/4) 1-Me H
5-ethyl-3-(trifluoromethyl)pyrazoI-l-yl X2 G-2 J-3 (2/4) 1-Me H
3,5-bis-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-3 (2/4) 1-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-3 (2/4) 1-Me H l-rnethyl-4-(trifluorornethyl)imidazol-2-yl X2 G-2 J-3 (2/4) 1-Me H
2,5-dichlorophenyl X2 G-2 J-4 (2/5) - H 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-4 (2/5) - H
2 ,5-dimethylphenyl X2 G-2 J-4 (2/5) - H 2-methyl-5-(trifluoromethyl)phεnyl X2 G-2 J-4 (2/5) - H
3 ,5-dimethylρyrazol- 1 -yl X2 G-2 J-4 (2/5) - H
5 -methyl-3 -(trifluoromethyl)pyrazol- 1 -y 1 X2 G-2 J-4 (2/5) - H
5-chloro-3 -(trifluoromethy l)pyτazol- 1 -yl X2 G-2 J-4 (2/5) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J^ (2/5) - H
5-ethyl-3-(trifluorornethyl)pyrazol-l-yl X2 G-2 J-4 (2/5) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-4 (2/5) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-4 (2/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-4 (2/5) - H
2,5-dichlorophenyl X2 G-2 J-8 (5/3) - H 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-8 (5/3) - H
2,5-dimethylphenyl X2 G-2 J-8 (5/3) - H 2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-8 (5/3) - H
3 ,5 -dimethy lpyrazol- 1 -yl X2 G-2 J-8 (5/3) - H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-8 (5/3) - H
5-chloro-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-8 (5/3) - H
5-bromo-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-8 (5/3) - H
5-ethyl-3-(trifluoromethyl)pyra2ol-]-yl X2 G-2 J-8 (5/3) - H
3,5-bis-(trifluoromethyI)pyrazol-l -yl X2 G-2 J-8 (5/3) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-8 (5/3) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-8 (5/3) - H
2,5-dichlorophenyl X2 G-2 J-9 (5/3) - H 2-chloro-5 -(trifluoromethyl)phenyl X2 G-2 J-9 (5/3) H Rl X (R5)v R7a
2,5-dimethylphenyl G-2 J-9 (5/3) H 2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-9 (5/3) H
3 ,5-dimethylpyrazol- 1 -yl X2 G-2 J-9 (5/3) H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-9 (5/3) H
5-chloro-3 -(trifluoromethyl)pyτazol- 1 -yl X2 G-2 J-9 (5/3) H
5-bromo-3-(trifluoromethyl)pyrazol-I-yl X2 G-2 J-9 (5/3) H
S-ethyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-9 (5/3) H
3,5-bis-(trifluoromethyl)pyrazol-l -yl X2 G-2 J-9 (5/3) H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-9 (5/3) H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-9 (5/3) H
2,5-dichlorophenyl X2 G-2 J-I1 (3/5) H 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-Il (3/5) H
2,5-dimethylphenyl X2 G-2 J-Il (3/5) ' - H 2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-Il (3/5) H
3,5-dimethylpyrazol-l-yl X2 G-2 J-Il (3/5) H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-Il (3/5) H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-Il (3/5) H
5-bromo-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-Il (3/5) H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-I 1 (3/5) H
3 ,5 -bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-Il (3/5) H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-Il (3/5) H l-methyl-4-(trifluoroinethyl)imidazol-2-yl X2 G-2 J-Il (3/5) H
2,5-dichlorophenyl X2 G-2 J-12 (3/5) H 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-12 (3/5) H
2,5-dimethylphenyl X2 G-2 J-12 (3/5) H 2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-12 (3/5) H
3 ,5-dimethylpyrazol- 1 -yl X2 G-2 J-12 (3/5) H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-12 (3/5) H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-12 (3/5) H
5-bromo-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-12 (3/5) H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-12 (3/5) H
3,5-bis-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-12 (3/5) H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-12 (3/5) H Rl X G** J*** (R5)v R7a l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-12 (3/5) - H
2,5-dichlorophenyl X2 G-2 J-12 (3/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-12 (3/5) 1-Me H
2 ,5 -dimethylpheny 1 X2 G-2 J-12 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-12 (3/5) 1-Me H
3 ,5-dimethylpyrazol- 1 -yl X2 G-2 J-12 (3/5) 1-Me H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-12 (3/5) 1-Me H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-12 (3/5) 1-Me H
5-bromo-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-12 (3/5) 1-Me H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 ' G-2 J-12 (3/5) 1-Me H
3 ,5-bis-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-12 (3/5) 1-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-12 (3/5) 1-Me H l-methyl-4-(trifluoromethyl)imidazoI-2-yl X2 G-2 J-12 (3/5) 1-Me H
2,5-dichlorophenyl X2 G-2 J-14 (3/5) - H 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-14 (3/5) - H
2,5-dimethylphenyl X2 G-2 J-14 (3/5) - H 2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-14 (3/5) - H
3,5-dimethylpyrazol-l-yl X2 G-2 J-14 (3/5) - H
5-methy]-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-14 (3/5) - H
5-chloro-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-14 (3/5) - H
5-bromo-3-(trifluoroinethyl)pyrazol-l-yl X2 G-2 J-14 (3/5) - H
5-ethyl-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-14 (3/5) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-14 (3/5) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-14 (3/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-14 (3/5) - H
2,5-dichlorophenyl X2 G-2 J-15 (2/5) - H 2~chloro-5-(trifluoromethyl)phenyl X2 G-2 J-I5 (2/5) - H
2,5-dimethylphenyl X2 G-2 J-15 (2/5) - H 2-methyl-5-(trifluoromethyl)phenyl X2 . G-2 J-15 (2/5) - H
3 ,5-dimethy Ipyrazol- 1 -yl X2 G-2 J-15 (2/5) - H 5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-15 (2/5) - H 5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-15 (2/5) - H 5-bromo-3-(trifluoromethyl)ρyrazol- 1 -yl X2 G-2 J-15 (2/5) H Rl X G** j*** (R5)v R7a
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-I5 (2/5) - H
3 ,5-bis-(trifluorornethyl)pyrazol- 1 -yl X2 G-2 J-15 (2/5) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-15 (2/5) - H l-methyl-4-(trifluoromethyl)iinidazol-2-yl X2 G-2 J-15 (2/5) - H
2,5-dichlorophenyl X2 G-2 J-16 (2/5) - H 2-chloro-5 -(trifluoromethyl)phenyl X2 G-2 J-16(2/5) - H
2,5-dimethylphenyl X2 G-2 J-16 (2/5) - H 2-methyl-5-(trifluoroπiethyl)phenyl X2 G-2 J-16 (2/5) - H
3 ,5-dimethylpyrazol- 1 -yl X2 G-2 J-16 (2/5) - H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-16 (2/5) - H
5-chJoro-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-16 (2/5) - H
5-bromo-3 -(trifluoromethyl)pyra2ol- 1 -yl X2 G-2 J-16 (2/5) - H
5-ethyl-3-(trifluorometbyl)pyrazol-l-yl X2 G-2 J-16 (2/5) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-16 (2/5) - H 1 -methyl-3 -(trifluoromethyl)pyrazol-5-yl X2 G-2 J-16 (2/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-16 (2/5) - H
2,5-dichlorophenyl X2 G-2 J-22 (2/4) - H 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-22 (2/4) - H
2 ,5 -dimethylphenyl X2 G-2 J-22 (2/4) - H 2-methyl-5 -(trifluoromethyl)phenyl X2 G-2 J-22 (2/4) - H
3 ,5 -dimethylpyrazol- 1 -yl X2 G-2 J-22 (2/4) - H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-22 (2/4) - H
5-chl oro-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-22 (2/4) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-22 (2/4) - H
5-ethyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-22 (2/4) - H
3,5-bis-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-22 (2/4) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-22 (2/4) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-22 (2/4) - H
2,5-dichlorophenyl X2 G-2 J-24 (2/4) - H 2-chloro-5 -(trifluoromethyl)phenyl X2 G-2 J-24 (2/4) - H
2,5-dimethylphenyl X2 G-2 J-24 (2/4) - H
2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-24 (2/4) - H
3 ,5 -dimethylpyrazol- 1 -yl X2 G-2 J-24 (2/4) H Rl X G** R7a
(R5)v
5-methyI-3-(trifluorornethyl)pyrazol-l-yl X2 G-2 J-24 (2/4) - H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-24 (2/4) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-24 (2/4) - H
5-ethyl-3-(trifluoromeihyl)pyrazol-l-yl X2 G-2 J-24 (2/4) - H
3 ,5-bis-(trifluoromethyl)pyrazol-l -yl X2 G-2 J-24 (2/4) - H l-methyI-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-24 (2/4) - H l-methyl-4-(trifluoromethyl)iinidazol-2-yl X2 G-2 J-24 (2/4) - H
2,5-dichlorophenyl X2 G-2 J-25 (2/4) - H 2-chloro-5 -(trifluoromethyl)phenyl X2 G-2 J-25 (2/4) - H
2,5-dimethylphenyl X2 G-2 J-25 (2/4) - H 2-π.ethyl-5-(trifluoromethyl)phenyl X2 G-2 J-25 (2/4) - H
3 ,5-dimethylρyra2θl- 1 -yl X2 G-2 J-25 (2/4) - H
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-25 (2/4) - H
5-chloro-3-(trifluoromethyl)pyrazol- 1 -yl X2- G-2 J-25 (2/4) - H
5-bromo-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-25 (2/4) - H
5-ethyl-3-(trifluoromethyl)pyτazoI-l -yl X2 G-2 J-25 (2/4) - H
3,5-bis-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-25 (2/4) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-25 (2/4) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-25 (2/4) - H
2,5-dichlorophenyl X2 G-2 J-26 (2/4) - H 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-26 (2/4) - H
2,5-dimethylphenyl X2 G-2 J-26 (2/4) - H 2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-26 (2/4) - H
3,5-dimethylpyrazol-l-yl X2 G-2 J-26 (2/4) - H
5-methyl-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-26 (2/4) - H
5-chloro-3-(trifluoroπiethyl)pyra2θl- 1 -yl X2 G-2 J-26 (2/4) - H
5-bromo-3-(trifluoroinethyl)pyrazol- 1 -yl X2 G-2 J-26 (2/4) - . H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yI X2 G-2 J-26 (2/4) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-26 (2/4) - H l-methyl-3-(trifluoromethyl)pyτazol-5-yl X2 G-2 J-26 (2/4) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-26 (2/4) - H
2,5-dichlorophenyl X2 G-2 J-26 (2/4) 1-Me H 2-chloro-5 -(trifluoromethyl)phenyl X2 G-2 J-26 (2/4) 1-Me H Rl X Q** j *** (RJ)v
2,5-dimethylphenyl X2 G-2 J-26 (2/4) 1-Me H • 2-methyl-5-(trifluoromethyl)pheπyl X2 G-2 J-26 (2/4) 1-Me H
3 ,5-dimethylpyrazol- 1 -yl X2 G-2 J-26 (2/4) 1-Me H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-26 (2/4) 1-Me H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-26 (2/4) 1-Me H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-26 (2/4) 1-Me H
5-ethyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-26 (2/4) 1-Me H
3,5-bis-(trifluαromethyl)pyrazol-l-yl X2 G-2 J-26 (2/4) 1-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-26 (2/4) 1-Me H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-26 (2/4) 1-Me H
2,5-dichlorophenyl X2 G-2 J-26 (2/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-26 (2/5) 1-Me H
2,5-ditnethylphenyl X2 G-2 J-26 (2/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-26 (2/5) 1-Me H
3 ,5-dimethylpyrazol- 1 -yl X2 G-2 J-26 (2/5) 1-Me H
5-methyl-3-(trifluoromethyl)pyrazol-l-yI X2 G-2 J-26 (2/5) 1-Me H
5-chloro-3-(trϋluoromethyl)pyrazol-l-yl X2 G-2 J-26 (2/5) l-Me H
5-bromo-3-(trifluofomethyl)pyrazo]-l-yl X2 G-2 J-26 (2/5) 1-Me H
5-ethyl-3-(trifluoromethyl)pyτazol-l-yl X2 G-2 J-26 (2/5) 1-Me H
3,5-bis-(triflυoromethyl)pyrazol-l -yl X2 G-2 J-26 (2/5) 1-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-26 (2/5) 1-Me H l-methyl-4-(trifluoromethy])imidazol-2-yl X2 G-2 J-26 (2/5) 1-Me H
2,5-dichlorophenyl X2 G-2 J-28 (3/5) - H 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-28 (3/5) - H
2,5-ditnethylphenyl X2 G-2 J-28 (3/5) - H 2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-28 (3/5) - H
3 ,5-dimethylpyrazol- 1 -yl X2 G-2 J-28 (3/5) - H
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-28 (3/5) - H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-28 (3/5) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-28 (3/5) - H
5-ethyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-28 (3/5) - H
3 ,5-bis-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-28 (3/5) - H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-28 (3/5) _ H Rl X G** J *** (R5)v R7a l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-28 (3/5) - H
2,5-dichlorophenyl X2 G-2 J-30 (3/5) - H 2-chIoro-5-(trifluoromethyl)phenyl X2 G-2 J-30 (3/5) - H
2,5-dimethylphenyl X2 G-2 J-30 (3/5) - H 2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-30 (3/5) - H
3 ,5-dimethylpyrazol- 1 -yl X2 G-2 J-30 (3/5) - H
5-methyI -3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-30 (3/5) - H
5-chloro-3 -(trifluoromethyl)pyrazol-.1 -yl X2 G-2 J-30 (3/5) - H
5-bromo-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-30 (3/5) - H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-30 (3/5) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-30 (3/5) - H l-methyl-3-(trifluorornethyl)pyrazol-5-yl X2 G-2 J-30.(3/5) - H
1 -methy l-4-(trifluoromethyl) imidazol-2-yl X2 G-2 J-30 (3/5) - H
2,5-dichlorophenyl X2 G-2 J-30 (3/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-30 (3/5) 1-Me H
2,5-dimethylphenyl X2 G-2 J-30 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-30 (3/5) 1-Me H
3 ,5-dhnethylpyrazol- 1 -yl X2 G-2 J-30 (3/5) 1-Me H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-30 (3/5) 1-Me H
5-chloro-3 -(trifluoromethyl)pyrazol- 1 -y 1 X2 G-2 J-30 (3/5) 1-Me H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-30 (3/5) 1-Me H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-30 (3/5) 1-Me H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -y 1 X2 G-2 J-30 (3/5) 1-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-30 (3/5) 1-Me H l-methyI-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-30 (3/5) 1-Me H
2,5-dichlorophenyl X2 G-2 J-36 (3/5) 1-Me H 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-36 (3/5) 1-Me H
2,5-dimethylphenyl X2 . G-2 J-36 (3/5) 1-Me H 2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-36 (3/5) 1-Me H
3 ,5-dimethylpyrazol- 1 -yl X2 G-2 J-36 (3/5) 1-Me H 5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-36 (3/5) 1-Me H 5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-36 (3/5) 1-Me H 5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-36 (3/5) 1-Me H Rl X G** J*** (R5)v R7a
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-36 (3/5) 1-Me H
3,5-bis-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-36 (3/5) 1-Me H l-methyI-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-36 (3/5) 1-Me H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-36 (3/5) 1-Me H
2,5-dichlorophenyl X2 G-2 J-37 (2/5) - H 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-37(2/5) - H
2 ,5 -dimethylphenyl X2 G-2 J-37 (2/5) - H 2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-37 (2/5) • - H
3 ,5-dimethylpyrazol- 1 -yl X2 G-2 J-37 (2/5) - H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-37 (2/5) - H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-37 (2/5) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-37 (2/5) - H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-37 (2/5) - H
3,5-bis-(trifluorornethyl)pyrazol- 1 -yl X2 G-2 J-37 (2/5) - H
1 -methyl-3 -(trifluoromethyl)pyrazol-5-yl X2 G-2 J-37 (2/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-37 (2/5) - H
2,5-dichlorophenyl X2 G-2 J-38 (2/5) - H 2-chJoro-5-(trifluoromethyl)phenyl X2 G-2 J-38 (2/5) - H
2,5-dimethylphenyI X2 G-2 J-38 (2/5) - H 2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-38 (2/5) - H
3 ,5-dimethylpyrazol- 1 -yl X2 G-2 J-38 (2/5) - H
5-methyl-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-38 (2/5) - H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-38 (2/5) - H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-38 (2/5) - H
5-ethyl-3-(trifluoromethyl)pyrazoI- 1 -yl X2 G-2 J-38 (2/5) - H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-38 (2/5) - H lτmethyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-38 (2/5) - H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-38 (2/5) - H
2,5-dichlorophenyl X2 G-2 J-39 (3/5) - H 2-chloro-5 -(trifluoromethyl)phenyl X2 G-2 J-39 (3/5) - H
2,5-dimethylphenyl X2 G-2 J-39 (3/5) - H
2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-39 (3/5) - H
3 ,5-dimethylpyrazol- 1 -yl X2 G-2 J-39 (3/5) • H Rl X G** J*** (R5), R?a
5-methyl-3-(trifluoromethyl)ρyrazol-l-yl X2 G-2 J-39 (3/5) H
5-chIoro-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-39 (3/5) H
5 -bromo-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-39 (3/5) H
5-ethyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-39 (3/5) H
3 , 5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-39 (3/5) H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-39 (3/5) H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-39 (3/5) H
2,5-dichlorophenyl X2 G-2 J-40 (3/5) H 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-40 (3/5) H
2,5-dimethylphenyl X2 G-2 J-40 (3/5) H 2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-40 (3/5) H
3,5-dimethyIpyrazol-l-yl X2 G-2 J-40 (3/5) H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-40 (3/5) H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-40 (3/5) H
5-bromo-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-40 (3/5) H
5-ethyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-40 (3/5) H
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-40 (3/5) H l-methyl-3-(trifluorometbyl)pyrazol-5-yl X2 G-2 J-40 (3/5) H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-40 (3/5) H
2,5-dichlorophenyl X2 G-2 J-69 (1/3) H 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-69 (1/3) H
2,5-dimethylphenyl X2 G-2 J-69 (1/3) H 2-methyl-5-(trifluorome(hyl)phenyl X2 G-2 J-69 (1/3) H
3,5-dimethylpyrazol- 1-yl X2 G-2 J-69 (1/3) H
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-69 (1/3) H
5-chloro-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-69 (1/3) H
5-bromo-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-69 (1/3) H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-69 (1/3) H
3 ,5-bis-(trifluoromethyl)pyrazoI- 1 -yl X2 G-2 J-69 (1/3) H l-methyl-3-{trifluoromethyl)pyrazol-5-yl X2 G-2 J-69 (1/3) H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-69 (1/3) H
2,5-dichlorophenyl X2 G-2 J-69 (1/4) H 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-69 (1/4) H Rl J *** (R5)v R7a
2,5-dimethylphenyl G-2 J-69 (1/4) H 2-methyl-5-(trifluoroτnethyl)phenyl X2 G-2 J-69 (1/4) H
3,5-dimethylpyrazol-l-yl X2 G-2 J-69 (1/4) H
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-69 (1/4) H
5-chloro-3 -(trifluoromethyl)pyra2θl- 1 -yl X2 G-2 J-69 (1/4) H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-69 (1/4) H
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-69 (1/4) H
3,5-bis-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-69 (1/4) H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-69 (1/4) H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-69 (1/4) H
2,5-dichlorophenyl X2 G-2 J-Il (3/5) 2-Me 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-Il (3/5) 2-Me
2,5-dimethylphenyl X2 G-2 J-Il (3/5) 2-Me 2-methyl-5-(trifluoromethyl)ρhenyl X2 G-2 J-Il (3/5) 2-Me
• 3,5-dimethylpyrazol-l-yl X2 G-2 J-I 1 (3/5) 2-Me
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-Il (3/5) 2-Me
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-Il (3/5) 2-Me
5 -bromo-3 -(tri fluoromethyl)pyrazol- 1 -yl X2 G-2 J-Il (3/5) 2-Me
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-Il (3/5) 2-Me
3,5-bis-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-Il (3/5) 2-Me
1 -methyl-3 -(trifluoromethyl)pyrazol-5-yl X2 G-2 J-Il (3/5) 2-Me l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-Il (3/5) 2-Me
2,5-dicWorophenyl X2 G-2 J-Il (3/5) 3-Me 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-Il (3/5) 3-Me
2,5-dimethylphenyl X2 G-2 J-11(3/5) 3-Me 2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-Il (3/5) 3-Me
3 ,5-dimethylρyrazol- 1 -yl X2 G-2 J-11 (3/5) 3-Me
5-methyl-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-Il (3/5) 3-Me
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-H (3/5) 3-Me
5-bromo-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-11(3/5) 3-Me
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-11(3/5) 3-Me
3 ,5-bis-(trifIuoromethyl)pyrazol-l -yl X2 G-2 J-Il (3/5) 3-Me l-methyl-3-(trifluoromethyl)pyrazoI-5-yl X2 G-2 J-II (3/5) 3-Me Rl X G** (RJ)v R'a l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-Il (3/5) - 3-Me
2,5-dichlorophenyl X2 G-2 J-Il (3/5) - 4-Me 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-Il (3/5) - 4-Me
2,5-dimethyIphenyl X2 G-2 J-Il (3/5) - 4-Me 2-methyl-5-(trifluorotnethyl)phenyl X2 G-2 J-Il (3/5) - 4-Me
3 ,5-dimethylpyrazol- 1 -yl X2 G-2 J-Il (3/5) - 4-Me
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-I 1 (3/5) - 4-Me
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-Il (3/5) - 4-Me
5-bromo-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-Il (3/5) - 4-Me
5-ethyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-Il (3/5) - 4-Me
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-Il (3/5) - 4-Me l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-Il (3/5) - 4-Me l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-Il (3/5) - 4-Me
2,5-dichlorophenyl X2 G-2 J-Il (3/5) - 2-Cl 2-chloro-5 -(trifluoromethyl)phenyl X2 G-2 J-Il (3/5) - 2-Cl
2,5-dimethylphenyl X2 G-2 J-Il (3/5) - 2-Cl 2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-Il (3/5) - 2-Cl
3,5-dimethylpyrazol-l -yl X2 G-2 J-Il (3/5) - 2-Cl
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-Il (3/5) - 2-Cl
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-Il (3/5) - 2-Cl
5 -bromo-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-11(3/5) - 2-Cl
5-ethyl-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-Il (3/5) - 2-Cl
3,5-bis-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-Il (3/5) - 2-Cl l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-Il (3/5) - 2-Cl l-methyl-4-(trifluoromethyl)iii)idazol-2-yl X2 G-2 J-Il (3/5) - 2-Cl
2 ,5 -dichloropheny 1 X2 G-2 J-Il (3/5) - 4-Cl 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-Il (3/5) - 4-Cl
2,5-dimethylphenyl X2- G-2 J-Il (3/5) - 4-Cl 2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-Il (3/5) - 4-Cl
3,5-dimethylpyrazol-l -yl X2 G-2 J-Il (3/5) - 4-Cl 5-methyl-3-(trifluorornethyl)pyrazol-l-yl X2 G-2 J-Il (3/5) - 4-Cl 5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-11 (3/5) - 4-Cl 5-bromo-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-11(3/5) 4-Cl
Figure imgf000184_0001
5-ethyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-Il (3/5) - 4-Cl
3 ,5-bis-(trifIuoromethyl)pyrazol- 1 -yl X2 G-2 J-Il (3/5) - 4-Cl
1 -methyl-3 -(trifluoromethyl)pyrazol-5-yl X2 G-2 J-11 (3/5) - 4-Cl l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-Il (3/5) - 4-Cl
2,5-dichlorophenyl X2 G-2 J-29 (3/5) - 2-Me 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-29 (3/5) - 2-Me
2,5-dimethylphenyl X2 G-2 J-29 (3/5) - 2-Me 2-methyl-5-(trifluoroπiethyl)phenyl X2 G-2 J-29 (3/5) - 2-Me
3,5-dimethylpyrazol-l-yl X2 G-2 J-29 (3/5) - 2-Me
5-methyl-3-(trifluoromethyl)pyra2ol-l-yl X2 G-2 J-29 (3/5) - 2-Me
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-29 (3/5) - 2-Me
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-29 (3/5) - 2-Me
5-ethy]-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J729 (3/5) - 2-Me
3 , 5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-29 (3/5) - 2-Me
1 -methyl-3 -(trifluoromethyl)pyrazol-5-yl X2 G-2 J-29 (3/5) - 2-Me l-methyl-4-(trifluoromethyI)imidazol-2-yl X2 G-2 J-29 (3/5) - 2-Me
2,5-dichlorophenyl X2 G-2 J-29 (3/5) - 3-Me 2-chloro-5 -(trifluoromethyl)phenyl X2 G-2 J-29 (3/5) - 3-Me
2,5-dimethylphenyl X2 G-2 J-29 (3/5) - 3-Me. 2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-29 (3/5) - 3-Me
3,5-dimethylpyrazol-l-yl X2 G-2 J-29 (3/5) - 3-Me
5-methyl-3-(trifϊuoromethyl)pyrazol-l-yl X2 G-2 J-29 (3/5) - 3-Me
5-chloro-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-29 (3/5) - 3-Me
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-29 (3/5) - 3-Me
5 -ethy l-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-29 (3/5) - 3-Me
3,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J:29 (3/5) - 3-Me l-methyl-3-(trifluoromethyl)pyra2ol-5-yl X2 G-2 J-29 (3/5) - 3-Me l-methyl-4-(trifluoromethyl)iniidazol-2-yl X2 G-2 J-29 (3/5) - 3-Me
2,5-dichlorophenyl X2 G-2 J-29 (3/5) - 4-Me 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-29 (3/5) - 4-Me
2,5-dimethylphenyl X2 G-2 J-29 (3/5) - 4-Me 2-methyl-5-(trifluoromethyl)pheπyl X2 G-2 J-29 (3/5) - 4-Me' 3,5-dimethylpyrazol-l-yl . X2 G-2 J-29 (3/5) _ 4-Me Rl X G** J*** (R5)v R7a
5-methyl-3-(trifluoromethyl)pyrazol- 1 -y] X2 G-2 J-29 (3/5) - 4-Me
5-chloro-3 -(trifluόromethytypyrazol- 1 -yl X2 G-2 J-29 (3/5) - 4-Me
5 -bromo-3 -(trifluoromethyl)pyrazol - 1 -y 1 X2 G-2 J-29 (3/5) - 4-Me
5-ethyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-29 (3/5) - 4-Me
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-29 (3/5) - 4-Me l-methyl-3-(trifluoromethyl)pyrazoI-5-yl X2 G-2 J-29 (3/5) - 4-Me l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-29 (3/5) - 4-Me
2,5-dichIoroρhenyl X2 G-2 J-29 (3/5) - 2-Cl 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-29 (3/5) - 2-Cl
2,5-dimethylphenyl X2 G-2 J-29 (3/5) - 2-Cl 2-methyl-5 -(trifluoromethyl)phenyl X2 G-2 J-29 (3/5) - 2-Cl
3,5-dimethyIpyrazol- 1 -yl X2 G-2 J-29 (3/5) - 2-Cl
- 5 -methyl-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-29 (3/5) - 2-Cl
5-chloro-3-(trifluoroπiethyl)pyrazol-l-yl X2 G-2 J-29 (3/5) - 2-Cl
5-bromo-3-(trifluoroiπethyl)pyrazol-l-yl X2 G-2 J-29(3/5) - 2-Cl
5-ethyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-29 (3/5) - 2-Cl
3 ,5-bis-(trifluoromethyl)ρyrazol- 1 -yl X2 G-2 J-29 (3/5) - 2-Cl
1 -methyl-3 -(trifluoromethyl)pyrazol-5-yl X2 G-2 J-29 (3/5) - 2-Cl l-methyI-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-29 (3/5) - 2-Cl
2,5-dichlorophenyl X2 G-2 J-29 (3/5) - 4-Cl 2-chloro-5-(trifluoromethyl)phenyI X2 G-2 J-29 (3/5) - 4-Cl
2,5-dimethylphenyl X2 G-2 J-29 (3/5) - 4-Cl 2-τnethyl-5-(trifluoromethyl)phenyl X2 ' G-2 J-29 (3/5) - 4-Cl
3 ,5-dimethylpyrazol- 1 -yl X2 G-2 J-29 (3/5) - 4-Cl
5-methyl-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-29 (3/5) - 4-Cl
5-chloro-3-(tri£luoromethyl)pyrazol-l-yl X2 G-2 J-29 (3/5) - 4-Cl
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-29 (3/5) - 4-Cl
5-e£hyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-29 (3/5) - 4-Cl
3 ,5-bis-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-29 (3/5) - 4-Cl l-rnethyI-3-(trifluoroinethyl)pyrazol-5-yl X2 G-2 J-29 (3/5) - 4-Cl l-methyl-4-(trifluoromethyl)i:rnidazol-2-yl X2 G-2 J-29 (3/5) - 4-Cl
2,5-dichlorophenyl X2 G-2 J-29 (3/5) 5-Me H 2-chloro-5 -(trifluoromethyl)phenyl X2 G-2 J-29 (3/5) 5-Me H Rl X (R5)v R7a
2,5-dimethylphenyl X2 G-2 J-29 (3/5) 5-Me H 2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-29 (3/5) 5-Me H
3,5-dimethylpyrazol-l-yl X2 G-2 J-29 (3/5) 5-Me H
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-29 (3/5) 5-Me H
5-chloro-3-(trifluoromethyl)pyr£izol- 1 -yl χ2 G-2 J-29 (3/5) 5-Me H
5-bromo-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-29 (3/5) 5-Me H
5-ethyl-3-(trifluoromethyI)pyτazol-l-yl X2 G-2 J-29 (3/5) 5-Me H
3 ,5-bis-(trifluoromethyI)pyra2ol- 1 -yl X2 G-2 J-29 (3/5) 5-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-29 (3/5) 5-Me H l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-29 (3/5) 5-Me H
2,5-dichlorophenyl X2 G-2 J-29 (3/5) 4-Me H 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-29 (3/5) 4-Me H
2,5-dimethylphenyl X2 G-2 J-29 (3/5) 4-Me H 2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-29 (3/5) 4-Me H
3,5-dimethylpyrazol-l-yl X2 G-2 J-29 (3/5) 4-Me H
5-methyl-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-29 (3/5) • 4-Me H
5-chJoro-3-(trifluoromethyl)ρyrazol- 1 -yl X2 G-2 J-29 (3/5) 4-Me H
5-bromo-3 -(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-29 (3/5) 4-Me H
5 -ethyl-3-{txifluoromethyl)pyrazol- 1 -yl X2 G-2 J-29 (3/5) 4-Me H
3,5-bis-(trifluoromethyl)pyrazol- 1-yl X2 G-2 J-29 (3/5) 4-Me H l-methyl-3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-29 (3/5) 4-Me H l-methyl-4-(tτifluoromethyl)imidazol-2-yl X2 G-2 J-29 (3/5) 4-Me H
2,5-dichlorophenyl X2 G-2 J-29 (3/5) 4,4-di-Me H 2-chloro-5-(trifluoromethyl)phenyl X2 G-2 J-29 (3/5) 4,4-di-Me H
2,5-dimethylphenyl X2 G-2 J-29 (3/5) 4,4-di-Me H 2-methyl-5-(trifluoromethyl)phenyl X2 G-2 J-29 (3/5) 4,4-di-Me H
3,5-dimethylpyrazol- 1 -yl X2 G-2 J-29 (3/5) 4,4-di-Me H
5-methyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-29 (3/5) 4,4-di-Me H
5-chloro-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 ' J-29 (3/5) 4,4-di-Me H
5-bromo-3-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-29 (3/5) 4,4-di-Me H
5-ethyl-3-(trifluoromethyl)pyrazol- 1 -yl X2 G-2 J-29 (3/5) 4,4-di-Me H
3,5-bis-(trifluoromethyl)pyrazol-l-yl X2 G-2 J-29 (3/5) 4,4-di-Me H
1 -methyl -3-(trifluoromethyl)pyrazol-5-yl X2 G-2 J-29 (3/5) 4,4-di-Me H Rl X j ♦** (R5)v R7a l-methyl-4-(trifluoromethyl)imidazol-2-yl X2 G-2 J-29 (3/5) 4,4-di-Me H
* The definitions of G and J in the compounds of this table are as defined in Exhibits 2 and 3 in the above Embodiments. The (R5)y column refers the substituents (R5)x shown on J groups in Exhibit 3 other than the phenyl ring substituted by R^a shown in the structure heading this table. R'a may be selected from H (to indicate no substitution on the phenyl ring) as well as the substituents defined for R' . A dash "— " in the (R5)y column indicates no substitution on J besides the phenyl ring substituted by R?a. •* R3a substituent in G is H. *** Numbers in parentheses refer to the attachment points on ring J.
The first number is the attachment point for ring G; the second number is the attachment point for the phenyl ring.
TABLE 5 -
Figure imgf000187_0001
wherein J is one of J-29- 1 through J-29-57 (as depicted in Exhibit A above). R1 is 2,5-dichlorophenyl; X is X1; G* is G-I.
J-29-1 J-29-11 J-29-21 J-29-31 J-29-41 J-29-51 J-29-2 J-29-12 J-29-22 J-29-32 J-29-42 J-29-52 J-29-3 J-29- 13 J-29-23 J-29-33 J-29-43 J-29-53 J-29-4 J-29-14 J-29-24 J-29-34 J-29-44 J-29-54 J-29-5 J-29-15 J-29-25 J-29-35 J-29-45 J-29-55 J-29-6 J-29-16 J-29-26 J-29-36 J-29-46 J-29-56 J-29-7 J-29-17 J-29-27 J-29-37 J-29-47 J-29-57 J-29-8 J-29- 18 J-29-28 J-29-38 J-29-48 J-29-9 J-29-19 J-29-29 J-29-39 J-29-49 J-29- 10 J-29-20
Figure imgf000187_0005
J-29-30
Figure imgf000187_0003
J-29-40
Figure imgf000187_0004
J-29-50
R1 is 2,5-dichlorophenyl; X is X2; G* is G-I.
J-29-1 J-29-2 J-29-3 J-29-4 J-29-5 J-29-6 J-29-7 J-29-16 J-29-25 J-29-34 J-29-43 J-29-52 J-29-8 J-29-17 J-29-26 J-29-35 J-29-44 J-29-53 J-29-9 J-29-18 J-29-27 J-29-36 J-29-45 J-29-54 J-29-10 J-29-19 J-29-28 J-29-37 J-29-46 J-29-55 J-29-11 J-29-20 J-29-29 J-29-38 J-29-47 J-29-56 J-29-12 J-29-21 J-29-30 J-29-39 J-29-48 J-29-57 J-29-13 J-29-22 J-29-31 J-29-40 J-29-49 J-29-14 J-29-23 J-29-32 J-29-41 J-29-50 J-29-15
Figure imgf000188_0005
J-29-24
Figure imgf000188_0004
J-29-33
Figure imgf000188_0001
J-29-42
Figure imgf000188_0002
J-29-51
Figure imgf000188_0003
R1 is 2,5-dichloroρhenyl; X is X1; * is G-2.
J-29-1 J-29-11 J-29-21 J-29-31 J-29-41 J-29-51 J-29-2 J-29-12 J-29-22 J-29-32 J-29-42 J-29-52 J-29-3 J-29-13 J-29-23 J-29-33 J-29-43 J-29-53 J-29-4 J-29-14 J-29-24 J-29-34 J-29-44 J-29-54 J-29-5 J-29-15 J-29-25 J-29-35 J-29-45 J-29-55 J-29-6 J-29-16 J-29-26 J-29-36 J-29-46 J-29-56 J-29-7 J-29-17 J-29-27 J-29-37 J-29-47 J-29-57 J-29-8 J-29-18 J-29-28 J-29-38 J-29-48 J-29-9 J-29-19 J-29-29 J-29-39 J-29-49 J-29-10
Figure imgf000188_0010
J-29-20 J-29-30
Figure imgf000188_0008
J-29-40
Figure imgf000188_0006
J-29-50
Figure imgf000188_0007
R1 is 2,5-dicMorophenyl; X is X2; * is G-2.
J-29-1 J-29-11 J-29-21 J-29-31 J-29-41 J-29-51 J-29-2 J-29-12 J-29-22 J-29-32 J-29-42 J-29-52 J-29-3 J-29-13 J-29-23 J-29-33 J-29-43 J-29-53 J-29-4 J-29-14 J-29-24 J-29-34 J-29-44 J-29-54 J-29-5 J-29-15 J-29-25 J-29-35 J-29-45 J-29-55 J-29-6 J-29-16 J-29-26 J-29-36 J-29-46 J-29-56 J-29-7 J-29-17 J-29-27 J-29-37 J-29-47 J-29-57 J-29-8 J-29-18 J-29-28 J-29-38 J-29-48 J-29-9 J-29-19 J-29-29 J-29-39 J-29-49 J-29-10 J-29-20 J-29-30 J-29-40 J-29-50
Figure imgf000188_0014
Figure imgf000188_0009
Figure imgf000188_0011
Figure imgf000188_0012
Figure imgf000188_0013
R1 is 2-chloro-5-(trifluoromethyl)phenyl; X is X1; G* is G-I.
J-29-1 J-29-11 J-29-21 J-29-31 J-29-41 J-29-51
J-29-2 J-29-12 J-29-22 J-29-32 J-29-42 J-29-52
J-29-3 J-29-13 J-29-23 J-29-33 J-29-43 J-29-53
J-29-4 J-29-14 J-29-24 J-29-34 J-29-44 J-29-54
J-29-5 J-29-15 J-29-25 J-29-35 J-29-45 J-29-55
J-29-6 J-29-16 J-29-26 J-29-36 J-29-46 J-29-56
J-29-7 J-29-17 J-29-27 J-29-37 J-29-47 J-29-57
J-29-8 J-29-18 J-29-28 .' J-29-38 J-29-48
J-29-9 J-29-19 J-29-29 J-29-39 J-29-49
J-29-10 J-29-20
Figure imgf000189_0004
J-29-30
Figure imgf000189_0001
J-29-40
Figure imgf000189_0002
J-29-50
Figure imgf000189_0003
R1 is 2-cMoro-5-(trifluoromethyl)phenyl; X is X2; G* i G-I.
J-29-1 J-29-11 J-29-21 J-29-31 J-29-41 J-29-51 J-29-2 J-29-12 J-29-22 J-29-32 J-29-42 J-29-52 J-29-3 J-29-13 J-29-23 J-29-33 J-29-43 J-29-53 J-29-4 J-29-14 J-29-24 J-29-34 J-29-44 J-29-54 J-29-5 J-29-15 J-29-25 J-29-35 J-29-45 J-29-55 J-29-6 J-29-16 J-29-26 J-29-36 J-29-46 J-29-56 J-29-7 J-29-17 J-29-27 J-29-37 J-29-47 J-29-57 J-29-8 J-29-18 J-29-28 J-29-38 J-29-48 J-29-9 J-29-19 J-29-29 J-29-39 J-29-49 J-29-10
Figure imgf000189_0008
J-29-20
Figure imgf000189_0009
J-29-30
Figure imgf000189_0005
J-29-40
Figure imgf000189_0007
J-29-50
Figure imgf000189_0006
R1 is 2-chloro-
J-29-1 J-29-2 J-29-3 J-29-4 J-29-5 J-29-6 J-29-7 J-29-8 J-29-9
Figure imgf000189_0010
J-29-55 I J-29-56 | J-29-57
R1 is 2-chloro-5-(trifluoromethyl)phenyl; X is X2; G* is G-2.
J-29-1 J-29-11 J-29-21 J-29-31 J-29-41 J-29-51 J-29-2 J-29-12 J-29-22 J-29-32 J-29-42 J-29-52 J-29-3 J-29-13 J-29-23 J-29-33 J-29-43 J-29-53 J-29-4 J-29-14 J-29-24 J-29-34 J-29-44 J-29-54 J-29-5 J-29-15 J-29-25 J-29-35 J-29-45 J-29-55 J-29-6 J-29-16 J-29-26 J-29-36 J-29-46 J-29-56 J-29-7 J-29-17 J-29-27 J-29-37 J-29-47 J-29-57 J-29-8 J-29-18 J-29-28 J-29-38 J-29-48 J-29-9 J-29-19 J-29-29 J-29-39 J-29-49 J-29-10
Figure imgf000190_0005
J-29-20
Figure imgf000190_0003
J-29-30
Figure imgf000190_0004
J-29-40
Figure imgf000190_0001
J-29-50
Figure imgf000190_0002
R1 is 2,5-dim
J-29-1 J-29-31 J-29-41 J-29-51 J-29-2 J-29-32 J-29-42 J-29-52 J-29-3 J-29-33 J-29-43 J-29-53 J-29-4 J-29-34 J-29-44 J-29-54 J-29-5 J-29-35 J-29-45 J-29-55 J-29-6 J-29-36 J-29-46 J-29-56 J-29-7 J-29-37 J-29-47 J-29-57 J-29-8 J-29-38 J-29-48 J-29-9 J-29-39 J-29-49 J-29-10
Figure imgf000190_0006
J-29-40
Figure imgf000190_0008
J-29-50
Figure imgf000190_0007
R1 is 2,5-dimethylphenyl; X is X2; G* is G-I .
J-29-1 J-29-9 J-29-17 J-29-25 J-29-33 J-29-41 J-29-2 J-29-10 J-29-18 J-29-26 J-29-34 J-29-42 J-29-3 J-29-11 J-29-19 J-29-27 J-29-35 J-29-43 J-29-4 J-29-12 J-29-20 J-29-28 J-29-36 J-29-44 J-29-5 J-29-13 J-29-21 J-29-29 J-29-37 J-29-45 J-29-6 J-29-14 J-29-22 J-29-30 J-29-38 J-29-46 J-29-7 J-29-15 J-29-23 J-29-31 J-29-39 J-29-47 J-29-8 J-29-16 J-29-24 J-29-32 J-29-40 J-29-48
Figure imgf000190_0012
Figure imgf000190_0013
Figure imgf000190_0010
Figure imgf000190_0011
Figure imgf000190_0009
J-29-49 J-29-51 J-29-53 J-29-55 J-29-57 J-29-50 J-29-52 J-29-54 J-29-56
R1 is 2,5-dimethylphenyl; X is X1; G* is G-2.
J-29-1 J-29-11 J-29-21 J-29-31 J-29-41 J-29-51 J-29-2 J-29-12 J-29-22 J-29-32 J-29-42 J-29-52 J-29-3 J-29-13 J-29-23 J-29-33 J-29-43 J-29-53 J-29-4 J-29-14 J-29-24 J-29-34 J-29-44 J-29-54 J-29-5 J-29-15 J-29-25 J-29-35 J-29-45 J-29-55 J-29-6 J-29-16 J-29-26 J-29-36 J-29-46 J-29-56 J-29-7 J-29-17 J-29-27 J-29-37 J-29-47 J-29-57 J-29-8 J-29-18 J-29-28 J-29-38 J-29-48 J-29-9 J-29-19 J-29-29 J-29-39 J-29-49 J-29-10 J-29-20 J-29-30
Figure imgf000191_0003
J-29-40
Figure imgf000191_0002
J-29-50
Figure imgf000191_0001
R1 is 2,5-di
J-29-1 J-29-31 J-29-41 J-29-51 J-29-2 J-29-32 J-29-42 J-29-52 J-29-3 J-29-33 J-29-43 J-29-53 J-29-4 J-29-34 J-29-44 J-29-54 J-29-5 J-29-35 J-29-45 J-29-55 J-29-6 J-29-36 J-29-46 J-29-56 J-29-7 J-29-37 J-29-47 J-29-57 J-29-8 J-29-38 J-29-48 J-29-9 J-29-39 J-29-49 J-29-10 J-29-40 J-29-50
Figure imgf000191_0004
Figure imgf000191_0006
Figure imgf000191_0005
R1 is 2-methyl-5-(trifluoromethyl)phenyl; X is X1; G* is G-I.
J-29-1 J-29-5 J-29-9 J-29-13 J-29-17 J-29-21 J-29-2 J-29-6 J-29-10 J-29-14 J-29-18 J-29-22 J-29-3 J-29-7 J-29-11 J-29-15 J-29-19 J-29-23 J-29-4 ■J-29-8 J-29-12 J-29-16 J-29-20 J-29-24
Figure imgf000191_0007
J-29-25 J-29-31 J-29-37 J-29-43 J-29-49 J-29-55 J-29-26 J-29-32 J-29-38 J-29-44 J-29-50 J-29-56 J-29-27 J-29-33 J-29-39 J-29-45 J-29-51 J-29-57 J-29-28 J-29-34 J-29-40 J-29-46 J-29-52 J-29-29 J-29-35 J-29-41 J-29-47 J-29-53 J-29-30
Figure imgf000192_0005
J-29-36
Figure imgf000192_0003
J-29-42 J-29-48
Figure imgf000192_0001
J-29-54
Figure imgf000192_0002
R1 is 2-methyl-5-(trifluoromethyl)phenyl; X is X2; G* G-I.
J-29-11 J-29-21 J-29-31 J-29-41 J-29-51 J-29-12 J-29-22 J-29-32 J-29-42 J-29-52 J-29-13 J-29-23 J-29-33 J-29-43 J-29-53 J-29-14 J-29-24 J-29-34 J-29-44 J-29-54 J-29-15 J-29-25 J-29-35 J-29-45 J-29-55 J-29-16 J-29-26 J-29-36 J-29-46 J-29-56 J-29-17 J-29-27 J-29-37 J-29-47 J-29-57 J-29-18 J-29-28 J-29-38 J-29-48 J-29-19 J-29-29 J-29-39 J-29-49
Figure imgf000192_0009
J-29-20
Figure imgf000192_0008
J-29-30
Figure imgf000192_0004
J-29-40
Figure imgf000192_0006
J-29-50
Figure imgf000192_0007
R1 is 2-methyl-5-(trifluoromethyl)phenyl; X is X1; G* s G-2.
J-29-1 J-29-11 J-29-21 J-29-31 J-29-41 J-29-51 J-29-2 J-29-12 J-29-22 J-29-32 J-29-42 J-29-52 J-29-3 J-29-13 J-29-23 J-29-33 J-29-43 J-29-53 J-29-4 J-29-14 J-29-24 J-29-34 J-29-44 J-29-54 J-29-5 J-29-15 J-29-25 J-29-35 J-29-45 J-29-55 J-29-6 J-29-16 J-29-26 J-29-36 J-29-46 J-29-56 J-29-7 J-29-17 J-29-27 J-29-37 J-29-47 J-29-57 J-29-8 J-29-18 J-29-28 J-29-38 J-29-48 J-29-9 J-29-19 J-29-29 J-29-39 J-29-49 J-29-10
Figure imgf000192_0013
J-29-20
Figure imgf000192_0014
J-29-30
Figure imgf000192_0012
J-29-40
Figure imgf000192_0010
J-29-50
Figure imgf000192_0011
J-29-51
J-29-52
J-29-53
J-29-54
J-29-55
J-29-56
J-29-57
Figure imgf000193_0001
R1 is 3,5-dimethylpyrazol-l-yl; X X1; G* is G-I.
J-29-1 J-29-11 J-29-21 J-29-31 J-29-41 J-29-51 J-29-2 J-29-12 J-29-22 J-29-32 J-29-42 J-29-52 J-29-3 J-29-13 J-29-23 J-29-33 J-29-43 J-29-53 J-29-4 J-29-14 J-29-24 J-29-34 J-29-44 J-29-54 J-29-5 J-29-15 J-29-25 J-29-35 J-29-45 J-29-55 J-29-6 J-29-16 J-29-26 J-29-36 J-29-46 J-29-56 J-29-7 J-29-17 J-29-27 J-29-37 J-29-47 J-29-57 J-29-8 J-29-18 J-29-28 J-29-38 J-29-48 J-29-9 J-29-19 J-29-29 J-29-39 J-29-49 J-29-10
Figure imgf000193_0006
J-29-20
Figure imgf000193_0002
J-29-30
Figure imgf000193_0005
J-29-40
Figure imgf000193_0004
J-29-50
Figure imgf000193_0003
R1 is 3,5-dimethylpyrazol-l-yl; X X2; G* is G-I
J-29-1 J-29-10 J-29-19 J-29-28 J-29-37 J-29-46 J-29-2 J-29-11 J-29-20 J-29-29 J-29-38 J-29-47 J-29-3 J-29-12 J-29-21 J-29-30 J-29-39 J-29-48 J-29-4 J-29-13 J-29-22 J-29-31 J-29-40 J-29-49 J-29-5 J-29-14 J-29-23 J-29-32 J-29-41 J-29-50 J-29-6 J-29-15 J-29-24 J-29-33 J-29-42 J-29-51 J-29-7 J-29-16 J-29-25 J-29-34 J-29-43 J-29-52 J-29-8 J-29-17 J-29-26 J-29-35 J-29-44 J-29-53 J-29-9 J-29-18 J-29-27 J-29-36 J-29-45 J-29-54
Figure imgf000193_0010
Figure imgf000193_0007
Figure imgf000193_0009
Figure imgf000193_0008
J-29-55 J-29-56 J-29-57
R1 is 3,5-dime lpyrazol-l-yl; X X1; G* is G-2.
J-29-1 J-29-11 J-29-21 J-29-31 J-29-41 J-29-51 J-29-2 J-29-12 J-29-22 J-29-32 J-29-42 J-29-52 J-29-3 J-29-13 J-29-23 J-29-33 J-29-43 J-29-53 J-29-4 J-29-14 J-29-24 J-29-34 J-29-44 J-29-54 J-29-5 J-29-15 J-29-25 J-29-35 J-29-45 J-29-55 J-29-6 J-29-16 J-29-26 J-29-36 J-29-46 J-29-56 J-29-7 J-29-17 J-29-27 J-29-37 J-29-47 J-29-57 J-29-8 J-29-18 J-29-28 J-29-38 J-29-48 J-29-9 J-29-19 J-29-29 J-29-39 J-29-49 J-29-10 J-29-20 J-29-30
Figure imgf000194_0001
J-29-40
Figure imgf000194_0002
J-29-50
Figure imgf000194_0003
R1 is 3,5-di ylpyrazol-l-yl; X X2; G* is G-2.
J-29-1 J-29-11 J-29-21 J-29-31 J-29-41 J-29-51 J-29-2 J-29-12 J-29-22 J-29-32 J-29-42 J-29-52 J-29-3 J-29-13 J-29-23 J-29-33 J-29-43 J-29-53 J-29-4 J-29-14 J-29-24 J-29-34 J-29-44 J-29-54 J-29-5 J-29-15 J-29-25 J-29-35 J-29-45 J-29-55 J-29-6 J-29-16 J-29-26 J-29-36 J-29-46 J-29-56 J-29-7 J-29-17 J-29-27 J-29-37 J-29-47 J-29-57 J-29-8 J-29-18 J-29-28 J-29-38 J-29-48 J-29-9 J-29-19 J-29-29 J-29-39 J-29-49 J-29-10
Figure imgf000194_0004
J-29-20
Figure imgf000194_0005
J-29-30
Figure imgf000194_0008
J-29-40
Figure imgf000194_0007
J-29-50
Figure imgf000194_0006
R1 is 3,5-dichloropyrazol-l-yI; X i X1; G* is G-I.
J-29-1 J-29-8 J-29-22 J-29-29 J-29-36 J-29-2 J-29-9 J-29-23 J-29-30 J-29-37 J-29-3 J-29-10 J-29-24 J-29-31 J-29-38 J-29-4 J-29-11 J-29-25 J-29-32 J-29-39 J-29-5 J-29-12 J-29-26 J-29-33 J-29-40 J-29-6 J-29-13 J-29-27 J-29-34 J-29-41 J-29-7 J-29-14
Figure imgf000194_0009
Figure imgf000194_0011
J-29-28 J-29-35
Figure imgf000194_0010
J-29-42 J-29-43 J-29-46 J-29-49 J-29-52 J-29-55 J-29-44 J-29-47 J-29-50 J-29-53 J-29-56 J-29-45 J-29-48 J-29-51 J-29-54 J-29-57
R1 is 3,5-d is G-I.
J-29-1 J-29-31 J-29-41 J-29-51 J-29-2 J-29-32 J-29-42 J-29-52 J-29-3 • J-29-33 J-29-43 J-29-53 J-29-4 J-29-34 J-29-44 J-29-54 J-29-5 J-29-35 J-29-45 J-29-55 J-29-6 J-29-36 J-29-46 J-29-56 J-29-7 J-29-37 J-29-47 J-29-57 J-29-8 J-29-38 J-29-48 J-29-9 J-29-39 J-29-49 J-29-10 J-29-40 J-29-50
Figure imgf000195_0001
Figure imgf000195_0004
Figure imgf000195_0003
Figure imgf000195_0002
R1 is 3,5-dichl
J-29-1 J-29-51 J-29-2 J-29-52 J-29-3 J-29-53 J-29-4 J-29-54 J-29-5 J-29-55 J-29-6 J-29-56 J-29-7 J-29-57 J-29-8 J-29-9 J-29-10
Figure imgf000195_0005
R1 is 3,5-dichloropyrazol-l-yl; X is X2; G* is G-2.
J-29-1 J-29-4 J-29-7 J-29-10 J-29-13 J-29-16 J-29-2 J-29-5 J-29-8 J-29-11 J-29-14 J-29-17 J-29-3 J-29-6 J-29-9 J-29-12 J-29-15 J-29-18 J-29-19 J-29-26 J-29-33 J-29-40 J-29-47 J-29-54 J-29-20 J-29-27 J-29-34 J-29-41 J-29-48 J-29-55 J-29-21 J-29-28 J-29-35. J-29-42 J-29-49 J-29-56 . J-29-22 J-29-29 J-29-36 J-29-43 J-29-50 J-29-57 J-29-23 J-29-30 J-29-37 J-29-44 J-29-51 J-29-24 J-29-31 J-29-38 J-29-45 J-29-52 J-29-25
Figure imgf000196_0005
J-29-32
Figure imgf000196_0003
J-29-39
Figure imgf000196_0004
J-29-46
Figure imgf000196_0001
J-29-53
Figure imgf000196_0002
R1 is 3,5-dib is G-I.
J-29-1 J-29-31 J-29-41 J-29-51 J-29-2 J-29-32 J-29-42 J-29-52 J-29-3 J-29-33 J-29-43 J-29-53 J-29-4 J-29-34 J-29-44 J-29-54 J-29-5 J-29-35 J-29-45 J-29-55 J-29-6 J-29-36 J-29-46 J-29-56 J-29-7 J-29-37 J-29-47 J-29-57 J-29-8 J-29-38 J-29-48 J-29-9 J-29-39 J-29-49 J-29-10
Figure imgf000196_0006
Figure imgf000196_0008
J-29-40
Figure imgf000196_0009
J-29-50
Figure imgf000196_0007
is G-I.
J-29-31 J-29-41 J-29-51 J-29-32 J-29-42 J-29-52 J-29-33 J-29-43 J-29-53 J-29-34 J-29-44 J-29-54 J-29-35 J-29-45 J-29-55 J-29-36 J-29-46 J-29-56 J-29-37 J-29-47 J-29-57 J-29-38 J-29-48 J-29-39 J-29-49 J-29-40 J-29-50
Figure imgf000196_0010
Figure imgf000196_0012
Figure imgf000196_0013
Figure imgf000196_0011
Figure imgf000197_0001
J-29-55 J-29-56 J-29-57
Figure imgf000198_0001
J
J-29-43 J-29-46 J-29-49 J-29-52 J-29-55 J-29-44 J-29-47 J-29-50 J-29-53 J-29-56 J-29-45 J-29-48 J-29-51 J-29-54 J-29-57
R1 is 5-chlo
J-29-1 J-29-51 J-29-2 J-29-52 J-29-3 J-29-53 J-29-4 J-29-54 J-29-5 J-29-55 J-29-6 J-29-56 J-29-7 J-29-57 J-29-8 J-29-9 J-29-10
R1 is 5-chl
J-29-1 J-29-51 J-29-2 J-29-52 J-29-3 J-29-53 J-29-4 J-29-54 J-29-5 J-29-55 J-29-6 J-29-56 J-29-7 J-29-57 J-29-8 J-29-9 J-29-10
Figure imgf000199_0001
R1 is S-chloro-S-CtrifluoromethyOpyrazol-l-yl; X is X1; G* is G-2
J
J-29-1 J-29-4 J-29-7 J-29-10 J-29-13 J-29-16 J-29-2 J-29-5 J-29-8 J-29-11 J-29-14 J-29-17 J-29-3 J-29-6 J-29-9 J-29-12 J-29-15 J-29-18 J-29-19 J-29-26 J-29-33 J-29-40 J-29-47 J-29-54 J-29-20 J-29-27 J-29-34 J-29-41 J-29-48 J-29-55 J-29-21 J-29-28 J-29-35 J-29-42 J-29-49 J-29-56 J-29-22 J-29-29 J-29-36 J-29-43 J-29-50 J-29-57 J-29-23 J-29-30 J-29-37 J-29-44 J-29-51 J-29-24 J-29-31 J-29-38 J-29-45 J-29-52 J-29-25
Figure imgf000200_0003
J-29-32 J-29-39 J-29-46
Figure imgf000200_0002
J-29-53
Figure imgf000200_0001
R1 is 5-chloro-3-(trifluoromethyl)pyrazol-l-yl; X is X2; G* is G-2.
J-29-l J-29-l 1 J-29-21 J-29-31 J-29-41 J-29-51 J-29-2 J-29-12 J-29-22 J-29-32 J-29-42 J-29-52 J-29-3 J-29-l 3 J-29-23 J-29-33 J-29-43 J-29-53 J-29-4 J-29-14 J-29-24 J-29-34 J-29-44 J-29-54 J-29-5 J-29-15 J-29-25 J-29-35 J-29-45 J-29-55 J-29-6 J-29-l 6 J-29-26 J-29-36 J-29-46 J-29-56 J-29-7 J-29-l 7 J-29-27 J-29-37 J-29-47 J-29-57 J-29-8 J-29-l 8 J-29-28 J-29-38 J-29-48 J-29-9 J-29-19 J-29-29 J-29-39 J-29-49 J-29-10 J-29-20 J-29-30
Figure imgf000200_0004
J-29-40
Figure imgf000200_0005
J-29-50
Figure imgf000200_0006
R1 is 5-bromo -(trifluqromethyl)pyrazol-l-yl; X is X1 ; G* is G-I.
J-29-l J-29-l 1 J-29-21 J-29-31 J-29-41 J-29-51
J-29-2 J-29-12 J-29-22 J-29-32 J-29-42 J-29-52
J-29-3 J-29-13 J-29-23 J-29-33 J-29-43 J-29-53
J-29-4 J-29-14 J-29-24 J-29-34 J-29-44 J-29-54
J-29-5 J-29-15 J-29-25 J-29-35 J-29-45 J-29-55
J-29-6 J-29-16 J-29-26 J-29-36 J-29-46 J-29-56
J-29-7 J-29-l 7 J-29-27 J-29-37 J-29-47 J-29-57
J-29-8 J-29-l 8 J-29-28 J-29-38 J-29-48
J-29-9 J-29-19 J-29-29 J-29-39 J-29-49
J-29-10
Figure imgf000200_0007
J-29-20 J-29-30 J-29-40
Figure imgf000200_0008
J-29-50
Figure imgf000200_0009
R1 is 5-bromo-3-(trifluoroinethyl)pyrazol-l-yl; X is X2; G* is G-I .
J-29-1 J-29-11 J-29-21 J-29-31 J-29-41 J-29-51 J-29-2 J-29-12 J-29-22 J-29-32 J-29-42 J-29-52 J-29-3 J-29-13 J-29-23 J-29-33 J-29-43 J-29-53 J-29-4 J-29-14 J-29-24 J-29-34 J-29-44 J-29-54 J-29-5 J-29-15 J-29-25 J-29-35 J-29-45 J-29-55 J-29-6 J-29-16 J-29-26 J-29-36 J-29-46 J-29-56 J-29-7 J-29-17 J-29-27 J-29-37 J-29-47 J-29-57 J-29-8 J-29-18 J-29-28 J-29-38 J-29-48 J-29-9 J-29-19 J-29-29 J-29-39 J-29-49 J-29-10
Figure imgf000201_0003
J-29-20 J-29-30 J-29-40
Figure imgf000201_0002
J-29-50
Figure imgf000201_0001
J-29-41 J-29-51
J-29-42 J-29-52
J-29-43 J-29-53
J-29-44 J-29-54
J-29-45 J-29-55
J-29-46 J-29-56
J-29-47 J-29-57
J-29-48
J-29-49
J-29-50
Figure imgf000201_0004
Figure imgf000201_0005
R1 is 5-bromo- -(trifluoromethyl)pyrazol-l-yl; X is X2; G* is G-2.
J-29-1 J-29-10 J-29-19 J-29-28 J-29-37 J-29-46 J-29-2 J-29-11 J-29-20 J-29-29 J-29-38 J-29-47 J-29-3 J-29-12 J-29-21 J-29-30 J-29-39 J-29-48 J-29-4 J-29-13 J-29-22 J-29-31 J-29-40 J-29-49 J-29-5 J-29-14 J-29-23 J-29-32 J-29-41 ■ J-29-50 J-29-6 J-29-15 J-29-24 J-29-33 J-29-42 J-29-51 J-29-7 J-29-16 J-29-25 J-29-34 J-29-43 J-29-52 J-29-8 J-29-17 J-29-26 J-29-35 J-29-44 J-29-53 J-29-9 J-29-18 J-29-27 J-29-36 J-29-45 J-29-54
Figure imgf000201_0008
Figure imgf000201_0007
Figure imgf000201_0006
J-29-55 J-29-56 J-29-57
Figure imgf000202_0003
R1 is 5-ethyl-3-(trifluoromethyl)pyrazol-l-yH X is X2; G* is G-I.
J-29-1 J-29-11 J-29-21 J-29-31 J-29-2 J-29-12 J-29-22 J-29-32 J-29-3 J-29-13 J-29-23 J-29-33 J-29-4 J-29-14 J-29-24 J-29-34 J-29-5 J-29-15 J-29-25 J-29-35 J-29-6 J-29-16 J-29-26 J-29-36 J-29-7 J-29-17 J-29-27 J-29-37 J-29-8 J-29-18 J-29-28 J-29-38 J-29-9 J-29-19 J-29-29 J-29-39 J-29-10 J-29-20 J-29-30 J-29-40
Figure imgf000202_0001
R1 is 5-ethyl-3-(trifluoromethyl)pyrazol-l-yl; X is X1; G* is G-2.
J-29-1 J-29-8 J-29-15 J-29-22 J-29-2 J-29-9 J-29-16 J-29-23 J-29-3 J-29-10 J-29-17 J-29-24 J-29-4 J-29-11 J-29-18 J-29-25 J-29-5 J-29-12 J-29-19 J-29-26 J-29-6 J-29-13 J-29-20 J-29-27 J-29-7 J-29-14 J-29-21 J-29-28
Figure imgf000202_0002
J-29-43 J-29-46 J-29-49 J-29-52 J-29-55
J-29-44 J-29-47 J-29-50 J-29-53 J-29-56
J-29-45 J-29-48 J-29-51 J-29-54 J-29-57
R1 is 5-ethyl-3- (trifluorometh>
J-29-41 J-29-51
J-29-42 J-29-52
J-29-43 J-29-53
J-29-44 J-29-54
J-29-45 J-29-55
J-29-46 J-29-56
J-29-47 J-29-57
J-29-48
J-29-49
Figure imgf000203_0002
J-29-50
Figure imgf000203_0001
R1 is 3,5-bis-(t fluoromethyl)pyra l-l-yl; X is X1; G* is G-I.
J-29-1 J-29-11 J-29-21 J-29-31 J-29-41 J-29-51
J-29-2 J-29-12 J-29-22 J-29-32 J-29-42 J-29-52
J-29-3 J-29-13 J-29-23 J-29-33 J-29-43 J-29-53
J-29-4 J-29-14 J-29-24 J-29-34 J-29-44 J-29-54
J-29-5 J-29-15 J-29-25 J-29-35 J-29-45 J-29-55
J-29-6 J-29-16 J-29-26 J-29-36 J-29-46 J-29-56
J-29-7 J-29-17 J-29-27 J-29-37 J-29-47 J-29-57
J-29-8 J-29-18 J-29-28 J-29-38 J-29-48
J-29-9 J-29-19' J-29-29 J-29-39 J-29-49
J-29-10 J-29-20
Figure imgf000203_0003
J-29-30
Figure imgf000203_0006
J-29-40
Figure imgf000203_0004
J-29-50
Figure imgf000203_0005
R1 is 3,5-bis-(trifluoromethyl)pyrazol-l-yl; X is X2; G* is G-I.
J
J-29-1 J-29-4 J-29-7 J-29-10 J-29-13 J-29-16 J-29-2 J-29-5 J-29-8 J-29-11 J-29-14 J-29-17 J-29-3 J-29-6 J-29-9 J-29-12 J-29-15 J-29-18 J-29-19 J-29-26 J-29-33 J-29-40 J-29-47 J-29-54 J-29-20 J-29-27 J-29-34 J-29-41 J-29-48 J-29-55 J-29-21 J-29-28 J-29-35 J-29-42 J-29-49 J-29-56 J-29-22 J-29-29 J-29-3S J-29-43 J-29-50 J-29-57 J-29-23 J-29-30 J-29-37 J-29-44 J-29-51 J-29-24 J-29-31 J-29-38 J-29-45 J-29-52 J-29-25
Figure imgf000204_0002
J-29-32
Figure imgf000204_0001
J-29-39 J-29-46 J-29-53
Figure imgf000204_0003
R1 is 3,5-bis-(trifluoromethyI)pyra2;ol-l-yl; X is X1; G* is G-2.
J-29-1 J-29-21 J-29-31 J-29-41 J-29-51 J-29-2 J-29-22 J-29-32 J-29-42 J-29-52 J-29-3 J-29-23 J-29-33 J-29-43 J-29-53 J-29-4 J-29-24 J-29-34 J-29-44 J-29-54 J-29-5 J-29-25 J-29-35 J-29-45 J-29-55 J-29-6 J-29-26 J-29-36 J-29-46 J-29-56 J-29-7 J-29-27 J-29-37 J-29-47 J-29-57 J-29-8 J-29-28 J-29-38 J-29-48 J-29-9 J-29-29 J-29-39 J-29-49 J-29-10
Figure imgf000204_0004
J-29-30
Figure imgf000204_0007
J-29-40
Figure imgf000204_0005
J-29-50
Figure imgf000204_0006
R1 is 3,5-bis-(trifluoromethyl)ρyrazol-l-yl; X is X2; G* is G-2.
J-29-1 J-29-51 J-29-2 J-29-52 J-29-3 J-29-53 J-29-4 J-29-54 J-29-5 J-29-55 J-29-6 J-29-56 J-29-7 J-29-57 J-29-8 J-29-9 J-29-10
Figure imgf000204_0008
Figure imgf000205_0001
J-29-55 J-29-56 J-29-57
Figure imgf000206_0004
R1 is 3-chloro- -(trifluoromethyl)pyrazol-l-yl; X is X1; G* is G-I.
J-29-1 J-29-11 J-29-21 J-29-31 J-29-41 J-29-51 J-29-2 J-29-12 J-29-22 J-29-32 J-29-42 J-29-52 J-29-3 J-29-13 J-29-23 J-29-33 J-29-43 J-29-53 J-29-4 J-29-14 J-29-24 J-29-34 j-29-44 J-29-54 J-29-5 J-29-15 J-29-25 J-29-35 J-29-45 J-29-55 J-29-6 J-29-16 J-29-26 J-29-36 J-29-46 J-29-56 J-29-7 J-29-17 J-29-27 J-29-37 J-29-47 J-29-57 J-29-8 J-29-18 J-29-28 J-29-38 J-29-48 J-29-9 J-29-19 J-29-29 J-29-39 J-29-49 J-29-10 J-29-20 J-29-30
Figure imgf000206_0001
J-29-40
Figure imgf000206_0003
J-29-50
Figure imgf000206_0002
R1 is 3-chIoro-5-(trifluoromethyl)pyrazol-l-yl; X is X2; G* is G-I.
J-29-1 J-29-8 J-29-15 J-29-22 J-29-29 J-29-36 J-29-2 J-29-9 J-29-16 J-29-23 J-29-30 J-29-37 J-29-3 J-29-10 J-29-17 J-29-24 J-29-31 J-29-38 J-29-4 ' J-29-11 J-29-18 J-29-25 J-29-32 J-29-39 J-29-5 J-29-12 J-29-19 J-29-26 J-29-33 J-29-40 J-29-6 J-29-13 J-29-20 J-29-27 J-29-34 J-29-41 J-29-7 J-29-14 J-29-21 J-29-28 J-29-35 J-29-42 J-29-43 J-29-46 J-29-49 J-29-52 J-29-55 J-29-44 J-29-47 J-29-50 J-29-53 J-29-56 J-29-45 J-29-48 J-29-51 J-29-54 J-29-57
Figure imgf000207_0001
-CtrifluoromethyOpyrazol-l-yl; X is X2; G* is G-2.
J-29-11 J-29-21 J-29-31 J-29-41 J-29-51 J-29-12 J-29-22 J-29-32 J-29-42 J-29-52 J-29-13 J-29-23 J-29-33 J-29-43 J-29-53 J-29-14 J-29-24 J-29-34 j-29-44 J-29-54 J-29-15 J-29-25 J-29-35 J-29-45 J-29-55 J-29-16 J-29-26 J-29-36 J-29-46 J-29-56 J-29-17 J-29-27 J-29-37 J-29-47 J-29-57 J-29-18 J-29-28 J-29-38 J-29-48 J-29-19 J-29-29 J-29-39 J-2949
Figure imgf000207_0002
J-29-20 J-29-30 J-29-40
Figure imgf000207_0003
J-29-50
Figure imgf000207_0004
R1 is 3-bromo-5-(trifluoromethyI)pyrazol-l-yl; X is X^; G* is G-I.
J-29-1 J-29-4 J-29-7 J-29-10 J-29-13 J-29-16 J-29-2 J-29-5 J-29-8 J-29-11 J-29-14 J-29-17 J-29-3 J-29-6 J-29-9 J-29-12 J-29-15 J-29-18 J-29-19 J-29-26 J-29-47 J-29-54 J-29-20 J-29-27 J-29-48 J-29-55 J-29-21 J-29-28 J-29-49 J-29-56 J-29-22 J-29-29 J-29-50 J-29-57 J-29-23 T-29-30 J-29-51 J-29-24 J-29-31 J-29-52 J-29-25 J-29-32
Figure imgf000208_0001
J-29-53
RI is 3-bromo is X^; G* is G-I.
J-29-1 J-29-31 J-29-41 J-29-51 J-29-2 J-29-32 J-29-42 J-29-52 J-29-3 J-29-33 J-29-43 J-29-53 J-29-4 J-29-34 J-29-44 J-29-54 J-29-5 J-29-35 J-29-45 J-29-55 J-29-6 J-29-36 J-29-46 J-29-56 J-29-7 J-29-37 J-29-47 J-29-57 J-29-8 J-29-38 J-29-48 J-29-9 J-29-39 J-29-49 J-29-10
Figure imgf000208_0002
J-29-40
Figure imgf000208_0004
J-29-50
Figure imgf000208_0003
R1 is 3-bromo-5-(trifluoromethyl)pyrazoI-l-yl; X is X1; G* is G-2.
J-29-1 J-29-11 J-29-21 J-29-31 J-29-41 J-29-51 J-29-2 J-29-12 J-29-22 J-29-32 J-29-42 J-29-52 J-29-3 J-29-13 J-29-23 J-29-33 J-29-43 J-29-53 J-29-4 J-29-14 J-29-24 J-29-34 J-29-44 J-29-54 J-29-5 J-29-15 J-29-25 J-29-35 J-29-45 J-29-55 J-29-6 J-29-16 J-29-26 J-29-36 J-29-46 J-29-56 J-29-7 J-29-17 J-29-27 J-29-37 J-29-47 J-29-57 J-29-8 J-29-18 J-29-28 J-29-38 J-29-48 J-29-9 J-29-19 J-29-29 J-29-39 J-29-49 J-29-10 J-29-20 J-29-30
Figure imgf000208_0005
J-29-40
Figure imgf000208_0006
J-29-50
Figure imgf000208_0007
Figure imgf000209_0006
R1 is 5-methoxy-3-(trifluoromethyl)pyrazol-l-yl; X is 1; G* is G-I.
J-29-l J-29-11 J-29-21 J-29-31 J-29-41 J-29-51 J-29-2 J-29-12 J-29-22 J-29-32 J-29-42 J-29-52 J-29-3 J-29-13 J-29-23 J-29-33 J-29-43 J-29-53 J-29-4 J-29-14 J-29-24 J-29-34 J-29-44 J-29-54 J-29-5 J-29-15 J-29-25 J-29-35 J-29-45 J-29-55 J-29-6 J-29-16 J-29-26 J-29-36 J-29-46 J-29-56 J-29-7 J-29-17 J-29-27 J-29-37 J-29-47 J-29-57 J-29-8 J-29-18 J-29-28 J-29-38 J-29-48 J-29-9 J-29-19 J-29-29 J-29-39 J-29-49 J-29-10 J-29-20 J-29-30 J-29-40
Figure imgf000209_0002
J-29-50
Figure imgf000209_0001
R1 is 5-methoxy-3-(trifluoroinethyl)pyrazol-l-yl; X is ; G* is G-I .
J-29-1 J-29-10 J-29-19 J-29-28 J-29-37 J-29-46
J-29-2 J-29-11 J-29-20 J-29-29 J-29-38 J-29-47
J-29-3 J-29-12 J-29-21 J-29-30 J-29-39 J-29-48
J-29-4 J-29-13 J-29-22 J-29-31 J-29-40 J-29-49
J-29-5 J-29-14 J-29-23 J-29-32 J-29-41 J-29-50
J-29-6 J-29-15 J-29-24 J-29-33 J-29-42 J-29-51
J-29-7 J-29-16 J-29-25 J-29-34 J-29-43 J-29-52
J-29-8 J-29-17 J-29-26 J-29-35 J-29-44 J-29-53
J-29-9 J-29-18 J-29-27 J-29-36 J-29-45 J-29-54
Figure imgf000209_0003
Figure imgf000209_0005
Figure imgf000209_0004
J-29-55 J-29-56 J-29-57
R* is 5-methoxy-3-(trifluoromethyl)pyrazol-l-yl; X is X1; G* is G-2.
J-29-1 J-29-11 J-29-21 J-29-51 J-29-2 J-29-12 J-29-22 J-29-52 J-29-3 J-29-13 J-29-23 J-29-53 J-29-4 J-29-14 J-29-24 J-29-54 J-29-5 J-29-15 J-29-25 J-29-55 J-29-6 J-29-16 J-29-26 J-29-56 J-29-7 J-29-17 J-29-27 J-29-57 J-29-8 J-29-18 J-29-28 J-29-9 J-29-19 J-29-29 J-29-10 J-29-20 J-29-30
Figure imgf000210_0001
Figure imgf000210_0002
R1 is 5-methoxy-3-(trifluoromethyl)pyrazol-l-yl; X is 2; G* is G-2.
J-29-1 J-29-11 J-29-21 J-29-31 J-29-41 J-29-51 J-29-2 J-29-12 J-29-22 J-29-32 J-29-42 J-29-52 J-29-3 J-29-13 J-29-23 J-29-33 J-29-43 J-29-53 J-29-4 J-29-14 J-29-24 J-29-34 j-29-44 J-29-54 J-29-5 J-29-15 J-29-25 J-29-35 J-29-45 J-29-55 J-29-6 J-29-16 J-29-26 J-29-36 J-29-46 J-29-56 J-29-7 J-29-17 J-29-27 J-29-37 J-29-47 J-29-57 J-29-8 J-29-18 J-29-28 J-29-38 J-29-48 J-29-9 J-29-19 J-29-29 J-29-39 J-29-49 J-29-10 J-29-20 J-29-30
Figure imgf000210_0005
J-29-40
Figure imgf000210_0003
J-29-50
Figure imgf000210_0004
R1 is 5-difluoromethoxy-3-(trifluorom l-l-yl; X is X1; G* is G-I.
J-29-22 J-29-29 J-29-36 J-29-23 J-29-30 J-29-37 J-29-24 J-29-31 J-29-38 J-29-25 J-29-32 J-29-39 J-29-26 J-29-33 J-29-40 J-29-27 J-29-34 J-29-41 J-29-28 J-29-35 J-29-42
Figure imgf000210_0006
J-29-43 J-29-46 J-29-49 J-29-52 J-29-55 J-29-44 J-29-47 J-29-50 J-29-53 J-29-56 J-29-45 J-29-48 J-29-51 J-29-54 J-29-57
X2; G* is G
J-29-41 J-29-51 J-29-42 J-29-52 J-29-43 J-29-53 J-29-44 J-29-54 J-29-45 J-29-55 J-29-46 J-29-56 J-29-47 J-29-57 J-29-48 J-29-49
Figure imgf000211_0001
Figure imgf000211_0003
J-29-50
Figure imgf000211_0002
R1 is 5-difluoromethoxy-3-(trifluoromethyl)pyrazol-l-yl; X is X1; G* is G-2.
J-29-1 J-29-51
J-29-2 J-29-52
J-29-3 J-29-53
J-29-4 J-29-54
J-29-5 J-29-55
J-29-6 J-29-56
J-29-7 J-29-57
J-29-8
J-29-9
J-29-10
Figure imgf000211_0005
Figure imgf000211_0004
R1 is 5-diQuoromethoxy-3-(trifluoromethyl)pyrazol-l-yl; X is X2; G* is G-2.
J-29-1 J-29-4 J-29-7 J-29-10 J-29-13 J-29-16 J-29-2 J-29-5 J-29-8 J-29-11 Jτ29-14 J-29-17 J-29-3 J-29-6 J-29-9 J-29-12 J-29-15 J-29-18 J-29-19 J-29-26 J-29-20 J-29-27 J-29-21 J-29-28 J-29-22 J-29-29 J-29-23 J-29-30 J-29-24 J-29-31 J-29-25 J-29-32
Figure imgf000212_0001
Table 5 above identifies particular compounds comprising a J group selected from J-29-1 through J-29-57 (i.e. particular examples of J-29). As many J-29-1 to J-29-57 include a chiral center, these J groups are illustrated in a particular enantiomeric configuration, which in some instances may provide the greatest fungicidal activity. One skilled in the art immediately recognizes the antipode (i.e. opposite enantiomer) for each of the compounds listed, and furthermore understands that the enantiomers can be present as pure enantiomers or in mixtures enriched in one enantiomer or in racemic mixtures. ** R3a substituent in G is H.
TABLE 6
Figure imgf000212_0002
R4al R4a2 Aa R4al R4a2 Aa
Me MeO H Me MeO CH2CO2Et Et • Me H Et Me CH2CO2Et Et Et H Et Et CH2CO2Et Et Cl H Et Cl CH2CO2Et Et Br H Et Br CH2CO2Et Et I H Et I CH2CO2Et Et CF2H H Et CF2H CH2CO2Et Et CF3 H Et CF3 CH2CO2Et Et • CF3CH2 H Et CF3CH2 CH2CO2Et Et CF3CF2 H Et CF3CF2 CH2CO2Et Et CCl3 H Et CCl3 CH2CO2Et Et MeO H Et MeO CH2CO2Et Cl Me H Cl Me CH2CO2Et Cl Et H Cl Et CH2CO2Et Cl Cl H Cl Cl CH2CO2Et Cl Br H Cl Br CH2CO2Et Cl I H Cl I CH2CO2Et Ct CF2H H Cl CF2H CH2CO2Et Cl CF3 H Cl CF3 CH2CO2Et Cl CF3CH2 H Cl CF3CH2 CH2CO2Et Cl CF3CF2 H Cl CF3CF2 CH2CO2Et Cl CCl3 H Cl CCl3 CH2CO2Et Cl MeO H Cl MeO CH2CO2Et Br Me H Br Me CH2CO2Et Br Et H Br Et CH2CO2Et Br Cl H Br Cl CH2CO2Et Br Br H Br Br CH2CO2Et Br I H Br I CH2CO2Et Br CF2H H Br CF2H CH2CO2Et Br CF3 H Br CF3 CH2CO2Et Br CF3CH2 H Br CF3CH2 CH2CO2Et Br CF3CF2 H Br CF3CF2 CH2CO2Et Br CCl3 H Br CCl3 CH2CO2Et Br MeO H Br MeO CH2CO2Et I Me H I Me CH2CO2Et I Et H I Et CH2CO2Et I Cl H I Cl CH2CO2Et
Figure imgf000214_0001
R4al R4a2 Aa R4al R4a2 Aa
CF3CH2 CF3CH2 H CF3CH2 CF3CH2 CH2CO2Et
CF3CH2 CF3CF2 H CF3CH2 CF3CF2 CH2CO2Et
CF3CH2 CCl3 H CF3CH2 CCl3 CH2CO2Et
CF3CH2 MeO H CF3CH2 MeO CH2CO2Et
CF3CF2 Me H CF3CF2 Me CH2CO2Et
CF3CF2 Et H CF3CF2 Et CH2CO2Et
CF3CF2 Cl H CF3CF2 Cl CH2CO2Et
CF3CF2 Br H CF3CF2 Br CH2CO2Et
CF3CF2 I H CF3CF2 I CH2CO2Et
CF3CF2 CF2H H CF3CF2 CF2H CH2CO2Et
CF3CF2 CF3 H CF3CF2 CF3 CH2CO2Et
CF3CF2 CF3CH2 H CF3CF2 CF3CH2 CH2CO2Et
CF3CF2 CF3CF2 H CF3CF2 CF3CF2 CH2CO2Et
CF3CF2 CCl3 H CF3CF2 CCl3 CH2CO2Et
CF3CF2 MeO H CF3CF2 MeO CH2CO2Et
CCl3 Me H CCl3 Me CH2CO2Et
CCl3 Et H CCl3 Et CH2CO2Et
CCl3 Cl H CCl3 Cl CH2CO2Et
CCl3 Br H CCl3 Br CH2CO2Et
CCl3 I H CCl3 I CH2CO2Et
CCl3 CF2H H CCl3 CF2H CH2CO2Et
CCl3 CF3 H CCl3 CF3 CH2CO2Et
CCl3 CF3CH2 H CCl3 CF3CH2 CH2CO2Et
CCl3 CF3CF2 H CCl3 CF3CF2 CH2CO2Et
CCl3 CCl3 H CCl3 CCl3 CH2CO2Et
CCl3 MeO H CCl3 MeO CH2CO2Et
MeO Me H MeO Me CH2CO2Et
MeO Et H MeO Et CH2CO2Et
MeO Cl H MeO Cl CH2CO2Et
MeO Br H MeO Br CH2CO2Et
MeO I H MeO I CH2CO2Et
MeO CF2H H MeO CF2H CH2CO2Et
MeO CF3 H MeO CF3 CH2CO2Et
MeO CF3CH2 H MeO • CF3CH2 CH2CO2Et
MeO CF3CF2 H MeO CF3CF2 CH2CO2Et
MeO CCl3 H MeO CCl3 CH2CO2Et
MeO MeO H MeO MeO CH2CO2Et R4al R4a2 Aa R4al R4a2 Aa
Me Me CH2CO2H Me Me CH2C(=O)C1 Me Et CH2CO2H Me Et CH2Q=O)Cl Me Cl CH2CO2H Me Cl CH2C(=O)C1 Me Br CH2CO2H Me Br CH2Q=O)Cl Me 1 CH2CO2H Me I CH2C(=O)C1 Me CF2H CH2CO2H Me CF2H CH2C(=O)C1 Me CF3 CH2CO2H Me CF3 CH2CC=O)Cl Me CF3CH2 CH2CO2H Me CF3CH2 CH2CC=O)Cl Me CF3CF2 CH2CO2H Me CF3CF2 CH2CC=O)Cl Me CCl3 • CH2CO2H Me CCl3 CH2CC=O)CI Me MeO CH2CO2H Me MeO CH2CC=O)Cl Et Me CH2CO2H Et Me CH2CC=O)Cl Et Et CH2CO2H Et Et CH2CC=O)Cl Et Cl CH2CO2H Et Cl CH2CC=O)Cl Et Br CH2CO2H Et Br CH2CC=O)Cl Et I CH2CO2H Et I CH2CC=O)Cl Et CF2H CH2CO2H Et CF2H CH2CC=O)Cl Et CF3 CH2CO2H Et CF3 CH2CC=O)Cl Et CF3CH2 CH2CO2H Et CF3CH2 CH2CC=O)Cl Et CF3CF2 CH2CO2H Et CF3CF2 CH2CC=O)Cl Et CCl3 CH2CO2H Et CCl3 CH2CC=O)Cl Et MeO CH2CO2H Et MeO CH2CC=O)Cl Cl Me CH2CO2H Cl Me CH2CC=O)Cl Cl Et CH2CO2H Cl Et CH2CC=O)Cl Cl Cl CH2CO2H Cl Cl CH2CC=O)Cl Cl Br CH2CO2H Cl Br CH2CC=O)Cl Cl I CH2CO2H Cl I CH2CC=O)Cl Cl CF2H CH2CO2H Cl CF2H CH2CC=O)Cl Cl CF3 CH2CO2H Cl CF3 CH2CC=O)Cl Cl CF3CH2 CH2CO2H Cl CF3CH2 CH2CC=O)Cl Cl CF3CF2 CH2CO2H Cl CF3CF2 CH2CC=O)Cl Cl CCl3 CH2CO2H Cl CCl3 CH2CC=O)Cl Cl MeO CH2CO2H Cl MeO CH2CC=O)Cl Br Me CH2CO2H Br Me CH2CC=O)Cl Br Et CH2CO2H Br Et CH2CC=O)Cl Br Cl CH2CO2H Br Cl CH2CC=O)Cl Br Br CH2CO2H Br Br CH2CC=O)Cl
Figure imgf000217_0001
Figure imgf000218_0001
Figure imgf000219_0001
Figure imgf000219_0002
R4al R4a2 R4al R4a2 Z3
Me CF3CH2 CN Me CF3CH2 C(=S)NH2
Me CF3CF2 CN Me CF3CF2 C(=S)NH2
Me CCl3 CN Me CCl3 C(=S)NH2
Me MeO CN Me MeO CC=S)NH2
Et Me CN Et Me CC=S)NH2
Et Et CN Et Et CC=S)NH2
Et Cl CN Et Cl CC=S)NH2
Et Br CN Et Br CC=S)NH2
Et I CN Et I CC=S)NH2
Et CF2H CN Et CF2H CC=S)NH2
Et CF3 CN Et CF3 CC=S)NH2
Et CF3CH2 CN Et CF3CH2 C(=S)NH2
Et CF3CF2 CN Et CF3CF2 CC=S)NH2
Et CCl3 CN Et CCl3 CC=S)NH2
Et MeO CN Et MeO C(=S)NH2
Cl Me CN Cl Me CC=S)NH2
Cl Et CN Cl Et CC=S)NH2
Cl • Cl CN Cl Cl CC=S)NH2
Cl Br CN Cl Br CC=S)NH2
Cl I CN Cl I C(=S)NH2
Cl CF2H CN Cl CF2H CC=S)NH2
Cl CF3 CN Cl CF3 CC=S)NH2
Cl CF3CH2 CN Cl CF3CH2 CC=S)NH2
Cl CF3CF2 CN Cl CF3CF2 CC=S)NH2
Cl CCl3 CN Cl CCl3 CC=S)NH2
Cl MeO CN Cl MeO CC=S)NH2
Br Me CN Br Me CC=S)NH2
Br Et CN Br Et CC=S)NH2
Br Cl CN Br Cl CC=S)NH2
Br Br CN Br Br CC=S)NH2
Br I CN Br I- CC=S)NH2
Br CF2H CN Br CF2H CC=S)NH2
Br CF3 CN Br CF3 CC=S)NH2
Br CF3CH2 CN Br CF3CH2 • CC=S)NH2
Br CF3CF2 CN Br CF3CF2 CC=S)NH2
Br CCl3 CN Br CCl3 CC=S)NH2
Br MeO CN Br MeO CC=S)NH2 R4al R4a2 Z3 R4al R14a2 Z3
I Me CN I Me CC=S)NH2
I . Et CN I Et 'CC=S)NH2 I Cl CN I Cl C(=S)NH2 I Br CN I . Br CC=S)NH2 I I CN I I C(=S)NH2 I CF2H CN I CF2H CC=S)NH2 I CF3 CN I CF3 CC=S)NH2 I CF3CH2 CN I CF3CH2 CC=S)NH2 I CF3CF2 CN I CF3CF2 CC=S)NH2 I CCl3 CN I CCl3 CC=S)NH2 I MeO CN I MeO CC=S)NH2
CF2H Me CN CF2H Me CC=S)NH2
CF2H Et CN CF2H Et CC=S)NH2
CF2H Cl CN CF2H Cl CC=S)NH2
CF2H Br CN CF2H Br CC=S)NH2
CF2H I CN CF2H I CC=S)NH2
CF2H CF2H CN CF2H CF2H CC=S)NH2
CF2H CF3 CN CF2H CF3 CC=S)NH2
CF2H CF3CH2 CN CF2H CF3CH2 CC=S)NH2
CF2H CF3CF2 CN CF2H CF3CF2 CC=S)NH2
CF2H CCl3 CN CF2H CCl3 CC=S)NH2
CF2H MeO CN CF2H MeO CC=S)NH2
CF3 Me CN CF3 Me CC=S)NH2
CF3 Et CN CF3 Et CC=S)NH2
CF3 Cl CN CF3 Cl CC=S)NH2
CF3 Br CN CF3 Br CC=S)NH2
CF3 I CN CF3 I CC=S)NH2
CF3 CF2H CN CF3 CF2H CC=S)NH2
CF3 CF3 CN CF3 CF3 CC=S)NH2
CF3 CF3CH2 CN CF3 CF3CH2 C(=S)NH2
CF3 CF3CF2 CN CF3 CF3CF2 CC=S)NH2
CF3 CCl3 CN CF3 CCl3 CC=S)NH2
CF3 MeO CN CF3 MeO C(=S)NH2
CF3CH2 Me CN CF3CH2 Me CC=S)NH2 CF3CH2 Et CN CF3CH2 Et CC=S)NH2 CF3CH2 Cl CN CF3CH2 Cl C(=S)NH2 CF3CH2 Br CN CF3CH2 Br CC=S)NH2
Figure imgf000222_0001
R4al R4a2 Z3 R4al R4a2 Z3
MeO CF3CF2 CN MeO CF3CF2 C(=S)NH2
MeO CCl3 CN MeO CCl3 Q=S)NH2
MeO MeO CN MeO MeO C(=S)NH2
OCF2H Me CN OCF2H Me C(=S)NH2
OCF2H Et CN OCF2H Et C(=S)NH2
OCF2H Cl CN OCF2H Cl C(=S)NH2
OCF2H Br CN OCF2H Br C(=S)NH2
OCF2H I CN OCF2H I C(=S)NH2
OCF2H CF2H CN ■ OCF2H CF2H CC=S)NH2
OCF2H CF3 CN OCF2H CF3 C(=S)NH2
OCF2H CF3CH2 CN OCF2H CF3CH2 Q=S)NH2
OCF2H CF3CF2 CN OCF2H CF3CF2 Q=S)NH2
OCF2H CCl3 CN OCF2H CCl3 Q=S)NH2
OCF2H MeO CN OCF2H MeO Q=S)NH2
TABLE 8
Figure imgf000223_0001
wherein J^ is one of J-29-1 through J-29-58 (as depicted in Exhibit A above).
Figure imgf000223_0002
Figure imgf000224_0001
J-29-14
J-29-14
J-29-14
J-29-14
J-29-14
J-29-14
J-29-14
J-29-14
J-29-14
J-29-14
J-29-14
J-29-15
J-29-15
J-29-15
J-29-15
J-29-15
J-29-15
J-29-15
J-29-15
J-29-15
J-29-15
J-29-15
J-29-15
J-29-15
J-29-15
J-29-15
J-29-15
J-29-15
J-29-16
J-29-16
J-29-16
J-29-16
J-29-16
J-29-16
J-29-16
J-29-16
Figure imgf000225_0001
J-29-16
Figure imgf000226_0001
Figure imgf000227_0001
J-29-33
J-29-34
J-29-34
J-29-34
J-29-34
J-29-34
J-29-34
J-29-34
J-29-34
J-29-34
J-29-34
J-29-34
J-29-34
J-29-34
J-29-34
J-29-34
J-29-34
J-29-34
J-29-35
J-29-35
J-29-35
J-29-35
J-29-35
J-29-35
J-29-35
J-29-35
J-29-35
J-29-35
J-29-35
J-29-35
J-29-35
J-29-35
J-29-35
J-29-35
J-29-35
J-29-36
J-29-36
Figure imgf000228_0001
J-29-40
J-29-40
J-29-40
J-29-40
J-29-40
J-29-40 ■ J-29-40
J-29-40
J-29-40
J-29-41
J-29-41
J-29-41
J-29-41
J-29-41
J-29-41
J-29-41
J-29-41
J-29-41
J-29-41
J-29-41
J-29-41
J-29-41
J-29-41
J-29-41
J-29-41
J-29-41
J-29-42
J-29-42
J-29-42
J-29-42
J-29-42
J-29-42
J-29-42
J-29-42
J-29-42
J-29-42
Figure imgf000229_0001
J-29-42
Figure imgf000230_0001
J-29-53
J-29-53
J-29-53
J-29-53 . J-29-53
J-29-53
J-29-53
J-29-53
J-29-54
J-29-54
J-29-54
J-29-54
J-29-54
J-29-54
J-29-54
J-29-54
J-29-54
J-29-54
J-29-54
J-29-54
J-29-54
J-29-54
J-29-54
J-29-54
J-29-54
J-29-55
J-29-55
J-29-55
J-29-55
J-29-55
J-29-55
J-29-55
J-29-55
J-29-55
J-29-55
J-29-55
J-29-55
Figure imgf000231_0001
J-29-57
J-29-58
J-29-58
J-29-58
J-29-58
J-29-58
J-29-58
J-29-58
J-29-58
J-29-58
J-29-58
J-29-58
J-29-58
J-29-58
J-29-58
J-29-58
J-29-58
J-29-58
Figure imgf000232_0001
Table 8 above identifies particular compounds comprising a J1 group selected from J-29-1 through J-29-58. As many J-29-1 through J-29-58 include a chiral center, these J1 groups are illustrated in a particular enantiomeric configuration, which in some instances may provide the greatest fungicidal activity for compounds of Formula 1. One skilled in the art immediately recognizes the antipode (i.e. opposite enantiomer) for each of the compounds listed, and furthermore understands that the enantiomers can be present as pure enantiomers or in mixtures enriched in one enantiomer or in racemic mixtures.
Formulation/Utility A compound of Formula 1 of this invention will generally be used as a fungicidal active ingredient in a composition, i.e. formulation, with at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, which serve as a carrier. The formulation or composition ingredients are selected to be consistent with the physical properties of the active ingredient, mode of application and environmental factors such as soil type, moisture and temperature.
Useful formulations include both liquid and solid compositions. Liquid compositions include solutions (including emulsifiable concentrates), suspensions, emulsions (including microemulsions and/or suspoemulsions) and the tike, which optionally can be thickened into gels. The general types of aqueous liquid compositions are soluble concentrate, suspension concentrate, capsule suspension, concentrated emulsion, microemulsion and suspo-emulsion. The general types of nonaqueous liquid compositions are emulsifiable concentrate, microemulsifiable concentrate, dispersible concentrate and oil dispersion. The general types of solid compositions are dusts, powders, granules, pellets, pills, pastilles, tablets, filled films (including seed coatings) and the like, which can be water-dispersible ("wettable") or water-soluble. Films and coatings formed from film- forming solutions or flowable suspensions are particularly useful for seed treatment. Active ingredient can be (micro)encapsulated and further formed into a suspension or solid formulation; alternatively the entire formulation of active ingredient can be encapsulated (or "overcoated"). Encapsulation can control or deϊay release of the active ingredient. An emulsifiable granule combines the advantages of both an emulsifiable concentrate formulation and a dry granular formulation. High-strength compositions are primarily used as intermediates for further formulation. Sprayable formulations are typically extended in a suitable medium before spraying.
Such liquid and solid formulations are formulated to be readily diluted in the spray medium, usually water. Spray volumes can range from about from about one to several thousand liters per hectare, but more typically are in the range from about ten to several hundred liters per hectare. Sprayable formulations can be tank mixed with water, or another suitable medium for foliar treatment by aerial or ground application, or for application to the growing medium of the plant. Liquid and dry formulations can be metered directly into drip irrigation systems or metered into the furrow during planting. Liquid and solid formulations can be applied onto vegetable seeds as seed treatments before planting to protect developing roots and other subterranean plant parts and/or foliage through systemic uptake. The formulations will typically contain effective amounts of active ingredient, diluent and surfactant within the following approximate ranges which add up to 100 percent by weight.
Weight Percent
Active Ingredient Diluent Surfactant
Water-Dispersible and Water-soluble 0.001-90 0-99.999 0-15 Granules, Tablets and Powders.
Oil Dispersions, Suspensions, 1-50 40-99 0-50 Emulsions, Solutions (including Emulsifiable Concentrates)
Dusts 1-25 70-99 0-5
Granules and Pellets 0.001-99 5-99.999 0-15
High Strength Compositions 90-99 0-10 0-2 . Solid diluents include, for example, clays such ' as beήtonite, montmorillonite, attapulgite and kaolin, gypsum, cellulose, titanium dioxide, zinc oxide, starch, dextrin, sugars (e.g., lactose, sucrose), silica, talc, mica, diatomaceous earth, urea, calcium carbonate, sodium carbonate and bicarbonate, and sodium sulfate. Typical solid diluents are described in Watkins et al., Handbook of Insecticide Dust Diluents and Carriers, 2nd Ed., Dorland Books, Caldwell, New Jersey.
Liquid diluents include, for example, water, Λ^V-dimethylaLkanamides (e.g., Λy\T-dimethylformamide), limonene, dimethyl sulfoxide, N-alkylpyrrolidones (e.g., iV-methylpyrrolidinone), ethylene glycol, Methylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, propylene carbonate, butylene carbonate, paraffins (e.g., white mineral oils, normal paraffins, isoparaffϊns), alkylbenzenes, alkylnaphthalenes, glycerine, glycerol triacetate, sorbitol, triacetin, aromatic hydrocarbons, dearomatized aliphatics, alkylbenzenes, alkylnaphthalenes, ketones such as cyclohexanone, 2-heptanone, isophorone and 4-hydroxy-4-methyl-2-pentanone, acetates such as isoamyl acetate, hexyl acetate, heptyl acetate, octyl acetate, nonyl acetate, tridecyl acetate and isobornyl acetate, other esters such as alkylated lactate esters, dibasic esters and γ-butyrolactone, and alcohols, which can be linear, branched, saturated or unsaturated, such as methanol, ethanol, n-propanol, isopropyl alcohol, n-butanol, isobutyl alcohol, H-hexanol, 2-ethylhexanol, n-octanol, decanol, isodecyl alcohol, isooctadecanol, cetyl alcohol, lauryl alcohol, tridecyl alcohol, oleyl alcohol, cyclohexanol, tetrahydrofurfuryl alcohol, diacetone alcohol and benzyl alcohol. Liquid diluents also include glycerol esters of saturated and unsaturated fatty acids (typically C6-C22)' sucn ^ plant seed and fruit oils (e.g., oils of olive, castor, linseed, sesame, corn (maize), peanut, sunflower, grapeseed, safflower, cottonseed, soybean, rapeseed, coconut and palm kernel), animal-sourced fats (e.g., beef tallow, pork tallow, lard, cod liver oil, fish oil), and mixtures thereof. Liquid diluents also include alkylated fatty acids (e.g., methylated, ethylated, butylated) wherein the fatty acids may be obtained by hydrolysis of glycerol esters from plant and animal sources, and can be purified by distillation. Typical liquid diluents are described in Marsden, Solvents Guide, 2nd Ed., Interscience, New York, 1950. The solid and liquid compositions of the present invention often include one or more surfactants. Surfactants can be classified as nonionic, anionic or cationic. Nonionic surfactants useful for the present compositions include, but are not limited to: alcohol alkoxylates such as alcohol alkoxylates based on natural and synthetic alcohols (which may be branched or linear) and prepared from the alcohols and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof; amine ethoxylates, alkanolamides and ethoxylated alkanolamides; alkoxylated triglycerides such as ethoxylated soybean, castor and rapeseed oils; alkylphenol alkoxylates such as octylphenol ethoxylates, nonylphenol ethoxylates, dinonyl phenol ethoxylates and dodecyl phenol ethoxylates (prepared from the phenols and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); block polymers prepared from ethylene oxide or propylene oxide and reverse block polymers where the terminal blocks are prepared from propylene oxide; ethoxylated fatty acids; ethoxylated fatty esters and oils; ethoxylated methyl esters; ethoxylated tristyrylphenol (including those prepared from ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); fatty acid esters, glycerol esters, lanolin-based derivatives, polyethoxylate esters such as polyethoxylated sorbitan fatty acid esters, polyethoxylated sorbitol fatty acid esters and polyethoxylated glycerol fatty acid esters; other sorbitan derivatives such as sorbitan esters; polymeric surfactants such as random copolymers, block copolymers, alkyd peg (polyethylene glycol) resins, graft or comb polymers and star polymers; polyethylene glycols (pegs); polyethylene glycol fatty acid esters; silicone-based surfactants; and sugar- derivatives such as sucrose esters, alkyl polyglycosides and alkyl polysaccharides.
Useful anionic surfactants include, but are not limited to: alkylaryl sulfonic acids and their salts; carboxylated alcohol or alkylphenol ethoxylates; diphenyl sulfonate derivatives; lignin and lignin derivatives such as lignosulfonates; maleic or succinic acids or their anhydrides; olefin sulfonates; phosphate esters such as phosphate esters of alcohol alkoxylates, phosphate esters of alkylphenol alkoxylates and phosphate esters of styryl phenol ethoxylates; protein-based surfactants; sarcosine derivatives; styryl phenol ether sulfate; sulfates and sulfonates of oils and fatty acids; sulfates and sulfonates of ethoxylated alkylphenols; sulfates of alcohols; sulfates of ethoxylated alcohols; sulfonates of amines and amides such as ΛyV-alkyltaurates; sulfonates of benzene, cumene, toluene, xylene, and dodecyl and tridecylbenzenes; sulfonates of condensed naphthalenes; sulfonates of naphthalene and alkyl naphthalene; sulfonates of fractionated petroleum; sulfosuccinamates; and sulfosuccinates and their derivatives such as dialkyl sulfosuccinate salts. Useful cationic surfactants include, but are not limited to: amides and ethoxylated amides; amines such as N-a\kyl propanediamines, tripropylenetriamines and dipropylenetetramines, and ethoxylated amines, ethoxylated diamines and propoxylated amines (prepared from the amines and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); amine salts such as amine acetates and diamine salts; quaternary ammonium salts such as quaternary salts, ethoxylated quaternary salts and diquaternary salts; and amine oxides such as alkyldimethylamine oxides and bis-(2-hydroxyethyl)-alkylamine oxides.
Also useful for the present compositions are mixtures of nonionic and anionic surfactants or mixtures of nonionic and cationic surfactants. Nonionic, anionic and cationic surfactants and their recommended uses are disclosed in a variety of published references including McCutcheon 's Emulsifiers and Detergents, annual American and International Editions published by McCutcheon's Division, The Manufacturing Confectioner Publishing Co.; Sisely and Wood, Encyclopedia of Surface Active Agents, Chemical Publ. Co., Inc., New York, 1964; and A. S. Davidson and B. Milwidsky, Synthetic Detergents, Seventh Edition, John Wiley and Sons, New York, 1987.
Compositions of this invention may also contain formulation auxiliaries and additives, known to those skilled in the art as formulation aids. Such formulation auxiliaries and additives may control: pH (buffers), foaming during processing (antifoams such polyorganosiloxanes (e.g., Rhodorsil® 416)), sedimentation of active ingredients (suspending agents), viscosity (thixotropic thickeners), in-container microbial growth (antimicrobials), product freezing (antifreezes), color (dyes/pigment dispersions (e.g., Pro- lzed® Colorant Red)), wash-off (film formers or stickers), evaporation (evaporation retardants), and other formulation attributes. Film formers include, for example, polyvinyl acetates, polyvinyl acetate copolymers, polyvinylpyrrolidone-vinyl acetate copolymer, polyvinyl alcohols, polyvinyl alcohol copolymers and waxes. Examples of formulation auxiliaries and additives include those listed in McCutcheon 's Volume 2: Functional Materials, annual International and North American editions published by McCutcheon's Division, The Manufacturing Confectioner Publishing Co.; and PCT Publication WO 03/024222.
Solutions, including emulsifiable concentrates, can be prepared by simply mixing the ingredients. If the solvent of a liquid composition intended for use as an emulsifiable concentrate is water-immiscible, an emulsifϊer is typically added to emulsify the active- containing solvent upon dilution with water. Active ingredient slurries, with particle diameters of up to 2,000 μm can be wet milled using media mills to obtain particles with average diameters below 3 μm. Aqueous slurries can be made into finished suspension concentrates (see, for example, U.S. 3,060,084) or further processed by spray drying to form water-dispersible granules. Dry formulations usually require dry milling processes, which produce average particle diameters in the 2 to 10 μm range. Dusts and powders can be prepared by blending and, usually, grinding as in a hammer mill or fluid-energy mill. Granules and pellets can be prepared by spraying the active material upon preformed granular carriers or by agglomeration techniques. See Browning, "Agglomeration", Chemical Engineering, December 4, 1967, pp 147-48, Perry's Chemical Engineer's Handbook, 4th Ed., McGraw-Hill, New York, 1963, pages 8-57 and following, and WO 91/13546. Pellets can be prepared as described in U.S. 4,172;714. Water-dispersible and water-soluble granules can be prepared as taught in U.S. 4,144,050, U.S. 3,920,442 and DE 3,246,493. Tablets can be prepared as taught in U.S. 5,180,587, U.S. 5,232,701 and U.S. 5,208,030. Films can be prepared as taught in GB 2,095,558 and U.S. 3,299,566. For further information regarding the art of formulation, see T. S. Woods, "The
Formulator's Toolbox — Product Forms for Modem Agriculture" in Pesticide Chemistry and Bioscience, The Food-Environment Challenge, T. Brooks and T. R. Roberts, Eds., Proceedings of the 9th International Congress on Pesticide Chemistry, The Royal Society of Chemistry, Cambridge, 1999, pp. 120-133. See also U.S. 3,235,361, Col. 6, line 16 through Col. 7, line 19 and Examples 10-41; U.S. 3,309,192, Col. 5, line 43 through Col. 7, line 62 and Examples 8, 12, 15, 39, 41, 52, 53, 58, 132, 138-140, 162-164, 166, 167 and 169-182; U.S. 2,891,855, CoL 3, line 66 through Col. 5, line 17 and Examples 1-4; Klingman, Weed Control as a Science, John Wiley and Sons, Inc., New York, 1961, pp 81—96; Hance et al., Weed Control Handbook, 8th Ed., Blackwell Scientific Publications, Oxford, 1989; and Developments in formulation technology, PJB Publications, Richmond, UK, 2000.
In the following Examples, all percentages are by weight and all formulations are prepared in conventional ways. Compound numbers refer to compounds in Index Table A. Example A
High Strength Concentrate
Compound 1 98.5 % silica aerogel 0.5 % synthetic amorphous fine silica 1.0 %. Example B Wettable Powder
Compound 2 65.0 % dodecylphenol polyethylene glycol ether 2.0 % sodium ligninsulfonate 4.0 % sodium silicoaluminate 6.0 % montmorillonite (calcined) 23.0 %.
Example C Granule
Compound 16 10.0 % attapulgite granules (low volatile matter,
0.71/0.30 mm; U.S.S. No. 25-50 sieves) 90.0 %.
Example D Aqueous Suspension
Compound 37 25.0 % hydrated attapulgite . 3.0 % crude calcium ligninsulfonate 10.0 % sodium dihydrogen phosphate 0.5 % water 61.5 %. Example E Extruded Pellet
Compound 107 25.0 % anhydrous sodium sulfate 10.0 % crude calcium ligninsulfonate 5.0 % sodium alkylnaphthalenesulfonate 1.0 % calcium/magnesium bentonite 59.0 %.
Example F Microemulsion Compound 44 . 1.0 % triacetine 30.0 %
C8- Cio alkylpolyglycoside 30.0 % glyceryl monooleate 19.0 % water 20.0 %. Example G
Emulsifϊable Concentrate
Compound 1 10.0 %
C8-C]0 fatty acid methyl ester 70.0 % polyoxyethylene sorbitol hexoleate 20.0 %. The compounds of Formula 1 of this invention are useful as plant disease control agents. The present invention therefore further comprises a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof to be protected, or to the plant seed to be protected, an effective amount of a compound of the invention or a fungicidal composition containing said compound. The compounds and/or compositions of this invention provide control of diseases caused by a broad spectrum of fungal plant pathogens in the Basidiomycete, Ascomycete, Oomycete and Deuteromycete classes. They are effective in controlling a broad spectrum of plant diseases, particularly foliar pathogens of ornamental, turf, vegetable, field, cereal, and fruit crops. These pathogens include: Oomycetes, including Phytophthora diseases such as Phytophthora infestans, Phytophthora megasperma, Phytophthora parasitica, Phytophthora cinnamomi and Phytophthora capsici, Pythium diseases such as Pythium aphanidermatum, and diseases in the Peronosporaceae family such as Plasmopara viticola, Peronospora spp. (including Peronospora tabacina and Peronospora parasitica), Pseudoperonospora spp. (including Pseudoperonospora cubensis) and Bremia lactucae; Ascomycetes, including Alternaria diseases such as Alternaria solani and Altemaria brassicae, Guignardia diseases such as Guignardia bidwell, Venturia diseases such as Venturia inaequalis, Septoria diseases such as Septoria nodorum and Septoria tritici, powdery mildew diseases such as Erysiphe 14647
238
spp. (including Erysiphe graminis and Erysiphe polygoni), Uncinula necatur, Sphaerotheca fiiligena and Podosphaera leucotricha, Pseudocercosporella herpotrichoides, Botrytis diseases such as Botrytis cinerea, Monilinia fructicola, Sclerotinia diseases such as
Sclerotinia sclerotiorum, Magnaporthe grisea, Phomopsis viticola, Helminthosporium diseases such as Helminthosporium tritici repentis, Pyrenophora teres, anthracnose diseases such as Glomerella or Colletotrichum spp. (such as CoHetotrichum graminicola and
Colletotrichum orbiculare), and Gaeumannomyces graminis; Basidiotnycetes, including rust diseases caused by Puccinia spp. (such as Puccinia recondita, Puccinia striiformis, Puccinia hordei, Puccinia graminis and Puccinia arachidis), Hemileia vastatrix and Phakopsora pachyrhi∑i; other pathogens including Rhizoctonia spp. (such as Rhizoctonia solani); Fusarium diseases such as Fusarium roseum, Fusarium graminearum and Fusarium oxysporum; Verticillium dahliae; Sclerotium rolfsii; Rynchosporium secalis; Cercosporidium personatum, Cercospora arachidicola and Cercospora beticola; and other genera and species closely related to these pathogens. In addition to their fungicidal activity, the compositions or combinations also have activity against bacteria such as Erwinia amylovora, Xanthomonas campestris, Pseudomonas syringae, and other related species. Of note is control provided of disease caused by the Ascomycete and Oomycete classes. Of particular note is control provided of disease caused by the Oomycete class.
Plant disease control is ordinarily accomplished by applying an effective amount of a compound of this invention either pre- or post-infection, to the portion of the plant to be protected such as the roots, stems, foliage, fruit, seeds, tubers or bulbs, or to the media (soil or sand) in which the plants to be protected are growing. The compounds can also be applied to seeds to protect the seeds and seedlings developing from the seeds. The compounds can also be applied through irrigation water to treat plants. Rates of application for these compounds can. be influenced by many factors of the environment and should be determined under actual use conditions. Foliage can normally be protected when treated at a rate of from less than about 1 g/ha to about 5,000 g/ha of active ingredient. Seed and seedlings can normally be protected when seed is treated at a rate of from about 0.1 to about 1O g per kilogram of seed. Compounds of this invention can also be mixed with one or more other insecticides, fungicides, nematocides, bactericides, acaricides, growth regulators, chemosterilants, semiochemicals, repellents, attractants, pheromones, feeding stimulants or other biologically active compounds to form a multi-component pesticide giving an even broader spectrum of agricultural protection. Examples of such agricultural protectants with which compounds of this invention can be formulated are: insecticides such as abamectin, acephate, acetamiprid, amidoflumet (S-1955), avermectin, azadirachtin, azinphos-methyl, bifenthrin, bifenazate, buprofezin, carbofuran, cartap, chlorantraniliprole (DPX-E2Y45), chlorfenapyr, chlorfluazuron, chlorpyrifos, chlorpyrifos-methyl, chromafenozide, clothianidin, cyflumetofen, cyfluthrin, beta-cyfluthrin, cyhalothrin, lambda-cyhalothrin, cypermethrin, cyromazine, deltamethrin, diafenthiuron, diazinon, dieldrin, diflubenzuron, dimefluthrin, dimethoate, dinotefuran, diofenolan, emamectin, endosulfaα, esfenvalerate, ethiprole, fenothiocarb, fenoxycarb, fenpropathrin, fenvalerate, fipronil, flonicamid, flubendiamide, flucythrinate, tau-fluvalinate, flufenerim (UR-50701), flufenoxuron, fonophos, halofenozide, hexaflumuron, hydramethybion, imidacloprid, indoxacarb, isofenphos, lufenuron, malathion, metaflumizone, metaldehyde, methamidophos, methidathϊon, methomyl, methoprene, methoxychlor, metofluthrin, monocrotophos, methoxyfenozide, nitenpyram, nithiazine, novaluron, noviflumuron (XDE-007), oxamyl, parathion, parathion-methyl, permethxin, phorate, phosalone, phosmet, phosphamidon, pirimicarb, profenofos, profluthrin, pymetrozine, pyrafluprole, pyrethrin, pyridalyl, pyrifluquinazon, pyriprole, pyriproxyfen, rotenone, ryanodine, spinetoram, spinosad, spirodiclofen, spiromesifen (BSN 2060), spirotetramat, sulprofos, tebufenozide, teflubenzuron, tefluthrin, terbufos, tetrachlorvinphos, thiacloprid, thiamethoxam, thiodicarb, tbiosultap-sodium, tralomethrin, triazamate, trichlorfon and triflumuron; fungicides such as acibenzolar, aldimorph, amisulbrom, anilazine, azaconazole, azoxystrobin, benalaxyl, benodanil, benomyl, benthiavalicarb, benthiavalicarb-isopropyl, binapacryl, biphenyl, bitertanol, bixafen, blasticidiB-S, Bordeaux mixture (tribasic copper sulfate), boscalid/nicobifen, bromuconazole, bupirimate, buthiobate, carboxin, carpropamid, captafol, captan, carbendazim, chloroneb, chlorothalonil, 5-chloro-6- (2,4,6-trifluorophenyl)-7-(4-methylpiperidin-l -yl)[ 1 ,2,4]triazolo[ 1 ,5-«]pyrimidine, chlozolinate, clotrimazole, copper oxychloride, copper salts such as copper sulfate and copper hydroxide, cyazofamid, cyflufenamid, cymoxanil, cyproconazole, cyprodinil, dichlofluanid, diclocyrnet, diclomezine, dicloran, diethofencarb, difenoconazole, diflumetorim, dimethirirnol, N-[I-(I jS-dimethylbuty^phenylJ-S-fluoro-l^-dimethyl-liϊ- pyrazol-4-carboxamide, dimethomorph, dimoxystrobin, diniconazole, diniconazole-M, dinocap, discostrobin, dithianon, dodemorph, dodine, econazole, edifenphos, enestroburin, epoxiconazole, etaconazole, ethaboxam, ethirimol, etbxidiazole, famoxadone, fenamidone, fenarimol, fenbuconazole, fencaramid, fenfuram, fenhexamide, fenoxanil, fenpiclonil, fenpropidin, fenpropimorph, fentin acetate, fentin chloride, fentin hydroxide, ferbam, ferfurazoate, ferimzone, fiuazinam, fludioxonil, flumetover, flumorph, fluopicolide, fluopyram, fluoxastrobin, fluquinconazole, fluquinconazole, flusilazole, flusulfamide, flutolanil, flutriafol, folpet, fosetyl-aluminum, fuberidazole, furalaxyl, furametapyr, hexaconazole, hymexazole, guazatine, imazalil, imibenconazole, iminoctadine, iodicarb, ipconazole, iprobenfos, iprodione, iprovalicarb, isoconazole, isoprothiolane, isotianil, kasugamycin, kresoxim-methyl, mancozeb, mandipropamid, maneb, mapanipyrin, mefenoxam, mepronil, meptyldinocap, metalaxyl, metconazole, methasulfocarb, metiram, metominostrobin, mepanipyrim, metiram, metrafenone, miconazole, myclobutanil, naftifine, neo-asozin (ferric methanearsonate), nuarimol, octhilinone, ofurace, orysastrobin, oxadixyl, oxolinic acid, oxpoconazole, oxycarboxin, oxytetracycline, paclobutrazol, penconazole, pencycuron, penthiopyrad, perfurazoate, phosphonic acid, phthalide, picobenzamid, picoxystrobin, piperalin, polyoxin, probenazole, prochloraz, procymidone, propamocarb, propamocarb-hydrochloride, propiconazole, propineb, proquinazid, prothiocarb, prothioconazole, pyraclostrobin, pryazophos, pyribencarb, pyrifenox, pyrimethanil, pyrifenox, pyrolnitrine, pyroquilon, quinconazole, qtiinoxyfen, quintozene, silthiofam, simeconazole, spkoxamine, streptomycin, sulfur, tebuconazole, techrazene, tecloftalam, tecnazene, terbinafine, tetraconazole, thiabendazole, thifluzamide, thiophanate, thiophanate- methyl, thiram, tiadinil, tolclofos-methyl, tolyfluanid, triadimefon, triadimenol, triarimol, triazoxide, tricyclazole, tridemorph, triflumizole, trimoprhamide tricyclazole, trifloxystrobin, triforine, triticonazole, uniconazole, validamycin, vinclozolin, zineb, ziram and zoxamide; nematocides such as aldicarb, aldoxycarb, fenamiphos, imicyafos and oxamyl; bactericides such as streptomycin; acaricides such as amitraz, chinomethionat, chlorobenzilate, cyenopyrafen, cyhexatin, dicofol, dienochlor, etoxazole, fenazaquin, fenbutatin oxide, fenpropathrin, fenpyroximate, hexythiazox, propargite, pyridaben and tebufenpyrad; and biological agents such as Bacillus thuringiensis, Bacillus thuringiensis delta endotoxin, baculovirus, and entomopathogenic bacteria, virus and fungi. Descriptions of various commercially available compounds listed above may be found in The Pesticide Manual, Thirteenth Edition, C.D.S. Thomlin, ed., British Crop Protection Council, 2003. For embodiments where one or more of these various mixing partners are used, the weight ratio of these various mixing partners (in total) to the compound of Formula 1 is typically between about 1:100 and about 3000:1. Of note are weight ratios between about 1:30 and about 300:1 (for example ratios between about 1:1 and about 30:1). It will be evident that including these additional components may expand the spectrum of diseases controlled beyond the spectrum controlled by the compound of Formula 1 alone.
In one mixture embodiment, granules of a solid composition comprising a compound of Formula 1 is mixed with granules of a solid composition comprising another agricultural protectant. These granule mixtures can be in accordance with the general granule mixture disclosure of PCT Patent Publication WO 94/24861 or more preferably the homogenous granule mixture teaching of U.S. Patent 6,022,552.
Of note are combinations (e.g., in the form of compositions) of a compound of Formula 1 with at least one other fungicide. Of particular note are such combinations where the other fungicide has different site of action from the compound of Formula 1. In certain instances, combinations with other fungicides having a similar spectrum of control but a different site of action will be particularly advantageous for resistance management. Of particular note are compositions which in addition to compound of Formula 1 include at least one compound selected from the group consisting of (1) alkylenebis(dithiocarbamate) fungicides; (2) cymoxanil; (3) phenylamide fungicides; (4) pyrimidinone fungicides; (5) chlorothalonil; (6) carboxamides acting at complex II of the fungal mitochondrial respiratory electron transfer site; (7) quinoxyfen; (8) metrafenone; (9) cyflufenarnid; (10) cyprodinil; (11) copper compounds; (12) phthalimide fungicides; (13) fosetyl-aluminum; (14) benzimidazole fungicides; (15) cyazofamid; (16) fluazinam; (17) iprovalicarb; (18) propamocarb; (19) validomycin; (20) dichlorophenyl dicarboximide fungicides; (21) zoxamide; (22) fluopicolide; (23) mandipropamid; (24) carboxylic acid amides acting on phospholipid biosynthesis and cell wall deposition; (25) dimethomorph; (26) non-DMI sterol biosynthesis inhibitors; (27) inhibitors of demethylase in sterol biosynthesis; (28) bc\ complex fungicides; and salts of compounds of (1) through (28). Further descriptions of classes of fungicidal compounds are provided below.
Pyrimidinone fungicides (group (4)) include compounds of Formula Al
Figure imgf000242_0001
Al wherein M forms a fused phenyl, thiophene or pyridine ring; R11 is C^-Cs alkyl; R12 is C1-Cg alkyl or C1-C6 alkoxy; R13 is halogen; and R14 is hydrogen or halogen. Pyrimidinone fungicides are described in PCT Patent Application Publication
WO 94/26722 and U.S. Patents 6,066,638, 6,245,770, 6,262,058 and 6,277,858. Of note are pyrimidinone fungicides selected from the group: 6-bromo-3-propyl-2-propyIoxy- 4(3H)-quinazolinone, 6,8-diiodo-3-propyl-2-propyloxy-4(3H)-quinazolinone, 6-iodo- 3-propyl-2-propyloxy-4(3H)-quinazolinone (proquinazid), ό-chloro^-propoxy-S-propyl- thieno[2,3-d]pyrimidin-4(3iϊ)-one, 6-bromo-2-propoxy-3-propylthieno[2,3-cf|pyrimidin- 4(3H)-one, 7-bromo-2-ρropoxy-3-propylthieno[3,2-f/]pyrimidin-4(3iϊ)-one, 6-bromo- 2-propoxy-3-propylpvrido[2,3-d]ρyrimidin-4(3Hr)-one, 6,7-dϊbromo-2-propoxy-3-propyl- tnieno[3,2-£/]pyrimidin-4(3Η)-one, and 3-(cyclopropylmethyl)-6-iodo-2-(propylthio)pyrido- [2,3-<φyrimidin-4(3H)-one. Sterol biosynthesis inhibitors (group (27)) control fungi by inhibiting enzymes in the sterol biosynthesis pathway. Demethylase-inhibiting fungicides have a common site of action within the fungal sterol biosynthesis pathway, involving inhibition of demethylation at position 14 of lanosterol or 24-methylene dihydrolanosterol, which are precursors to sterols in fungi. Compounds acting at this site are often referred to as demethylase inhibitors, DMI fungicides, or DMIs. The demethylase enzyme is sometimes referred to by other names in the biochemical literature, including cytochrome P-450 (14DM). The demethylase enzyme is described in, for example, J. Biol. Chem. 1992, 267, 13175-79 and references cited therein. DMI fungicides are divided between several chemical classes: azoles (including triazoles and imidazoles), pyrimidines, piperazines and pyridines. The triazoles include azaconazole, bromuconazole, cyproconazole, difenoconazole, diniconazole (including diniconazole-M), epoxiconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, metconazole, myclobutanil, penconazole, propiconazole, prothioconazole, quinconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triticonazole and uniconazole. The imidazoles include clotrimazole, econazole, imazalil, isoconazole, miconazole, oxpoconazole, prochloraz and triflumizole. The pyrimidines include fenarimol, nuarimol and triarimol. The piperazines include triforine. The pyridines include buthiobate and pyrifenox. Biochemical investigations have shown that all of the above mentioned fungicides are DMI fungicides as described by K. H. Kuck et al. in Modern Selective Fungicides - Properties, Applications and Mechanisms of Action, H. Lyr (Ed.), Gustav Fischer Verlag: New York, 1995, 205-258. bc\ Complex Fungicides (group 28) have a fungicidal mode of action which inhibits the bc\ complex in the mitochondrial respiration chain. The bc\ complex is sometimes referred to by other names in the biochemical literature, including complex III of the electron transfer chain, and ubihydroquinonexytochrome c oxidoreductase. This complex is uniquely identified by Enzyme Commission number ECl.10.2.2. The bcγ complex is described in, for example, J. Biol. Chem. 1989, 264, 14543-48; Methods Enzymol. 1986, 126, 253—71; and references cited therein. Strobilurin fungicides such as azoxystrobin, dimoxystrobin, enestroburin (SYP-Z071), fluoxastrobin, kresoxim-methyl, metominostrobin, orysastrobin, picoxystrobin, pyraclostrobin and trifloxystrobin are known to have this mode of action (H. Sauter et al., Angew. Chem. Int. Ed. 1999, 38, 1328-1349). Other fungicidal compounds that inhibit the bc\ complex in the mitochondrial respiration chain include famoxadone and fenamidone.
Alkylenebis(dithiocarbamate) fungicides (group (I)) include compounds such as mancozeb, maneb, propineb and zineb. Phenylamide fungicides (group (3)) include compounds such as metalaxyl, benalaxyl, furalaxyl and oxadixyl. Carboxamides (group (6)) include compounds such as boscalid, carboxin, fenfuram, flutolanil, furametpyr, mepronil, oxycarboxin, thifluzamide, penthiopyrad and iV-[2-(l,3-dimethylbutyl)phenyl]-5-fluoro-l,3- dimethyl-lH-pyrazole-4-carboxamide (PCT Patent Publication WO 2003/010149), and are known to inhibit mitochondrial function by disrupting complex II (succinate dehydrogenase) in the respiratory electron transport chain. Copper compounds (group (H)) include compounds such as copper oxychloride, copper sulfate and copper hydroxide, including compositions such as Bordeaux mixture (tribasic copper sulfate). Phthalimide fungicides (group (12)) include compounds such as folpet and captan. Benzimidazole fungicides (group (14)) include benomyl and carbendazim. Dichlorophenyl dicarboximide fungicides (group (20)) include chlozolinate, dichlozoline, iprodione, isovaledione, myclozolin, procymidone and vinclozolin.
Non-DMI sterol biosynthesis inhibitors (group (26)) include morpholine and piperidine fungicides. The morpholines and piperidines are sterol biosynthesis inhibitors that have been shown to inhibit steps in the sterol biosynthesis pathway at a point later than the inhibitions achieved by the DMI sterol biosynthesis (group (27)). The morpholines include aldimorph, dodemorph, fenpropimorph, tridemorph and trimorphamide. The piperidines include fenpropidin.
Of note are these methods where plant diseases caused by Oomycete fungal plant pathogens are controlled.
The following Tests demonstrate the control efficacy of compounds of this invention on specific pathogens. The pathogen control protection afforded by the compounds is not limited, however, to these species. See Index Tables A for compound descriptions. The stereocenters labeled as "R" (rectus) and "S" (sinister) are based on the Cahn-Ingold-Prelog system as used by Chemical Abstracts; a stereocenter label followed by an asterisks "**■" means the stereochemical description is relative to other stereocenters, and the compound is racemic. The abbreviation "Ex." stands for "Example" and is followed by a number indicating in which example the compound is prepared. Index Table A lists the molecular weight of the highest isotopic abundance . parent ion (M+l) formed by addition of H+ (molecular weight of 1) to the molecule, observed by mass spectrometry using atmospheric pressure chemical ionization (AP+). Chiral separation of Compound 1 into Compounds 3 and 4 was accomplished using a preparative CHIRALP AK® AD-RH column (Chiral Technologies, Inc., West Chester, PA, U.S.A.) containing silica gel coated with amylose- tris(3,5-dimethylphenyl carbamate) and eluted with a water-methanol gradient. Specific rotation ([α]D) was measured in ethanol solution at 25 0C using a 100-mm path cell.
INDEX TABLE A
Figure imgf000244_0001
G is as defined in Exhibit 2; R-* a in G is H. L groups are defined as illustrated below.
Figure imgf000245_0001
L-I L-2 L-3
Figure imgf000245_0002
L-4 L-5 L-6
Figure imgf000245_0003
L-7 L-8 L-9
Figure imgf000245_0004
L-IO L-Il L-12
Figure imgf000245_0005
L-13 L-14 L-15
Figure imgf000246_0001
L-19 L-20 L-21
Figure imgf000246_0002
L-22 L-23 L-24
Figure imgf000246_0003
L-25 L-26 L-27
Figure imgf000246_0004
L-28 L-29 L-30
Figure imgf000247_0001
Figure imgf000248_0001
Figure imgf000249_0001
Figure imgf000250_0001
AP+
Figure imgf000251_0001
105 lyl 532
L-I G-I 4,5-dihydro-5-ethyl-5-phenyl-3-isoxazo
106 L-I χi G-I 4,5-dihydro-5-(4-biphenyl)-3-isoxazolyl 580
107 (Ex. 10) L-IO χi G-I 4,5-dihydro-5 -ρhenyl-3-isoxazolyl 524
108 L-I X1 G-I (4i?,5JR)-4,5-dihydro-4,5-diphenyl-li/-imidazol-2-yl 579
Figure imgf000251_0002
110 L-I X1 G-I 4,5-dihydro-5-(4-hydroxyphenyl)-3-isoxazolyl 520 111 pyrazinyl)-3-isoxazolyl 506 L-I X1 G-I 4,5-dihydro-5-(2-
Figure imgf000251_0003
113 562
L-I χi G-I 4,5-dihydro-5-(4-acetoxyphenyl)-3-isoxazolyl
114 L-I χi G-I 4,5-dihydro-5-(2-trifluoromethylphenyl)-3-isoxazolyl 572
115 L-I χi G-I 4,5-dihydro-5-(3-trifluoromethylphenyl)-3-isoxazolyl 572
116 L-I χi G-I 4,5-dihydro-5-(methoxycarbonylmethyl)-3-isoxazolyl 500
117 L-I X1 G-I 4,5-dihydro-5-(phenylsulfonyl)-3-isoxazolyl 568
118 L-I X1 G-I (5i?)-4,5-dihydro-l-inethyI-5-phenyl-lH-iinidazol-2-yl 517
119 L-I χi G-I (45)5i?)-4,5-dihydro-4,5-diphenyl-l-£/-imida2;ol-2-yl 579
120 L-I χi G-I 4-chlorophenyl 469
121 L-I χi G-I 2-chlorophenyl 469
122 L-I χi G-I 4-(trifluoromethyl)phenyl 503
123 L-I χi G-I 3-chlorophenyl 469
124 L-I χi G-I 3-pyridyl 436
125 L-I χi G-I 4,5-dihydro-5-(3,4-dihydroxyphenyl)-3-isoxazolyl 536
126 (Ex. 11) L-I l χi G-I 4,5-dihydro-5-phenyl-3-isoxazolyl 568
127 L- 12 χi G-I 4,5-dihydro-5-phenyl-3-isoxazolyl 658
128 (Ex. 1) L-13 χi G-I 4,5-dihydro-5-phenyl-3-isoxazolyl 504 AP+
Figure imgf000252_0001
130 (Ex. 6) ihydro-5-phenyl-3-isoxazolyl 520
L-14 χi G-I 4,5-d
131 534
L-I χi G-I 4,5-dihydro-5-(2-methoxyphenyl)-3-isoxazolyl
132 592
L-I χi G-I 4,5-dihydro-5-methyl-5-(2,5-dicWoro-3-thienyl)-3-isoxazolyl
133 G-I 4,5-dihydro-5-(2,5-dimethylphenyl)-3-isoxazolyl 532
L-I χi
134 hydro-5-(4-methoxycarbonylphenyl)-3-isoxazolyl 562
L-I χi G-I 4,5-di
135 6-diclilorophenyl)-3-isoxa2olyl 572
L-I χi G-I 4,5-dihydro-5-(2,
Figure imgf000252_0002
139 ro-5,5-diphenyl-3-isoxazolyl 580
L-I χi G-I 4,5-dihyd
140 l-3-isoxazolyl 548
L-I χi G-I 4,5-dihydro-5-(2-methoxyphenyl)-5-methy
141 548
L-I χi G-I 4,5-dihydro-5-(methoxymethyl)-5-phenyl-3-isoxazolyl
142 L-I χi G-I 4,5-dihydro-5-(methylthiomethyl)-5-phenyl-3-isoxazolyl 564
143 L-I χi GG--II 4,5-dihydro-5 -(methylsulfonylmethyl)-5-phenyl-3-isoxazolyl 596
144 L-I χi GG--II 4,5-dihydro-5-(methylsulfinylmethyl)-5-phenyl-3-isoxazolyl 580
145 L-I X1 G-I 531
Figure imgf000252_0003
AP+
Figure imgf000253_0001
510
148 L-I χi G-I 4,5-dih.ydro-5-(3-thienyl)-3-isoxazolyl
449
149 L-I χi G-I 3-methylphenyl
465
150 L-I χi G-I 4-methoxyphenyl
449
151 L-I χi G-I 4-methylphenyl
465
152 L-I χi G-I 3-methoxyphenyl
153 L-I χi G-I 2-meihoxyphenyl 465
154 (Ex. 7) L-I X2 G-I 4,5-dihydro-5-ρhenyl-3-isoxazolyl 505
155 L-I χi G-I 4,5-dihydro-5-(2,4>6-trimethoxyphenyl)-3-isoxazolyl 594
Figure imgf000253_0002
159 L-I X1 G-I 4,5-dihydro-5-hydroxymethyl-5-phenyl-3-isoxazolyl 534 AP+
Figure imgf000254_0001
161 L-I χi G-I 4,5-dihydro-5-(2-methylρhenyl)-3-isoxazolyl 518
162 L-I χi G-I 4,5-dihydro-5-thien-2-yl-3-isoxazolyl 510
163 L-8 χi G-I 4,5-dihydτo-5-methyl-5-phenyl-3-isoxazolyl 464
Figure imgf000254_0002
166 L-20 χi G-I 4,5-dihydro-5-phenyl-3-isoxazolyl 490
167 L-21 χi G-I 4,5-dihydro-5-phenyl-3 -isoxazolyl 647
168 L-23 χi G-I 4,5-dihydro-5-phenyl-3-isoxazolyl 579
Figure imgf000254_0003
172 L-24 X1 G-I 4,5-dihydro-5-phenyl-3-isoxazolyl 562 AP+
Figure imgf000255_0001
178 L-I χi G-I 4,5-dihydro-5-(2,6-dimethylphenyl)-3-isoxazolyl 532
179 L-I χi G-I 4,5-dihydro-5-(2,4,6-trimethylphenyl)-3-isoxazolyl 546
180 L-I χi G-I 4,5-dihydro-5-pyridiα-4-yI-3-isoxazolyl 505
181 L-I X1 G-I
Figure imgf000255_0002
AP+
Figure imgf000256_0001
183 L-I χi G-I 4,5-dihydro-5-phenyl- 1 H-pyrazol-3 -yl 503
184 L-I χi G-I 4,5-dihydro-5-phenyl-(l-methyl-lH-pyrazol-3-yl) 517
Figure imgf000256_0002
189 L-I χi G-I 4,5-dihydro-5-(2-brorao-phenyl)-3-isoxazolyl 582 190 L-26 X1 G-I 4,5-dihydro-5-phenyl-3-isoxazolyl 524
191 L-I X1 G-I 518
Figure imgf000256_0003
AP+
Figure imgf000257_0001
197 L-I χi G-I 4J5-dihydro-5-phenyl-(l-acetyl-lH-pyrazol-3-yl) 545
Figure imgf000257_0002
201 L-I X1 G-I 4,5-dihydro-5-(4-methylthiazol-5-yl)-3-isoxazolyl 525
Figure imgf000257_0003
AP+
Cmpd. L X G Z1-J (M+l)
203 L-I xi G-I 3-isoxazolyl 425
204 L-I χi G-I 4,5-dihydro-5-phenoxy-3-isoxazolyl 520
205 L-I χi G-I 4,5-dihydro-5-methyl -5-(2-methylphenyl)-3-isoxazolyl 532
206 L-I χi G-I 4,5-dihydro-5-(2,6-dimethoxyphenyl)-3-isoxazolyl 564
Figure imgf000258_0001
210 L-I χi G-I 5-(2-hydroxycarbonylphenyl)-3-isoxazolyl 546 211 L-I χi G-I 4,5-dihydro-5-( 1 , 1 -dirαethylethoxy)-3 -isoxazolyl 500
Figure imgf000258_0002
214 L-I X1 G-I 4,5-dihydro-5-(2,6-difluorophenyl-3-isoxazolyl 540
Figure imgf000258_0003
AP+
Figure imgf000259_0001
217 (Ex. 13) L-I χ3 G-I 4,5-dihydro-5-phenyl-3-isoxazolyl 502
Figure imgf000259_0002
219 L-I χi G-I 4,5-dihydro-5-(l-methylbenziinidazol-2-yl)-3-isoxa2olyl 558
220 L-I χi G-I 4,5-dihydro-5-(2-cyanophenyl)-3-isoxazolyl 529
221 ' L-I χi G-I 4,5-dihydro-5-2-methoxycarbonylphenyl)-3-isoxazolyl 562
Figure imgf000259_0003
Figure imgf000260_0001
AP+
Figure imgf000261_0001
237 L-29 χi G-I 4,5-dihydro-5-phenyl-3-isoxazolyl 508
238 L-30 χi G-I 4,5-dihydro-5-phenyl-3-isoxazolyl 508
239 L-31 χi G-I 4,5-dihydro-5-phenyl-3-isoxazolyl 566
240 L-32 χi G-I 4,5-dihydro-5-phenyl-3-isoxazolyI 562
241 L-33 χi G-I 4,5-dihydro-5-phenyl-3-isoxazolyI 534
242 L-I X1 G-I 520
Figure imgf000261_0002
Figure imgf000262_0001
AP+
Figure imgf000263_0001
257 L-22 χi G-I 4,5-dihydro-5-phenyl-3-isoxazolyl 506
258 L-25 χi G-I 4,5-dihydro-5-phenyl-3-isoxazolyl 556
259 L-27 χi G-I 4,5-dihydro-5-phenyl-3-isoxazolyl 520
260 L-5 χi G-I 4,5-dihydro-5-methyl-5-phenyl-3-isoxazolyl 572
261 L-IO χi G-I 4,5-dihydro-5-methyl-5-phenyl-3-isoxazolyl 538
262 L-I χi G-I 4,5-dihydro-5-(2-aminosulfonylbenzyl)-3-isoxazolyl 597
263 L-I χi G-I 4,5-dihydro-5-(2-acetoxyphenyl)-3-isoxazolyl 562
4,5-dihydro-5-(JV-methyl-N-phenylcarbonylamino)-3-
264 L-I χi G-I 561 isoxazolyl
265 L-I χi G-I 4,5-dihydro-5-cyano-5-phenyl-3-isoxazolyl 529
Figure imgf000263_0002
268 L-I χi G-I 4-ethylphenyl 463
269 L-I χi G-I 4-trifluoτometfaoxyphenyl 519
270 L-I χi G-I 4-methoxycarbonylphenyl 493
271 L-I χi G-I ,4-propylphenyl 477
272 L-I χi G-I 4-methylthiopheαyl 481
273 L-I χi G-I 4-isopropylphenyl 477
274 L-I χi G-I 4-isobutylphenyl 491
Figure imgf000263_0003
AP+
Figure imgf000264_0001
277 L-8 X1 G-I 4,5-dihydro-5-(2,4,6-trimethoxyphenyl)-3-isoxazolyl 540
Figure imgf000264_0002
AP+
Figure imgf000265_0001
[Note I]: Faster eluting enantiomer from the CHIRALP AK® AD-RH column using methanol in water as eluant, specific rotation = -98.8 °. Analysis using analytical CHIRALP AK® AD-RH column indicated about 100% optical purity. [Note 2]: Slower eluting enantiomer from the CHIRALP AK® AD-RH reverse phase column using methanol in water as eluant, specific rotation = +88 °. Analysis using analytical CHIRALP AK® AD-RH column indicated about 93% optical purity. [Note 3]: Diastereomer A. [Note 4]: Diastereomer B. [Note 5]: Mixture of isomers.
BIOLOGICAL EXAMPLES OF THE INVENTION
General protocol for preparing test suspensions for Test A-C: The test compounds were first dissolved in acetone in an amount equal to 3 % of the final volume and then suspended at the desired concentration (in ppm) in acetone and purified water (50/50 mix by volume) containing 250 ppm of the surfactant Trem® 014 (polyhydric alcohol esters). The resulting test suspensions were then used in Tests A-C. Spraying a 200 ppm test suspension to the point of run-off on the test plants was equivalent to a rate of 500 g/ha.
TEST A
Grape seedlings were inoculated with a spore suspension of Plasmopara viticola (the causal agent of grape downy mildew) and incubated in a saturated atmosphere at 20 0C for 24 h. After a short drying period, the test suspension was sprayed to the point of run-off on the grape seedlings, which were then moved to a growth chamber at 20 0C for 5 days, after which time the grape seedling were placed back into a saturated atmosphere at 20 0C for 24 h. Upon removal, visual disease ratings were made. TEST B
The test suspension was sprayed to the point of run-off on tomato seedlings. The following day the seedlings were inoculated with a spore suspension of Phytophthora infestans (the causal agent of tomato late blight) and incubated in a saturated atmosphere at
20 0C for 24 h, and then moved to a growth chamber at 20 0C for 5 days, after which time visual disease ratings were made.
TEST C
Tomato seedlings were inoculated with a spore suspension of Phytophthora infestans (the causal agent of tomato late blight) and incubated in a saturated atmosphere at 20 0C for
17 h. After a short drying period, the test suspension was sprayed to the point of run-off on the tomato seedlings, which were then moved to a growth chamber at 20 0C for 4 days, after which time visual disease ratings were made.
In addition to Tests A-C, the compounds were also sprayed on 2 separate sets of tomato plants, which were inoculated with Botrytis cinerea or Alternaria solani 24 h after treatment, bluegrass plants, which were inoculated with Pythium aphanidermatum 24 h after treatment and 3 separate sets of wheat plants, which were inoculated with Erysiphe graminis f. sp. tritici, Puccinia recondita or Septoria nodorum 24 h after treatment. Test compounds did not show noticeable activity against these additional pathogens under the test conditions at the application rates tested.
Results for Tests A-C are given in Table A. hi the table, a rating of 100 indicates 100 % disease control and a rating of 0 indicates no disease control (relative to the controls). A dash (-) indicates no test results. TABLE A
RESULTS OF BIOLOGICAL TESTS
Figure imgf000266_0001
Figure imgf000267_0001
Figure imgf000268_0001
Figure imgf000269_0001
Figure imgf000270_0001
* indicates compounds tested at 40 ppm. ** indicates compounds tested at lOppm.

Claims

CLAIMSWhat is claimed is:
1. A compound selected from Formula 1, an JV^oxide and salt thereof,
Figure imgf000271_0001
wherein
R1 is an optionally substituted phenyl, naphthalenyl or 5- or 6-membered heteroaromatic ring;
A is CHR15 orNR16;
R15 is H, halogen, cyano, hydroxy, -CHO, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 haloalkenyl, C2-C4 haloalkynyl, C2-C4 alkoxyalkyl, C2-C4 alkylthioalkyl, C2-C4 alkylsulfmylalkyl, C2-C4 alkylsulfonylalkyl, C2-C4 alkylcarbonyl, C2-C4 haloaUkylcarbonyl, C2-C5 alkoxycarbonyl, C3-C5 alkoxycarbonylalkyl, C2-Cs alkylaminocarbonyl, C3-C5 dialkylaminocarbonyl, C1-C4 alkoxy, C1-C4 haloalkoxy, Cj-C4 alkylthio, C1- C4 haloalkylthio, C i-C4 alkylsulfinyl, C X-C4 haloalkylsulfinyl, C t-C4 alkylsulfonyl or C1-C4 haloalkylsulfonyl;
R16 is H, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C2-C4 haloalkenyl, C2-C4 haloalkynyl, C2-C4 alkoxyalkyl, C2-C4 alkylthioalkyl, C2- C4 alkylsulfmylalkyl, C2-C4 alkylsulfonylalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C5 alkoxycarbonyl, C3-C5 alkoxycarbonylalkyl, C2-C5 alkylaminocarbonyl, C3-C5 dialkylaminocarbonyl, C1-C4 alkylsulfonyl or C1- C4 haloalkylsulfonyl;
W is O or S;
X is a radical selected from
Figure imgf000271_0002
χl • X3 X^
Figure imgf000272_0001
x x9 wherein the bond of X1, χ2, χ3, χ4, χ5s X6? χ7? χ8 or χ9 which is identified with "t" is connected to the carbon atom identified with "q" of Formula 1, the bond which is identified with "u" is connected to the carbon atom identified with "r" of
Formula 1, and the bond which is identified with "v" is connected to G; each R2 is independently C1-C4 alkyl, C1-C4 alkenyl, C1-C4 haloalkyl, C1-C4 alkoxy, halogen, cyano or hydroxy; or two R2 are taken together as C1-C4 alkyl ene or C2— C4 alkenylene to form a bridged bicyclic or fused bicyclic ring system; or two R2 attached to adjacent ring carbon atoms joined by a double bond are taken together as -CH=CH-CH=CH- optionally substituted with 1 to 3 substituents selected from C1-C4 alkyl, C]-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, halogen, hydroxy, amino, cyano and nitro; G is an optionally substituted 5-membered heteroaromatic ring or 5-membered saturated or partially saturated heterocyclic ring;
J is a 5-, 6- or 7-membered ring, a 8- to 11-membered bicyclic ring system or a 7- to 11-membered spirocyclic ring system, each ring or ring system containing ring members selected from carbon and optionally 1 to 4 heteroatoms selected from up to 2 O, up to 2 S and up to 4 N, and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O), S(O)2 and SiR17RlS5 each ring or ring system optionally substituted with 1 to 5 substituents independently selected from R5; each R5 is independently H, halogen, cyano, hydroxy, amino, nitro, -CHO, -C(=O)OH, -C(=O)NH2, -NR25R26, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C4-C1Q alkylcycloalkyl, C4-C10 cycloalkylalkyl, C6-C14 cycloalkylcycloalkyl, C4-C10 halocycloalkylalkyl, C5-C10 alkylcycloalkylalkyl, C3-C8 cycloalkenyl, C3-C8 halocycloalkenyl, C2-C6 alkoxyalkyl, C4-C10 cycloalkoxyalkyl, C3-C8 alkoxyalkoxyalkyl, C2-C6 alkylthioalkyl, C2-C6 alkylsulfinylalkyl, C2-C6 alkylsulfonylalkyl, C2-C6 alkylaminoalkyl, C3-C8 dialkylaminoalkyl, C2-C6 haloalkylaminoalkyl, C4-C10 cycloalkylaminoalkyl, C2-Cg alkylcarbonyl, C2-C6.haloalkylcarbonyl, C4-C8 cycloalkylcarbonyl, C2- Cg alkoxycarbonyl, C4-Cg cycloalkoxycarbonyl, Cs-C10 cycloalkylalkoxycarbonyl, C2-C6 alkylaminocarbonyl, C3-C8 dialkylarninocarbonyl, C4-C8 cycloalkylaminocarbonyl, C2-C6 haloalkoxyalkyl, C1-C6 hydroxyalkyl, Cj-C6 alkoxy, C1-C6 haloalkoxy, C3-C8 cycloalkoxy, C3-
Cg halocycloalkoxy, C4-C10 cycloalkylalkoxy, C2-C6 alkenyl'oxy, C2-C6 haloalkenyloxy, C2-C6 alkynyloxy, C2-C6 haloalkynyloxy, C2-C6 alkoxyalkoxy, C2-C6 alkylcarbonyloxy, C2-C6 haloalkylcarbonyloxy, C4-C8 cycloalkylcarbonyloxy, C3-C6 alkylcarbonylalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C3-C8 cycloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C3-Cg cycloalkylsulfonyl, C3-C1Q trialkylsilyl, C1-C6 alkylsulfonylamino, C1-C6 haloalkylsulfonylamino or -Z2Q; R25 is H, C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, C2-C6 alkylcarbonyl, C2- C6 haloalkylcarbonyl, C2-C6 alkoxycarbonyl or C2-C6 haloalkoxycarbonyl;
R26 is C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, C2-C6 alkylcarbonyl, C2-C6 haloalkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 haloalkoxycarbonyl or -Z4Q; each R17 and R18 is independently C1-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl, C3- C5 cycloalkyl, C3-C6 halocycloalkyl, C4-C10 cycloalkylalkyl, C4-C7 alkylcycloalkyl, C5-C7 alkylcycloalkylalkyl, C1-C5 haloalkyl, C1-C5 alkoxy or
Figure imgf000273_0001
each Q is independently phenyl, benzyl, naphthalenyl, a 5- or 6-membered heteroaromatic ring or an 8- to 11-membered heteroaromatic bicyclic ring system, each optionally substituted with 1 to 5 substituents independently selected from R7 on carbon atom ring members and R12 on nitrogen atom ring members; or each Q is independently a 3- to 7-membered nonaromatic carbocyclic ring, a 5-, 6- or 7-membered nonaromatic heterocyclic ring or an 8- to 11-membered nonaromatic bicyclic ring system, each optionally including ring members selected from the group consisting OfCC=O), C(=S), S(O), S(O)2 and SiR17R18, and optionally substituted with 1 to 5 substituents independently selected from R7 on carbon atom ring members and R12 on nitrogen atom ring members; each R7 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C1o cycloalkylalkyl, C4-C1 () alkylcycloalkyl, C5-C1Q alkylcycloalkylalkyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl,
C3-C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1- C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylthio, C1-C4 haloalkylsulfinyl, C1-C4 haloalkylsulfonyl, C1-C4 alkylarnino, C2-Cg dialkylamino, C3-C6 cycloalkylamino, C2-C4 alkoxyalkyl, C 1-^4 hydroxyalkyl, C2-C4 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-Cg alkylcarbonylthio, C2-Cg alkylaminocarbonyl, C3-C8 dialkylaminocarbonyl or C3-C6 trialkylsilyl; or R5 and R7 are taken together with the atoms linking R5 and R7 to form an optionally substituted 5- to 7-membered ring containing ring members selected from carbon and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and up to 1 N and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O), S(O)2 and SiR17R18; R12 is H, C1-C3 alkyl, C1-C3 alkylcarbonyl, C1-C3 alkoxy or C1-C3 alkoxycarbonyl; each Z1 and Z2 is independently a direct bond, O, C(=O), S(O)m, CHR20 or NR21; each Z4 is independently O, C(=O), S(O)m or CHR20; each R20 is independently H, C1-C4 alkyl or C1-C4 haloalkyl; each R21 is independently H, C1-Cg alkyl, C1-Cg haloalkyl, C3-Cg cycloalkyl, C2-C6 alkylcarbonyl, C2-Cg haloalkylcarbonyl, C2-Cg alkoxycarbonyl or C2-Cg haloalkoxycarbonyl ; each m is independently 0, 1 or 2; and n is 0, 1 or 2; provided that: (a) when R1 is unsubstituted thienyl, X is X1 and the ring containing X is saturated, G is an unsubstituted thiazole ring connected at its 2-position to X and at its 4-position to Z1 in Formula 1, A is CHR15, R15 is H, and J is an isoxazole ring connected at its 4-position to Z1 and substituted at its 5-position with methyl and at its 3-position with meta-substituted phenyl, then Z1 is O, C(=O), S(O)m, CHR20 or NR21; and
(b) when A is NR16, X is X1 or X2, Z1 is a direct bond, and J is phenyl, then J is substituted with at least one R5 other than H, F, Cl, CN, OCH3, CF3 and CH3.
2. A compound of Claim 1 wherein
G is a 5-membered heteroaromatic ring or 5-membered saturated or partially saturated heterocyclic ring, each ring optionally substituted with up to 2 substituents selected from R3 on carbon ring members and selected from R1 J on nitrogen ring members; R1 is a phenyl or 5- or 6-membered heteroaromatic ring optionally substituted with 1 to 2 substituents independently selected from R4a on carbon ring members and ' R4b on nitrogen ring members; each R2 is independently C1-C2 alkyl, C1-C2 haloalkyl, C1-C2 alkoxy, halogen, cyano or hydroxy; each R3 is independently C1-C3 alkyl, C1-C3 haloalkyl or halogen; each R4a is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl, C4-C10 alkylcycloalkyl, C5-C10 alkylcycloalkylalkyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3-C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C4 alkoxy,
C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylthio, C1-C4 haloalkylsulfinyl, C1-C4 haloalkylsulfonyl, C1-C4 alkylamino, C2-Cg dialkylamino, C3-C6 cycloalkylamino, C2-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C2-C4 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-C6 alkylcarbonylthio, C2-C6 alkylaminocarbonyl, C3-Cg dialkylaminocarbonyl or C3-C6 trialkylsilyl; each R4b is independently C1-C6 alkyl, C3-C6 alkenyl, C3-C6 alkynyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C3-C6 haloalkenyl, C3-C6 haloalkynyl, C3-C6 halocycloalkyl or C2-C4 alkoxyalkyl; each R11 is independently C1-C3 alkyl;
R15 is H, halogen, cyano, hydroxy, -CHO, C1-C4 alkyl, Ci-C4 haloalkyl or C2-C5 alkoxycarbonyl;
R16 is H, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl or C2-C4 alkoxycarbonyl; when R5 and R7 are taken together with the atoms linking R5 and R7 to form an optionally substituted 5- to 7-membered ring, then R5 and R7 are taken together with the atoms linking R5 and R7 to form a 5- to 7-membered ring containing ring members selected from carbon and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and up to 1 N, and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O), S(O)2 and
SiR17R18, the ring optionally substituted on ring members other than the atoms linking R5 and R7 with up to 4 substituents selected from R8; each R8 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-Ci0 cycloalkylalkyl, C4-Cj0 alkylcycloalkyl, C5-C10 alkylcycloalkylalkyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl,
C3-C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, Ci-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylthio, C1-C4 haloalkylsulfinyl, C1-C4 haloalkylsulfonyl, C1-C4 alkylamino, C2-Cg dialkylamino, C3-C6 cycloalkylamino, C2-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C2-C4 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-C6 alkylcarbonylthio, C2-C6 alkylaminocarbonyl, C3-C8 dialkylaminocarbonyl or C3-C6 trialkylsilyl; and each Z4 is independently C(=O) or S(O)2.
3. A compound of Claim 2 wherein
G is one of G-I through G-59 wherein the bond projecting to the left is bonded to X, and bond projecting to the right is bonded to Z1;
J is one of J-I through J-82 wherein the bond shown projecting to the left is bonded to Zl;
Q is one of Q-I through Q-102; R1 is one of U-I through U-50; each R2 is independently methyl, methoxy, cyano or hydroxy; each R3a is independently selected from H and R3; each R5 is independently H5 cyano, C1-Cg alkyl, C2-C6 alkenyl, C2-Cg alkynyl, C1-
Cg haloalkyl, C2— Cg haloalkenyl, C2— Cg haloalkynyl, C3-Cg cycloalkyl, C3— Cg halocycloalkyl, C4— C10 alkylcycloalkyl, C4— C 10 cycloalkylalkyl, C2-Cg alkoxyalkyl, C4-C10 cycloalkoxyalkyl, C3~Cg alkoxyalkoxyalkyl, C2-Cg alkylthioalkyl, C2-Cg alkoxycarbonyl, C1-Cg alkoxy, C1-Cg haloalkoxy, C3-Cg cycloalkoxy, C3-Cg halocycloalkoxy, C4-C10 cycloalkylalkoxy, C2-Cg alkenyloxy, C2~Cg haloalkenyloxy, C2-Cg alkynyloxy, C2-Cg haloalkynyloxy, C2-Cg alkoxyalkoxy, C2-Cg alkylcarbonyloxy, C2-Cg haloalkylcarbonyloxy, C4-Cg cycloalkylcarbonyloxy, C3-Cg alkylcarbonylalkoxy, C1-Cg alkylthio, C1-C6 haloalkylthio, C3-C8 cycloalkylthio, C3-C10 trialkylsilyl, -NR25R26 or Z2Q;
R1 la is selected from H and R1 1; R15 is H, cyano, hydroxy, methyl or methoxycarbonyl; R*6 is H, methyl, methylcarbonyl or methoxycarbonyl; each Z4 is C(=O); k is 0, 1 or 2; p is O, 1,2 or 3; and x is an integer from 0 to 5; provided that:
(a) when R4 is attached to a carbon ring member, said R4 is selected from R4a; (b) when R4 is attached to a nitrogen ring member (e.g., in U-4, U-11 through U-15,
U-24 through U-26, U-31 or U-35), said R4 is selected from R4b;
(c) when G is G-6, G- 16 or G-42, and each R3a is other than H, then R1 l a is H;
(d) when G is G-25 or G-31, then at least one R3a is H; and
(e) when G is one of G-31 through G-35, then Z1 is a direct bond or CHR20.
4. A compound of Claim 3 wherein
G is selected from G-I, G-2, G-7, G-8, G-14, G-15, G-23, G-24, G-26, G-27, G-36, G- 37, G-38, G-49, G-50 and G-55; J is selected from J-1, 3-2, J-3, J-4, J-5, J-7, J-8, J-9, J-IO5 J-I l, J-12, J-14, J-15, J-16,
J-20, J-24, J-25, J-26, J-29, J-30, J-37, J-38, J-45 and J-69; each Q is independently Q-I, Q-20, Q-32 through Q-34, Q-45 through Q-47, Q-60 through Q-73, Q-76 through Q-79, Q-84 through Q-94 and Q-98 through Q-102; A is CH2 orNH;
W is O;
X is X1, X2 or X3; each R5 is independently H, cyano, C1-Cg alkyl, C1-Cg haloalkyl, C3-Cg cycloalkyl,
C3-Cg halocycloalkyl, C2-Cg alkoxyalkyl, C1-C6 alkoxy, C1-Cg haloalkoxy, C3-Cg cycloalkoxy, C2-Cg alkenyloxy, C2-Cg haloalkenyloxy, C2-Cg alkynyloxy, C2-Cg alkoxyalkoxy, C2-Cg alkylcarbonyloxy, C2-Cg haloalkylcarbonyloxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C3-C10 trialkylsilyl, -NR25R26 or Z2Q; Z1 is a direct bond; Z2 is a direct bond or NR21 ;
Rl is selected from U-I through U-3, U-11, U-13, U-20, U-22, U-23, U-36 through U-
39 and U-50; each R3 is independently methyl or halogen; each R4a is independently C1-C2 alkyl, C1-C2 haloalkyl, halogen, C1-C2 alkoxy or C1~C2 haloalkoxy; each R4b is independently C1-C2 alkyl or C1-C2 haloalkyl; each R7 is independently halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, hydroxy, C1-
C2 alkoxy or C1-C2 haloalkoxy; k is 1 or 2; and n is 0.
5. A compound of Claim 4 wherein
A is CH2;
G is selected from G-I, G-2, G-15, G-26, G-27, G-36, G-37 and G-38; and G is unsubstituted; J is selected from J-4, J-5, J-8, J-11, J-15, J-16, J-20, J-29, J-30, J-37, J-38, and J-69;
Q is selected from Q-I, Q-45, Q-63, Q-64, Q-65, Q-68, Q-69, Q-70, Q-71, Q-72, Q-73, Q-76. Q-78, Q-79, Q-84, Q-85, Q-98, Q-99, Q-100, Q-101 and Q-102;
X is X1 or X2; and the ring comprising X is saturated;
Rl is U- l or U-50; each R4a is independently C1-C2 alkyl, trifluoromethyl, Cl, Br, I or methoxy; each R4b is independently C1-C2 alkyl or trifluoromethyl; and each R5 is independently H, cyano, C1-Cg alkyl, C^-Cg haloalkyl, C1-Cg alkoxy, C1- C6 haloalkoxy, -NR25R26 or Z2Q.
6. A compound of Claim 5 wherein
G is selected from G-I, G-2, G-15, G-26 and G-36; J is selected from J-4, J-5, J-I l, J-20, J-29, J-37, J-38, and J-69;
Q is selected from Q-45, Q-63, Q-64, Q-65, Q-68, Q-69, Q-IO, Q-71, Q-72 and Q-85; and X is X*.
7. A compound of Claim 1 wherein R1 is an optionally substituted phenyl or 5- or 6-membered heteroaromatic ring;
A is CH2 or NH;
X is Xl, X2, X3, X4, χ5, χ6s χ7 or X«; each R2 is independently C1-C4 alkyl, C1-C4 alkenyl, C1-C4 haloalkyl, C1-C4 alkoxy, halogen, cyano or hydroxy; or two R2 are taken together as C1-^ alkylene or C2-C3 alkenylene to form a bridged bicyclic ring system; or two R2 attached to adjacent ring carbon atoms joined by a double bond are taken together as -CH=CH-CH=CH- optionally substituted with 1 to 3 substituents selected from C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, halogen, hydroxy, amino, cyano and nitro;
G is an optionally substituted 5-membered heteroaromatic ring or 5-membered saturated or partially saturated heterocyclic ring;
J is a 5- or 6-membered ring or a 8- to 11-membered bicyclic ring system, each ring or ring system containing ring members selected from carbon and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and up to 3 N, and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O), or S(O)2, each ring or ring system optionally substituted with 1 to 5 substituents independently selected from R5; each R5 is independently H, C1-Cg alkyl, C2-Cg alkenyl, C2-Cg alkynyl, Cβ-Cg cycloalkyl, C4-C10 cycloalkylalkyl, C4-C10 alkylcycloalkyl, C5-C10 alkylcycloalkylalkyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3~C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 alkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylthio, C1-C6 haloalkylsulfinyl, C1-C6 haloalkylsulfonyl, C1-C6 alkylamino, C2-Cg dialkylamino, C3~Cg cycloalkylamino, C2-C6 alkoxyalkyl,
C2-C6 haloalkoxyalkyl, C1-C6 hydroxyalkyl, C2-C6 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-C6 alkylcarbonylthio, C2-C6 alkylaminocarbonyl, C3-C8 dialkylaminocarbonyl, C3-C6 trialkylsilyl, or -Z2Q; each Q is independently an optionally substituted phenyl, benzyl, naphthalenyl, C3-Cg cycloalkyl, C3-C6 cycloalkenyl or 5- or 6-membered heteroaromatic ring, each optionally substituted with 1 to 3 substituents selected from R? on carbon ring members and R12 on nitrogen ring members; each R7 is independently C]-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl, C4-C10 alkylcycloalkyl, Cs-C10 alkylcycloalkylalkyl, Ci-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3-C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C4 alkoxy,
C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylthio, C1-C4 haloalkylsulfmyl, C1-C4 haloalkylsulfonyl, C1-C4 alkylamino, C2-Cg dialkylamino, C3-C6 cycloalkylamino, C2-C4 alkoxyalkyl, C1- C4 hydroxyalkyl, C2-C4 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-C6 alkylcarbonylthio, C2-C6 alkylaminocarbonyl, C3-Cg dialkylaminocarbonyl or C3-C6 trialkylsilyl; or
R5 and R7 are taken together with the atoms linking R5 and R7 to form an optionally substituted 5- to 7-membered ring containing as ring members 2 to 7 carbon atoms and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and up to 1 N;
R12 is C1-C3 alkyl; each Z1 and Z2 are independently a direct bond, O, S(O)n,, CEDR20 or NR21; and
R21 is H or C1-C3 alkyl.
8. A compound of Claim 7 wherein G is a 5-membered heteroaromatic ring or 5-membered saturated or partially saturated heterocyclic ring, each ring optionally substituted with up to 2 substituents selected from R3 on carbon ring members and selected from R11 on nitrogen ring members;
R1 is a phenyl or 5- or 6-membered heteroaromatic ring optionally substituted with 1 to 2 substituents independently selected from R4a on carbon ring members and
R4b on nitrogen ring members; each R3 is independently C1-C3 alkyl, C1-C3 haloalkyl or halogen; each R4a is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl, C4-C10 alkylcycloalkyl, C5-C10 alkylcycloalkylalkyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl,
C3-C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylthio, C1-C4 haloalkylsulfinyl, C1-C4 haloalkylsulfonyl, C1-C4 alkylamino, C2— Cg dialkylamino, C3— C5 cycloalkylarnino, C2— C4 alkoxyalkyl, C1-C4 hydxoxyalkyl, C2-C4 alkylcarbonyl, C2~C6 alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-C6 alkylcarbonylthio, C2-C6 alkylaminocarbonyl, C3-C8 dialkylaminocarbonyl or C3~C6 trialkylsilyl; each R4b is independently C1-C6 alkyl, C3-C6 alkenyl, C3-C6 alkynyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C3-C6 haloalkenyl, C3-C6 haloalkynyl, C3-C6 halocycloalkyl or C2-C4 alkoxyalkyl; each R11 is independently C1-C3 alkyl; and when R5 and R7 are taken together with the atoms linking R5 and R7 to form an optionally substituted 5- to 7-membered ring, then R5 and R7 are taken together with the atoms linking R5 and R7 to form a 5- to 7-membered ring containing as ring members 2 to 7 carbon atoms and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and up to 1 N, optionally substituted with up to 2 substituents selected from R8; and each R8 is independently C1-C3 alkyl.
9. A compound of Claim 8 wherein
G is one of G-I through G-55;
J is one of J-I through J-82;
Q is one of Q-I through Q-55; R1 is one of U-I through U-50; each R3a is independently selected from H and R3;
R1 la is selected from H and R1 * ; k is 0, 1 or 2; p is 0, 1 or 2; and x is an integer from 0 to 5; provided that:
(a) when R4 is attached to a carbon ring member, said R4 is selected from R4a;
(b) when R4 is attached to a nitrogen ring member (e.g., in U-4, U-11 through U-15,
U-24 through U-26, U-31 or U-35), said R4 is selected from R4b; (c) when G is G-6, G- 16 or G-42, and each R3a is other than H, then R1 la is H;
(d) when G is G-25 or G-31, then at least one R3a is H; and
(e) when G is one of G-31 through G-35; then Z1 is a direct bond or CHR20.
10. A compound of Claim 9 wherein
G is selected from G-I, G-2, G-15, G-26, G-27, G-36, G-37 and G-38; J is selected from J-I, J-2, J-3, J-4, J-5, J-7, J-8, J-9, J-10, J-I l, J-12, J-14, J-IS, J-16,
J-20, J-24,. J-25, J-26, J-29, J-30, J-45 and J-69; each Q is independently Q-I, Q-20, Q-32 to 34, Q-45 Q-46 or Q-47; W is O;
X is Xl, X? αr χ3; each Z1 and Z2 is a direct bond;
R1 is selected from U-I through U-3, U-Il, U-13, U-20, U-22, U-23, U-36 through U- 39 and U-50; each R3 is independently methyl or halogen; each R4a is independently C1-C2 a&yl> Ci-C2 haloalkyl, halogen or C1-C2 alkoxy; each R4b is independently Ci-C2 alkyl or Ci-C2 haloalkyl; one instance of R5 is Z2Q and other instances of R5 are independently selected from H, C !-C4 alkyl, C ^C4 haloalkyl and halogen; each R7 is independently halogen, Cj- C3 alkyl, Ci- C3 haloalkyl, hydroxy, Ci-C2 alkoxy or Cj-C2 haloalkoxy; k is 1 or 2; and n is 0.
11. A compound of Claim 10 wherein
A is CH2;
G is selected from G-I, G-2, G-15, G-26, and G-36; and G is unsubstituted;
J is selected from J-Il, J-25, 3-26, J-29 and J-30;
Q is selected from Q-I and Q-45; X is X1 or X2; and the ring comprising X is saturated;
RMs U-I or U-50; each R4a is independently Ci-C2 alkyl, trifluoromethyl, Cl, Br, I or methoxy; and each R4b is independently Ci-C2 alkyl or trifluoromethyl.
12. A compound of Claim 11 wherein J is selected from J-11 and J-29;
X is X1; and each R4a is independently Ci-C2 alkyl, trifluoromethyl or Cl.
13. A compound of Claim 1 wherein
R1 is U-I or U-50 wherein when R4 is attached to a carbon ring member, said R4 is selected from R4a, and when R4 is attached to a nitrogen ring member, said R4 is selected from R4b; each R4a is independently Ci-C2 alkyl, trifluoromethyl, Cl, Br, I or methoxy; each R4b is independently Ci-C2 alkyl or trifluoromethyl;
A is CH2; W is O;
X is X1 or X2 and ring comprising X is saturated; each R2 is independently ethyl, methoxy, cyano or hydroxy; G is selected from G-I, G-2, G-15, G-26 and G-36 wherein the bond projecting to the left is bonded to X, and bond projecting to the right is bonded to Z1; and G is unsubstituted; each R3a is. independently selected from H and R3 ; each R3 is independently methyl or halogen;
J is selected from J-I l, J-25, J-26, J-29 and J-30; wherein the bond shown projecting to the left is bonded to Z1; each R5 is independently H, halogen, cyano, hydroxy, amino, nitro, -CHO, -C(=O)OH,
-C(=O)NH2, -NR25R26, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3-C8 cycloallcyl, C3-C8 halocycloalkyl, C4-C]O alkylcycloalkyl, C4-C1Q cycloalkylalkyl, C6-C14 cycloalkylcycloalkyl, C4-C1Q halocycloalkylalkyl, C5-C1Q alkylcycloalkylalkyl, C3-C8 cycloalkenyl, C3-Cg halocycloalkenyl, C2-C6 alkoxyalkyl, C4-C10 cycloalkoxyalkyl, C3-C8 alkoxyalkoxyalkyl, C2-C6 alkylthioalkyl, C2-C6 alkylsulfinylalkyl, C2-C6 alkylsulfonylalkyl, C2-C6 alkylaminoalkyl, C3-Cg. dialkylaminoalkyl, C2-C6 haloalkylaminoalkyl, C4-C1Q cycloalkylaminoalkyl, C2-C6 alkylcarbonyl, C2-C6 haloalkylcarbonyl, C4-Cg cycloalkylcarbonyl, C2- C6 alkoxycarbonyl, C4-Cg cycloalkoxycarbonyl, Cs-C1Q cycloalkylalkoxycarbonyl, C2-C6 alkylaminocarbonyl, C3-C8 dialkylaminocarbonyl, C4-C8 cycloalkylaminocarbonyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C8 cycloalkoxy, C3-Cg halocycloalkoxy, C4-C1Q cycloalkylalkoxy, C2-C6 alkenyloxy, C2-C6 haloalkenyloxy, C2-C6 alkynyloxy, C2-C6 haloalkynyloxy, C2-C6 alkoxyalkoxy, C2-C6 alkylcarbonyloxy, C2-C6 haloalkylcarbonyloxy, C4-C8 cycloalkylcarbonyloxy, C3-C6 alkylcarbonylalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C3-C8 cycloalkylthio, C1-C6 alkylsulfϊnyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C3-Cg cycloalkylsulfonyl, C3-C1Q trialkylsilyl, C1-C6 alkylsulfonylamino, C1-C6 haloalkylsulfonylamino or -Z2Q;
R25 is H, C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, C2-C6 alkylcarbonyl, C2- C6 haloalkylcarbonyl, C2-C6 alkoxycarbonyl or C2-C6 haloalkoxycarbonyl;
R26 is C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, C2-C6 alkylcarbonyl, C2-C6 haloalkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 haloalkoxycarbonyl or -Z4Q; each Q is selected from Q-I , Q-45 and Q-63; each R7 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C10 cycloalkylalkyl, C4-C10 alkylcycloalkyl, C5-C10 alkylcycloalkylalkyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3-C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylthio, C1-C4 haloalkylsulfinyl, C1-C4 haloalkylsulfonyl, C1-C4 alkylamino, C2-Cg dialkylamino, C3-C6 cycloalkylamino, C2~C4 alkoxyalkyl, C1-C4 hydroxyalkyl. C2-C4 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-Cg alkylcarbonyloxy, C2-Cg alkylcarbonylthio, C2-Cg alkylatninocarbonyl, C3-Cg dialkylaminocarbonyl or C3-Cg trialkylsilyl; or
R5 and R7 are taken together with the atoms linking R5 and R7 to form a 5- to
7-membered ring containing as ring members 2 to 7 carbon atoms and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S, up to 1 Si and up. to 1 N, the ring optionally substituted on ring members other than the atoms linking R5 and R7 with up to 4 substituents selected from R^; each R8 is independently C1-C6 alkyl, C2-Cg alkenyl, C2-Cg alkynyl, C3-Cg cycloalkyl, C4-C1Q cycloalkylalkyl, C4-C1Q alkylcycloalkyl, Cs-C1Q alkylcycloalkylalkyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3-C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C4 alkόxy, .:=τr-Gl-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfønyl,
C1-C4 haloalkylthio, C1-C4 haloalkylsulfinyi, C1-C4 haloalkylsulfonyl, C1-C4 alkylamino, C2-Cg dialkylamino, C3-Cg cycloalkylamino, C2-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C2-C4 alkylcarbonyl, C2-Cg alkoxycarbonyl, C2-Cg alkylcarbonyloxy, C2-Cg alkylcarbonylthio, C2-C6 alkylaminocarbonyl, C3-Cg dialkylaminocarbonyl or C3-C6 trialkylsilyl; and
R12 is C1-C3 alkyl; each Z1 and Z2 is a direct bond; each Z4 is independently C(=O) or S(O)2; n is 0, 1 or 2; k is 0, 1 or 2; p is 0, 1 or 2; x is an integer from 0 to 5; provided that when R1 is unsύbstituted thienyl, X is X1, G is an unsubstituted thiazole ring connected at its 2-position to X and at its 4-position to Z1 in Formula 1, and J is an isoxazole ring connected at its 4-position to Z1 and substituted at its 5-position with methyl, then J is not substituted and at its 3 -position with meta-substituted phenyl.
14. A compound of Claim 1 wherein each R5 is independently H, halogen, cyano, hydroxy, amnio, nitro, -CHO, -C(=O)OH,
-C(=O)NH2, -NR25R26, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C4-C10 alkylcycloalkyl, C4-C10 cycloalkylalkyl, C6-C14 cycloalkylcycloalkyl, C4-C10 halocycloalkylalkyl, C5-C10 alkylcycloalkylalkyl, C3-Cg cycloalkenyl, C3-C3 halocycloalkenyl, C2-C6 alkoxyalkyl, C4-C1Q cyclόalkoxyalkyl, C3-Cs alkoxyalkoxyalkyl, C2-C6 alkylthioalkyl, C2-C6 alkylsulfinylalkyl, C2-C6 alkylsulfonylalkyl, C2-C6 alkylaminoalkyl, C3-C8 dialkylaminoalkyl, C2-C6 haloalkylaminoalkyl, C4-CjQ cycloalkylaminoalkyl, C2-C6 alkylcarbonyl, C2-C6 haloalkylcarbonyl, C4-Cg cycloalkylcarbonyl, C2-
C6 alkoxycarbonyl, C4-Cg cycloalkoxycarbonyl, C5-C10 cycloalkylalkoxycarbonyl, C2-C6 alkylaminocarbonyl, C3-C8 dialkylaminocarbonyl, C4-Cg cycloalkylaminocarbonyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-Cg cycloalkoxy, C3-C8 halocycloalkoxy, C4-C1Q cycloalkylalkoxy, C2-C6 alkenyloxy, C2-C6 haloalkenyloxy, C2-C6 alkynyloxy,
C2-C6 haloalkynyloxy, C2-C6 alkoxyalkoxy, C2-C6 alkylcarbonyloxy, C2-C6 haloalkylcarbonyloxy, C4-Cg cycloalkylcarbonyloxy, C3-C6 alkylcarbonylalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C3-Cg cycloalkylthio, Cj-C6 alkylsulfinyl, Cj-C6 haloalkylsulfinyl, C1-C6 alky lsulfonyl, G^-C6 haloalkylsulfonyl, C3-Cg cycloalkylsulfonyl, C3-C1Q
• trialkylsilyl, C1-C6 alkylsulfonylamino, C1-C6 haloalkylsulfonylamino or -Z2Q; each Q is independently phenyl, benzyl, naphthalenyl, a 5- or 6-membered heteroaromatic ring or an 8- to 11-membered heteroaromatic bicyclic ring system, each optionally substituted with 1 to 5 substituents independently selected from R7 on carbon atom ring members and R12 on nitrogen atom ring members; or each Q is independently a 3- to 7-membered nonaromatic carbocyclic ring, a 5-, 6- or 7-membered nonaromatic heterocyclic ring or an 8- to 11-membered nonaromatic bicyclic ring system, each optionally including ring members selected from the group consisting of C(=O), C(=S), S(O), S(O)2 and SiR17R18, and optionally substituted with 1 to 5 substituents independently selected from R7 on carbon atom ring members and R12 on nitrogen atom ring members; each R7 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C1Q cycloalkylalkyl, C4-C1Q alkylcycloalkyl, Cs-C1Q alkylcycloalkylalkyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl,
C3-C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylthio, C1-C4 haloalkylsulfinyl, C1-C4 haloalkylsulfonyl, C1-C4 alkylamino, C2-Cg dialkylamino, C3-C6 cycloalkylamino, C2-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C2-C4 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-C6 alkylcarbonylthio, C2-C6 alkylaminocarbonyl, C3-Cg dialkylaminocarbonyl or C3-C6 trialkylsilyl; or R5 and R7 are taken together with the atoms linking R5 and R7 to form an optionally substituted 5- to 7-membered ring containing as ring members 2 to 7 carbon atoms and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S, up to 1 Si and up to 1 N; R12 is C1-C3 alkyl; each Z1 and Z2 is independently a direct bond, O, C(=O), S(O)m, CHR20 or NR21; each Z4 is independently O, C(=O), S(O)m or CHR20; each R20 is independently H, Cγ-C4 alkyl or C1-C4 haloalkyl; each R21 is independently H, C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, C2-C6 alkylcarbonyl, C2-C6 haloalkylcarbonyl, C2-C6 alkoxycarbonyl or C2-C6 haloalkoxycarbonyl; each m is independently 0, 1 or 2; and n is 0, 1 or 2; provided that: — - when R1 is unsubstituted thienyl, X is X1 and the ring containing X is saturated, G is an unsubstituted thiazole ring connected at its 2-ρosition to X and at its 4-position to Z1 in Formula 1, A is CHR15, R15 is H, and J is an isoxazole ring connected at its 4-position to Z1 and substituted at its 5-position with methyl and at its 3-position with meta-substituted phenyl, then Z1 is O, C(=O), S(O)m, CHR20 Or NR21.
15. A compound of Claim 14 wherein
G is a 5-membered heteroaromatic ring or 5-membered saturated or partially saturated heterocyclic ring, each ring optionally substituted with up to 2 substituents selected from R3 on carbon ring members and selected from R11 on nitrogen ring members;
R1 is a phenyl or 5- or 6-membered heteroaromatic ring optionally substituted with 1 to 2 substituents independently selected from R4a on carbon ring members and R4b on nitrogen ring members; each R2 is independently Cj-C2 alkyl, C1-C2 haloalkyl, C1-C2 alkoxy, halogen, cyano or hydroxy; each R3 is independently C1-C3 alkyl, C1-C3 haloalkyl or halogen; each R4a is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C1Q cycloalkylalkyl, C-I-C10 alkylcycloalkyl, C5-CJ0 alkylcycloalkylalkyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3-C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1- C4 alkoxy,
C1-C4 haloalkoxy, Cχ-C4 alkylthio, C1-XI^ alkylsulfϊnyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylthio, C1-C4 haloalkylsulfinyl, C1-C4 haloalkylsulfonyl, C1-C4 alkylamino, C2-Cg dialkylamino, C3-C6 cycloalkylamino, C2-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C2-C4 alkylcarbonyl, C2-CO alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-Cg alkylcafbonylthio, C2-C6 alkylaminocarbonyl, C3-C8 dialkylaminocarbonyl or C3~C6 trialkylsilyl; 5 each R4b is independently C1-C6 alkyl, C3-C6 alkenyl, C3-C6 alkynyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C3-C6 haloalkenyl, C3-C6 haloalkynyl, C^-Cβ halocycloalkyl or C2-C4 alkoxyalkyl; each R11 is independently C1-C3 alkyl; R15 is H, halogen, cyano, hydroxy, -CHO, C1-C4 alkyl, C1-C4 haloalkyl or C2-Cs
10 alkoxycarbonyl;
R16 is H, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl or C2-C4 alkoxycarbonyl; when R5 and R? are taken together with the atoms linking R5 and R7 to form an optionally substituted 5- to 7-membered ring, then R5 and R7 are taken together
-15 with the atoms linking R5 and R7 to form a 5- to 7-membered ring containing as ring members 2 to 7 carbon atoms and optionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S, up to 1 Si and up to 1 N, the ring optionally substituted on ring members other than the atoms linking R5 and R7 with up to 4 substituents selected from R8;
20 each R8 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C1Q cycloalkylalkyl, C4-C1O alkylcycloalkyl, Cs-C10 alkylcycloalkylalkyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, C3-C6 halocycloalkyl, halogen, hydroxy, amino, cyano, nitro, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl,
25 C1-C4 haloalkylthio, C1-C4 haloalkylsulfinyl, C t-C4 haloalkylsulfonyl, C T-C4 alkylamino, C2-Cg dialkylamino, C3-C6 cycloalkylamino, C2-C4 alkoxyalkyl, C1-C4 hydroxyalkyl, C2-C4 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylcarbonyloxy, C2-C6 alkylcarbonylthio, C2-C6 alkylaminocarbonyl, C3-Cg dialkylaminocarbonyl or C3-C6 trialkylsilyl; and
30 each Z4 is independently C(=O) or S(O)2.
16. A compound of Claim 1 selected from the group consisting of:
4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-l-[[5-methyl-3- (trifluoromemyl)-lH-pyrazol-l-yl]acetyl]piperidine and its enantiomer, l-[[5-methyl-3-(trifluoromethyl)-l/f-pyrazoH-yl]acetyl]-4-[4-(5-phenyl-3- 35 isoxazolyl)r2-thiazolyl]piperidine, l.[4-[4-[(5R)-4,5-dihydro-5-methyl-5-phenyl-3-isoxazolyl]-2-ihia2θlyl]-l- piperidinyl3-2-[5-methyl-3-(trifluoromethyl)-lH-pyra2ol-l -yl]ethanone and its enantiomer,
2-[5-methyl-3-(trifluoromethyl)-lH"-ρyrazol-l-yl]-l-[4-[4-[(3aS',9bΛ),3a,4,5,.9b- tetrahydronaphth[2,l-ύr|isoxazol-3-yl]-2-thiazolyl]-l-piperidinyl]ethanone and its enantiomer, l-[4-[4-[(5jR)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-l-piperidinyl]-2-[5- emyl-3-(trifluoromethyl)-lH-pyrazol-l-yl]ethanone and its enantiomer,
2-[3,5-bis(trifluoromethyl)-lH-pyrazol-l-yl]-l-[4-[4-[(5R)-4,5-dihydro-5-phenyl-3- isoxazolyl]-2-thiazolyl]-l-ρiperidinyl]ethanone and its enantiomer, l_[4-[4_[(5/?)_3'j4'.(iihydrospiro[isoxazole-5(4H),ll,(21H)-naphthalen]-3-yl]-2- thiazolyl]- 1 -piperidinyl] -2-[5-methyl-3 -(trifluoromethyl)- lH-pyrazol- 1 -yl] ethanone and its enantiomer, l_[4-[4-[(5R)-2,3-dmyclrospiro[lH-indene-l,5l(4lH)-isoxazol]-31-yl]-2-thiazolyl]-l- piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-lH-pyrazol-l-yl]ethanone and its enantiomer,
2-[5-chloro-3-(trifluoromethyl)-li?-ρyrazol-l-yl]-l-[4-[4-[(5R)-4,5-dihydro-5- phenyl-3-isoxazoly]-2-thiazolyl]-l-piperidinyl]ethanone and its enantiomer,
2-[(5/?)-4J5-dihydro-3-[2-[l-[2-[5-methyl-3-(trifluoromethyl)-lHr-pyrazol-l- yl]acetyl]-4-piperidinyl]-4-thiazolyl-5-isoxazolyl]-lH'-isoindole-l,3(2H)-dione and its enantiomer,
2^5-cMoro-3<trifluoromethyl)-lH-ρyrazol-l-yl]-l-[4-[4-[(lie)-2,3-dihydrospiro[lH;- indene- 1,5' (4'ϋ)-isoxazol] -3 ' -yl]-2-thiazolyl]- 1 -piperidinyljethanone and its enantiomer, 2-[5-chloro-3-(trifluoromethyl)-lH;-pyrazol-l-yl]-l-[4-[4-[(l'JR)-3',4'- dihydrospiro[isoxazole-5(4H),r(2'iϊ)-naphthalen]-3-yl]-2-thiazolyl]-l- piperidinyl] ethanone and its enantiomer,
2-[5-methyl-3-(trifluoromethyl)-li?-pyrazol-l-yl]-l-[4-[4-(3i2)-spiro[benzofuran- 3(2iϊ),5'(4'H)-isoxazol]-3'-yl-2-thiazolyl]-l-piperidinyl]ethanone and its enantiomer, l-[4-[4-[(li?)-2,3-dmydrospiro[lH-indene-l,5'(4'H)-isoxazol]-3'-yl]-2-thiazolyl]-l- piperiαinyl^-CSjS-dimethyl-lH-pyrazol-l-yOethanone and its enantiomer,
2-[3,5-bis(trifluoromethyl)-lH;-pyrazol-l-yl]-l-[4-[4-[(l'Λ)-3',4'- dihydrospiro[isoxazole-5(4H),r(2'Η)-naρhthalen]-3-yl]-2-thiazolyl]-l - piperidinyl]ethanone and its enantiomer, 2-[3,5-bis(trifluoromethyl)-lH"-pyrazol-l-yl]-l-[4-[4-[(lΛ)-2J3-dihydrospiro[lH;- indene-l,5'(4'i/)-isoxazol]-3'-yl]-2-thiazolyl]-l-piperidinyl]ethanone and. its enantiomer,
1 -[4-[4-[(5R)-5-(2,6-dichlorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]- 1 - piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-l-yl]ethanone and its enantiomer, l-[4-[4-[(5R)-4,5-dihydro-5-[2-(trifluoromethyl)phenyl]-3-isoxazolyl]-2-thiazolyl]- 1 -piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-l -yl]ethanone and its enantiomer, l-[4-[4-[(5R)-4,5-dihydro-5-(2-methylphenyl)-3-isoxazolyl]-2-thiazolyl]-l- piperidinyl]-2-[5-nαethyl-3-(trifluoroπiethyl)-1H-pyrazol-l-yl]ethanone and its enantiomer, l-[4-[4-[(5R)-5-(2,6-dimethylphenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-l- piperidinyl]-2-[5-methyl-3-(trifluoromethy1lH)- -pyrazol- 1 -yl]ethanone and its enantiomer,
1 -[4-[4-[(5R)-4,5-dihydro-5-(2,4,6-trimethylphenyl)-3 -isoxazolyl]-2-thiazolyl]- 1 - piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol- 1 -yljethanone and its enantiomer, l-[4-[4-[(l'i?)-3%4'-dihydrospiro[isoxazole-5(4itϊ),l'(2'iϊ)-naphthalen]-3-yl]-2- miazolyl]-l-piperidinyl]-2-(3,5-dirnethyl-lHr-pyrazol-l-yl)ethanone and its enantiomer, l-[4-[4-[(5R)-4,5-dihydro-5-(2,4,6-trimethoxyphenyl)-3-isoxazolyl]-2-thiazolyl]-l- piperidinyl]-2-[5-methyl-3-(trifluoromethyl)- 1 H-pyτazol- 1 -yl] ethanone and its enantiomer, S-tCS^-^S-dihydro-S-^-tl-^-tS-methyl-S-Ctrifluoromethy^-liy-pyrazol-l- yl]acetyl]-4-piperidinyl]-4-thiazolyl]-5-isoxazolyl]-2(3iϊ)-benzoxazolone and its enantiomer, l-[4-[4-[(5R)-5-(2,6-difluorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-l- piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-lH-pyrazol-l-yl]ethanone and its enantiomer,
2-[(5R)-4,5-dihydro-3-[2-[l-[2-[5-methyl-3-(trifluoromethyl)-liy-pyrazol-l- yl]acetyl]-4-piperidinyl]-4-thiazolyl]-5-isoxazolyl]benzonitrile and its enantiomer, 2-[5-cMoro-3-(trifluoromethyl)- ltf-pyrazol-l-yl]- 1 -[4-[4-[(5R)-4,5-diliydro-5- methyl-5-phenyl-3-isoxazolyl]-2-thiazolyl]-l-piperidinyl]ethanone and its enantiomer,
2-[3,5-bis(triflyoromethyl)-l-rr-pyrazol-l-yl]-l-[4-[4-[(5R)-4,5-dihydro-5-methyl-5- phenyl-3-isoxazolyl]-2-thiazolyl]-l-piperidinyl]ethanone and its enantiomer,
1 -[4-[4-[(5R)-5-(2-chlorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]- 1 - piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-lH-pyrazol-l-yl]ethanone and its enantiomer, l-[4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-l-piperidinyl]-2-[3- methyl-5-(trifluoromethyl)-lH/-pyrazol-l-yl]ethanone and its enantiomer, l-[4-[4-[(45)-2,3-dihydrospiro[4/f-l -benzopyran-4,5'(4'H)-isoxazol]-3'-yl)-2- thiazolyl] - 1 -piperidinyl] -2- [5 -methyl-3 -(trifluoromethyl)- 1 H-pyrazol- 1 -yl] ethanone and its enantiomer, and
(5R)-4>5-dihydro-3-[2-[l-[2-[5-methyf-3-(trifluoromethyl)-lH-pyrazol-l-yl]acetyl]- 4-piperidinyl]-4-thiazolyl]-5-phenyl-5-isoxazolecarbonitrile and its enantiomer.
17. A compound selected from Formula IB, an iV-oxide and salt thereof
Figure imgf000289_0001
wherein each R4al and R4a2 is independently C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, cyclopropyl, C1-C3 haloalkyl, C2-C3 haloalkenyl, C2-C3 haloalkynyl, halocyclopropyl, halogen, cyano, nitro, C1-C2 alkoxy, C1-C2 haloalkoxy, C1- C2 alkylthio, C1-C2 haloalkylthio, C2-C3 alkoxyalkyl, C2-C3 alkylcarbonyl, C2-C3 alkoxycarbonyl, C2-C3 alkylaminocarbonyl or C3- C4 dialkylaminocarbonyl; and Z3 is CN or CO=S)NH2.
18. A compound of Claim 17 wherein each R4al and R4a2 is independently C1-C3 alkyl, C1-C3 haloalkyl, halogen, cyano, C1-C2 alkoxy or C1-C2 haloalkoxy.
19. A compound of Claim 17 selected from the group consisting of: l-[2-[5-methyl-3-(trifluoromethyl)-lH;-pyra2ol-l-yl]acetyl]-4- piperidinecarbothioamide, l-[2-[3,5-bis(trifluoromethyl)-lH-pyrazol-l-yl]acetyl]-4-piperidinecaxbothioamide, l-[2-[5-memyl-3-(trifluoromethyl)-l/f-pyrazol-l-yl]acetyl]-4-piperidinecarbonitrile, and l-[2-[3,5-bis(trifluoromethyl)-liϊ-pyrazol-l-yl]acetyl]-4-piperidinecarbonitrile.
20. A compound selected from Formula 1C, an N-oxide and salt thereof,
Figure imgf000290_0001
1C wherein
M is C1-C3 alkyl, C1-C3 haloalkyl, hydroxy, C1-C^ alkoxy, C1-C2 haloalkoxy, C1-
C4 alkylamino, C2-C3 dialkylamino, 1-piperidinyl, 1-pyrrolidinyl or
4-morpholinyl; and JMs
Figure imgf000290_0002
J-29-7 J-29-8 J-29-9
Figure imgf000291_0001
J-29-10 J-29-11 J-29-12
Figure imgf000291_0002
J-29-13 J-29-14 J-29-15
Figure imgf000291_0003
J-29-19 J-29-20 J-29-21
Figure imgf000291_0004
Figure imgf000291_0005
J-29-24
Figure imgf000292_0001
J-29-25 J-29-26 J-29-27
Figure imgf000292_0002
J-29-28 J-29-29 J-29-30
Figure imgf000292_0003
J-29-31 J-29-32 J-29-33
Figure imgf000292_0004
J-29-37 J-29-38 J-29-39
Figure imgf000293_0001
J-29-43 J-29-44 J-29-45
Figure imgf000293_0002
J-29-49 J-29-50 J-29-51
Figure imgf000293_0003
J-29-52 J-29-53 J-29-54
Figure imgf000294_0001
J-29-55 J-29-56 J-29-57
Figure imgf000294_0002
J-29-58
21. A method for controlling plant diseases caused by .Oomycete fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of a compound selected from the group consisting of the compounds of Claim 1, compounds within the scope of exclusion of proviso (a) of Claim 1 and compounds within the scope of exclusion of proviso (b) of Claim 1.
22. A fungicidal composition comprising (1) a compound selected from the group consisting of the compounds of Claim 1, compounds within the scope of exclusion of proviso (a) of Claim 1 and compounds within the scope of exclusion of proviso (b) of Claim 1, and (2) at least one other fungicide.
23. A fungicidal composition comprising (1) a fungicidally effective amount of a compound selected from the group consisting of the compounds of Claim I3 compounds within the scope of exclusion of proviso (a) of Claim 1 and compounds within the scope of exclusion of proviso (b) of Claim 1, and (2) at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents.
PCT/US2007/014647 2006-07-27 2007-06-22 Fungicidal azocyclic amides WO2008013622A2 (en)

Priority Applications (49)

Application Number Priority Date Filing Date Title
CN201710112212.2A CN107021962A (en) 2006-07-27 2007-07-27 Fungicidal azocyclic amides
DK07836278.7T DK2049111T3 (en) 2006-07-27 2007-07-27 1- (ACETYL) -PIPERIDINE AND 1- (ACETYL) -PIPERAZINE DERIVATIVES AS FUNGICIDES FOR USE IN PLANT PROTECTION
CN201510114576.5A CN104774201A (en) 2006-07-27 2007-07-27 Fungicidal azocyclic amides
JP2009521846A JP6118011B2 (en) 2006-07-27 2007-07-27 Bactericidal and fungicidal azo cyclic amide
EP17172140.0A EP3239137B1 (en) 2006-07-27 2007-07-27 (5r)-4,5-dihydro-isoxazole derivatives as well as 1-(2-chloroacetyl)-4-piperidine-carbonitrile and -carboxamide derivatives as intermediates in the preparation of e.g. 4-[4-[(5r)-4,5-dihydro-isoxazol-3-yl]-thiazol-2-yl]-piperidine derivatives as fungicides for crop protection
PL07836278T PL2049111T3 (en) 2006-07-27 2007-07-27 1-(acetyl)-piperidine and 1-(acetyl)-piperazine derivatives as fungicides for use in plant protection
PT78362787T PT2049111T (en) 2006-07-27 2007-07-27 1-(acetyl)-piperidine and 1-(acetyl)-piperazine derivatives as fungicides for use in plant protection
MEP-23/09A ME00586A (en) 2006-07-27 2007-07-27 Fungicidal azocyclic amides
KR1020147033282A KR101564187B1 (en) 2006-07-27 2007-07-27 Fungicidal azocyclic amides
ES07836278.7T ES2637336T3 (en) 2006-07-27 2007-07-27 Derivatives of 1- (acetyl) -piperidine and 1- (acetyl) -piperazine as fungicides for use in plant protection
PCT/US2007/016875 WO2008013925A2 (en) 2006-07-27 2007-07-27 Fungicidal azocyclic amides
CN200780028120.0A CN101888843B (en) 2006-07-27 2007-07-27 Fungicidal azocyclic amides
CN201410806789.XA CN104478805B (en) 2006-07-27 2007-07-27 Fungicidal azocyclic amides
EP17172323.2A EP3239145B1 (en) 2006-07-27 2007-07-27 1-[2-[3,5-substituted-1h-pyrazol-1-yl]acetyl]-4-piperidine-carbonitrile and -carbothiamide derivatives as intermediates in the preparation of fungicides for crop protection
CN201710113323.5A CN106986866B (en) 2006-07-27 2007-07-27 Fungicidal azacyclic amides
EP13196711.9A EP2712616B1 (en) 2006-07-27 2007-07-27 Intermediates for the preparation of 1-(acetyl)-piperidine and 1-(acetyl)-piperazine derivatives as fungicides for use in plant protection
US12/303,256 US8642634B2 (en) 2006-07-27 2007-07-27 Fungicidal azocyclic amides
KR1020097004083A KR20090033496A (en) 2006-07-27 2007-07-27 Fungicidal azocyclic amides
EP07836278.7A EP2049111B1 (en) 2006-07-27 2007-07-27 1-(acetyl)-piperidine and 1-(acetyl)-piperazine derivatives as fungicides for use in plant protection
CN201210260720.2A CN102816148B (en) 2006-07-27 2007-07-27 Fungicidal azocyclic amides
MYPI20090076A MY148424A (en) 2006-07-27 2007-07-27 Fungicidal azocyclic amides
BRPI0713833-4A BRPI0713833B1 (en) 2006-07-27 2007-07-27 COMPOUND, PLANT DISEASE CONTROL METHOD AND FUNGICIDAL COMPOSITIONS
LTEP07836278.7T LT2049111T (en) 2006-07-27 2007-07-27 1-(acetyl)-piperidine and 1-(acetyl)-piperazine derivatives as fungicides for use in plant protection
ES13196711.9T ES2632597T3 (en) 2006-07-27 2007-07-27 Intermediates for the preparation of derivatives of 1- (acetyl) -piperidine and 1- (acetyl) -piperazine as fungicides for use in plant protection
SI200731951T SI2049111T1 (en) 2006-07-27 2007-07-27 1-(acetyl)-piperidine and 1-(acetyl)-piperazine derivatives as fungicides for use in plant protection
AU2007277157A AU2007277157B2 (en) 2006-07-27 2007-07-27 Fungicidal azocyclic amides
MX2009000920A MX2009000920A (en) 2006-07-27 2007-07-27 Fungicidal azocyclic amides.
MX2014005660A MX337779B (en) 2006-07-27 2007-07-27 Fungicidal azocyclic amides.
CA2653640A CA2653640C (en) 2006-07-27 2007-07-27 Fungicidal azocyclic amides
PL17172323T PL3239145T3 (en) 2006-07-27 2007-07-27 1-[2-[3,5-substituted-1h-pyrazol-1-yl]acetyl]-4-piperidine-carbonitrile and -carbothiamide derivatives as intermediates in the preparation of fungicides for crop protection
NZ572915A NZ572915A (en) 2006-07-27 2007-07-27 Fungicidal azocyclic amides
GEAP200711072A GEP20125505B (en) 2006-07-27 2007-07-27 Fungicidal azocylic amides
PL17172140T PL3239137T3 (en) 2006-07-27 2007-07-27 (5r)-4,5-dihydro-isoxazole derivatives as well as 1-(2-chloroacetyl)-4-piperidine-carbonitrile and -carboxamide derivatives as intermediates in the preparation of e.g. 4-[4-[(5r)-4,5-dihydro-isoxazol-3-yl]-thiazol-2-yl]-piperidine derivatives as fungicides for crop protection
IL195509A IL195509A (en) 2006-07-27 2008-11-25 Substituted cyclic amide compound, a method for controlling plant diseases and a fungicidal composition
CO09005501A CO6150154A2 (en) 2006-07-27 2009-01-22 FUNGICIDE AZOCICLIC AMIDAS
IL224109A IL224109A (en) 2006-07-27 2013-01-03 Isoxazole derivatives for use as fungicides
US14/087,481 US9090604B2 (en) 2006-07-27 2013-11-22 Fungicidal azocyclic amides
IL231012A IL231012A (en) 2006-07-27 2014-02-17 Fungicidal azocyclic amides
JP2015006554A JP2015110611A (en) 2006-07-27 2015-01-16 Fungicidal azocyclic amides
US14/748,390 US9920030B2 (en) 2006-07-27 2015-06-24 Fungicidal azocyclic amides
US14/748,372 US9604962B2 (en) 2006-07-27 2015-06-24 Fungicidal azocyclic amides
JP2016200559A JP6333913B2 (en) 2006-07-27 2016-10-12 Bactericidal and fungicidal azo cyclic amide
HRP20171019TT HRP20171019T1 (en) 2006-07-27 2017-07-04 1-(acetyl)-piperidine and 1-(acetyl)-piperazine derivatives as fungicides for use in plant protection
CY20171100880T CY1120559T1 (en) 2006-07-27 2017-08-18 DERIVATIVES 1- (ACETYL) -Piperidine AND 1- (ACETYL) -PIPERAZINE AS Fungicides FOR USE IN PLANT PROTECTION
JP2017245666A JP6572294B2 (en) 2006-07-27 2017-12-22 Bactericidal and fungicidal azo cyclic amide
NL350089C NL350089I2 (en) 2006-07-27 2018-08-22 Oxathia piproline
LTPA2019008C LTC2049111I2 (en) 2006-07-27 2019-03-13 Derivatives of 1- (acetyl) -piperidine and 1- (acetyl) -piperazine as fungicides for use in plant protection
LTPA2021503C LTPA2021503I1 (en) 2006-07-27 2021-02-11 Derivatives of 1- (acetyl) -piperidine and 1- (acetyl) -piperazine as fungicides for use in plant protection
FR22C1026C FR22C1026I1 (en) 2006-07-27 2022-06-09 1-(ACETYL)-PIPERIDINE AND 1-(ACETYL)-PIPERAZINE DERIVATIVES AS FUNGICIDES FOR USE IN PLANT PROTECTION

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83382406P 2006-07-27 2006-07-27
US60/833,824 2006-07-27
US89717307P 2007-01-24 2007-01-24
US60/897,173 2007-01-24

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/303,256 Continuation-In-Part US8642634B2 (en) 2006-07-27 2007-07-27 Fungicidal azocyclic amides
PCT/US2007/016875 Continuation-In-Part WO2008013925A2 (en) 2006-07-27 2007-07-27 Fungicidal azocyclic amides

Publications (2)

Publication Number Publication Date
WO2008013622A2 true WO2008013622A2 (en) 2008-01-31
WO2008013622A3 WO2008013622A3 (en) 2008-03-27

Family

ID=38834472

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2007/014647 WO2008013622A2 (en) 2006-07-27 2007-06-22 Fungicidal azocyclic amides
PCT/US2007/016875 WO2008013925A2 (en) 2006-07-27 2007-07-27 Fungicidal azocyclic amides

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2007/016875 WO2008013925A2 (en) 2006-07-27 2007-07-27 Fungicidal azocyclic amides

Country Status (33)

Country Link
US (1) US8642634B2 (en)
EP (4) EP3239145B1 (en)
JP (4) JP6118011B2 (en)
KR (2) KR101564187B1 (en)
CN (6) CN106986866B (en)
AR (1) AR063213A1 (en)
AU (1) AU2007277157B2 (en)
CA (1) CA2653640C (en)
CL (1) CL2007002185A1 (en)
CO (1) CO6150154A2 (en)
CY (2) CY1120559T1 (en)
DK (1) DK2049111T3 (en)
ES (2) ES2637336T3 (en)
FR (1) FR22C1026I1 (en)
GE (1) GEP20125505B (en)
GT (1) GT200900017A (en)
HR (1) HRP20171019T1 (en)
HU (2) HUS000510I2 (en)
IL (3) IL195509A (en)
LT (3) LT2049111T (en)
ME (1) ME00586A (en)
MX (2) MX2009000920A (en)
MY (1) MY148424A (en)
NZ (1) NZ572915A (en)
PE (2) PE20080952A1 (en)
PH (1) PH12008502812A1 (en)
PL (3) PL3239137T3 (en)
PT (1) PT2049111T (en)
RU (1) RU2453544C3 (en)
SI (1) SI2049111T1 (en)
TW (4) TW201636331A (en)
UY (2) UY30510A1 (en)
WO (2) WO2008013622A2 (en)

Cited By (331)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008091580A3 (en) * 2007-01-25 2008-09-12 Du Pont Fungicidal amides
WO2009055514A2 (en) * 2007-10-23 2009-04-30 E. I. Du Pont De Nemours And Company Fungicidal mixtures
WO2009094445A2 (en) * 2008-01-25 2009-07-30 E. I. Du Pont De Nemours And Company Fungicidal hetercyclic compounds
WO2009141096A1 (en) * 2008-05-21 2009-11-26 Bayer Cropscience Ag Substituted spiro-isoxazolines
WO2010014257A3 (en) * 2008-08-01 2010-06-03 Purdue Pharma L.P. Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof
WO2010066353A1 (en) * 2008-12-11 2010-06-17 Bayer Cropscience Ag Thiazolyl oxime ether and hydrazones asl plant protection agent
DE102010000662A1 (en) 2009-03-18 2010-10-21 Bayer Cropscience Ag New thiazole compounds useful to combat e.g. plant pathogenic fungus, bacteria and algae, and as herbicides, growth regulators, agents to improve plant properties, antimycotics, insecticides, virucides and Rickettsia-like organism
WO2010123791A1 (en) * 2009-04-22 2010-10-28 E. I. Du Pont De Nemours And Company Solid forms of an azocyclic amide
US20100286147A1 (en) * 2008-01-25 2010-11-11 E.I. Dupont De Nemours And Company Fungicidal amides
WO2010149275A1 (en) * 2009-06-23 2010-12-29 Bayer Cropscience Aktiengesellschaft Thiazolylpiperidine derivates as fungicides
WO2011015524A2 (en) 2009-08-03 2011-02-10 Bayer Cropscience Ag Fungicide heterocycles derivatives
WO2011018401A1 (en) 2009-08-12 2011-02-17 Syngenta Participations Ag Microbiocidal heterocycles
WO2011018415A2 (en) 2009-08-12 2011-02-17 Syngenta Participations Ag Microbiocidal heterocycles
WO2011051244A1 (en) 2009-10-30 2011-05-05 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives
EP2326631A2 (en) * 2008-08-18 2011-06-01 Yale University Mif modulators
WO2011076699A1 (en) 2009-12-21 2011-06-30 Bayer Cropscience Ag Bis(difluormethyl)pyrazoles used as fungicides
WO2011076510A1 (en) 2009-12-22 2011-06-30 Syngenta Participations Ag Pyrazole derivatives
WO2011080254A2 (en) 2009-12-28 2011-07-07 Bayer Cropscience Ag Fungicide hydroximoyl-heterocycles derivatives
WO2011085170A1 (en) * 2010-01-07 2011-07-14 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
KR20110091798A (en) * 2008-12-02 2011-08-12 이 아이 듀폰 디 네모아 앤드 캄파니 Fungicidal heterocyclic compounds
WO2011134969A1 (en) 2010-04-28 2011-11-03 Bayer Cropscience Ag Ketoheteroarylpiperidine and ketoheteroarylpiperazine derivates as fungicides
WO2011134912A1 (en) 2010-04-28 2011-11-03 Bayer Cropscience Ag Fungicide hydroximoyl-heterocycles derivatives
WO2011134911A2 (en) 2010-04-28 2011-11-03 Bayer Cropscience Ag Fungicide hydroximoyl-tetrazole derivatives
WO2011134913A1 (en) 2010-04-28 2011-11-03 Bayer Cropscience Ag Fungicide hydroximoyl-heterocycles derivatives
WO2011144586A1 (en) 2010-05-18 2011-11-24 Bayer Cropscience Ag Bis(difluoromethyl) pyrazoles as fungicides
WO2011146182A1 (en) * 2010-05-20 2011-11-24 E. I. Du Pont De Nemours And Company Fungicidal oximes and hydrazones
WO2011147765A1 (en) 2010-05-27 2011-12-01 Bayer Cropscience Ag Pyridinylcarboxylic acid derivatives as fungicides
WO2011151370A1 (en) 2010-06-03 2011-12-08 Bayer Cropscience Ag N-[(het)arylalkyl)] pyrazole (thio)carboxamides and their heterosubstituted analogues
WO2011151368A2 (en) 2010-06-03 2011-12-08 Bayer Cropscience Ag Fungicide n-[(trisubstitutedsilyl)methyl]-carboxamide derivatives
WO2011151369A1 (en) 2010-06-03 2011-12-08 Bayer Cropscience Ag N-[(het)arylethyl)] pyrazole(thio)carboxamides and their heterosubstituted analogues
WO2012010567A1 (en) 2010-07-19 2012-01-26 Syngenta Participations Ag Isoxazole, isothiazole, furane and thiophene compounds as microbicides
WO2012010568A1 (en) 2010-07-19 2012-01-26 Syngenta Participations Ag Microbicides
WO2012010579A2 (en) 2010-07-20 2012-01-26 Bayer Cropscience Ag Benzocycloalkenes as antifungal agents
WO2012020060A1 (en) 2010-08-11 2012-02-16 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
EP2423210A1 (en) 2010-08-25 2012-02-29 Bayer CropScience AG Heteroarylpiperidine and heteroarylpiperazine derivatives as fungicides
WO2012025557A1 (en) 2010-08-25 2012-03-01 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
WO2012038476A1 (en) 2010-09-22 2012-03-29 Bayer Cropscience Ag Use of active ingredients for controlling nematodes in nematode-resistant crops
WO2012038521A1 (en) 2010-09-23 2012-03-29 Syngenta Participations Ag Novel microbiocides
WO2012041874A1 (en) 2010-10-01 2012-04-05 Syngenta Participations Ag Fungicidal compositions
WO2012045798A1 (en) 2010-10-07 2012-04-12 Bayer Cropscience Ag Fungicide composition comprising a tetrazolyloxime derivative and a thiazolylpiperidine derivative
WO2012052489A1 (en) 2010-10-21 2012-04-26 Bayer Cropscience Ag 1-(heterocyclic carbonyl) piperidines
WO2012052490A1 (en) 2010-10-21 2012-04-26 Bayer Cropscience Ag N-benzyl heterocyclic carboxamides
WO2012055837A1 (en) 2010-10-27 2012-05-03 Bayer Cropscience Ag Heteroaryl piperidine and heteroaryl piperazine derivatives as fungicides
WO2012056003A1 (en) 2010-10-28 2012-05-03 Syngenta Participations Ag Novel microbicides
WO2012059497A1 (en) 2010-11-02 2012-05-10 Bayer Cropscience Ag N-hetarylmethyl pyrazolylcarboxamides
WO2012062844A1 (en) 2010-11-12 2012-05-18 Syngenta Participations Ag Novel microbiocides
WO2012066122A1 (en) 2010-11-18 2012-05-24 Syngenta Participations Ag 2 - (pyridin- 2 -yl) -quinazoline derivatives and their use as microbicides
WO2012065945A1 (en) 2010-11-15 2012-05-24 Bayer Cropscience Ag 5-halogenopyrazole(thio)carboxamides
WO2012065947A1 (en) 2010-11-15 2012-05-24 Bayer Cropscience Ag 5-halogenopyrazolecarboxamides
WO2012065944A1 (en) 2010-11-15 2012-05-24 Bayer Cropscience Ag N-aryl pyrazole(thio)carboxamides
WO2012069366A1 (en) 2010-11-23 2012-05-31 Syngenta Participations Ag Insecticidal compounds
WO2012069633A1 (en) 2010-11-25 2012-05-31 Syngenta Participations Ag Microbicidal heterocycles
WO2012069601A1 (en) 2010-11-25 2012-05-31 Syngenta Participations Ag Substituted quinazolines as fungicides
WO2012072575A1 (en) 2010-12-01 2012-06-07 Bayer Cropscience Ag Pyrazole carboxylic acid amides useful for the reduction of mycotoxin contamination in plants
WO2012072660A1 (en) 2010-12-01 2012-06-07 Bayer Cropscience Ag Use of fluopyram for controlling nematodes in crops and for increasing yield
WO2012076563A1 (en) 2010-12-08 2012-06-14 Basf Se Fungicidal mixtures
WO2012080376A1 (en) 2010-12-17 2012-06-21 Syngenta Participations Ag Insecticidal compounds
WO2012082580A2 (en) 2010-12-17 2012-06-21 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
WO2012089757A1 (en) 2010-12-29 2012-07-05 Bayer Cropscience Ag Fungicide hydroximoyl-tetrazole derivatives
EP2474542A1 (en) 2010-12-29 2012-07-11 Bayer CropScience AG Fungicide hydroximoyl-tetrazole derivatives
WO2012104273A1 (en) * 2011-02-01 2012-08-09 Bayer Cropscience Ag Heteroaryl piperidine and heteroaryl piperazine derivatives as fungicides
WO2012107475A1 (en) 2011-02-10 2012-08-16 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2012107434A1 (en) 2011-02-09 2012-08-16 Syngenta Participations Ag Insecticidal compounds
WO2012107477A1 (en) 2011-02-10 2012-08-16 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2012117021A2 (en) 2011-03-03 2012-09-07 Syngenta Participations Ag Novel microbiocidal oxime ethers
WO2012126881A1 (en) 2011-03-22 2012-09-27 Syngenta Participations Ag Insecticidal compounds
WO2012143395A1 (en) 2011-04-20 2012-10-26 Syngenta Participations Ag 4,5-dihydro-isoxazole derivatives as fungicides
EP2532233A1 (en) 2011-06-07 2012-12-12 Bayer CropScience AG Active compound combinations
WO2012175474A1 (en) 2011-06-20 2012-12-27 Syngenta Participations Ag 1,2,3 triazole pesticides
EP2540718A1 (en) 2011-06-29 2013-01-02 Syngenta Participations AG. Novel insecticides
WO2013006738A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
WO2013007550A1 (en) 2011-07-08 2013-01-17 Syngenta Participations Ag Fungicide mixtures
WO2013011010A1 (en) 2011-07-19 2013-01-24 Syngenta Participations Ag Fungizide mixtures
WO2013014227A1 (en) 2011-07-27 2013-01-31 Bayer Intellectual Property Gmbh Seed dressing for controlling phytopathogenic fungi
WO2013026900A1 (en) 2011-08-23 2013-02-28 Syngenta Participations Ag Pyridine derivatives as microbiocides
WO2013037768A1 (en) 2011-09-15 2013-03-21 Bayer Intellectual Property Gmbh Piperidine pyrazoles as fungicides
WO2013050261A1 (en) 2011-10-03 2013-04-11 Syngenta Participations Ag Insecticidal 2-methoxybenzamide derivatives
WO2013056915A1 (en) 2011-10-18 2013-04-25 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2013056911A1 (en) 2011-10-18 2013-04-25 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2013064519A1 (en) 2011-11-04 2013-05-10 Syngenta Participations Ag Pesticidal compounds
WO2013064520A1 (en) 2011-11-04 2013-05-10 Syngenta Participations Ag Pesticidal compounds
WO2013064518A1 (en) 2011-11-04 2013-05-10 Syngenta Participations Ag Pesticidal compounds
WO2013064521A1 (en) 2011-11-04 2013-05-10 Syngenta Participations Ag Pesticidal compounds
WO2013092460A1 (en) 2011-12-20 2013-06-27 Syngenta Participations Ag Cyclic bisoxime microbicides
WO2013092519A1 (en) 2011-12-19 2013-06-27 Bayer Cropscience Ag Use of anthranilic acid diamide derivatives for pest control in transgenic crops
WO2013098229A2 (en) 2011-12-27 2013-07-04 Bayer Intellectual Property Gmbh Heteroarylpiperidine and piperazine derivatives as fungicides
WO2013116251A2 (en) 2012-02-01 2013-08-08 E. I. Du Pont De Nemours And Company Fungicidal pyrazole mixtures
WO2013120940A2 (en) 2012-02-14 2013-08-22 Syngenta Participations Ag Novel compounds
WO2013124275A1 (en) 2012-02-22 2013-08-29 Bayer Cropscience Ag Use of succinate dehydrogenase inhibitors (sdhis) for controlling wood diseases in grape.
WO2013127704A1 (en) 2012-02-27 2013-09-06 Bayer Intellectual Property Gmbh Active compound combinations containing a thiazoylisoxazoline and a fungicide
WO2013127789A1 (en) 2012-03-02 2013-09-06 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2013127784A1 (en) 2012-03-02 2013-09-06 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2013127808A1 (en) 2012-03-02 2013-09-06 Syngenta Participations Ag Microbiocidal pyrazole derivatives
EP2641901A1 (en) 2012-03-22 2013-09-25 Syngenta Participations AG. Novel microbiocides
EP2644595A1 (en) 2012-03-26 2013-10-02 Syngenta Participations AG. N-Cyclylamides as nematicides
WO2013192126A1 (en) 2012-06-22 2013-12-27 E. I. Du Pont De Nemours And Company Fungicidal 4-methylanilino pyrazoles
US8642634B2 (en) 2006-07-27 2014-02-04 E I Du Pont De Nemours And Company Fungicidal azocyclic amides
WO2014033164A1 (en) 2012-08-30 2014-03-06 Bayer Cropscience Ag Procedure for the decarboxylation of 3,5-bis(haloalkyl)-pyrazole-4-carboxylic acid derivatives
WO2014060176A1 (en) 2012-10-16 2014-04-24 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2014067838A1 (en) 2012-10-31 2014-05-08 Syngenta Participations Ag Insecticidal compounds
WO2014075873A1 (en) * 2012-11-13 2014-05-22 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2014075874A1 (en) * 2012-11-13 2014-05-22 Syngenta Participations Ag Microbiocidal pyrazole derivatives
US8765735B2 (en) 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
WO2014118143A1 (en) 2013-02-04 2014-08-07 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2014118170A1 (en) 2013-02-04 2014-08-07 Syngenta Participations Ag Novel microbiocides
WO2014118142A1 (en) 2013-02-01 2014-08-07 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2014131572A1 (en) 2013-02-27 2014-09-04 Syngenta Participations Ag Novel carboxamide compounds
WO2014154530A1 (en) 2013-03-25 2014-10-02 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2014161848A1 (en) 2013-04-02 2014-10-09 Syngenta Participations Ag Insecticidal compounds
WO2014161849A1 (en) 2013-04-02 2014-10-09 Syngenta Participations Ag Insecticidal compounds
WO2014167133A1 (en) 2013-04-12 2014-10-16 Syngenta Participations Ag Fungicides comprising boron
WO2014173880A1 (en) 2013-04-22 2014-10-30 Syngenta Participations Ag Novel microbiocides
EP2801575A1 (en) 2013-05-07 2014-11-12 Bayer CropScience AG Heteroaryldihydropyridine derivatives as fungicides
US8927551B2 (en) 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
WO2015003991A1 (en) 2013-07-12 2015-01-15 Syngenta Participations Ag Novel microbiocides
WO2015004091A1 (en) 2013-07-12 2015-01-15 Syngenta Participations Ag Nicotinamide derivatives and their use against nematodes
WO2015003951A1 (en) 2013-07-08 2015-01-15 Syngenta Participations Ag 4-membered ring carboxamides used as nematicides
WO2015028457A1 (en) * 2013-08-28 2015-03-05 Bayer Cropscience Ag Malonic ester derivatives of heteroarylpiperidines and -piperazines as fungicides
WO2015040141A1 (en) 2013-09-23 2015-03-26 Syngenta Participations Ag Cyclobutylcarboxamides as nematicides
WO2015055764A1 (en) 2013-10-18 2015-04-23 Syngenta Participations Ag 3-methanimidamid-pyridine derivatives as fungicides
US9090604B2 (en) 2006-07-27 2015-07-28 E I Du Pont De Nemours And Company Fungicidal azocyclic amides
WO2015144571A1 (en) 2014-03-24 2015-10-01 Bayer Cropscience Ag Phenylpiperidinecarboxamide derivatives as fungicides
US9149465B2 (en) 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
WO2015181097A1 (en) * 2014-05-28 2015-12-03 Bayer Cropscience Ag Process for preparing thiazole derivatives
US9266876B2 (en) 2012-02-02 2016-02-23 Actelion Pharmaceuticals Ltd. 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives
US9278962B2 (en) 2011-04-22 2016-03-08 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
AU2014202324B2 (en) * 2007-10-23 2016-05-19 Corteva Agriscience Llc Fungicidal compounds and mixtures
JP2016523838A (en) * 2013-05-22 2016-08-12 バイエル・クロップサイエンス・アクチェンゲゼルシャフト Method for producing 3,5-bis (fluoroalkyl) pyrazole derivative from α, α-dihaloamine
WO2016202761A1 (en) 2015-06-17 2016-12-22 Bayer Cropscience Aktiengesellschaft Active compound combinations
AU2015261660B2 (en) * 2010-08-25 2017-01-05 Bayer Cropscience Aktiengesellschaft Heteroarylpiperidine and -piperazine derivatives as fungicides
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US9604965B2 (en) 2010-04-23 2017-03-28 Cytokinetics, Inc. Substituted pyridazines as skeletal muscle modulators
KR20170036104A (en) 2014-08-13 2017-03-31 가부시키가이샤 에스디에스 바이오텍크 Condensed 11-member ring compound and agriculture and horticultural fungicide comprising same
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
WO2017076740A1 (en) 2015-11-04 2017-05-11 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2017076757A1 (en) 2015-11-02 2017-05-11 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2017081310A1 (en) 2015-11-13 2017-05-18 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2017081312A1 (en) 2015-11-13 2017-05-18 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2017085100A1 (en) 2015-11-19 2017-05-26 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2017085098A1 (en) 2015-11-19 2017-05-26 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2017094576A1 (en) 2015-12-01 2017-06-08 住友化学株式会社 Plant disease control composition, and plant disease control method
JP2017518999A (en) * 2014-06-11 2017-07-13 バイエル・クロップサイエンス・アクチェンゲゼルシャフト Process for producing 3,5-bis (haloalkyl) pyrazole derivatives via acylation of hydrazones
US9717243B2 (en) 2013-06-24 2017-08-01 Bayer Cropscience Aktiengesellschaft Piperidinecarboxylic acid derivatives as fungicides
US9730886B2 (en) 2010-04-23 2017-08-15 Cytokinetics, Inc. Amino-pyrimidine skeletal muscle modulators
WO2017138069A1 (en) 2016-02-08 2017-08-17 株式会社エス・ディー・エス バイオテック Germicidal composition
CN107056808A (en) * 2017-03-28 2017-08-18 上海大学 3 aryl substituted isoxazoles and succinimide class compound and its synthetic method
WO2017153200A1 (en) 2016-03-10 2017-09-14 Basf Se Fungicidal mixtures iii comprising strobilurin-type fungicides
US9790182B2 (en) 2014-06-11 2017-10-17 Bayer Cropscience Aktiengesellschaft Preparation of piperidine-4-carbothioamide
WO2017178245A1 (en) 2016-04-11 2017-10-19 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2017207368A1 (en) 2016-06-02 2017-12-07 BASF Agro B.V. Fungicidal compositions
WO2018050421A1 (en) 2016-09-13 2018-03-22 Basf Se Fungicidal mixtures i comprising quinoline fungicides
WO2018054711A1 (en) 2016-09-26 2018-03-29 Basf Se Pyridine compounds for controlling phytopathogenic harmful fungi
WO2018054721A1 (en) 2016-09-26 2018-03-29 Basf Se Pyridine compounds for controlling phytopathogenic harmful fungi
WO2018054723A1 (en) 2016-09-26 2018-03-29 Basf Se Pyridine compounds for controlling phytopathogenic harmful fungi
WO2018065182A1 (en) 2016-10-04 2018-04-12 Basf Se Reduced quinoline compounds as antifuni agents
US9951063B2 (en) 2014-03-24 2018-04-24 Idorsia Pharmaceuticals Ltd 8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives
WO2018073110A1 (en) 2016-10-20 2018-04-26 Basf Se Quinoline compounds as fungicides
US9994528B2 (en) 2010-04-23 2018-06-12 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
EP3338552A1 (en) 2016-12-21 2018-06-27 Basf Se Use of a tetrazolinone fungicide on transgenic plants
EP3339297A1 (en) 2016-12-20 2018-06-27 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2018114657A1 (en) 2016-12-20 2018-06-28 Syngenta Participations Ag N-cyclobutyl-thiazol-5-carboxamides with nematicidal activity
WO2018114393A1 (en) 2016-12-19 2018-06-28 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2018134127A1 (en) 2017-01-23 2018-07-26 Basf Se Fungicidal pyridine compounds
US10047080B2 (en) 2015-01-15 2018-08-14 Idorsia Pharmaceuticals Ltd. (R)-2-methyl-piperazine derivatives as CXCR3 receptor modulators
US10053457B2 (en) 2015-01-15 2018-08-21 Idorsia Pharmaceuticals Ltd. Hydroxyalkyl-piperazine derivatives as CXCR3 receptor modulators
WO2018149754A1 (en) 2017-02-16 2018-08-23 Basf Se Pyridine compounds
WO2018153730A1 (en) 2017-02-21 2018-08-30 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2018177970A1 (en) 2017-03-31 2018-10-04 Basf Se Process for preparing chiral 2,3-dihydrothiazolo[3,2-a]pyrimidin-4-ium compounds
US10093626B2 (en) 2015-03-05 2018-10-09 Bayer Cropscience Aktiengesellschaft Process for preparing piperidine-4-carbothioamide hydrochloride
WO2018184882A1 (en) 2017-04-06 2018-10-11 Basf Se Pyridine compounds
WO2018184970A1 (en) 2017-04-07 2018-10-11 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2018188962A1 (en) 2017-04-11 2018-10-18 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2018193387A1 (en) 2017-04-19 2018-10-25 Pi Industries Ltd. Heterocyclic compounds with microbiocidal properties
WO2018193385A1 (en) 2017-04-20 2018-10-25 Pi Industries Ltd. Novel phenylamine compounds
WO2018202737A1 (en) 2017-05-05 2018-11-08 Basf Se Fungicidal mixtures comprising triazole compounds
WO2018202428A1 (en) 2017-05-02 2018-11-08 Basf Se Fungicidal mixture comprising substituted 3-phenyl-5-(trifluoromethyl)-1,2,4-oxadiazoles
WO2018202491A1 (en) 2017-05-04 2018-11-08 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
WO2018202487A1 (en) 2017-05-04 2018-11-08 Basf Se Substituted 5-(haloalkyl)-5-hydroxy-isoxazoles for combating phytopathogenic fungi
WO2018210661A1 (en) 2017-05-15 2018-11-22 Basf Se Heteroaryl compounds as agrochemical fungicides
WO2018210658A1 (en) 2017-05-15 2018-11-22 Basf Se Heteroaryl compounds as agrochemical fungicides
WO2018210659A1 (en) 2017-05-15 2018-11-22 Basf Se Heteroaryl compounds as agrochemical fungicides
WO2018210660A1 (en) 2017-05-15 2018-11-22 Basf Se Heteroaryl compounds as agrochemical fungicides
WO2018219797A1 (en) 2017-06-02 2018-12-06 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2018219725A1 (en) 2017-05-30 2018-12-06 Basf Se Pyridine and pyrazine compounds
WO2018234139A1 (en) 2017-06-19 2018-12-27 Basf Se 2-[[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]aryloxy](thio)acetamides for combating phytopathogenic fungi
WO2019002158A1 (en) 2017-06-30 2019-01-03 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
WO2019038042A1 (en) 2017-08-21 2019-02-28 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
WO2019042932A1 (en) 2017-08-31 2019-03-07 Basf Se Method of controlling rice pests in rice
WO2019042800A1 (en) 2017-08-29 2019-03-07 Basf Se Pesticidal mixtures
EP3453706A1 (en) 2017-09-08 2019-03-13 Basf Se Pesticidal imidazole compounds
WO2019048989A1 (en) 2017-09-08 2019-03-14 Pi Industries Ltd. Novel fungicidal heterocyclic compounds
WO2019048988A1 (en) 2017-09-08 2019-03-14 Pi Industries Ltd. Novel fungidal heterocyclic compounds
WO2019052932A1 (en) 2017-09-18 2019-03-21 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
WO2019057660A1 (en) 2017-09-25 2019-03-28 Basf Se Indole and azaindole compounds with substituted 6-membered aryl and heteroaryl rings as agrochemical fungicides
WO2019068810A1 (en) 2017-10-06 2019-04-11 Bayer Aktiengesellschaft Use of compositions comprising fluopyram for enhancing antioxidative fitness of plants
US10259807B2 (en) 2013-07-22 2019-04-16 Idorsia Pharmaceuticals Ltd. 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
WO2019072906A1 (en) 2017-10-13 2019-04-18 Basf Se Imidazolidine pyrimidinium compounds for combating animal pests
WO2019101511A1 (en) 2017-11-23 2019-05-31 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
WO2019115343A1 (en) 2017-12-15 2019-06-20 Basf Se Fungicidal mixture comprising substituted pyridines
WO2019115511A1 (en) 2017-12-14 2019-06-20 Basf Se Fungicidal mixture comprising substituted 3-phenyl-5-(trifluoromethyl)-1,2,4-oxadiazoles
WO2019123196A1 (en) 2017-12-20 2019-06-27 Pi Industries Ltd. Fluoralkenyl compounds, process for preparation and use thereof
WO2019121143A1 (en) 2017-12-20 2019-06-27 Basf Se Substituted cyclopropyl derivatives
WO2019121525A1 (en) 2017-12-20 2019-06-27 Bayer Aktiengesellschaft Use of fungicides for controlling mosaic scab in apples
WO2019137995A1 (en) 2018-01-11 2019-07-18 Basf Se Novel pyridazine compounds for controlling invertebrate pests
WO2019145140A1 (en) 2018-01-09 2019-08-01 Basf Se Silylethynyl hetaryl compounds as nitrification inhibitors
WO2019150311A1 (en) 2018-02-02 2019-08-08 Pi Industries Ltd. 1-3 dithiol compounds and their use for the protection of crops from phytopathogenic microorganisms
WO2019154663A1 (en) 2018-02-07 2019-08-15 Basf Se New pyridine carboxamides
WO2019154665A1 (en) 2018-02-07 2019-08-15 Basf Se New pyridine carboxamides
EP3530116A1 (en) 2018-02-27 2019-08-28 Basf Se Fungicidal mixtures comprising xemium
EP3530118A1 (en) 2018-02-26 2019-08-28 Basf Se Fungicidal mixtures
EP3533333A1 (en) 2018-03-02 2019-09-04 Basf Se Fungicidal mixtures comprising pydiflumetofen
EP3533331A1 (en) 2018-03-02 2019-09-04 Basf Se Fungicidal mixtures comprising pydiflumetofen
WO2019166558A1 (en) 2018-02-28 2019-09-06 Basf Se Use of pyrazole propargyl ethers as nitrification inhibitors
WO2019166257A1 (en) 2018-03-01 2019-09-06 BASF Agro B.V. Fungicidal compositions of mefentrifluconazole
WO2019166561A1 (en) 2018-02-28 2019-09-06 Basf Se Use of alkoxypyrazoles as nitrification inhibitors
WO2019166560A1 (en) 2018-02-28 2019-09-06 Basf Se Use of n-functionalized alkoxy pyrazole compounds as nitrification inhibitors
WO2019166252A1 (en) 2018-02-28 2019-09-06 Basf Se Fungicidal mixtures comprising fenpropidin
EP3536150A1 (en) 2018-03-06 2019-09-11 Basf Se Fungicidal mixtures comprising fluxapyroxad
WO2019175712A1 (en) 2018-03-14 2019-09-19 Basf Corporation New uses for catechol molecules as inhibitors to glutathione s-transferase metabolic pathways
WO2019175713A1 (en) 2018-03-14 2019-09-19 Basf Corporation New catechol molecules and their use as inhibitors to p450 related metabolic pathways
EP3556744A1 (en) 2013-12-23 2019-10-23 Syngenta Participations Ag Insecticidal compounds
WO2019219464A1 (en) 2018-05-15 2019-11-21 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
WO2019219529A1 (en) 2018-05-15 2019-11-21 Basf Se Mixtures comprising benzpyrimoxan and oxazosulfyl and uses and methods of applying them
WO2019224092A1 (en) 2018-05-22 2019-11-28 Basf Se Pesticidally active c15-derivatives of ginkgolides
WO2020002472A1 (en) 2018-06-28 2020-01-02 Basf Se Use of alkynylthiophenes as nitrification inhibitors
WO2020020777A1 (en) 2018-07-23 2020-01-30 Basf Se Use of substituted 2-thiazolines as nitrification inhibitors
WO2020020765A1 (en) 2018-07-23 2020-01-30 Basf Se Use of a substituted thiazolidine compound as nitrification inhibitor
WO2020035826A1 (en) 2018-08-17 2020-02-20 Pi Industries Ltd. 1,2-dithiolone compounds and use thereof
EP3613736A1 (en) 2018-08-22 2020-02-26 Basf Se Substituted glutarimide derivatives
EP3628156A1 (en) 2018-09-28 2020-04-01 Basf Se Method for controlling pests of sugarcane, citrus, rapeseed, and potato plants
EP3628157A1 (en) 2018-09-28 2020-04-01 Basf Se Method of controlling insecticide resistant insects and virus transmission to plants
EP3628158A1 (en) 2018-09-28 2020-04-01 Basf Se Pesticidal mixture comprising a mesoionic compound and a biopesticide
WO2020064492A1 (en) 2018-09-28 2020-04-02 Basf Se Method of controlling pests by seed treatment application of a mesoionic compound or mixture thereof
EP3643705A1 (en) 2018-10-24 2020-04-29 Basf Se Pesticidal compounds
WO2020095161A1 (en) 2018-11-05 2020-05-14 Pi Industries Ltd. Nitrone compounds and use thereof
US10654827B2 (en) 2016-08-19 2020-05-19 Gilead Sciences, Inc. Therapeutic compounds
EP3670501A1 (en) 2018-12-17 2020-06-24 Basf Se Substituted [1,2,4]triazole compounds as fungicides
US10696657B2 (en) 2018-02-16 2020-06-30 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds
EP3696177A1 (en) 2019-02-12 2020-08-19 Basf Se Heterocyclic compounds for the control of invertebrate pests
US10779536B2 (en) 2014-11-07 2020-09-22 Basf Se Pesticidal mixtures
EP3730489A1 (en) 2019-04-25 2020-10-28 Basf Se Heteroaryl compounds as agrochemical fungicides
US10836746B2 (en) 2018-02-15 2020-11-17 Gilead Sciences, Inc. Therapeutic compounds
US10849892B2 (en) 2017-08-17 2020-12-01 Gilead Sciences, Inc. Choline salt forms of an HIV capsid inhibitor
WO2020239517A1 (en) 2019-05-29 2020-12-03 Basf Se Mesoionic imidazolium compounds and derivatives for combating animal pests
WO2020244970A1 (en) 2019-06-06 2020-12-10 Basf Se New carbocyclic pyridine carboxamides
WO2020244968A1 (en) 2019-06-06 2020-12-10 Basf Se Fungicidal n-(pyrid-3-yl)carboxamides
WO2020244969A1 (en) 2019-06-06 2020-12-10 Basf Se Pyridine derivatives and their use as fungicides
EP3766879A1 (en) 2019-07-19 2021-01-20 Basf Se Pesticidal pyrazole derivatives
EP3769623A1 (en) 2019-07-22 2021-01-27 Basf Se Mesoionic imidazolium compounds and derivatives for combating animal pests
US10905122B2 (en) 2016-03-16 2021-02-02 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on cereals
WO2021063736A1 (en) 2019-10-02 2021-04-08 Basf Se Bicyclic pyridine derivatives
WO2021063735A1 (en) 2019-10-02 2021-04-08 Basf Se New bicyclic pyridine derivatives
WO2021094903A1 (en) 2019-11-11 2021-05-20 Pi Industries Ltd. 1-(4-(4-(5-phenyl-4,5-dihydroisoxazol-3-yl)thiazol-2-yl)piperidin-1-yl)-ethan-1-one derivatives and related compounds as fungicides for crop protection
WO2021094904A2 (en) 2019-11-11 2021-05-20 Pi Industries Ltd. Novel sulfilimines or sulfoximines containing fungicidal heterocyclic compounds
WO2021094905A1 (en) 2019-11-11 2021-05-20 Pi Industries Ltd. 1 -(4-(4-(5-phenyl-4,5-dihydroisoxazol-3-yl)thiazol-2-yl)piperidin-1 -yl)-ethan-1 -one derivatives and related compounds as fungicides for crop protection
WO2021122752A1 (en) 2019-12-19 2021-06-24 Bayer Aktiengesellschaft Process for preparing [3-chloro-2-[3-[2-[1-(2-chloroacetyl)-4-piperidyl]thiazol-4-yl]-4,5-dihydroisoxazol-5-yl]phenyl] methanesulfonate
WO2021130143A1 (en) 2019-12-23 2021-07-01 Basf Se Enzyme enhanced root uptake of agrochemical active compound
CN113185509A (en) * 2020-04-17 2021-07-30 华中师范大学 Compound containing indole ring structure, preparation method and application thereof, and bactericide
WO2021170463A1 (en) 2020-02-28 2021-09-02 BASF Agro B.V. Methods and uses of a mixture comprising alpha-cypermethrin and dinotefuran for controlling invertebrate pests in turf
WO2021175669A1 (en) 2020-03-04 2021-09-10 Basf Se Use of substituted 1,2,4-oxadiazoles for combating phytopathogenic fungi
WO2021209360A1 (en) 2020-04-14 2021-10-21 Basf Se Fungicidal mixtures comprising substituted 3-phenyl-5-(trifluoromethyl)-1,2,4-oxadiazoles
EP3903582A1 (en) 2020-04-28 2021-11-03 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors ii
EP3903583A1 (en) 2020-04-28 2021-11-03 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors iii
EP3903584A1 (en) 2020-04-28 2021-11-03 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors iv
EP3903581A1 (en) 2020-04-28 2021-11-03 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors i
WO2021219513A1 (en) 2020-04-28 2021-11-04 Basf Se Pesticidal compounds
EP3909950A1 (en) 2020-05-13 2021-11-17 Basf Se Heterocyclic compounds for the control of invertebrate pests
WO2021249800A1 (en) 2020-06-10 2021-12-16 Basf Se Substituted [1,2,4]triazole compounds as fungicides
EP3939961A1 (en) 2020-07-16 2022-01-19 Basf Se Strobilurin type compounds and their use for combating phytopathogenic fungi
WO2022017836A1 (en) 2020-07-20 2022-01-27 BASF Agro B.V. Fungicidal compositions comprising (r)-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1- (1,2,4-triazol-1-yl)propan-2-ol
EP3945089A1 (en) 2020-07-31 2022-02-02 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors v
US11241012B2 (en) 2016-03-16 2022-02-08 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on soybean
EP3960727A1 (en) 2020-08-28 2022-03-02 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors vi
US11267799B2 (en) 2017-08-17 2022-03-08 Gilead Sciences, Inc. Solid forms of an HIV capsid inhibitor
US11274076B2 (en) 2016-02-08 2022-03-15 Gowan Company, L.L.C. Process for preparing 1, 2-benzenedimethanol compound
EP3970494A1 (en) 2020-09-21 2022-03-23 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors viii
WO2022064453A1 (en) 2020-09-26 2022-03-31 Pi Industries Ltd. Nematocidal compounds and use thereof
WO2022090071A1 (en) 2020-11-02 2022-05-05 Basf Se Use of mefenpyr-diethyl for controlling phytopathogenic fungi
WO2022090069A1 (en) 2020-11-02 2022-05-05 Basf Se Compositions comprising mefenpyr-diethyl
WO2022089969A1 (en) 2020-10-27 2022-05-05 BASF Agro B.V. Compositions comprising mefentrifluconazole
WO2022106304A1 (en) 2020-11-23 2022-05-27 BASF Agro B.V. Compositions comprising mefentrifluconazole
WO2022130188A1 (en) 2020-12-15 2022-06-23 Pi Industries Ltd. Agrochemical composition comprising piperidine thiazole compounds
EP4018830A1 (en) 2020-12-23 2022-06-29 Basf Se Pesticidal mixtures
WO2022167488A1 (en) 2021-02-02 2022-08-11 Basf Se Synergistic action of dcd and alkoxypyrazoles as nitrification inhibitors
EP4043444A1 (en) 2021-02-11 2022-08-17 Basf Se Substituted isoxazoline derivatives
US11425909B2 (en) 2016-03-16 2022-08-30 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on fruits
WO2022238157A1 (en) 2021-05-11 2022-11-17 Basf Se Fungicidal mixtures comprising substituted 3-phenyl-5-(trifluoromethyl)-1,2,4-oxadiazoles
WO2022243111A1 (en) 2021-05-18 2022-11-24 Basf Se New substituted pyridines as fungicides
WO2022243523A1 (en) 2021-05-21 2022-11-24 Basf Se Use of an n-functionalized alkoxy pyrazole compound as nitrification inhibitor
WO2022243810A1 (en) 2021-05-15 2022-11-24 Pi Industries Ltd. Novel agrochemical composition comprising piperidine thiazole compounds
WO2022243109A1 (en) 2021-05-18 2022-11-24 Basf Se New substituted quinolines as fungicides
WO2022243107A1 (en) 2021-05-18 2022-11-24 Basf Se New substituted pyridines as fungicides
WO2022243521A1 (en) 2021-05-21 2022-11-24 Basf Se Use of ethynylpyridine compounds as nitrification inhibitors
EP4094579A1 (en) 2021-05-28 2022-11-30 Basf Se Pesticidal mixtures comprising metyltetraprole
WO2022268810A1 (en) 2021-06-21 2022-12-29 Basf Se Metal-organic frameworks with pyrazole-based building blocks
EP4119547A1 (en) 2021-07-12 2023-01-18 Basf Se Triazole compounds for the control of invertebrate pests
WO2023007429A1 (en) 2021-07-29 2023-02-02 Pi Industries Ltd. Preparation of phenyl sulfilimines or sulfoximines containing thiazolyl-piperidinyl compounds and intermediates thereof
WO2023011957A1 (en) 2021-08-02 2023-02-09 Basf Se (3-quinolyl)-quinazoline
WO2023011958A1 (en) 2021-08-02 2023-02-09 Basf Se (3-pirydyl)-quinazoline
EP4140995A1 (en) 2021-08-27 2023-03-01 Basf Se Pyrazine compounds for the control of invertebrate pests
EP4140986A1 (en) 2021-08-23 2023-03-01 Basf Se Pyrazine compounds for the control of invertebrate pests
EP4151631A1 (en) 2021-09-20 2023-03-22 Basf Se Heterocyclic compounds for the control of invertebrate pests
EP4154714A2 (en) 2013-10-03 2023-03-29 Syngenta Participations Ag Fungicidal compositions
WO2023072671A1 (en) 2021-10-28 2023-05-04 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors ix
WO2023072670A1 (en) 2021-10-28 2023-05-04 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors x
EP4194453A1 (en) 2021-12-08 2023-06-14 Basf Se Pyrazine compounds for the control of invertebrate pests
US11680064B2 (en) 2020-06-25 2023-06-20 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
EP4198023A1 (en) 2021-12-16 2023-06-21 Basf Se Pesticidally active thiosemicarbazone compounds
EP4198033A1 (en) 2021-12-14 2023-06-21 Basf Se Heterocyclic compounds for the control of invertebrate pests
EP4238971A1 (en) 2022-03-02 2023-09-06 Basf Se Substituted isoxazoline derivatives
US11787825B2 (en) 2021-12-03 2023-10-17 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
WO2023203066A1 (en) 2022-04-21 2023-10-26 Basf Se Synergistic action as nitrification inhibitors of dcd oligomers with alkoxypyrazole and its oligomers
US11807625B2 (en) 2019-11-26 2023-11-07 Gilead Sciences, Inc. Capsid inhibitors for the prevention of HIV
WO2024028243A1 (en) 2022-08-02 2024-02-08 Basf Se Pyrazolo pesticidal compounds
EP4342885A1 (en) 2022-09-20 2024-03-27 Basf Se N-(3-(aminomethyl)-phenyl)-5-(4-phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-amine derivatives and similar compounds as pesticides
US11944611B2 (en) 2018-07-16 2024-04-02 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
EP4361126A1 (en) 2022-10-24 2024-05-01 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors xv
WO2024104814A1 (en) 2022-11-16 2024-05-23 Basf Se Fungicidal mixture comprising substituted pyridines
WO2024104815A1 (en) 2022-11-16 2024-05-23 Basf Se Substituted benzodiazepines as fungicides
WO2024104818A1 (en) 2022-11-16 2024-05-23 Basf Se Substituted benzodiazepines as fungicides
WO2024104813A1 (en) 2022-11-14 2024-05-23 Basf Se Fungicidal mixture comprising substituted pyridines
WO2024104823A1 (en) 2022-11-16 2024-05-23 Basf Se New substituted tetrahydrobenzoxazepine
WO2024104822A1 (en) 2022-11-16 2024-05-23 Basf Se Substituted tetrahydrobenzodiazepine as fungicides
EP4389210A1 (en) 2022-12-21 2024-06-26 Basf Se Heteroaryl compounds for the control of invertebrate pests
WO2024165343A1 (en) 2023-02-08 2024-08-15 Basf Se New substituted quinoline compounds for combatitng phytopathogenic fungi
US12084467B2 (en) 2021-12-03 2024-09-10 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
WO2024194038A1 (en) 2023-03-17 2024-09-26 Basf Se Substituted pyridyl/pyrazidyl dihydrobenzothiazepine compounds for combatting phytopathogenic fungi
EP4455137A1 (en) 2023-04-24 2024-10-30 Basf Se Pyrimidine compounds for the control of invertebrate pests
WO2024223034A1 (en) 2023-04-26 2024-10-31 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors xvi

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55576B1 (en) 2005-12-13 2017-05-31 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
NZ589395A (en) * 2007-04-25 2011-04-29 Syngenta Participations Ag Fungicidal compositions containing cyprodinil and a benzonobornene amide derivative useful for controlling diseases on plants caused by phytopathogens
US20090170867A1 (en) 2007-04-27 2009-07-02 Shionogi & Co., Ltd. Trpv1 antagonists including sulfonamide substituent and uses thereof
BRPI0814254B8 (en) 2007-06-13 2021-05-25 Incyte Corp Janus kinase inhibitor salts (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile, their method of preparation and composition that comprises them
EP2070413A1 (en) 2007-12-11 2009-06-17 Bayer CropScience AG Active compound combinations
EP2151434A1 (en) * 2008-08-05 2010-02-10 Institut Pasteur Alkoxypyrazoles and the process for their preparation
WO2010037479A1 (en) * 2008-10-01 2010-04-08 Bayer Cropscience Ag Heterocyclyl-substituted thiazoles as plant protection agents
EP2184276A1 (en) 2008-11-07 2010-05-12 Universite Paul Cezanne Aix-Marseille Iii Process to prepare new substituted 1H-Benzo(d) imidazol-2(3h)-Ones, New intermediates and their use as bace 1 inhibitors
JOP20190230A1 (en) 2009-01-15 2017-06-16 Incyte Corp Processes for preparing jak inhibitors and related intermediate compounds
CN106967070A (en) 2009-05-22 2017-07-21 因塞特控股公司 It is used as the compound of JAK inhibitor
NZ596479A (en) 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011056291A1 (en) * 2009-11-06 2011-05-12 Bayer Cropscience Ag Use of succinate dehydrogenase inhibitors for extending shelf life of fruits and vegetables
RS54823B1 (en) 2010-03-10 2016-10-31 Incyte Holdings Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
CA2799928C (en) 2010-05-21 2020-03-31 Incyte Corporation Topical formulation for a jak inhibitor
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
US8933085B2 (en) 2010-11-19 2015-01-13 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
JP5876146B2 (en) 2011-06-20 2016-03-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Azetidinylphenyl, pyridyl, or pyrazinylcarboxamide derivatives as JAK inhibitors
RU2621708C2 (en) 2011-06-22 2017-06-07 ПУРДЬЮ ФАРМА Эл. Пи. Antagonists of trpv1, containing dihydroxy group as substitute, and their use
WO2013009971A1 (en) 2011-07-12 2013-01-17 E. I. Du Pont De Nemours And Company Detection and screening method and materials useful in performance thereof
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
EP2623496A1 (en) 2012-02-01 2013-08-07 Bayer CropScience AG Method for producing 3,5-bis(fluoralkyl)-pyrazol-4-carboxylic acid derivatives and 3,5-bis(fluoralkyl)-pyrazoles
EP2644688B1 (en) * 2012-03-27 2017-11-08 International Flavors & Fragrances Inc. Novel pyrimidine derivatives and their use in perfume compositions
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
MX2014015511A (en) 2012-06-22 2015-03-19 Du Pont Fungicidal heterocyclic compounds.
EA201590930A1 (en) 2012-11-15 2015-08-31 Инсайт Корпорейшн DOSAGE FORMS OF RUXOLITINIB WITH Slow Release.
WO2014127195A1 (en) * 2013-02-15 2014-08-21 Monsanto Technology Llc 3,5-disubstituted-4,5-dihydro-1,2,4-oxadiazoles for controlling nematode pests
UA121532C2 (en) 2013-03-06 2020-06-10 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATES IN THE PREPARATION OF JAK INHIBITOR
WO2014187774A1 (en) 2013-05-22 2014-11-27 Bayer Cropscience Ag Method for the production of 3,5-bis(fluoroalkyl) pyrazole derivatives
CN104336079A (en) * 2013-08-01 2015-02-11 陕西美邦农药有限公司 A compound sterilization composition containing oxathiapiprolin
SG10201801069QA (en) 2013-08-07 2018-03-28 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
CN104336024A (en) * 2013-08-08 2015-02-11 陕西美邦农药有限公司 Bactericidal composition containing fluorothiazolepyrithylone and amides
EP3015458A1 (en) 2014-11-03 2016-05-04 Bayer CropScience AG Process for preparing 3,5-bis(haloalkyl)pyrazole derivatives from a,a-dihaloamines and ketimines
TWI665192B (en) * 2014-05-28 2019-07-11 德商拜耳作物科學股份有限公司 Process for preparing dihydroisoxazole derivatives
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
EP3154947B1 (en) * 2014-06-11 2018-03-28 Bayer CropScience Aktiengesellschaft Process for preparing 3,5-bis(haloalkyl)pyrazoles via acylation of ketimines
TWI664905B (en) * 2014-07-29 2019-07-11 日商住友化學股份有限公司 Noxious arthropod controlling agent containing amide compound
CN107207435B (en) 2015-01-16 2020-05-19 拜耳作物科学股份公司 Process for preparing 4-cyanopiperidine hydrochloride
BR112017018992B1 (en) 2015-03-05 2022-02-08 Bayer Cropscience Aktiengesellschaft PROCESS FOR PREPARATION OF SUBSTITUTED PHENYLISOXAZOLINE DERIVATIVES
AU2016246410B2 (en) * 2015-04-10 2020-11-05 Fmc Corporation Substituted cyclic amides as herbicides
BR112017028115A2 (en) 2015-06-26 2018-08-28 Bayer Cropscience Ag Process for preparing substituted pyrazoles containing haloalkoxy and haloalkylthio groups from ¿, ¿-dihaloalkylamines and ketimines
CN109689629B (en) 2016-09-21 2022-11-29 拜耳作物科学股份公司 Process for preparing 3-fluoroalkyl-5-pyrazole carboxylic acid esters and 3-fluoroalkyl-5-pyrazole carboxylic acids
CA3044280A1 (en) * 2016-11-22 2018-05-31 Dow Agrosciences Llc Fungicidal compounds and mixtures for fungal control in cereals
AU2017365179B2 (en) * 2016-11-22 2021-09-02 Corteva Agriscience Llc Fungicidal compounds and mixtures for fungal control in cereals
CN106746601B (en) 2016-12-30 2019-06-04 东旭集团有限公司 It is used to prepare the composition, glassware and purposes of glass
CN109699654A (en) * 2017-10-26 2019-05-03 佛山市盈辉作物科学有限公司 A kind of composition pesticide of fluorine-containing thiazole pyrrole ethyl ketone and shenqinmycin
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CN108184866A (en) * 2018-01-16 2018-06-22 安徽省农业科学院植物保护与农产品质量安全研究所 A kind of bactericidal composition of fluorine-containing thiazole pyrrole ethyl ketone and Flutriafol
HRP20220510T1 (en) 2018-01-30 2022-05-27 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
IL277538B2 (en) 2018-03-30 2024-09-01 Incyte Corp Treatment of hidradenitis suppurativa using jak inhibitors
CN110437224B (en) * 2018-05-04 2023-09-19 华中师范大学 Compound containing cyclopyrazole structure, preparation method and application thereof, and bactericide
WO2020034992A1 (en) * 2018-08-14 2020-02-20 华中师范大学 Fused heterocycle structure-containing compound, preparation method therefor and applications thereof, and fungicide
CN110818707B (en) * 2018-08-14 2022-04-01 华中师范大学 Compound containing fused heterocyclic structure, preparation method and application thereof, and bactericide
US20210330676A1 (en) * 2018-08-22 2021-10-28 Merck Sharp & Dohme Corp. Novel aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
CN109111371B (en) * 2018-09-27 2021-08-06 江西万里药业有限公司 Preparation method of hydrazino ethyl acetate hydrochloride
CN117263945A (en) * 2019-02-19 2023-12-22 四川科伦博泰生物医药股份有限公司 Heterocyclic compound, pharmaceutical composition containing same, preparation method and application thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN111587889A (en) * 2020-07-01 2020-08-28 安徽省农业科学院植物保护与农产品质量安全研究所 Bactericidal composition containing oxathiapiprolin and carboxin
CN115594670A (en) * 2021-06-28 2023-01-13 浙江省化工研究院有限公司（Cn） Trifluoromethyl containing oxadiazole derivatives, preparation method and application thereof
AR126600A1 (en) * 2021-07-29 2023-10-25 Pi Industries Ltd NOVEL STYRENE COMPOUNDS AND A PROCESS FOR THE PREPARATION THEREOF
CN116199683A (en) * 2021-11-30 2023-06-02 江苏中旗科技股份有限公司 Compound containing oxadiazole structure, preparation method and application thereof, and bactericide
CN118303394A (en) * 2023-02-07 2024-07-09 广西壮族自治区农业科学院 Bactericide composition containing thymol and fluorothiazole pyrithione

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2254320A1 (en) * 1973-12-17 1975-07-11 Thomae Gmbh Dr K
WO2004058751A1 (en) * 2002-12-24 2004-07-15 Metris Therapeutics Limited Piperidinyl-thiazole carboxamide derivatives for altering vascular tone
WO2005003128A1 (en) * 2003-06-25 2005-01-13 Merck Patent Gmbh Thiazolylpiperidine derivatives as mtp inhibitors
WO2006032322A1 (en) * 2004-09-20 2006-03-30 4Sc Ag NOVEL HETEROCYCLIC NF-κB INHIBITORS
WO2007064553A2 (en) * 2005-11-29 2007-06-07 Merck & Co., Inc. Thiazole derivatives as cxcr3 receptor modulators
WO2007070433A2 (en) * 2005-12-12 2007-06-21 Merck & Co., Inc. 2-arylthiazole derivatives as cxcr3 receptor modulators

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2602796A (en) * 1950-11-24 1952-07-08 American Cyanamid Co 1-carbamyl-4-thiazolyl piperazines
US2891855A (en) 1954-08-16 1959-06-23 Geigy Ag J R Compositions and methods for influencing the growth of plants
US3235361A (en) 1962-10-29 1966-02-15 Du Pont Method for the control of undesirable vegetation
US3060084A (en) 1961-06-09 1962-10-23 Du Pont Improved homogeneous, readily dispersed, pesticidal concentrate
US3299566A (en) 1964-06-01 1967-01-24 Olin Mathieson Water soluble film containing agricultural chemicals
US3309192A (en) 1964-12-02 1967-03-14 Du Pont Method of controlling seedling weed grasses
US3557089A (en) 1968-12-27 1971-01-19 Du Pont Preparation of l-(carbamoyl)-n-(carbamoyloxy) thioformimidates from acetoacetamides
US4144050A (en) 1969-02-05 1979-03-13 Hoechst Aktiengesellschaft Micro granules for pesticides and process for their manufacture
US3920442A (en) 1972-09-18 1975-11-18 Du Pont Water-dispersible pesticide aggregates
US4089672A (en) 1972-12-20 1978-05-16 The Upjohn Company 1-(Substituted-hydrocarbyl)-di- and trihalopyrazoles
US4172714A (en) 1976-12-20 1979-10-30 E. I. Du Pont De Nemours And Company Dry compactible, swellable herbicidal compositions and pellets produced therefrom
GB2095558B (en) 1981-03-30 1984-10-24 Avon Packers Ltd Formulation of agricultural chemicals
EP0094498A3 (en) * 1982-05-06 1985-04-03 American Cyanamid Company Antiatherosclerotic 1-piperazine derivatives
DE3246493A1 (en) 1982-12-16 1984-06-20 Bayer Ag, 5090 Leverkusen METHOD FOR PRODUCING WATER-DISPERSIBLE GRANULES
DE3332271A1 (en) * 1983-09-07 1985-03-21 Bayer Ag, 5090 Leverkusen HERBICIDES CONTAINING METRIBUZINE IN COMBINATION WITH SUBSTITUTED AZOLYL DERIVATIVES
DE3537762A1 (en) 1984-12-20 1986-07-03 Bayer Ag, 5090 Leverkusen Process for the preparation of N-tert-alkylpyridine-carboxamides
EP0206523B1 (en) * 1985-06-18 1991-12-04 Imperial Chemical Industries Plc Heterocyclic compounds as fungicides
US5180587A (en) 1988-06-28 1993-01-19 E. I. Du Pont De Nemours And Company Tablet formulations of pesticides
ZW13690A1 (en) 1989-08-30 1990-11-21 Aeci Ltd Active ingredient dosage device
AU651335B2 (en) 1990-03-12 1994-07-21 E.I. Du Pont De Nemours And Company Water-dispersible or water-soluble pesticide granules from heat-activated binders
EP0480679B1 (en) 1990-10-11 1996-09-18 Sumitomo Chemical Company Limited Pesticidal composition
ES2149764T3 (en) * 1991-04-15 2000-11-16 Aventis Cropscience Gmbh PROTECTING AGENTS OF PLANTS CONTAINING ISOXAZOLINES OR ISOTIAZOLINS, NEW ISOXAZOLINS AND ISOTIAZOLINS AND PROCEDURE FOR THEIR PREPARATION.
WO1993014080A1 (en) * 1992-01-15 1993-07-22 E.I. Du Pont De Nemours And Company Bridged heterocyclic fungicides
EP0630370A1 (en) 1992-03-11 1994-12-28 E.I. Du Pont De Nemours And Company Fungicidal oxazolidinones
AU4288293A (en) * 1992-04-27 1993-11-29 E.I. Du Pont De Nemours And Company Fungicidal 1,3,4-oxadiazines and 1,3,4-thiadiazines
DE4305502A1 (en) * 1993-02-23 1994-08-25 Basf Ag Ortho-substituted 2-methoxyiminophenylacetic acid methylamides
FR2704387B1 (en) 1993-04-28 1995-06-09 Rhone Poulenc Agrochimie CONCENTRATED COMPOSITIONS OF MATERIALS ACTIVE IN AGRICULTURE.
CN1050355C (en) 1993-05-12 2000-03-15 纳幕尔杜邦公司 Fungicidal fused bicyclic pyrimidinones
DE4331448A1 (en) * 1993-09-16 1995-03-23 Hoechst Schering Agrevo Gmbh Substituted isoxazolines, processes for their preparation, compositions containing them and their use as safeners
AU677448B2 (en) * 1993-11-19 1997-04-24 E.I. Du Pont De Nemours And Company Fungicidal cyclic amides
GB9416364D0 (en) 1994-08-12 1994-10-05 Fine Organics Ltd Preparation of thioamides
EP0799202A1 (en) * 1994-12-23 1997-10-08 Dr. Karl Thomae GmbH Piperazine derivatives, medicaments containing the same, their use and process for preparing the same
ZA964248B (en) 1995-06-23 1997-11-27 Du Pont Uniform mixtures of pesticidal granules.
BR9609613A (en) 1995-07-05 1999-05-25 Du Pont Compound fungicidal composition and method of controlling plant diseases
CN1213373A (en) 1996-03-11 1999-04-07 诺瓦提斯公司 Pyrimidin-4-one-derivatives as pesticide
CN1242767A (en) * 1996-11-01 2000-01-26 纳幕尔杜邦公司 Fungicidal cyclic amides
FR2758327B1 (en) * 1997-01-15 1999-04-02 Pf Medicament NEW ARYLPIPERAZINES DERIVED FROM PIPERIDINE
JP2001511147A (en) * 1997-02-04 2001-08-07 ザ・ボード・オブ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・アーカンソー Fungicidal and fungicidal carboxamides
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
GB9719411D0 (en) 1997-09-12 1997-11-12 Ciba Geigy Ag New Pesticides
AU1455500A (en) * 1998-10-29 2000-05-22 Trega Biosciences, Inc. Oxadiazole, thiadiazole and triazole derivatives and combinatorial libraries thereof
GB9902234D0 (en) * 1999-02-01 1999-03-24 Zeneca Ltd Expression system
DE10136065A1 (en) * 2001-07-25 2003-02-13 Bayer Cropscience Ag pyrazolylcarboxanilides
TW200724033A (en) 2001-09-21 2007-07-01 Du Pont Anthranilamide arthropodicide treatment
JP4471262B2 (en) * 2002-03-07 2010-06-02 株式会社エス・ディー・エス バイオテック Substituted isoxazole alkylamine derivatives and agricultural and horticultural fungicides
WO2004069818A1 (en) * 2003-01-17 2004-08-19 Cv Therapeutics Inc. Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
CL2004000366A1 (en) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USE OF A COMBINATION OF A QUINASA P38 INHIBITING DERIVED COMPOUND OF PIRAZOL, AND AN ACE INHIBITOR TO TREAT RENAL DYSFUNCTION, CARDIOVASCULAR AND VASCULAR DISEASE, RETINOPATHY, NEUROPATIA, EDOTEL, INSOTUNATIO OPINION.
BRPI0417267A (en) * 2003-12-22 2007-04-17 Pfizer triazole derivatives as vasopressin antagonists
FR2865733B1 (en) 2004-02-04 2007-10-12 Merck Sante Sas THIAZOLYLIMIDAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND MEDICINE APPLICATIONS THEREOF
WO2005087765A1 (en) 2004-03-04 2005-09-22 Arena Pharmaceuticals, Inc. Ligands of follicle stimulating hormone receptor and methods of use thereof
EP1735622A2 (en) 2004-04-13 2006-12-27 Arena Pharmaceuticals, Inc. Modulators of human g protein-coupled receptors for the treatment of hyperglycemia and related disorders
JP4789934B2 (en) 2004-05-24 2011-10-12 アムジエン・インコーポレーテツド Inhibitors of type 1 11-beta-hydroxysteroid dehydrogenase
US20080108686A1 (en) * 2004-06-18 2008-05-08 Basf Aktiengesellschaft N-(Ortho-Phenyl)-1-Methyl-3-Difluoromethylpyrazole-4-Carboxanilides And Their Use As Fungicides
JP5043668B2 (en) 2004-09-20 2012-10-10 ゼノン・ファーマシューティカルズ・インコーポレイテッド Heterocyclic derivatives and their use as therapeutic agents
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
DE102004055582A1 (en) * 2004-11-18 2006-05-24 Bayer Cropscience Ag N-heterocyclic-phthalic
AU2005318419A1 (en) * 2004-12-23 2006-06-29 Chiesi Farmaceutici S.P.A. Azole derivatives with antimuscarinic activity
EP1831164A1 (en) 2004-12-24 2007-09-12 AstraZeneca AB Heterocyclic compounds as ccr2b antagonists
US7754724B2 (en) 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
TW200738701A (en) * 2005-07-26 2007-10-16 Du Pont Fungicidal carboxamides
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
WO2008091594A2 (en) 2007-01-24 2008-07-31 E. I. Du Pont De Nemours And Company Fungicidal mixtures
ES2531256T3 (en) 2007-01-25 2015-03-12 Du Pont Fungicidal amides
TWI428091B (en) 2007-10-23 2014-03-01 Du Pont Fungicidal mixtures
WO2009094407A2 (en) 2008-01-25 2009-07-30 E. I. Du Pont De Nemours And Company Fungicidal amides
BRPI0905759A2 (en) 2008-01-25 2015-07-14 Du Pont Compound selected from compounds of formula 1 and non-oxides and salts thereof, method for controlling plant diseases caused by oomycota fungal plant pathogens and fungicidal composition
WO2011146182A1 (en) * 2010-05-20 2011-11-24 E. I. Du Pont De Nemours And Company Fungicidal oximes and hydrazones

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2254320A1 (en) * 1973-12-17 1975-07-11 Thomae Gmbh Dr K
WO2004058751A1 (en) * 2002-12-24 2004-07-15 Metris Therapeutics Limited Piperidinyl-thiazole carboxamide derivatives for altering vascular tone
WO2005003128A1 (en) * 2003-06-25 2005-01-13 Merck Patent Gmbh Thiazolylpiperidine derivatives as mtp inhibitors
WO2006032322A1 (en) * 2004-09-20 2006-03-30 4Sc Ag NOVEL HETEROCYCLIC NF-κB INHIBITORS
WO2007064553A2 (en) * 2005-11-29 2007-06-07 Merck & Co., Inc. Thiazole derivatives as cxcr3 receptor modulators
WO2007070433A2 (en) * 2005-12-12 2007-06-21 Merck & Co., Inc. 2-arylthiazole derivatives as cxcr3 receptor modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WADE, PETER ET AL: "Acid-catalyzed nitronate cycloaddition reactions. Useful Syntheses and simple transformations of 3-Acyl- and 3-Alkenylisoxazolines" J.ORG:CHEM., vol. 49, 1984, pages 4595-4601, XP002463515 *

Cited By (488)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642634B2 (en) 2006-07-27 2014-02-04 E I Du Pont De Nemours And Company Fungicidal azocyclic amides
US9604962B2 (en) 2006-07-27 2017-03-28 E I Du Pont De Nemours And Company Fungicidal azocyclic amides
US9920030B2 (en) 2006-07-27 2018-03-20 E I Du Pont De Nemours And Company Fungicidal azocyclic amides
US9090604B2 (en) 2006-07-27 2015-07-28 E I Du Pont De Nemours And Company Fungicidal azocyclic amides
US8420673B2 (en) 2007-01-25 2013-04-16 E I Du Pont De Nemours And Company Fungicidal amides
WO2008091580A3 (en) * 2007-01-25 2008-09-12 Du Pont Fungicidal amides
AU2014202324B2 (en) * 2007-10-23 2016-05-19 Corteva Agriscience Llc Fungicidal compounds and mixtures
CN101969781A (en) * 2007-10-23 2011-02-09 杜邦公司 Fungicidal compounds and mixtures
WO2009055514A2 (en) * 2007-10-23 2009-04-30 E. I. Du Pont De Nemours And Company Fungicidal mixtures
CN101969781B (en) * 2007-10-23 2015-01-28 杜邦公司 Fungicidal compounds and mixtures
WO2009055514A3 (en) * 2007-10-23 2010-03-25 E. I. Du Pont De Nemours And Company Fungicidal compounds and mixtures
US8449898B2 (en) 2007-10-23 2013-05-28 E I Du Pont De Nemours And Company Fungicidal mixtures
CN101970432A (en) * 2008-01-25 2011-02-09 杜邦公司 Fungicidal hetercyclic compounds
US20100286147A1 (en) * 2008-01-25 2010-11-11 E.I. Dupont De Nemours And Company Fungicidal amides
WO2009094445A2 (en) * 2008-01-25 2009-07-30 E. I. Du Pont De Nemours And Company Fungicidal hetercyclic compounds
EP2402332A3 (en) * 2008-01-25 2014-10-29 E.I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
US8349870B2 (en) 2008-01-25 2013-01-08 E I Du Pont De Nemours And Company Fungicidal hetercyclic compounds
WO2009094445A3 (en) * 2008-01-25 2010-08-26 E. I. Du Pont De Nemours And Company Fungicidal hetercyclic compounds
CN101970432B (en) * 2008-01-25 2014-05-28 杜邦公司 Fungicidal hetercyclic compounds
AU2009206522B2 (en) * 2008-01-25 2013-12-19 E. I. Du Pont De Nemours And Company Fungicidal amides
WO2009141096A1 (en) * 2008-05-21 2009-11-26 Bayer Cropscience Ag Substituted spiro-isoxazolines
DE102008001932A1 (en) 2008-05-21 2009-11-26 Bayer Cropscience Ag Substituted spiroisoxazolines
WO2010014257A3 (en) * 2008-08-01 2010-06-03 Purdue Pharma L.P. Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof
EP2676956A1 (en) * 2008-08-01 2013-12-25 Purdue Pharma L.P. Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof
US8324249B2 (en) 2008-08-01 2012-12-04 Purdue Pharma L.P. Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof
US11584717B2 (en) 2008-08-18 2023-02-21 Yale University MIF modulators
EP2326631A4 (en) * 2008-08-18 2012-03-21 Univ Yale Mif modulators
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
EP2326631A2 (en) * 2008-08-18 2011-06-01 Yale University Mif modulators
US10202343B2 (en) 2008-08-18 2019-02-12 Yale University MIF modulators
KR101716514B1 (en) * 2008-12-02 2017-03-14 이 아이 듀폰 디 네모아 앤드 캄파니 Fungicidal heterocyclic compounds
US8618137B2 (en) 2008-12-02 2013-12-31 E I Du Pont De Nemours And Company Fungicidal heterocyclic compounds
KR20110091798A (en) * 2008-12-02 2011-08-12 이 아이 듀폰 디 네모아 앤드 캄파니 Fungicidal heterocyclic compounds
JP2012511525A (en) * 2008-12-11 2012-05-24 バイエル・クロップサイエンス・アーゲー Thiazolyl oxime ethers and hydrazones as plant protection agents
US8697878B2 (en) 2008-12-11 2014-04-15 Bayer Cropscience Ag Thiazolyl oxime ethers and hydrazones as crop protection agents
CN102292334A (en) * 2008-12-11 2011-12-21 拜尔农作物科学股份公司 Thiazolyl oxime ether and hydrazones asl plant protection agent
US9215875B2 (en) 2008-12-11 2015-12-22 Bayer Intellectual Property Gmbh Thiazolyl oxime ethers and hydrazones as crop protection agents
WO2010066353A1 (en) * 2008-12-11 2010-06-17 Bayer Cropscience Ag Thiazolyl oxime ether and hydrazones asl plant protection agent
DE102010000662A1 (en) 2009-03-18 2010-10-21 Bayer Cropscience Ag New thiazole compounds useful to combat e.g. plant pathogenic fungus, bacteria and algae, and as herbicides, growth regulators, agents to improve plant properties, antimycotics, insecticides, virucides and Rickettsia-like organism
JP2016041720A (en) * 2009-04-22 2016-03-31 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーＥ．Ｉ．Ｄｕ Ｐｏｎｔ Ｄｅ Ｎｅｍｏｕｒｓ Ａｎｄ Ｃｏｍｐａｎｙ Solid forms of azacyclic amide
CN102459256A (en) * 2009-04-22 2012-05-16 纳幕尔杜邦公司 Solid forms of an azocyclic amide
WO2010123791A1 (en) * 2009-04-22 2010-10-28 E. I. Du Pont De Nemours And Company Solid forms of an azocyclic amide
CN102459256B (en) * 2009-04-22 2015-08-26 纳幕尔杜邦公司 A kind of solid form of azo cyclic amide
US9062040B2 (en) 2009-04-22 2015-06-23 E I Du Pont De Nemours And Company Solid forms of an azocyclic amide
JP2012524784A (en) * 2009-04-22 2012-10-18 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー Solid form of azo cyclic amide
AU2010239456B2 (en) * 2009-04-22 2016-07-07 Corteva Agriscience Llc Solid forms of an azocyclic amide
US8669277B2 (en) 2009-04-22 2014-03-11 E I Du Pont De Nemours And Company Solid forms of an azocyclic amide
US8765735B2 (en) 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8927551B2 (en) 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en) 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
CN104059059A (en) * 2009-06-23 2014-09-24 拜尔农作物科学股份公司 Thiazolylpiperidine Derivates As Fungicides
CN102459254A (en) * 2009-06-23 2012-05-16 拜尔农作物科学股份公司 Thiazolylpiperidine derivatives as fungicides
EP2272846A1 (en) 2009-06-23 2011-01-12 Bayer CropScience AG Thiazolylpiperidine derivatives as fungicide
WO2010149275A1 (en) * 2009-06-23 2010-12-29 Bayer Cropscience Aktiengesellschaft Thiazolylpiperidine derivates as fungicides
WO2011015524A2 (en) 2009-08-03 2011-02-10 Bayer Cropscience Ag Fungicide heterocycles derivatives
WO2011018415A2 (en) 2009-08-12 2011-02-17 Syngenta Participations Ag Microbiocidal heterocycles
WO2011018401A1 (en) 2009-08-12 2011-02-17 Syngenta Participations Ag Microbiocidal heterocycles
WO2011051244A1 (en) 2009-10-30 2011-05-05 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives
US8501781B2 (en) 2009-10-30 2013-08-06 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives
US9167821B2 (en) 2009-12-21 2015-10-27 Bayer Intellectual Property Gmbh Bis(difluoromethyl)pyrazoles as fungicides
US9247748B2 (en) 2009-12-21 2016-02-02 Bayer Intellectual Property Gmbh Bis(difluoromethyl)pyrazoles as fungicides
WO2011076699A1 (en) 2009-12-21 2011-06-30 Bayer Cropscience Ag Bis(difluormethyl)pyrazoles used as fungicides
KR101808074B1 (en) 2009-12-21 2017-12-12 바이엘 크롭사이언스 악티엔게젤샤프트 Bis(difluoromethyl)-pyrazoles used as fungicides
JP2013515028A (en) * 2009-12-21 2013-05-02 バイエル・クロップサイエンス・アーゲー Bis (difluoromethyl) pyrazole as a fungicide
CN102781937A (en) * 2009-12-21 2012-11-14 拜尔农作物科学股份公司 Bis(difluormethyl)pyrazoles used as fungicides
US8524743B2 (en) 2009-12-21 2013-09-03 Bayer Cropscience Ag Bis(difluoromethyl)pyrazoles as fungicides
US9751871B2 (en) 2009-12-21 2017-09-05 Bayer Intellectual Property Gmbh Bis(difluoromethyl)pyrazoles as fungicides
WO2011076510A1 (en) 2009-12-22 2011-06-30 Syngenta Participations Ag Pyrazole derivatives
WO2011080254A2 (en) 2009-12-28 2011-07-07 Bayer Cropscience Ag Fungicide hydroximoyl-heterocycles derivatives
WO2011085170A1 (en) * 2010-01-07 2011-07-14 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
US8835427B2 (en) 2010-01-07 2014-09-16 E I Du Pont De Nemours And Company Fungicidal heterocyclic compounds
AU2011204323B2 (en) * 2010-01-07 2013-12-12 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
CN102791133A (en) * 2010-01-07 2012-11-21 纳幕尔杜邦公司 Fungicidal heterocyclic compounds
CN102791133B (en) * 2010-01-07 2015-09-23 纳幕尔杜邦公司 Fungicidal hetercyclic compounds
JP2013516483A (en) * 2010-01-07 2013-05-13 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー Bactericidal and fungicidal heterocyclic compounds
US9730886B2 (en) 2010-04-23 2017-08-15 Cytokinetics, Inc. Amino-pyrimidine skeletal muscle modulators
US10076519B2 (en) 2010-04-23 2018-09-18 Cytokinetics, Inc. Substituted pyridazines as skeletal muscle modulators
US9604965B2 (en) 2010-04-23 2017-03-28 Cytokinetics, Inc. Substituted pyridazines as skeletal muscle modulators
US10272030B2 (en) 2010-04-23 2019-04-30 Cytokinetics, Inc. Amino-pyrimidine skeletal muscle modulators
US9994528B2 (en) 2010-04-23 2018-06-12 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
US10765624B2 (en) 2010-04-23 2020-09-08 Cytokinetics, Inc. Amino-pyrimidine skeletal muscle modulators
US11369565B2 (en) 2010-04-23 2022-06-28 Cytokinetics, Inc. Amino-pyrimidine skeletal muscle modulators
US9220266B2 (en) 2010-04-28 2015-12-29 Bayer Intellectual Property Gmbh Ketoheteroarylpiperidine and -piperazine derivatives as fungicides
WO2011134969A1 (en) 2010-04-28 2011-11-03 Bayer Cropscience Ag Ketoheteroarylpiperidine and ketoheteroarylpiperazine derivates as fungicides
WO2011134912A1 (en) 2010-04-28 2011-11-03 Bayer Cropscience Ag Fungicide hydroximoyl-heterocycles derivatives
US9357779B2 (en) 2010-04-28 2016-06-07 Bayer Intellectual Property Gmbh Ketoheteroarylpiperdine and -piperazine derivatives as fungicides
WO2011134911A2 (en) 2010-04-28 2011-11-03 Bayer Cropscience Ag Fungicide hydroximoyl-tetrazole derivatives
WO2011134913A1 (en) 2010-04-28 2011-11-03 Bayer Cropscience Ag Fungicide hydroximoyl-heterocycles derivatives
WO2011144586A1 (en) 2010-05-18 2011-11-24 Bayer Cropscience Ag Bis(difluoromethyl) pyrazoles as fungicides
US8815775B2 (en) 2010-05-18 2014-08-26 Bayer Cropscience Ag Bis(difluoromethyl)pyrazoles as fungicides
US8722678B2 (en) 2010-05-20 2014-05-13 E I Du Pont De Nemours And Company Fungicidal oximes and hydrazones
AU2011256730B2 (en) * 2010-05-20 2015-07-09 E. I. Du Pont De Nemours And Company Fungicidal oximes and hydrazones
WO2011146182A1 (en) * 2010-05-20 2011-11-24 E. I. Du Pont De Nemours And Company Fungicidal oximes and hydrazones
CN102933577A (en) * 2010-05-20 2013-02-13 纳幕尔杜邦公司 Fungicidal oximes and hydrazones
CN102933577B (en) * 2010-05-20 2014-08-06 纳幕尔杜邦公司 Fungicidal oximes and hydrazones
US8604040B2 (en) 2010-05-27 2013-12-10 Bayer Cropscience Ag Pyridinylcarboxylic acid derivatives as fungicides
WO2011147765A1 (en) 2010-05-27 2011-12-01 Bayer Cropscience Ag Pyridinylcarboxylic acid derivatives as fungicides
US8748420B2 (en) 2010-05-27 2014-06-10 Bayer Cropscience Ag Pyridinylcarboxylic acid derivatives as fungicides
WO2011151370A1 (en) 2010-06-03 2011-12-08 Bayer Cropscience Ag N-[(het)arylalkyl)] pyrazole (thio)carboxamides and their heterosubstituted analogues
WO2011151368A2 (en) 2010-06-03 2011-12-08 Bayer Cropscience Ag Fungicide n-[(trisubstitutedsilyl)methyl]-carboxamide derivatives
WO2011151369A1 (en) 2010-06-03 2011-12-08 Bayer Cropscience Ag N-[(het)arylethyl)] pyrazole(thio)carboxamides and their heterosubstituted analogues
WO2012010568A1 (en) 2010-07-19 2012-01-26 Syngenta Participations Ag Microbicides
WO2012010567A1 (en) 2010-07-19 2012-01-26 Syngenta Participations Ag Isoxazole, isothiazole, furane and thiophene compounds as microbicides
WO2012010579A2 (en) 2010-07-20 2012-01-26 Bayer Cropscience Ag Benzocycloalkenes as antifungal agents
CN103153992B (en) * 2010-08-11 2016-01-20 拜耳知识产权有限责任公司 As heteroaryl piperidine and the heteroaryl bridged piperazine derivatives of sterilant
WO2012020060A1 (en) 2010-08-11 2012-02-16 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
CN103153992A (en) * 2010-08-11 2013-06-12 拜耳知识产权有限责任公司 Heteroarylpiperidine and -piperazine derivatives as fungicides
WO2012025557A1 (en) 2010-08-25 2012-03-01 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
AU2015261660B2 (en) * 2010-08-25 2017-01-05 Bayer Cropscience Aktiengesellschaft Heteroarylpiperidine and -piperazine derivatives as fungicides
CN105601627B (en) * 2010-08-25 2019-04-09 拜耳作物科学股份公司 Heteroaryl piperidine and heteroaryl based piperazine derivative as fungicide
AU2011295045B2 (en) * 2010-08-25 2015-09-10 Bayer Cropscience Aktiengesellschaft Heteroarylpiperidine and -piperazine derivatives as fungicides
CN103180317A (en) * 2010-08-25 2013-06-26 拜耳知识产权有限责任公司 Heteroarylpiperidine and -piperazine derivatives as fungicides
US20180007903A1 (en) * 2010-08-25 2018-01-11 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
AP3444A (en) * 2010-08-25 2015-10-31 Bayer Ip Gmbh Heteroarylpiperidine and piperazine derivatives asfungicides
EP2423210A1 (en) 2010-08-25 2012-02-29 Bayer CropScience AG Heteroarylpiperidine and heteroarylpiperazine derivatives as fungicides
US9150565B2 (en) 2010-08-25 2015-10-06 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
EA023204B9 (en) * 2010-08-25 2016-08-31 Байер Интеллектуэль Проперти Гмбх Heteroarylpiperidine and -piperazine derivatives as fungicides
US9006266B2 (en) 2010-08-25 2015-04-14 Bayer Intellectual Property Gmbh Heteroarylpiperidine and -piperazine derivatives as fungicides
US9930890B2 (en) 2010-08-25 2018-04-03 Bayer Intellectual Property Gmbh Heteroarylpiperidine and -piperazine derivatives as fungicides
EP3109248A1 (en) 2010-08-25 2016-12-28 Bayer Intellectual Property GmbH Heteroarylpiperidine and -piperazine derivatives as fungicides
US9434723B2 (en) 2010-08-25 2016-09-06 Bayer Intellectual Property Gmbh Heteroarylpiperidine and -piperazine derivatives as fungicides
CN103180317B (en) * 2010-08-25 2016-03-23 拜耳知识产权有限责任公司 As heteroaryl piperidine and the heteroaryl bridged piperazine derivatives of sterilant
US10499641B2 (en) 2010-08-25 2019-12-10 Bayer Cropscience Aktiengesellschaft Heteroarylpiperidine and -piperazine derivatives as fungicides
US8759527B2 (en) 2010-08-25 2014-06-24 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
EP3241829A1 (en) 2010-08-25 2017-11-08 Bayer Intellectual Property GmbH Heteroarylpiperidine and -piperazine derivatives as fungicides
CN105601627A (en) * 2010-08-25 2016-05-25 拜耳知识产权有限责任公司 Heteroarylpiperidine and -piperazine derivatives as fungicides
EA023204B1 (en) * 2010-08-25 2016-05-31 Байер Интеллектуэль Проперти Гмбх Heteroarylpiperidine and -piperazine derivatives as fungicides
US9770027B2 (en) 2010-08-25 2017-09-26 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
KR101807640B1 (en) 2010-08-25 2017-12-11 바이엘 인텔렉쳐 프로퍼티 게엠베하 Heteroarylpiperidine and -piperazine derivatives as fungicides
WO2012038476A1 (en) 2010-09-22 2012-03-29 Bayer Cropscience Ag Use of active ingredients for controlling nematodes in nematode-resistant crops
WO2012038521A1 (en) 2010-09-23 2012-03-29 Syngenta Participations Ag Novel microbiocides
EP3175712A1 (en) 2010-10-01 2017-06-07 Syngenta Participations Ag Fungicidal compositions
WO2012041874A1 (en) 2010-10-01 2012-04-05 Syngenta Participations Ag Fungicidal compositions
US9408391B2 (en) 2010-10-07 2016-08-09 Bayer Intellectual Property Gmbh Fungicide composition comprising a tetrazolyloxime derivative and a thiazolylpiperidine derivative
WO2012045798A1 (en) 2010-10-07 2012-04-12 Bayer Cropscience Ag Fungicide composition comprising a tetrazolyloxime derivative and a thiazolylpiperidine derivative
WO2012052489A1 (en) 2010-10-21 2012-04-26 Bayer Cropscience Ag 1-(heterocyclic carbonyl) piperidines
WO2012052490A1 (en) 2010-10-21 2012-04-26 Bayer Cropscience Ag N-benzyl heterocyclic carboxamides
US9512117B2 (en) 2010-10-27 2016-12-06 Bayer Intellectual Property Gmbh Heteroaryl piperidine and heteroaryl piperazine derivatives as fungicides
US9975889B2 (en) 2010-10-27 2018-05-22 Bayer Intellectual Property Gmbh Heteroaryl piperidine and heteroaryl piperazine derivatives as fungicides
WO2012055837A1 (en) 2010-10-27 2012-05-03 Bayer Cropscience Ag Heteroaryl piperidine and heteroaryl piperazine derivatives as fungicides
CN103492379B (en) * 2010-10-27 2018-06-15 拜耳知识产权有限责任公司 As the heteroaryl piperidine of fungicide and heteroaryl based piperazine derivative
US9914728B2 (en) 2010-10-27 2018-03-13 Bayer Intellectual Property Gmbh Heteroaryl piperidine and heteroaryl piperazine derivatives as fungicides
CN103492379A (en) * 2010-10-27 2014-01-01 拜耳知识产权有限责任公司 Heteroaryl piperidine and heteroaryl piperazine derivatives as fungicides
KR101797074B1 (en) 2010-10-27 2017-11-13 바이엘 인텔렉쳐 프로퍼티 게엠베하 Heteroaryl piperidine and heteroaryl piperazine derivatives as fungicides
JP2013542212A (en) * 2010-10-27 2013-11-21 バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー Heteroarylpiperidine and heteroarylpiperazine derivatives as fungicides
JP2016128458A (en) * 2010-10-27 2016-07-14 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Heteroaryl piperidine and heteroaryl piperazine derivatives as fungicides
WO2012056003A1 (en) 2010-10-28 2012-05-03 Syngenta Participations Ag Novel microbicides
WO2012059497A1 (en) 2010-11-02 2012-05-10 Bayer Cropscience Ag N-hetarylmethyl pyrazolylcarboxamides
WO2012062844A1 (en) 2010-11-12 2012-05-18 Syngenta Participations Ag Novel microbiocides
WO2012065945A1 (en) 2010-11-15 2012-05-24 Bayer Cropscience Ag 5-halogenopyrazole(thio)carboxamides
WO2012065947A1 (en) 2010-11-15 2012-05-24 Bayer Cropscience Ag 5-halogenopyrazolecarboxamides
WO2012065944A1 (en) 2010-11-15 2012-05-24 Bayer Cropscience Ag N-aryl pyrazole(thio)carboxamides
US9206137B2 (en) 2010-11-15 2015-12-08 Bayer Intellectual Property Gmbh N-Aryl pyrazole(thio)carboxamides
WO2012066122A1 (en) 2010-11-18 2012-05-24 Syngenta Participations Ag 2 - (pyridin- 2 -yl) -quinazoline derivatives and their use as microbicides
WO2012069366A1 (en) 2010-11-23 2012-05-31 Syngenta Participations Ag Insecticidal compounds
WO2012069633A1 (en) 2010-11-25 2012-05-31 Syngenta Participations Ag Microbicidal heterocycles
WO2012069601A1 (en) 2010-11-25 2012-05-31 Syngenta Participations Ag Substituted quinazolines as fungicides
WO2012072660A1 (en) 2010-12-01 2012-06-07 Bayer Cropscience Ag Use of fluopyram for controlling nematodes in crops and for increasing yield
WO2012072575A1 (en) 2010-12-01 2012-06-07 Bayer Cropscience Ag Pyrazole carboxylic acid amides useful for the reduction of mycotoxin contamination in plants
WO2012076563A1 (en) 2010-12-08 2012-06-14 Basf Se Fungicidal mixtures
WO2012082580A3 (en) * 2010-12-17 2013-08-01 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
JP2014501246A (en) * 2010-12-17 2014-01-20 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー Bactericidal and fungicidal azo cyclic amide
CN103384470A (en) * 2010-12-17 2013-11-06 纳幕尔杜邦公司 Fungicidal azocyclic amides
WO2012080376A1 (en) 2010-12-17 2012-06-21 Syngenta Participations Ag Insecticidal compounds
WO2012082580A2 (en) 2010-12-17 2012-06-21 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
WO2012089757A1 (en) 2010-12-29 2012-07-05 Bayer Cropscience Ag Fungicide hydroximoyl-tetrazole derivatives
EP2474542A1 (en) 2010-12-29 2012-07-11 Bayer CropScience AG Fungicide hydroximoyl-tetrazole derivatives
KR101848116B1 (en) 2011-02-01 2018-04-11 바이엘 인텔렉쳐 프로퍼티 게엠베하 Heteroaryl piperidine and heteroaryl piperazine derivatives as fungicides
US9204649B2 (en) 2011-02-01 2015-12-08 Bayer Intellectual Property Gmbh Heteroarylpiperidine and- piperazine derivates as fungicides
US8822693B2 (en) 2011-02-01 2014-09-02 Bayer Cropscience Ag Heteroarylpiperidine and-piperazine derivatives as fungicides
WO2012104273A1 (en) * 2011-02-01 2012-08-09 Bayer Cropscience Ag Heteroaryl piperidine and heteroaryl piperazine derivatives as fungicides
WO2012107434A1 (en) 2011-02-09 2012-08-16 Syngenta Participations Ag Insecticidal compounds
WO2012107477A1 (en) 2011-02-10 2012-08-16 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2012107475A1 (en) 2011-02-10 2012-08-16 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2012117021A2 (en) 2011-03-03 2012-09-07 Syngenta Participations Ag Novel microbiocidal oxime ethers
WO2012126881A1 (en) 2011-03-22 2012-09-27 Syngenta Participations Ag Insecticidal compounds
WO2012143395A1 (en) 2011-04-20 2012-10-26 Syngenta Participations Ag 4,5-dihydro-isoxazole derivatives as fungicides
US9278962B2 (en) 2011-04-22 2016-03-08 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
EP2532233A1 (en) 2011-06-07 2012-12-12 Bayer CropScience AG Active compound combinations
WO2012168188A1 (en) 2011-06-07 2012-12-13 Bayer Intellectual Property Gmbh Active compound combinations
AP3634A (en) * 2011-06-07 2016-03-08 Bayer Ip Gmbh Active compound combinations
US9144238B2 (en) 2011-06-07 2015-09-29 Bayer Intellectual Property Gmbh Active compound combinations
WO2012175474A1 (en) 2011-06-20 2012-12-27 Syngenta Participations Ag 1,2,3 triazole pesticides
WO2013000931A1 (en) 2011-06-29 2013-01-03 Syngenta Participations Ag Insecticidally active pyridyl-thiazole and pyridyl-thiadiazole derivatives
EP2540718A1 (en) 2011-06-29 2013-01-02 Syngenta Participations AG. Novel insecticides
WO2013006738A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
US11034668B2 (en) 2011-07-06 2021-06-15 Gilead Sciences, Inc. Compounds for the treatment of HIV
US9944619B2 (en) 2011-07-06 2018-04-17 Gilead Sciences, Inc. Compounds for the treatment of HIV
US9540343B2 (en) 2011-07-06 2017-01-10 Gilead Sciences, Inc. Compounds for the treatment of HIV
US10370358B2 (en) 2011-07-06 2019-08-06 Gilead Sciences, Inc. Compounds for the treatment of HIV
WO2013007550A1 (en) 2011-07-08 2013-01-17 Syngenta Participations Ag Fungicide mixtures
WO2013011010A1 (en) 2011-07-19 2013-01-24 Syngenta Participations Ag Fungizide mixtures
WO2013014227A1 (en) 2011-07-27 2013-01-31 Bayer Intellectual Property Gmbh Seed dressing for controlling phytopathogenic fungi
WO2013026900A1 (en) 2011-08-23 2013-02-28 Syngenta Participations Ag Pyridine derivatives as microbiocides
US10004232B2 (en) 2011-09-15 2018-06-26 Bayer Intellectual Property Gmbh Piperidine pyrazoles as fungicides
CN103827112A (en) * 2011-09-15 2014-05-28 拜耳知识产权有限责任公司 Piperidine pyrazoles as fungicides
WO2013037768A1 (en) 2011-09-15 2013-03-21 Bayer Intellectual Property Gmbh Piperidine pyrazoles as fungicides
EP3366675A1 (en) 2011-10-03 2018-08-29 Syngenta Participations Ag Insecticidal 2-methoxybenzamide derivatives
WO2013050261A1 (en) 2011-10-03 2013-04-11 Syngenta Participations Ag Insecticidal 2-methoxybenzamide derivatives
WO2013056915A1 (en) 2011-10-18 2013-04-25 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2013056911A1 (en) 2011-10-18 2013-04-25 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2013064518A1 (en) 2011-11-04 2013-05-10 Syngenta Participations Ag Pesticidal compounds
WO2013064521A1 (en) 2011-11-04 2013-05-10 Syngenta Participations Ag Pesticidal compounds
WO2013064519A1 (en) 2011-11-04 2013-05-10 Syngenta Participations Ag Pesticidal compounds
WO2013064520A1 (en) 2011-11-04 2013-05-10 Syngenta Participations Ag Pesticidal compounds
WO2013092519A1 (en) 2011-12-19 2013-06-27 Bayer Cropscience Ag Use of anthranilic acid diamide derivatives for pest control in transgenic crops
WO2013092460A1 (en) 2011-12-20 2013-06-27 Syngenta Participations Ag Cyclic bisoxime microbicides
EP2921481A1 (en) 2011-12-27 2015-09-23 Bayer Intellectual Property GmbH 4-piperidine carboxylic acid derivatives
US10426169B2 (en) 2011-12-27 2019-10-01 Bayer Intellectual Property Gmbh Heteroarylpiperidine and -piperazine derivatives as fungicides
TWI609865B (en) * 2011-12-27 2018-01-01 拜耳智慧財產有限公司 Compounds for preparing heteroarylpiperidine and-piperazine derivatives as fungicides
EP2921495A1 (en) 2011-12-27 2015-09-23 Bayer Intellectual Property GmbH Heteroarylpiperidine and heteroarylpiperazine derivatives as fungicides
US9375009B2 (en) 2011-12-27 2016-06-28 Bayer Intellectual Property Gmbh Heteroarylpiperidine and piperazine derivatives as fungicides
EP2921494A1 (en) 2011-12-27 2015-09-23 Bayer Intellectual Property GmbH Heteroarylpiperidine and heteroarylpiperazine derivatives
KR20140108702A (en) * 2011-12-27 2014-09-12 바이엘 인텔렉쳐 프로퍼티 게엠베하 Heteroarylpiperidine and piperazine derivatives as fungicides
EP2921491A1 (en) 2011-12-27 2015-09-23 Bayer Intellectual Property GmbH Intermediates for the production of heteroarylpiperidine and heteroarylpiperazine derivatives as fungicides
EP2921493A1 (en) 2011-12-27 2015-09-23 Bayer Intellectual Property GmbH Heteroarylpiperidine and heteroarylpiperazine derivatives
EP2921485A1 (en) 2011-12-27 2015-09-23 Bayer Intellectual Property GmbH Isoxazole derivatives
EP2921492A1 (en) 2011-12-27 2015-09-23 Bayer Intellectual Property GmbH Heteroarylpiperidine and heteroarylpiperazine derivatives
JP2018140991A (en) * 2011-12-27 2018-09-13 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Heteroaryl piperidine derivative as bactericide and heteroaryl piperazine derivative
EP2921484A1 (en) 2011-12-27 2015-09-23 Bayer Intellectual Property GmbH Oxazole derivatives
WO2013098229A2 (en) 2011-12-27 2013-07-04 Bayer Intellectual Property Gmbh Heteroarylpiperidine and piperazine derivatives as fungicides
KR102015968B1 (en) 2011-12-27 2019-08-29 바이엘 인텔렉쳐 프로퍼티 게엠베하 Heteroarylpiperidine and piperazine derivatives as fungicides
WO2013116251A2 (en) 2012-02-01 2013-08-08 E. I. Du Pont De Nemours And Company Fungicidal pyrazole mixtures
EP3254563A1 (en) 2012-02-01 2017-12-13 E. I. du Pont de Nemours and Company Intermediates in the preparation of fungicidal pyrazoles
US9266876B2 (en) 2012-02-02 2016-02-23 Actelion Pharmaceuticals Ltd. 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives
WO2013120940A2 (en) 2012-02-14 2013-08-22 Syngenta Participations Ag Novel compounds
WO2013124275A1 (en) 2012-02-22 2013-08-29 Bayer Cropscience Ag Use of succinate dehydrogenase inhibitors (sdhis) for controlling wood diseases in grape.
WO2013127704A1 (en) 2012-02-27 2013-09-06 Bayer Intellectual Property Gmbh Active compound combinations containing a thiazoylisoxazoline and a fungicide
US12102087B2 (en) 2012-02-27 2024-10-01 Bayer Cropscience Aktiengesellschaft Active compound combinations containing a thiazoylisoxazoline and a fungicide
US9629367B2 (en) 2012-02-27 2017-04-25 Bayer Intellectual Property Gmbh Active compound combinations containing a thiazoylisoxazoline and a fungicide
US10375961B2 (en) 2012-02-27 2019-08-13 Bayer Intellectual Property Gmbh Active compound combinations containing a thiazoylisoxazoline and a fungicide
US11147274B2 (en) 2012-02-27 2021-10-19 Bayer Intellectual Property Gmbh Active compound combinations containing a thiazoylisoxazoline and a fungicide
WO2013127784A1 (en) 2012-03-02 2013-09-06 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2013127789A1 (en) 2012-03-02 2013-09-06 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2013127808A1 (en) 2012-03-02 2013-09-06 Syngenta Participations Ag Microbiocidal pyrazole derivatives
EP2641901A1 (en) 2012-03-22 2013-09-25 Syngenta Participations AG. Novel microbiocides
WO2013139822A1 (en) 2012-03-22 2013-09-26 Syngenta Participations Ag Novel bisoxime microbiocides
EP2644595A1 (en) 2012-03-26 2013-10-02 Syngenta Participations AG. N-Cyclylamides as nematicides
WO2013143811A1 (en) 2012-03-26 2013-10-03 Syngenta Participations Ag N-cyclylamides as nematicides
WO2013192126A1 (en) 2012-06-22 2013-12-27 E. I. Du Pont De Nemours And Company Fungicidal 4-methylanilino pyrazoles
US9145370B2 (en) 2012-08-30 2015-09-29 Bayer Cropscience Ag Procedure for the decarboxylation of 3,5-bis(haloalkyl)-pyrazole-4-carboxylic acid derivatives
WO2014033164A1 (en) 2012-08-30 2014-03-06 Bayer Cropscience Ag Procedure for the decarboxylation of 3,5-bis(haloalkyl)-pyrazole-4-carboxylic acid derivatives
WO2014060176A1 (en) 2012-10-16 2014-04-24 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2014067838A1 (en) 2012-10-31 2014-05-08 Syngenta Participations Ag Insecticidal compounds
WO2014075874A1 (en) * 2012-11-13 2014-05-22 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2014075873A1 (en) * 2012-11-13 2014-05-22 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2014118142A1 (en) 2013-02-01 2014-08-07 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2014118170A1 (en) 2013-02-04 2014-08-07 Syngenta Participations Ag Novel microbiocides
WO2014118143A1 (en) 2013-02-04 2014-08-07 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2014131572A1 (en) 2013-02-27 2014-09-04 Syngenta Participations Ag Novel carboxamide compounds
WO2014154530A1 (en) 2013-03-25 2014-10-02 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2014161849A1 (en) 2013-04-02 2014-10-09 Syngenta Participations Ag Insecticidal compounds
WO2014161848A1 (en) 2013-04-02 2014-10-09 Syngenta Participations Ag Insecticidal compounds
WO2014167133A1 (en) 2013-04-12 2014-10-16 Syngenta Participations Ag Fungicides comprising boron
WO2014173880A1 (en) 2013-04-22 2014-10-30 Syngenta Participations Ag Novel microbiocides
EP2801575A1 (en) 2013-05-07 2014-11-12 Bayer CropScience AG Heteroaryldihydropyridine derivatives as fungicides
JP2016523838A (en) * 2013-05-22 2016-08-12 バイエル・クロップサイエンス・アクチェンゲゼルシャフト Method for producing 3,5-bis (fluoroalkyl) pyrazole derivative from α, α-dihaloamine
US9717243B2 (en) 2013-06-24 2017-08-01 Bayer Cropscience Aktiengesellschaft Piperidinecarboxylic acid derivatives as fungicides
WO2015003951A1 (en) 2013-07-08 2015-01-15 Syngenta Participations Ag 4-membered ring carboxamides used as nematicides
WO2015003991A1 (en) 2013-07-12 2015-01-15 Syngenta Participations Ag Novel microbiocides
WO2015004091A1 (en) 2013-07-12 2015-01-15 Syngenta Participations Ag Nicotinamide derivatives and their use against nematodes
US10259807B2 (en) 2013-07-22 2019-04-16 Idorsia Pharmaceuticals Ltd. 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
US9924721B2 (en) 2013-08-28 2018-03-27 Bayer Cropscience Aktiengesellschaft Malonic ester derivatives of heteroarylpiperidines and -piperazines as fungicides
WO2015028457A1 (en) * 2013-08-28 2015-03-05 Bayer Cropscience Ag Malonic ester derivatives of heteroarylpiperidines and -piperazines as fungicides
WO2015040141A1 (en) 2013-09-23 2015-03-26 Syngenta Participations Ag Cyclobutylcarboxamides as nematicides
EP4154714A2 (en) 2013-10-03 2023-03-29 Syngenta Participations Ag Fungicidal compositions
WO2015055764A1 (en) 2013-10-18 2015-04-23 Syngenta Participations Ag 3-methanimidamid-pyridine derivatives as fungicides
EP3556744A1 (en) 2013-12-23 2019-10-23 Syngenta Participations Ag Insecticidal compounds
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
WO2015144571A1 (en) 2014-03-24 2015-10-01 Bayer Cropscience Ag Phenylpiperidinecarboxamide derivatives as fungicides
US9951063B2 (en) 2014-03-24 2018-04-24 Idorsia Pharmaceuticals Ltd 8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives
WO2015181097A1 (en) * 2014-05-28 2015-12-03 Bayer Cropscience Ag Process for preparing thiazole derivatives
CN106414437A (en) * 2014-05-28 2017-02-15 拜耳作物科学股份公司 Process for preparing thiazole derivatives
US10336742B2 (en) 2014-05-28 2019-07-02 Bayer Cropscience Aktiengesellschaft Process for preparing thiazole derivatives
JP2017518999A (en) * 2014-06-11 2017-07-13 バイエル・クロップサイエンス・アクチェンゲゼルシャフト Process for producing 3,5-bis (haloalkyl) pyrazole derivatives via acylation of hydrazones
US9790182B2 (en) 2014-06-11 2017-10-17 Bayer Cropscience Aktiengesellschaft Preparation of piperidine-4-carbothioamide
US9980487B2 (en) 2014-08-13 2018-05-29 Sds Biotech K.K. Fused 11-membered compounds and agricultural/horticultural fungicides containing them
US10104891B2 (en) 2014-08-13 2018-10-23 Sds Biotech K.K. Fused 11-membered compounds and agricultural/horticultural fungicides containing them
KR20170036104A (en) 2014-08-13 2017-03-31 가부시키가이샤 에스디에스 바이오텍크 Condensed 11-member ring compound and agriculture and horticultural fungicide comprising same
US10779536B2 (en) 2014-11-07 2020-09-22 Basf Se Pesticidal mixtures
US10047080B2 (en) 2015-01-15 2018-08-14 Idorsia Pharmaceuticals Ltd. (R)-2-methyl-piperazine derivatives as CXCR3 receptor modulators
US10053457B2 (en) 2015-01-15 2018-08-21 Idorsia Pharmaceuticals Ltd. Hydroxyalkyl-piperazine derivatives as CXCR3 receptor modulators
US10093626B2 (en) 2015-03-05 2018-10-09 Bayer Cropscience Aktiengesellschaft Process for preparing piperidine-4-carbothioamide hydrochloride
WO2016202761A1 (en) 2015-06-17 2016-12-22 Bayer Cropscience Aktiengesellschaft Active compound combinations
WO2017076757A1 (en) 2015-11-02 2017-05-11 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2017076740A1 (en) 2015-11-04 2017-05-11 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2017081310A1 (en) 2015-11-13 2017-05-18 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2017081312A1 (en) 2015-11-13 2017-05-18 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2017085100A1 (en) 2015-11-19 2017-05-26 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2017085098A1 (en) 2015-11-19 2017-05-26 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2017094576A1 (en) 2015-12-01 2017-06-08 住友化学株式会社 Plant disease control composition, and plant disease control method
WO2017138069A1 (en) 2016-02-08 2017-08-17 株式会社エス・ディー・エス バイオテック Germicidal composition
US11274076B2 (en) 2016-02-08 2022-03-15 Gowan Company, L.L.C. Process for preparing 1, 2-benzenedimethanol compound
US11903387B2 (en) 2016-02-08 2024-02-20 Gowan Company, L.L.C. Fungicidal composition
WO2017153200A1 (en) 2016-03-10 2017-09-14 Basf Se Fungicidal mixtures iii comprising strobilurin-type fungicides
US10905122B2 (en) 2016-03-16 2021-02-02 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on cereals
US11425909B2 (en) 2016-03-16 2022-08-30 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on fruits
US11241012B2 (en) 2016-03-16 2022-02-08 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on soybean
WO2017178245A1 (en) 2016-04-11 2017-10-19 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2017207368A1 (en) 2016-06-02 2017-12-07 BASF Agro B.V. Fungicidal compositions
US10654827B2 (en) 2016-08-19 2020-05-19 Gilead Sciences, Inc. Therapeutic compounds
US11993583B2 (en) 2016-08-19 2024-05-28 Gilead Sciences, Inc. Therapeutic compounds
WO2018050421A1 (en) 2016-09-13 2018-03-22 Basf Se Fungicidal mixtures i comprising quinoline fungicides
WO2018054723A1 (en) 2016-09-26 2018-03-29 Basf Se Pyridine compounds for controlling phytopathogenic harmful fungi
WO2018054721A1 (en) 2016-09-26 2018-03-29 Basf Se Pyridine compounds for controlling phytopathogenic harmful fungi
WO2018054711A1 (en) 2016-09-26 2018-03-29 Basf Se Pyridine compounds for controlling phytopathogenic harmful fungi
WO2018065182A1 (en) 2016-10-04 2018-04-12 Basf Se Reduced quinoline compounds as antifuni agents
WO2018073110A1 (en) 2016-10-20 2018-04-26 Basf Se Quinoline compounds as fungicides
WO2018114393A1 (en) 2016-12-19 2018-06-28 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
EP3339297A1 (en) 2016-12-20 2018-06-27 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2018114657A1 (en) 2016-12-20 2018-06-28 Syngenta Participations Ag N-cyclobutyl-thiazol-5-carboxamides with nematicidal activity
EP3338552A1 (en) 2016-12-21 2018-06-27 Basf Se Use of a tetrazolinone fungicide on transgenic plants
WO2018134127A1 (en) 2017-01-23 2018-07-26 Basf Se Fungicidal pyridine compounds
WO2018149754A1 (en) 2017-02-16 2018-08-23 Basf Se Pyridine compounds
WO2018153730A1 (en) 2017-02-21 2018-08-30 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
CN107056808A (en) * 2017-03-28 2017-08-18 上海大学 3 aryl substituted isoxazoles and succinimide class compound and its synthetic method
EP3978504A1 (en) 2017-03-31 2022-04-06 Basf Se Chiral 2,3-dihydrothiazolo[3,2-a]pyrimidine derivatives for combating animal pests
WO2018177970A1 (en) 2017-03-31 2018-10-04 Basf Se Process for preparing chiral 2,3-dihydrothiazolo[3,2-a]pyrimidin-4-ium compounds
WO2018184882A1 (en) 2017-04-06 2018-10-11 Basf Se Pyridine compounds
WO2018184970A1 (en) 2017-04-07 2018-10-11 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2018188962A1 (en) 2017-04-11 2018-10-18 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2018193387A1 (en) 2017-04-19 2018-10-25 Pi Industries Ltd. Heterocyclic compounds with microbiocidal properties
WO2018193385A1 (en) 2017-04-20 2018-10-25 Pi Industries Ltd. Novel phenylamine compounds
US11524934B2 (en) 2017-04-20 2022-12-13 Pi Industries Ltd Phenylamine compounds
WO2018202428A1 (en) 2017-05-02 2018-11-08 Basf Se Fungicidal mixture comprising substituted 3-phenyl-5-(trifluoromethyl)-1,2,4-oxadiazoles
WO2018202491A1 (en) 2017-05-04 2018-11-08 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
WO2018202487A1 (en) 2017-05-04 2018-11-08 Basf Se Substituted 5-(haloalkyl)-5-hydroxy-isoxazoles for combating phytopathogenic fungi
WO2018202737A1 (en) 2017-05-05 2018-11-08 Basf Se Fungicidal mixtures comprising triazole compounds
WO2018210660A1 (en) 2017-05-15 2018-11-22 Basf Se Heteroaryl compounds as agrochemical fungicides
WO2018210661A1 (en) 2017-05-15 2018-11-22 Basf Se Heteroaryl compounds as agrochemical fungicides
WO2018210658A1 (en) 2017-05-15 2018-11-22 Basf Se Heteroaryl compounds as agrochemical fungicides
WO2018210659A1 (en) 2017-05-15 2018-11-22 Basf Se Heteroaryl compounds as agrochemical fungicides
WO2018219725A1 (en) 2017-05-30 2018-12-06 Basf Se Pyridine and pyrazine compounds
WO2018219797A1 (en) 2017-06-02 2018-12-06 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2018234139A1 (en) 2017-06-19 2018-12-27 Basf Se 2-[[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]aryloxy](thio)acetamides for combating phytopathogenic fungi
WO2019002158A1 (en) 2017-06-30 2019-01-03 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
US11833143B2 (en) 2017-08-17 2023-12-05 Gilead Sciences, Inc. Choline salt forms of an HIV capsid inhibitor
US11267799B2 (en) 2017-08-17 2022-03-08 Gilead Sciences, Inc. Solid forms of an HIV capsid inhibitor
US11266638B2 (en) 2017-08-17 2022-03-08 Gilead Sciences, Inc. Choline salt forms of an HIV capsid inhibitor
US11845739B2 (en) 2017-08-17 2023-12-19 Gilead Sciences, Inc. Solid forms of an HIV capsid inhibitor
US10849892B2 (en) 2017-08-17 2020-12-01 Gilead Sciences, Inc. Choline salt forms of an HIV capsid inhibitor
WO2019038042A1 (en) 2017-08-21 2019-02-28 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
WO2019042800A1 (en) 2017-08-29 2019-03-07 Basf Se Pesticidal mixtures
EP3915379A1 (en) 2017-08-29 2021-12-01 Basf Se Pesticidal mixtures
WO2019043183A1 (en) 2017-08-31 2019-03-07 Basf Se Method of controlling rice pests in rice
WO2019042932A1 (en) 2017-08-31 2019-03-07 Basf Se Method of controlling rice pests in rice
WO2019048989A1 (en) 2017-09-08 2019-03-14 Pi Industries Ltd. Novel fungicidal heterocyclic compounds
WO2019048988A1 (en) 2017-09-08 2019-03-14 Pi Industries Ltd. Novel fungidal heterocyclic compounds
EP3453706A1 (en) 2017-09-08 2019-03-13 Basf Se Pesticidal imidazole compounds
WO2019052932A1 (en) 2017-09-18 2019-03-21 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
WO2019057660A1 (en) 2017-09-25 2019-03-28 Basf Se Indole and azaindole compounds with substituted 6-membered aryl and heteroaryl rings as agrochemical fungicides
WO2019068810A1 (en) 2017-10-06 2019-04-11 Bayer Aktiengesellschaft Use of compositions comprising fluopyram for enhancing antioxidative fitness of plants
WO2019072906A1 (en) 2017-10-13 2019-04-18 Basf Se Imidazolidine pyrimidinium compounds for combating animal pests
WO2019101511A1 (en) 2017-11-23 2019-05-31 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
WO2019115511A1 (en) 2017-12-14 2019-06-20 Basf Se Fungicidal mixture comprising substituted 3-phenyl-5-(trifluoromethyl)-1,2,4-oxadiazoles
WO2019115343A1 (en) 2017-12-15 2019-06-20 Basf Se Fungicidal mixture comprising substituted pyridines
WO2019121525A1 (en) 2017-12-20 2019-06-27 Bayer Aktiengesellschaft Use of fungicides for controlling mosaic scab in apples
WO2019121143A1 (en) 2017-12-20 2019-06-27 Basf Se Substituted cyclopropyl derivatives
WO2019123196A1 (en) 2017-12-20 2019-06-27 Pi Industries Ltd. Fluoralkenyl compounds, process for preparation and use thereof
WO2019145140A1 (en) 2018-01-09 2019-08-01 Basf Se Silylethynyl hetaryl compounds as nitrification inhibitors
WO2019137995A1 (en) 2018-01-11 2019-07-18 Basf Se Novel pyridazine compounds for controlling invertebrate pests
WO2019150311A1 (en) 2018-02-02 2019-08-08 Pi Industries Ltd. 1-3 dithiol compounds and their use for the protection of crops from phytopathogenic microorganisms
WO2019154663A1 (en) 2018-02-07 2019-08-15 Basf Se New pyridine carboxamides
WO2019154665A1 (en) 2018-02-07 2019-08-15 Basf Se New pyridine carboxamides
US11753399B2 (en) 2018-02-15 2023-09-12 Gilead Sciences, Inc. Therapeutic compounds
US10836746B2 (en) 2018-02-15 2020-11-17 Gilead Sciences, Inc. Therapeutic compounds
US11267801B2 (en) 2018-02-15 2022-03-08 Gilead Sciences, Inc. Therapeutic compounds
US10696657B2 (en) 2018-02-16 2020-06-30 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds
US12122765B2 (en) 2018-02-16 2024-10-22 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds
US11760746B2 (en) 2018-02-16 2023-09-19 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds
US11117886B2 (en) 2018-02-16 2021-09-14 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds
EP3530118A1 (en) 2018-02-26 2019-08-28 Basf Se Fungicidal mixtures
EP3530116A1 (en) 2018-02-27 2019-08-28 Basf Se Fungicidal mixtures comprising xemium
WO2019166558A1 (en) 2018-02-28 2019-09-06 Basf Se Use of pyrazole propargyl ethers as nitrification inhibitors
WO2019166561A1 (en) 2018-02-28 2019-09-06 Basf Se Use of alkoxypyrazoles as nitrification inhibitors
WO2019166560A1 (en) 2018-02-28 2019-09-06 Basf Se Use of n-functionalized alkoxy pyrazole compounds as nitrification inhibitors
WO2019166252A1 (en) 2018-02-28 2019-09-06 Basf Se Fungicidal mixtures comprising fenpropidin
WO2019166257A1 (en) 2018-03-01 2019-09-06 BASF Agro B.V. Fungicidal compositions of mefentrifluconazole
EP3533333A1 (en) 2018-03-02 2019-09-04 Basf Se Fungicidal mixtures comprising pydiflumetofen
EP3533331A1 (en) 2018-03-02 2019-09-04 Basf Se Fungicidal mixtures comprising pydiflumetofen
EP3536150A1 (en) 2018-03-06 2019-09-11 Basf Se Fungicidal mixtures comprising fluxapyroxad
WO2019175712A1 (en) 2018-03-14 2019-09-19 Basf Corporation New uses for catechol molecules as inhibitors to glutathione s-transferase metabolic pathways
WO2019175713A1 (en) 2018-03-14 2019-09-19 Basf Corporation New catechol molecules and their use as inhibitors to p450 related metabolic pathways
WO2019219464A1 (en) 2018-05-15 2019-11-21 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
WO2019219529A1 (en) 2018-05-15 2019-11-21 Basf Se Mixtures comprising benzpyrimoxan and oxazosulfyl and uses and methods of applying them
WO2019224092A1 (en) 2018-05-22 2019-11-28 Basf Se Pesticidally active c15-derivatives of ginkgolides
WO2020002472A1 (en) 2018-06-28 2020-01-02 Basf Se Use of alkynylthiophenes as nitrification inhibitors
US11944611B2 (en) 2018-07-16 2024-04-02 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
WO2020020777A1 (en) 2018-07-23 2020-01-30 Basf Se Use of substituted 2-thiazolines as nitrification inhibitors
WO2020020765A1 (en) 2018-07-23 2020-01-30 Basf Se Use of a substituted thiazolidine compound as nitrification inhibitor
WO2020035826A1 (en) 2018-08-17 2020-02-20 Pi Industries Ltd. 1,2-dithiolone compounds and use thereof
EP3613736A1 (en) 2018-08-22 2020-02-26 Basf Se Substituted glutarimide derivatives
EP3628156A1 (en) 2018-09-28 2020-04-01 Basf Se Method for controlling pests of sugarcane, citrus, rapeseed, and potato plants
WO2020064408A1 (en) 2018-09-28 2020-04-02 Basf Se Method of controlling insecticide resistant insects and virus transmission to plants
EP3628157A1 (en) 2018-09-28 2020-04-01 Basf Se Method of controlling insecticide resistant insects and virus transmission to plants
EP3628158A1 (en) 2018-09-28 2020-04-01 Basf Se Pesticidal mixture comprising a mesoionic compound and a biopesticide
WO2020064492A1 (en) 2018-09-28 2020-04-02 Basf Se Method of controlling pests by seed treatment application of a mesoionic compound or mixture thereof
WO2020064480A1 (en) 2018-09-28 2020-04-02 Basf Se Pesticidal mixture comprising a mesoionic compound and a biopesticide
WO2020083733A1 (en) 2018-10-24 2020-04-30 Basf Se Pesticidal compounds
EP3643705A1 (en) 2018-10-24 2020-04-29 Basf Se Pesticidal compounds
WO2020095161A1 (en) 2018-11-05 2020-05-14 Pi Industries Ltd. Nitrone compounds and use thereof
EP3670501A1 (en) 2018-12-17 2020-06-24 Basf Se Substituted [1,2,4]triazole compounds as fungicides
EP3696177A1 (en) 2019-02-12 2020-08-19 Basf Se Heterocyclic compounds for the control of invertebrate pests
EP3730489A1 (en) 2019-04-25 2020-10-28 Basf Se Heteroaryl compounds as agrochemical fungicides
WO2020239517A1 (en) 2019-05-29 2020-12-03 Basf Se Mesoionic imidazolium compounds and derivatives for combating animal pests
WO2020244970A1 (en) 2019-06-06 2020-12-10 Basf Se New carbocyclic pyridine carboxamides
WO2020244968A1 (en) 2019-06-06 2020-12-10 Basf Se Fungicidal n-(pyrid-3-yl)carboxamides
WO2020244969A1 (en) 2019-06-06 2020-12-10 Basf Se Pyridine derivatives and their use as fungicides
WO2021013561A1 (en) 2019-07-19 2021-01-28 Basf Se Pesticidal pyrazole and triazole derivatives
EP3766879A1 (en) 2019-07-19 2021-01-20 Basf Se Pesticidal pyrazole derivatives
EP3769623A1 (en) 2019-07-22 2021-01-27 Basf Se Mesoionic imidazolium compounds and derivatives for combating animal pests
WO2021063736A1 (en) 2019-10-02 2021-04-08 Basf Se Bicyclic pyridine derivatives
WO2021063735A1 (en) 2019-10-02 2021-04-08 Basf Se New bicyclic pyridine derivatives
WO2021094905A1 (en) 2019-11-11 2021-05-20 Pi Industries Ltd. 1 -(4-(4-(5-phenyl-4,5-dihydroisoxazol-3-yl)thiazol-2-yl)piperidin-1 -yl)-ethan-1 -one derivatives and related compounds as fungicides for crop protection
WO2021094904A2 (en) 2019-11-11 2021-05-20 Pi Industries Ltd. Novel sulfilimines or sulfoximines containing fungicidal heterocyclic compounds
WO2021094903A1 (en) 2019-11-11 2021-05-20 Pi Industries Ltd. 1-(4-(4-(5-phenyl-4,5-dihydroisoxazol-3-yl)thiazol-2-yl)piperidin-1-yl)-ethan-1-one derivatives and related compounds as fungicides for crop protection
US11807625B2 (en) 2019-11-26 2023-11-07 Gilead Sciences, Inc. Capsid inhibitors for the prevention of HIV
WO2021122752A1 (en) 2019-12-19 2021-06-24 Bayer Aktiengesellschaft Process for preparing [3-chloro-2-[3-[2-[1-(2-chloroacetyl)-4-piperidyl]thiazol-4-yl]-4,5-dihydroisoxazol-5-yl]phenyl] methanesulfonate
WO2021130143A1 (en) 2019-12-23 2021-07-01 Basf Se Enzyme enhanced root uptake of agrochemical active compound
WO2021170463A1 (en) 2020-02-28 2021-09-02 BASF Agro B.V. Methods and uses of a mixture comprising alpha-cypermethrin and dinotefuran for controlling invertebrate pests in turf
WO2021175669A1 (en) 2020-03-04 2021-09-10 Basf Se Use of substituted 1,2,4-oxadiazoles for combating phytopathogenic fungi
WO2021209360A1 (en) 2020-04-14 2021-10-21 Basf Se Fungicidal mixtures comprising substituted 3-phenyl-5-(trifluoromethyl)-1,2,4-oxadiazoles
CN113185509A (en) * 2020-04-17 2021-07-30 华中师范大学 Compound containing indole ring structure, preparation method and application thereof, and bactericide
WO2021219513A1 (en) 2020-04-28 2021-11-04 Basf Se Pesticidal compounds
EP3903582A1 (en) 2020-04-28 2021-11-03 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors ii
EP3903581A1 (en) 2020-04-28 2021-11-03 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors i
EP3903584A1 (en) 2020-04-28 2021-11-03 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors iv
EP3903583A1 (en) 2020-04-28 2021-11-03 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors iii
EP3909950A1 (en) 2020-05-13 2021-11-17 Basf Se Heterocyclic compounds for the control of invertebrate pests
WO2021249800A1 (en) 2020-06-10 2021-12-16 Basf Se Substituted [1,2,4]triazole compounds as fungicides
US11680064B2 (en) 2020-06-25 2023-06-20 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
US12077537B2 (en) 2020-06-25 2024-09-03 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
EP3939961A1 (en) 2020-07-16 2022-01-19 Basf Se Strobilurin type compounds and their use for combating phytopathogenic fungi
WO2022017836A1 (en) 2020-07-20 2022-01-27 BASF Agro B.V. Fungicidal compositions comprising (r)-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1- (1,2,4-triazol-1-yl)propan-2-ol
EP3945089A1 (en) 2020-07-31 2022-02-02 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors v
EP3960727A1 (en) 2020-08-28 2022-03-02 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors vi
EP3970494A1 (en) 2020-09-21 2022-03-23 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors viii
WO2022064453A1 (en) 2020-09-26 2022-03-31 Pi Industries Ltd. Nematocidal compounds and use thereof
WO2022089969A1 (en) 2020-10-27 2022-05-05 BASF Agro B.V. Compositions comprising mefentrifluconazole
WO2022090071A1 (en) 2020-11-02 2022-05-05 Basf Se Use of mefenpyr-diethyl for controlling phytopathogenic fungi
WO2022090069A1 (en) 2020-11-02 2022-05-05 Basf Se Compositions comprising mefenpyr-diethyl
WO2022106304A1 (en) 2020-11-23 2022-05-27 BASF Agro B.V. Compositions comprising mefentrifluconazole
WO2022130188A1 (en) 2020-12-15 2022-06-23 Pi Industries Ltd. Agrochemical composition comprising piperidine thiazole compounds
EP4018830A1 (en) 2020-12-23 2022-06-29 Basf Se Pesticidal mixtures
WO2022167488A1 (en) 2021-02-02 2022-08-11 Basf Se Synergistic action of dcd and alkoxypyrazoles as nitrification inhibitors
EP4043444A1 (en) 2021-02-11 2022-08-17 Basf Se Substituted isoxazoline derivatives
WO2022238157A1 (en) 2021-05-11 2022-11-17 Basf Se Fungicidal mixtures comprising substituted 3-phenyl-5-(trifluoromethyl)-1,2,4-oxadiazoles
WO2022243810A1 (en) 2021-05-15 2022-11-24 Pi Industries Ltd. Novel agrochemical composition comprising piperidine thiazole compounds
WO2022243109A1 (en) 2021-05-18 2022-11-24 Basf Se New substituted quinolines as fungicides
WO2022243107A1 (en) 2021-05-18 2022-11-24 Basf Se New substituted pyridines as fungicides
WO2022243111A1 (en) 2021-05-18 2022-11-24 Basf Se New substituted pyridines as fungicides
WO2022243521A1 (en) 2021-05-21 2022-11-24 Basf Se Use of ethynylpyridine compounds as nitrification inhibitors
WO2022243523A1 (en) 2021-05-21 2022-11-24 Basf Se Use of an n-functionalized alkoxy pyrazole compound as nitrification inhibitor
EP4094579A1 (en) 2021-05-28 2022-11-30 Basf Se Pesticidal mixtures comprising metyltetraprole
WO2022268810A1 (en) 2021-06-21 2022-12-29 Basf Se Metal-organic frameworks with pyrazole-based building blocks
EP4119547A1 (en) 2021-07-12 2023-01-18 Basf Se Triazole compounds for the control of invertebrate pests
WO2023007429A1 (en) 2021-07-29 2023-02-02 Pi Industries Ltd. Preparation of phenyl sulfilimines or sulfoximines containing thiazolyl-piperidinyl compounds and intermediates thereof
WO2023011957A1 (en) 2021-08-02 2023-02-09 Basf Se (3-quinolyl)-quinazoline
WO2023011958A1 (en) 2021-08-02 2023-02-09 Basf Se (3-pirydyl)-quinazoline
EP4140986A1 (en) 2021-08-23 2023-03-01 Basf Se Pyrazine compounds for the control of invertebrate pests
EP4140995A1 (en) 2021-08-27 2023-03-01 Basf Se Pyrazine compounds for the control of invertebrate pests
EP4151631A1 (en) 2021-09-20 2023-03-22 Basf Se Heterocyclic compounds for the control of invertebrate pests
WO2023072670A1 (en) 2021-10-28 2023-05-04 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors x
WO2023072671A1 (en) 2021-10-28 2023-05-04 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors ix
US11787825B2 (en) 2021-12-03 2023-10-17 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
US12084467B2 (en) 2021-12-03 2024-09-10 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
EP4194453A1 (en) 2021-12-08 2023-06-14 Basf Se Pyrazine compounds for the control of invertebrate pests
EP4198033A1 (en) 2021-12-14 2023-06-21 Basf Se Heterocyclic compounds for the control of invertebrate pests
EP4198023A1 (en) 2021-12-16 2023-06-21 Basf Se Pesticidally active thiosemicarbazone compounds
EP4238971A1 (en) 2022-03-02 2023-09-06 Basf Se Substituted isoxazoline derivatives
WO2023203066A1 (en) 2022-04-21 2023-10-26 Basf Se Synergistic action as nitrification inhibitors of dcd oligomers with alkoxypyrazole and its oligomers
WO2024028243A1 (en) 2022-08-02 2024-02-08 Basf Se Pyrazolo pesticidal compounds
EP4342885A1 (en) 2022-09-20 2024-03-27 Basf Se N-(3-(aminomethyl)-phenyl)-5-(4-phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-amine derivatives and similar compounds as pesticides
WO2024088792A1 (en) 2022-10-24 2024-05-02 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors xv
EP4361126A1 (en) 2022-10-24 2024-05-01 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors xv
WO2024104813A1 (en) 2022-11-14 2024-05-23 Basf Se Fungicidal mixture comprising substituted pyridines
WO2024104823A1 (en) 2022-11-16 2024-05-23 Basf Se New substituted tetrahydrobenzoxazepine
WO2024104822A1 (en) 2022-11-16 2024-05-23 Basf Se Substituted tetrahydrobenzodiazepine as fungicides
WO2024104814A1 (en) 2022-11-16 2024-05-23 Basf Se Fungicidal mixture comprising substituted pyridines
WO2024104818A1 (en) 2022-11-16 2024-05-23 Basf Se Substituted benzodiazepines as fungicides
WO2024104815A1 (en) 2022-11-16 2024-05-23 Basf Se Substituted benzodiazepines as fungicides
EP4389210A1 (en) 2022-12-21 2024-06-26 Basf Se Heteroaryl compounds for the control of invertebrate pests
WO2024165343A1 (en) 2023-02-08 2024-08-15 Basf Se New substituted quinoline compounds for combatitng phytopathogenic fungi
WO2024194038A1 (en) 2023-03-17 2024-09-26 Basf Se Substituted pyridyl/pyrazidyl dihydrobenzothiazepine compounds for combatting phytopathogenic fungi
EP4455137A1 (en) 2023-04-24 2024-10-30 Basf Se Pyrimidine compounds for the control of invertebrate pests
WO2024223034A1 (en) 2023-04-26 2024-10-31 Basf Se Use of strobilurin type compounds for combating phytopathogenic fungi containing an amino acid substitution f129l in the mitochondrial cytochrome b protein conferring resistance to qo inhibitors xvi

Also Published As

Publication number Publication date
MX337779B (en) 2016-03-18
TW200822865A (en) 2008-06-01
AU2007277157A1 (en) 2008-01-31
JP6572294B2 (en) 2019-09-04
ES2632597T3 (en) 2017-09-14
EP3239145A1 (en) 2017-11-01
EP3239137A1 (en) 2017-11-01
LTC2049111I2 (en) 2020-09-25
IL224109A (en) 2015-06-30
HUS000510I2 (en) 2021-03-29
TWI531317B (en) 2016-05-01
FR22C1026I1 (en) 2022-09-09
WO2008013925A3 (en) 2008-04-03
JP2018065861A (en) 2018-04-26
HUS2000021I1 (en) 2020-07-28
WO2008013925A2 (en) 2008-01-31
PL3239137T3 (en) 2019-07-31
CO6150154A2 (en) 2010-04-20
GT200900017A (en) 2011-09-06
LTPA2021503I1 (en) 2021-03-10
EP2712616A1 (en) 2014-04-02
ES2637336T3 (en) 2017-10-11
CN106986866A (en) 2017-07-28
NZ572915A (en) 2011-08-26
CY2021002I2 (en) 2022-03-24
CN104478805A (en) 2015-04-01
CL2007002185A1 (en) 2008-06-13
US20090156592A1 (en) 2009-06-18
PE20080952A1 (en) 2008-09-10
TWI561510B (en) 2016-12-11
EP2049111B1 (en) 2017-05-24
HUS2100017I1 (en) 2021-05-28
JP2015110611A (en) 2015-06-18
LTPA2019008I1 (en) 2019-04-10
TW201600514A (en) 2016-01-01
CA2653640C (en) 2016-10-25
MX2009000920A (en) 2009-02-04
PE20121386A1 (en) 2012-10-25
UY30510A1 (en) 2008-02-29
ME00586B (en) 2011-12-20
IL195509A (en) 2016-11-30
PT2049111T (en) 2017-08-29
RU2009106871A (en) 2010-09-10
JP2017039755A (en) 2017-02-23
PH12008502812A1 (en) 2008-01-31
MY148424A (en) 2013-04-30
JP2010509190A (en) 2010-03-25
IL195509A0 (en) 2009-09-01
EP2712616B1 (en) 2017-04-19
IL231012A0 (en) 2014-03-31
TW201636331A (en) 2016-10-16
AU2007277157B2 (en) 2013-01-31
CA2653640A1 (en) 2008-01-31
JP6333913B2 (en) 2018-05-30
TWI570111B (en) 2017-02-11
CY1120559T1 (en) 2019-07-10
PL2049111T3 (en) 2017-10-31
AR063213A1 (en) 2009-01-14
UY38537A (en) 2020-11-30
CN104478805B (en) 2017-04-12
CN101888843A (en) 2010-11-17
EP3239137B1 (en) 2019-02-13
CN107021962A (en) 2017-08-08
CN102816148A (en) 2012-12-12
KR20090033496A (en) 2009-04-03
EP3239145B1 (en) 2019-03-06
GEP20125505B (en) 2012-04-25
HRP20171019T1 (en) 2017-10-06
CN104774201A (en) 2015-07-15
JP6118011B2 (en) 2017-04-19
CN101888843B (en) 2015-04-15
IL231012A (en) 2015-06-30
TW201600507A (en) 2016-01-01
CN102816148B (en) 2015-01-28
DK2049111T3 (en) 2017-09-11
KR101564187B1 (en) 2015-10-28
WO2008013622A3 (en) 2008-03-27
PL3239145T3 (en) 2019-09-30
KR20140144747A (en) 2014-12-19
LT2049111T (en) 2017-07-25
RU2453544C3 (en) 2021-12-01
RU2453544C2 (en) 2012-06-20
CN106986866B (en) 2020-03-03
WO2008013925A4 (en) 2010-09-30
ME00586A (en) 2011-12-20
SI2049111T1 (en) 2017-12-29
BRPI0713833A2 (en) 2012-12-11
EP2049111A2 (en) 2009-04-22
US8642634B2 (en) 2014-02-04

Similar Documents

Publication Publication Date Title
AU2007277157B2 (en) Fungicidal azocyclic amides
CA2699933C (en) Fungicidal mixtures
AU2011204323B2 (en) Fungicidal heterocyclic compounds
AU2009206522B2 (en) Fungicidal amides
AU2009206468B2 (en) Fungicidal heterocyclic compounds
AU2006272551A1 (en) Fungicidal carboxamides
EP2121660A2 (en) Fungicidal amides
US9920030B2 (en) Fungicidal azocyclic amides
AU2014202324B2 (en) Fungicidal compounds and mixtures
BRPI0713833B1 (en) COMPOUND, PLANT DISEASE CONTROL METHOD AND FUNGICIDAL COMPOSITIONS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07796390

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07796390

Country of ref document: EP

Kind code of ref document: A2